---
document_datetime: 2023-09-21 18:23:01
document_pages: 153
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vosevi-epar-public-assessment-report_en.pdf
document_name: vosevi-epar-public-assessment-report_en.pdf
version: success
processing_time: 133.3242835
conversion_datetime: 2025-12-24 19:36:41.408398
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 June 2017 EMA/441550/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Vosevi

International non-proprietary name: sofosbuvir / velpatasvir / voxilaprevir

Procedure No. EMEA/H/C/004350/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | ..............................................7                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................8              |                                                                                                          |
| 2. Scientific discussion                                                                                                  | ................................................................................9                        |
| 2.1. Problem statement                                                                                                    | ...............................................................................................9         |
| 2.1.1. Disease or condition...........................................................................................9   |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                       | ....................................................................................................9    |
| 2.1.3. Aetiology and pathogenesis                                                                                         | ................................................................................9                        |
| 2.1.4. Clinical presentation...........................................................................................9  |                                                                                                          |
| 2.1.5. Management.....................................................................................................9   |                                                                                                          |
| 2.2. Quality aspects                                                                                                      | ..................................................................................................11     |
| 2.2.1. Introduction....................................................................................................11 |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................11    |                                                                                                          |
| 2.2.3. Finished Medicinal Product................................................................................19       |                                                                                                          |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................21                      |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................21                                                                                 |
| 2.2.6. Recommendations for future quality development                                                                     | ...............................................21                                                        |
| 2.3. Non-clinical aspects                                                                                                 | ............................................................................................22           |
| 2.3.1. Introduction....................................................................................................22 |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                       | .................................................................................................22      |
| 2.3.3. Pharmacokinetics.............................................................................................24    |                                                                                                          |
| 2.3.4. Toxicology                                                                                                         | ......................................................................................................25 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                          | .........................................................33                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................37         |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................38           |                                                                                                          |
| 2.4. Clinical aspects                                                                                                     | ..................................................................................................39     |
| 2.4.1. Introduction....................................................................................................39 |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................41    |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................60       |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................64           |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................70            |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                    | ..................................................................................................70     |
| 2.5.1. Discussion on clinical efficacy..........................................................................          | 117                                                                                                      |
| 2.5.2. Conclusions on the clinical efficacy...................................................................            | 119                                                                                                      |
| 2.6. Clinical safety                                                                                                      | .................................................................................................. 119   |
| 2.6.1. Discussion on clinical safety ............................................................................         | 138                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................            | 139                                                                                                      |
| 2.7. Risk Management Plan......................................................................................           | 140                                                                                                      |
| 2.8. Pharmacovigilance............................................................................................        | 145                                                                                                      |
| 2.9. New Active Substance.......................................................................................          | 145                                                                                                      |
| 2.10. Product information                                                                                                 | ........................................................................................ 146             |
| 2.10.1. User consultation.........................................................................................        | 146                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.10.2. Additional monitoring ................................................................................... 146      |
|----------------------------------------------------------------------------------------------------------------------------|
| 3.1. Therapeutic Context ......................................................................................... 147     |
| 3.1.1. Disease or condition....................................................................................... 147     |
| 3.1.2. Available therapies and unmet medical need..................................................... 147                 |
| 3.1.3. Main clinical studies ....................................................................................... 147   |
| 3.2. Favourable effects ............................................................................................ 147   |
| 3.3. Uncertainties and limitations about favourable effects........................................... 148                 |
| 3.4. Unfavourable effects......................................................................................... 149     |
| 3.5. Uncertainties and limitations about unfavourable effects ....................................... 150                  |
| 3.6. Effects Table.................................................................................................... 150 |
| 3.7. Benefit-risk assessment and discussion............................................................... 151             |
| 3.7.1. Importance of favourable and unfavourable effects............................................ 151                   |
| 3.7.2. Balance of benefits and risks........................................................................... 151        |
| 3.8. Conclusions ..................................................................................................... 151 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AASLD

American Association for the Study of Liver Diseases

ADME

absorption, distribution, metabolism, and elimination

AE

adverse event

ALT

alanine aminotransferase

ARV

antiretroviral

AST

aspartate aminotransferase

AUC

area under the plasma/serum concentration versus time curve

AUCinf

area under the plasma/serum concentration versus time curve extrapolated to

infinite time, calculated as AUC - last + (Clast/ λ z

)

AUCtau

area under the plasma/serum concentration versus time curve over the dosing interval

BCRP

breast cancer resistance protein

BCS

Biopharmaceutics Classification System

BHT

Butylated hydroxytoluene

BMI

body mass index

CFR

Code of Federal Regulations

CHMP

Committee for Medicinal Products for Human use

CI

confidence interval

CLcr

creatinine clearance

Cmax

maximum observed plasma/serum concentration of drug

CMH

Cochran-Mantel-Haenszel

CPP

Critical process parameter

CPT

Child-Pugh-Turcotte

CQA

Critical quality attribute

CYP

cytochrome P450 enzyme

DAA

direct-acting antiviral

DCV

daclatasvir (BMS-790052)

DDI

drug-drug interaction

DILI

drug-induced liver injury

DNA

deoxyribonucleic acid

DoE

Design of experiments

DSC

Differential scanning calorimetry

EASL

European Association for the Study of the Liver

EC

European Commission

EC50

half-maximal effective concentration

eGFR

estimated glomerular filtration rate

Emax

maximum (pharmacodynamics) effect

ESRD

end-stage renal disease

EU

European Union

FDA

Food and Drug Administration

FDC

fixed-dose combination

GC

Gas chromatography

Gilead

Gilead Sciences

GLSM

geometric least-squares mean

GMP

Good manufacturing practice

GVS

Gravimetric vapour sorption

H2RA

H2-receptor antagonist

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

HDPE

High density polyethylene

HIV, HIV-1

human immunodeficiency virus, type 1

HPLC

High performance liquid chromatography

IAC

Independent Adjudication Committee

ICH

International Council for Harmonisation (of Technical Requirements of

Pharmaceuticals for Human Use)

ICP

Inductively coupled plasma

ICP-OES

Inductively coupled plasma optical emission spectrometry

IDSA

Infectious Diseases Society of America

IL28B

IL28B gene

IR

Infrared

iVSR

integrated virology study report

LDV

ledipasvir (GS-5885)

LDV/SOF

ledipasvir/sofosbuvir (coformulated; Harvoni ® )

LLOQ

lower limit of quantitation

m

Module

MAH

Marketing authorisation holder

MATE1

multidrug and toxin extrusion 1

MCS

methylcyclopropane-1-sulfonamide

MoC

Methoxycarbonyl

N or n

number of subjects in a population (N) or subset (n)

NF

National formulary

NMT

Not more than

NMR

Nuclear magnetic resonance

NOAEL

no observed adverse effect level

NOEL

no observed effect level

NOR

Normal operating range

NS3/4

nonstructural protein 3/4

NS5A

nonstructural protein 5A

NS5B

nonstructural protein 5B

OAT

organic anion transporter

OATP

organic anion transporting polypeptide

OCT

organic cation transporter

PAR

Proven acceptable range

PD

pharmacodynamics(s)

PDE

Permitted daily exposure

PE

Polyethylene

PEG

Polyethylene glycol

Peg-IFN

pegylated interferon

P-gp

P-glycoprotein

Ph. Eur.

European Pharmacopoeia

PI

protease inhibitor

PK

pharmacokinetic(s)

PMI

Potential mutagenic impurity

PP

Polypropylene

ppm

Parts per million

<div style=\"page-break-after: always\"></div>

QbD

Quality by design

QP

Qualified person

QT

electrocardiographic interval between the beginning of the Q wave and

termination of the T wave, representing the time for both ventricular depolarization and repolarization to occur

QTc

QT interval corrected for heart rate

RAV

resistance-associated variant

RBV

Ribavirin

RH

Relative humidity

RNA

ribonucleic acid

RoI

Residue on ignition

SAE

serious adverse event

SD

standard deviation

SmPC

summary of product characteristics

SMV

simeprevir (TMC435)

SOF

sofosbuvir (Sovaldi ® )

SOF/VEL

sofosbuvir/velpatasvir (coformulated; Epclusa ® )

SOF/VEL/VOX

sofosbuvir/velpatasvir/voxilaprevir (coformulated)

SVR

sustained virologic response

SVRxx

sustained virologic response at 'xx' weeks following completion of all

treatment

Tg

glass transition temperature

TND

target not detected

TTC

Threshold of toxicological concern

UGT1A1

uridine diphosphate glucuronosyltransferase 1A1

ULN

upper limit of normal

UPLC

Ultra-performance liquid chromatography

US

United States

USP

United States pharmacopoeia

UV

Ultraviolet

VEL

velpatasvir (GS-5816)

VOX

voxilaprevir (GS-9857)

VOX DS

voxilaprevir drug substance

vs

Versus

XRPD

X-ray powder diffraction

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Gilead Sciences International Ltd submitted on 16 December 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Vosevi, through the centralised procedure falling within the Article 3 (1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 17 December 2015.

The applicant applied for the following indication:

## Treatment of chronic hepatitis C virus (HCV) infection in adults.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that sofosbuvir / velpatasvir / voxilaprevir was considered to be a new active substance.

The application submitted is a new fixed combination medicinal product.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0121/2016 on the agreement of a paediatric investigation plan (PIP) and on the granting of a deferral and on the granting of a waiver for sofosbuvir / velpatasvir / voxilaprevir.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Accelerated assessment

The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004.

## New active Substance status

The applicant requested the active substance voxilaprevir contained in the above fixed combination medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Filip Josephson Co-Rapporteur:  Greg Markey

- The application was received by the EMA on 16 December 2016.
- Accelerated Assessment procedure was agreed-upon by CHMP on 12 December 2016.
- The procedure started on 20 January 2017.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 22 March 2017. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 17 March 2017. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 29 March 2017. In accordance with Article 6(3) of Regulation (EC) No 726/2004, the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days.
- During the meeting on 6 April 2017, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP.
- During the meeting on 19 April 2017, the CHMP agreed on the consolidated List of Questions to be sent to the applicant.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 18 May 2017.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 9 June 2017.
- The Rapporteurs circulated the updated Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 16 June 2017.
- During the meeting on 22 June 2017, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Vosevi on 22 June 2017.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

The disease burden of HCV infection is due to progression of chronic liver disease, which can lead to cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. Globally, approximately 25% of all cirrhosis and HCC are attributable to HCV infection.

Curing HCV infection is associated with numerous health benefits, including more than 70% reduction in the risk of HCC and 90% reduction in the risk of liver related mortality and liver transplantation. The development of an integrated approach to prevention, control, and cure of HCV infection is necessary to address the growing global burden of disease.

## 2.1.1. Disease or condition

SOF/VEL/VOX is proposed for the treatment of chronic hepatitis C virus (HCV) infection in adults.

## 2.1.2. Epidemiology

Hepatitis C virus infection is a global health challenge with an estimated 150 million individuals infected worldwide.

## 2.1.3. Aetiology and pathogenesis

The hepatitis C virus (HCV) is a RNA virus that has 6 major genotypes and multiple sub-genotypes. There is a regional predominance of certain genotypes.

Hepatitis C is a blood-borne virus. Most infections occur as a result of sharing needles or other equipment to inject illicit drugs. HCV may or may not cause a short-term illness with features of acute hepatitis at the time of acquisition. About 70%-85% of infected persons do not clear the virus and therefore HCV becomes a long-term chronic infection. Chronic HCV infection is a serious disease that, left untreated, can be fatal due to decompensated liver cirrhosis and/or hepatocellular carcinoma (HCC). Globally, 27% of all cirrhosis and 25% of all HCC are attributable to HCV infection. In addition, persons with chronic HCV infection may develop extra-hepatic manifestations, such as cryoglobulinaemia, renal disease and porphyria cutanea tarda.

## 2.1.4. Clinical presentation

The majority of individuals with chronic HCV are not aware of the infection because they are not clinically ill. Others develop manifestations as described in 2.1.3.

## 2.1.5. Management

There is no vaccine against HCV.

Curing chronic HCV infection is associated with more than 70% reduction in the risk of HCC and 90% reduction in the risk of liver related mortality and liver transplantation.

<div style=\"page-break-after: always\"></div>

Within the last 5 years, HCV treatment has been transformed by the development and approval of DAAs that target viral proteins and cellular processes essential to HCV replication and which have activity against multiple HCV genotypes. Several of these agents with different viral targets are now available in FDC form for once daily dosing for 12 weeks and have been associated with &gt;90% cure rates.

Retreatment options are available for patients who have failed pegylated interferon (Peg IFN) and ribavirin (RBV) with or without an NS3/4A PI (e.g., telaprevir, boceprevir, simeprevir). Large registrational clinical studies have demonstrated that subjects previously treated with Peg IFN and RBV and who failed treatment can be retreated in a manner similar to the initial treatment of naive subjects; thus, currently approved DAA regimens are recommended for use in patients who failed treatment with Peg IFN and RBV. Additionally, there are approved DAA regimens which are indicated for treatment in patients who previously failed treatment with an NS3/4A PI with Peg IFN and RBV.

However, retreatment options are limited for patients who fail DAA only treatment with regimens that include an NS5A inhibitor. The current HCV treatment guidelines from the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) and European Association for the Study of the Liver (EASL) acknowledge the limited clinical data to support retreatment recommendations for these DAA experienced patients and suggest deferral of treatment for all patients without an urgent need for retreatment until more data and/or additional options become available.

## About the product

Sofosbuvir is a nucleotide analogue non-structural protein NS5B polymerase inhibitor approved for use in combination with other agents for the treatment of chronic HCV infection in adults in many countries the European Union (EU) (tradename Sovaldi®). Velpatasvir is an HCV NS5A inhibitor approved for use in combination with SOF for the treatment of chronic HCV infection in adults in several countries worldwide including the EU (tradename Epclusa®). Voxilaprevir is a novel pangenotypic HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity.

## Type of Application and aspects on development

The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest. This was based on the following:

- The data provided showed efficacy of SOF/VEL/VOX in patients who have previously failed on a DAA-containing regimen, addressing remaining unmet medical needs in the treatment of HCV infection.
- Voxilaprevir represents a new generation of NS3/4A inhibitors with high efficacy across all genotypes and with limited cross-resistance to previous generations of drugs, which may be considered a significant therapeutic innovation.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as a film-coated tablet containing 400 mg of sofosbuvir, 100 mg of velpatasvir and 100 mg of voxilaprevir as active substances.

Other ingredients are:

Tablet core: colloidal anhydrous silica, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose.

Film-coat: iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol, polyvinyl alcohol, talc and titanium dioxide (E171).

The product is available in HDPE bottles with polypropylene child-resistant closure, polyester coil and silica gel desiccant as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## Sofosbuvir

## General information

Sofosbuvir is the active substance of the already-authorised products Sovaldi, Harvoni and Eplcusa. Information on its quality is the same as in the Sovaldi and Harvoni dossiers which have been updated throughout the products' lifecycles.

The chemical name of sofosbuvir is ( S )-isopropyl-2-(( S )-(((2 R ,3 R ,4 R ,5 R )-5-(2,4-dioxo-3,4dihydropyrimidin-1(2 H )-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate corresponding to the molecular formula C22H29FN3O9P and has a relative molecular mass of 529 g/mol. It has the following structure:

<!-- image -->

## Figure 1. structure of sofosbuvir

The structure of Sofosbuvir was unambiguously confirmed by  1 H, 13 C, 31 P and  19 F NMR, UV spectroscopy, IR spectroscopy, mass spectrometry, elemental analysis and single crystal X-ray crystallography.

Sofosbuvir is a white to off-white non-hygroscopic crystalline solid, slightly soluble in water (pH 1.27.7), freely soluble in ethanol and acetone, soluble in 2-propanol, and insoluble in heptane.

Sofosbuvir is chiral and possesses 6 stereogenic centres. Enantiomeric purity is controlled in synthesis intermediates by chiral HPLC. Sofosbuvir exibits polymorphism. Eight polymorphic forms of sofosbuvir

<div style=\"page-break-after: always\"></div>

have been observed and the manufacturing process consistently produces sofosbuvir as the most thermodynamically stable polymorphic form that may contain a small amount of a metastable form that was determined to be pharmaceutically equivalent. Therefore it was considered acceptable not to control the presence of the metastable form in the active substance as per ICH Q6A (decision tree #4). Other polymorphic forms are excluded by the manufacturing process and their absence is confirmed by DSC.

## Manufacture, characterisation and process controls

Sofosbuvir is synthesized in six synthetic steps using three well-defined starting materials with acceptable specifications. During the procedure the applicant also introduced an alternative manufacturing process in addition to the previous one to reduce chlorinated solvent use and improve process efficiency. The alternative process was approved for Solvadi and Harvoni products (procedures EMEA/H/C/002798/WS0904/0027/G and EMEA/H/C/003850/WS0904/0027/G, approval date 7 April 2016). After recrystallisation, the active substance is then sieved or milled to afford material of a suitable particle size for formulation. GMP manufacturing for Sofosbuvir occurs at multiple manufacturers.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set based on the manufacturing experience to date.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

Sofosbuvir is packaged in double-lined polyethylene bags closed with plastic or wire ties. The bags are held in high-density polyethylene drums (or other suitable secondary container) with lids of appropriate size and fitted with a tamper-evident security seal. The polyethylene used complies with EC requirements.

## Specification

The active substance specification includes tests for appearance, identity (IR, HPLC), clarity of solution, assay (HPLC), impurities (HPLC), residual solvents and volatile organic impurities (GC), metals (ICPOES), particle size (Ph. Eur.), and polymorphic form (DSC - Ph. Eur.).

Rationale for the absence of tests for water content (non-hygroscopic) and microbiological testing (low water content and water activity, isolation from organic solvent) was considered justified. Residue on ignition testing is not suitable as the active substance contains phosphorous: this test is replaced with a combination of clarity of solution test and ICP for elemental impurities. The applicant committed to review the acceptance limits two residual solvents when sufficient commercial scale data is obtained from batches manufactured at the recently approved manufacturing site and from batches manufactured using the alternative process.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay has been presented.

Batch analysis data on 45 batches of the active substance ranging from laboratory through pilot to commercial scale, and used for development, stability, toxicology, clinical studies, and validation were

<div style=\"page-break-after: always\"></div>

provided. 3 of the 45 batches were manufactured according to the alternative manufacturing process. Assessment focussed primarily on later pilot commercial scale batches used for development, stability and validation. The results were within the specifications and consistent from batch to batch.

## Stability

Stability data were provided on two pilot scale batches of active substance from two of the three proposed sources in a container closure system representative of that intended for the market. For those batches, stability data are on-going and results were provided for up to one month under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines. The absence of stability data for the third active substance source was considered acceptable due to the fact that this manufacturer was approved for Solvadi and Harvoni products (EMEA/H/C/002798/WS0841/0026/G and EMEA/H/C/003850/WS0841/0018/G approved in December 2015).

Stability data were also provided for 6 batches of active substance from sources other than the ones proposed for this application. Results are available for 12 or 18 months under long term conditions at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines. Those stability data were considered to be also representative for all the proposed active substance sources.

Photostability testing following ICH guideline Q1B was performed on 1 batch. Stressed studies were carried out on a single batch between -20 and 50 ºC for up to 4 weeks. Forced degradation was carried out under acidic (0.1 M HCl), alkaline (10 mM Na2CO3) and oxidative (3% H2O2) conditions and at 105 ºC.

The parameters tested were appearance, assay, impurity content, water content, and polymorphic form. The analytical methods used were the same as for release, except for water content, measured by DVS, and were stability indicating.

Sofosbuvir was shown to be stable under long-term, accelerated and stressed conditions and is not sensitive to light. Forced degradation revealed that the active substance may degrade via oxidation or hydrolysis in solution, but remains stable in the solid state even up to 105 ºC after 1 week.

The stability results indicate that the active substance manufactured by the proposed suppliers is sufficiently stable. The stability results justify the proposed 24 months retest period in the proposed container.

## Velpatasvir

## General information

Velpatasvir is the active substance of the already-authorised product Eplcusa. Information on its quality is the same as in the Eplusa dossier which has been updated throughout the product's lifecycle.

The chemical name of velpatasvir is methyl {(1 R )-2-[(2 S ,4 S )-2-(5-{2-[(2 S ,5 S )-1-{(2 S )-2[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,11dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1 H -imidazol-2-yl)-4(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate corresponding to the molecular formula C49H54N8O8. It has a relative molecular mass of 883.0 g/mol and the following structure:

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Figure 2. structure of velpatasvir

The structure of velpatasvir was unambiguously confirmed by  1 H and  13 C NMR, UV spectroscopy, IR spectroscopy, mass spectrometry, elemental analysis and single crystal X-ray crystallography.

The active substance is a white to tan or yellow hygroscopic solid. The amorphous, free base velpatasvir is the only solid-state form known to date, despite efforts to achieve a crystalline solid form. Velpatasvir belongs to Biopharmaceutics Classification System (BCS) Class 4 (low solubility relative to dose and low permeability) and exhibits pH-dependent solubility; it is soluble at pH 1.2, sparingly soluble at pH 2 and practically insoluble at pH &gt; 5.

Velpatasvir exhibits stereoisomerism due to the presence of six chiral centres and is produced as a single stereoisomer.  The stereoisomers are controlled either as specified impurities in velpatasvir or by the specifications of active substance intermediates or by process design.

## Manufacture, characterisation and process controls

The active substance is synthesized by two manufacturers in seven main steps using four well defined starting materials with acceptable specifications.

Re-work and re-process procedures are described and are considered acceptable.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. Changes introduced have been presented in sufficient detail and have been justified.

The applicant has applied QbD principles in the development of the velpatasvir active substance manufacturing process. The active substance critical quality attributes were identified.

The preferred conditions for the manufacture of velpatasvir were selected through traditional univariate experimentation. Upon selection of the preferred conditions, additional studies were performed to establish proven acceptable ranges (PARs) for all important process parameters. These broad PARs support the more narrow normal operating ranges (NORs) used to describe the manufacturing process. The ranges included in manufacturing process description have been studied by univariate experiments. The applicant states that within the narrow ranges defined in the manufacturing description at each velpatasvir manufacturer, individualised set points are selected to tailor the process to their specific equipment and that they do not constitute a design space. The applicant clarified that design-of-experiments (DoE) studies were used to increase the understanding of potential multivariable interactions in the process and not to establish a design space for velpatasvir manufacture. A risk assessment was conducted to identify critical process parameters (CPPs). Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

<div style=\"page-break-after: always\"></div>

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. Impurity genesis, fate and purge studies are described and support the specifications for the starting materials, intermediates and active substance velpatasvir. Potentially mutagenic impurities (PMIs) that may arise from the synthesis of velpatasvir and may be present in the active substance have been identified. Control strategies for these PMIs were established with understanding of fate and purge and associated process controls. These strategies assure that the levels of these PMIs in the active substance are controlled below 30% of the concentration limit calculated based on the threshold of toxicological concern.

Velpatasvir is packaged in double polyethylene bags closed with plastic or wire ties; each double bag is contained in a polyethylene-lined aluminum foil pouch; the outer polyethylene-lined foil bag is heat sealed; the foil bags are placed in a high density polyethylene drum (or other suitable secondary containment) fitted with a lid. The polyethylene used for the bags complies with the Ph. Eur. requirements.

## Specification

The active substance specification includes tests for: appearance, identity (IR, HPLC), clarity of solution, assay (HPLC), impurities (HPLC, UPLC), residual solvents and organic volatile impurities (GC), water content (Ph. Eur.).

Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

Residue on ignition (RoI) is not included as an active substance release test because the velpatasvir manufacturing process and the required clarity of solution test provide adequate control for insoluble impurities including inorganic impurities. The absence of RoI test was considered acceptable.

In view of the content of elemental impurities observed, the absence of control of elemental impurities was considered acceptable.

Active substance particle size is not critical for tablet processability, stability, content uniformity, dissolution or appearance because of the finished product manufacturing process. Therefore the absence of active substance particle size control was considered acceptable.

Microbiological examination is not included in the specification for velpatasvir for the following reasons: the relationship between water content and water activity of velpatasvir is well understood, the acceptance limit for water content in velpatasvir ensures microbiological growth is not supported, the active substance container closure system minimizes increase in water content over time, and data are available to show low bioburden of the active substance at release and on stability. The absence of microbiological control was considered acceptable.

The absence of control of PMIs was considered acceptable in view of the control strategy implemented by the active substance manufacturer.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data are provided for 22 batches of velpatasvir ranging from laboratory through pilot to production scale used for non-clinical, clinical and stability studies. All studies have been conducted with the amorphous form of the active substance. The results are within the specifications and consistent from batch to batch.

<div style=\"page-break-after: always\"></div>

## Stability

Stability data were provided on seven batches of active substance stored in a container closure system representative of that intended for the market for up to twelve months under long term conditions at 30 ºC / 75% RH and for six months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines. The sizes of the stability batches were from pilot to production scale and the batches were from the proposed manufacturers.

The following parameters were tested : appearance, assay, impurity content, and water content at each scheduled time point. Microbiological examination is conducted at the initial and annual time points for samples stored under long term storage condition in accordance with USP &lt;61&gt; and &lt;62&gt; or Ph. Eur. 2.6.12. Currently the analytical methods used are the same as for release and for stability studies and are stability indicative. However over the course of clinical development, improvements were made to the analytical methods used to monitor critical quality attributes and stability of the drug substance. A bridging study was conducted by analysing three batches of velpatasvir using the test parameters of the clinical method and the intended commercial method. It has been demonstrated that data obtained using the clinical methods are valid and comparable to data obtained using the intended commercial method.

No significant changes were observed in any of the monitored parameters through the 12 months of storage at long term conditions and 6 months of storage conditions at accelerated conditions compared to the initial values.

Photostability testing following the ICH guideline Q1B was performed on one batch. Results showed that velpatasvir is photolabile. Results on stress conditions (-20 °C during four weeks and 50 °C/ambient conditions during two weeks) were also provided on one batch. Data confirmed that velpatasvir will remain stable at both extreme temperatures.

The stability results indicate that the active substance manufactured by the proposed suppliers is sufficiently stable. The stability results justify the proposed retest period of 24 months when stored in the proposed container.

## Voxilaprevir

## General information

The chemical name of voxilaprevir ethyl acetate solvate is (1a R ,5 S ,8 S ,9 S ,10 R ,22a R )-5tert -butylN -[(1 R ,2 R )-2 (difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8 H -7,10methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide ethyl acetate solvate (1:1) corresponding to the molecular formula C40H52N6O9S.C4H8O2. It has a relative molecular mass of 957.0 g/mol and the following structure:

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Figure 3. voxilaprevir structure

The structure of voxilaprevir was elucidated by 1 H and  13 C NMR, UV spectroscopy, IR spectroscopy, mass spectrometry, elemental analysis and single crystal X-ray crystallography.

It is a white to light brown hygroscopic crystalline solid, practically insoluble in aqueous media across the physiological pH range but very slightly soluble in fed and fasted state simulated small intestinal fluid. Several crystalline forms of voxilaprevir including the crystalline ethyl acetate solvate and the amorphous non-solvated form were identified during development. Voxilaprevir is isolated as a single polymorph of the ethyl acetate solvate. On drying, ethyl acetate can be removed resulting in amorphous voxilaprevir. The ethyl acetate solvate and amorphous non-solvated forms have similar solubility profiles in several organic solvents.

Voxilaprevir contains 8 chiral chiral centres and is produced as a single stereoisomer. The chiral purity of voxilaprevir is controlled through process design and limits in raw material specifications.

Voxilaprevir is considered to be a new active substance. The applicant demonstrated that neither it, nor its derivatives and salts have ever been active substances in products authorised in Europe.

## Manufacture, characterisation and process controls

Voxilaprevir is synthesized in six synthetic steps using well-defined starting materials with acceptable specifications.

CHMP raised a major objection requesting re-definition of one of the proposed starting materials to earlier compounds so that enough of the process is carried out under GMP and declared in the dossier to ensure sufficient regulatory oversight during the product lifecycle. The applicant was unable to accomplish this during the accelerated procedure and so made a commitment to re-define to two earlier starting materials via the appropriate variation. Suitable specifications for the new starting materials will be proposed, validated analytical methods will be presented, and an updated QP declaration will be provided.

The CHMP agreed to this proposal as no immediate concerns with regard to the quality of the alreadymanufactured active substance have arisen due to the lack of GMP control for the additional steps. Nevertheless, the re-definition of starting material is considered essential in ensuring the continued quality of the active substance throughout the product lifecycle.

Adequate in-process controls are applied during the synthesis and critical process parameters have been defined for critical steps. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The characterisation of the active substance and

<div style=\"page-break-after: always\"></div>

its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

The  active  substance  is  packaged  in  a  double  layer  of  closed  PE  bags  stored  inside  a  heat-sealed polyethylene-lined  aluminium  foil  pouch  which  comply  with  the  EC  directive  2002/72/EC  and  EC 10/2011 as amended.

## Specification

The active substance specification re-produced below includes tests for appearance, identity (IR, HPLC), clarity of solution (visual), assay (HPLC), impurities (HPLC), residual solvents (GC) and water content (Ph. Eur.).

A test for RoI is not included as the synthetic process uses few inorganic reagents and historical RoI measurement consistently failed to detect inorganic content. Elemental impurities were evaluated and controlled according to ICH Q3D and routine control of inorganic impurities by the manufacturing process was demonstrated. Adequate controls have been established to ensure batches of voxilaprevir are not capable of sustaining microbial growth.

Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set. Mutagenic and potentially mutagenic impurities were evaluated and controlled according to ICH M7.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data from 19 lab, pilot and production scale batches of the active substance covering the proposed commercial manufacturer as well as another used during development are provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data on 5 pilot to production scale batches of active substance from the proposed manufacturers stored in the intended commercial package for up to 12 months under long term conditions (30 ºC / 75% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. Samples were tested for appearance, assay, impurity content, water content and ethyl acetate content. The analytical methods are the same as those used for release. Microbial enumeration tests were carried out on an annual basis. No significant changes to any of the measured parameters were observed under either condition.

Photostability testing following the ICH guideline Q1B was performed on one batch. Results indicate that voxilaprevir is not photosensitive.

One batch was exposed to stressed conditions (-20  o C, 60 o C, 80 o C) in the solid state. No significant degradation was observed. The sample was also exposed to moist heat and aqueous base, acid and oxidant. Degradation was observed in all media and indicates that the analytical methods used are stability indicating.

The stability results indicate that the active substance manufactured by the proposed manufacturers is sufficiently stable. The stability results justify the proposed retest period of 24 months stored below 30 o C in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is an immediate release fixed dose combination of three active substances formulated as beige capsule-shaped film coated tablets embossed with 'GSI' on one face and '3' on the other. The quantitative composition is shown below.

Sofosbuvir exhibits high aqueous solubility but low apparent permeability and is thus a BCS class 3 molecule. The present formulation contains the same or similar excipients to those used in other marketed products containing sofosbuvir (Sovaldi, Harvoni and Epclusa) and draws on the experience gained from developing those formulations.

Both voxilaprevir and velpatasvir are poorly soluble in aqueous media. Velpatasvir is poorly permeable (BCS 4) whereas voxilaprevir is highly permeable (BCS 2). Therefore, approaches to development focussed on maximising dissolution rate whilst maintaining chemical and physical stability. The formulation drew on experience gained during development of Epclusa tablets.

Mutual compatibility of the 3 active substances was demonstrated by co-formulating them in the same ratio as in the finished product and carrying out a stability study under ICH conditions. No significant degradation was observed. Compatibility with excipients was monitored during formulation development and all three active substances were found to be stable with the excipients used in the proposed commercial formulation. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards except for the film coating material, Opadry II beige, which is tested according to an in-house standard and the colorant, iron oxide, contained in Opadry II beige, which complies with EU regulations. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

Voxilaprevir was initially formulated as a single agent tablet for use in phase 1 and 2 clinical trials. The tablet used in phase 3 trials contained all 3 active substances and is the same formulation proposed for commercialisation. Relative bioavailability studies were used to demonstrate similar pharmacokinetic behaviour of the various formulations.

Finished product critical quality attributes (CQAs) were identified using QbD principles. The impact of raw material and intermediate material attributes on the CQAs was evaluated and suitable limits were set for relevant attributes in the intermediates. Target set-points and PARs were defined for critical steps of the manufacturing process and were considered justified.

The dissolution method needed to take into account the different physicochemical properties and stability profiles of the three active substances. Development of the dissolution method has been described. The method was evaluated against meaningful changes in process parameters and input material attributes. Given the nature of the formulation, and overall control strategy, the dissolution method is considered to be sufficiently discriminatory.

The primary packaging is a white HDPE bottle with a PP continuous thread child-resistant cap, lined with induction activated aluminium foil. Each bottle contains silica gel desiccant and polyester coil. The materials comply with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

<div style=\"page-break-after: always\"></div>

## Manufacture of the product and process controls

The manufacturing process consists of 3 parts: preparation of the two finished product intermediates followed  by  manufacture  of  the  finished  product.  Suitable  specifications,  holding  times,  and  storage conditions  have  been  defined  for  the  intermediates.  The  intermediates  are  made  by  feed  solution preparation, drying, secondary drying, and packaging.

The manufacturing process of the finished product consists of 6 main steps: blending and milling of sofosbuvir,  the  intermediates,  and  intra-granular  excipients;  roller  compaction;  milling  and  blending with extra-granular excipients; compression; film-coating; packaging. The process is considered to be a standard manufacturing process.

Critical steps in the manufacture of the finished product have been defined. The process for production of one intermediate has been validated on commercial scale. The process for production of the other will be validated on commercial scale prior to circulation, although manufacture of clinical batches on a slightly smaller scale has demonstrated robustness of the process. An acceptable validation protocol has been presented. Manufacture of the film-coated tablets will be carried out prior to commercialization and a suitable validation protocol has been provided. It has been demonstrated that the  manufacturing  process  is  capable  of  producing  the  finished  product  of  intended  quality  in  a reproducible manner. The in-process controls are adequate for this type of manufacturing process and pharmaceutical form.

## Product specification

The finished product release specifications (Table 5) include appropriate tests for this kind of dosage form including appearance, identification (HPLC, UV), water content (Ph. Eur.), strength (assay, UPLC), degradation products (UPLC), uniformity of dosage units (Ph. Eur.), dissolution (UPLC) and microbiological examination (Ph. Eur.). No test for elemental impurities is required, in line with ICH Q3D, as each elemental impurity tested was well below 30% of its PDE.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for 7 pilot and 1 production scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data from 4 batches (17-22% of proposed commercial batch size) of finished product stored under long term conditions (30 ºC / 75% RH) for up to 18 months at and for up to 6 months under accelerated conditions (40 ºC / 75% RH), according to the ICH guidelines, were provided. The batches are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.  Samples  were  tested  for  appearance,  water  content,  strength,  degradation  products, dissolution, and microbiological examination. The analytical procedures used are stability indicating. No significant  changes  to  any  of  the  measured parameters  were  observed  and  all  remained  well  within specifications under both sets of conditions.

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. Stressed studies were also carried out at -20  o C and 60  o C for 2 weeks. Results indicate that the tablets are stable to all tested conditions and are not photosensitive.

<div style=\"page-break-after: always\"></div>

Stability of the intermediates was also evaluated under ICH long term and accelerated conditions as for the  film-coated  tablets.  No  significant  changes  to  any  of  the  measured  parameters  were  observed under either set of conditions. A photostability study was also carried out, along with stressed studies at -20 and 60  o C. Although the intermediates are both hygroscopic and photosensitive, the proposed packaging provides adequate protection.

Based on available stability data, the proposed shelf-life of 24 months stored in the original package to protect from moisture as stated in the SmPC (section 6.3) is acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substances and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, discussed further in section 2.2.6.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP notes that the applicant has agreed with the Committee's recommendation to re-define one starting material and will provide the relevant information via the appropriate post-approval variation which will be submitted by January 2018.

- to redefine one of the starting materials for synthesis of voxilaprevir to agreed upstream compounds.
- to update the relevant sections of the documentation (such as S.2.2 and S.2.3) after the redefinition. A non-comprehensive list of changes include:
- o All GMP-starting material manufacturers should be stated with names and addresses
- o The syntheses of the GMP-starting materials from all suppliers should be described
- o Specifications for the re-defined GMP-starting materials should be provided

An updated QP-declaration, based on on-site audits, should be presented.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Hepatitis C virus (HCV) infection is a global health challenge with an estimated 150 million individuals infected worldwide (World Health Organization (WHO) 2015). The disease burden of HCV infection is due to progression of chronic liver disease, which can lead to cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. Globally, 27% of all cirrhosis and 25% of all HCC are attributable to HCV infection (Perz et al 2006).

Within the last 5 years, HCV treatment has been transformed by the development and approval of direct-acting antiviral agents (DAAs) that target viral proteins and cellular processes essential to HCV replication. These treatment regimens are well tolerated and effective, resulting in the cure of HCV infection in ≥ 95% of treated patients (Foster et al 2015; Feld et al 2015). There is, however, a population of patients who fail DAA-based therapies. The present application concerns a DAA combination of 3 drug classes that may offer improved efficacy for patients who have failed prior DAA treatment.

The non-clinical package in support of this application is based on the non-clinical studies of the individual components SOF and VEL, as well as new non-clinical studies conducted on VOX. A few nonclinical studies on SOF and VEL have been identified as new, notably the VEL transgenic mouse carcinogenicity study and three impurity qualification studies. Novel data with voxilaprevir are presented. There are no nonclinical pharmacology data with the triple combination SOF+VEL+VOX.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## Sofosbuvir

Sofosbuvir is a HCV non-structural protein (NS)5B polymerase nucleotide inhibitor that demonstrates potent in vitro inhibition of HCV replicon ribonucleic acid (RNA) replication. Sofosbuvir has been approved for use once daily for the treatment of chronic HCV infection in adults. Sofosbuvir is a nucleotide prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate that is converted to the active uridine analogue triphosphate form (GS 461203) within the hepatocyte. GS-461203 is incorporated by the HCV NS5B polymerase during HCV RNA replication, and acts to inhibit RNA replication via chain termination. SOF exhibits broad genotypic coverage in genotypes 1 to 6 replicon assays.

## Velpatasvir

Velpatasvir is a HCV NS5A inhibitor that has displayed potent in vitro inhibition of HCV RNA replication across genotypes 1 to 6 in replicon cell lines. The non-structural protein 5A (NS5A) protein of HCV is an essential viral protein that plays roles in both viral RNA replication and the assembly of HCV virions. Experimental data support the conclusion that VEL targets NS5A as its mode of action.

## Voxilaprevir

Voxilaprevir is a macrocyclic HCV NS3/4A protease inhibitor (PI) which exhibits antiviral activity against HCV genotypes 1 to 6 and has improved resistance profile compared with previous HCV PIs.

<div style=\"page-break-after: always\"></div>

## Secondary pharmacodynamic studies

## Sofosbuvir

Sofosbuvir was studied for cytotoxicity with multiple cell lines. The concentration resulting in 50% cytotoxicity was &gt;50 μM for all cell lines. Sofosbuvir showed no mitochondrial toxicity at concentrations up to 100 μM. Sofosbuvir showed no activity against host DNA and RNA polymerases

In a screen with a panel of receptors, enzymes and ion channels, sofosbuvir at 10 μM did not show greater than 50% inhibition at any target.

## Velpatasvir

Velpatasvir was tested for antiviral effect with a large panel of viruses. Velpatasvir did not show any activity against any virus in the panel. Velpatasivr was studied for cytotoxicity with 4 human cell lines. The concentration resulting in 50% cytotoxicity was &gt;44 μM for three of the cell line and 4 μM for one of the cell lines. At 10 μM, velpatasivr did not show &gt;50% inhibition with any of the targets in a standard screen.

## Voxilaprevir

The activity of VOX was tested against multiple other viruses besides HCV. These viruses included BVDV, a virus that belongs to the same virus family as HCV (Flaviviridae), and 5 unrelated viruses including RSV, HRV, influenza virus (FLU), HBV, and HIV. VOX showed no relevant activity to any of these viruses.

The in vitro cytotoxicity of VOX was evaluated in human cell lines of various tissue origins, including 2 hepatic cell lines (Huh 7 and HepG2), the prostate carcinoma cell line PC 3, the T lymphoblastoid MT 4 cell line, and the normal diploid lung derived MRC 5 cell line. The results indicate that VOX had a low level of cellular cytotoxicity and provided &gt; 1000 fold selectivity relative to the antiviral activity across all cell lines tested.

VOX was tested for its ability to inhibit 5 mammalian proteases including 3 serine proteases. Voxilaprevir had &gt; 400,000 fold selectivity against all mammalian proteases tested.

Voxilaprevir was screened against a panel of receptors, ion channels, and transporters. Although significant binding (IC50 0.74 µM) was observed to the tachykinin, neurokinin (NK) 1 receptor, only weak antagonist activity (approximately 33% inhibition at 10 µM) was subsequently demonstrated which is &gt; 11,000 fold above the estimated free drug concentration (0.0024 µM) at the mean VOX Cmax  with the SOF/VEL/VOX FDC.

## Safety pharmacology programme

## Sofosbuvir

There were no findings in any study suggesting a potential for clinically relevant adverse neurological, cardiovascular, or respiratory effects.

<div style=\"page-break-after: always\"></div>

## Velpatasvir

There were no findings in any study suggesting a potential for clinically relevant adverse neurological, cardiovascular, or respiratory effects.

## Voxilaprevir

The potential neurological effects of VOX when administered as a single dose via oral gavage were assessed in male Sprague Dawley rats. No VOX-related effects were observed on mortality, clinical observations, or neurological function up to 48 hours post-dose. The VOX NOEL for neurological function for male rats is 100 mg/kg, the highest dose administered.

The in vitro effects of VOX on the hERG channel current, a surrogate for IKr, the rapidly activating delayed rectifier cardiac potassium current, was assessed at near-physiological temperature. Due to solubility limitations under conditions of the assay, the IC50 for the inhibitory effect of VOX on hERG potassium current was not calculated but was estimated to be greater than 30  M.

The potential CV effects of VOX were evaluated when administered via oral capsule to instrumented male Beagle dogs. No VOX-related mortality; morbidity; clinical observations; or effects on body weight, food consumption, or body temperature occurred, and no effects on ECG and hemodynamic parameters were observed up to 20 mg/kg, the highest dose tested.

The effects of orally administered VOX on respiratory function was assessed in Sprague Dawley rats. No VOX-related effects on respiratory function were observed up to 48 hours post-dose. Based on these results, the NOEL for respiratory function in male rats is 100 mg/kg VOX, the highest dose administered.

## 2.3.3. Pharmacokinetics

Studies on pharmacokinetic drug interactions are presented in the section on clinical pharmacokinetics.

No novel studies on nonclinical pharmacokinetics have been performed with sofosburvir (SOF) or velpatasvir (VEL). For these components of the FDC, the application is based on the nonclinical pharmacokinetics documentation previously assessed in the MAA procedures for Sovaldi (SOF) and Epclusa (SOF+VEL). Novel data with voxilaprevir (VOX) are presented. There are no nonclinical pharmacokinetics data with the triple combination SOF+VEL+VOX

## Sofosbuvir

Sofosbuvir is a nucleotide prodrug and requires activation in hepatocytes to form the pharmacologically active triphosphate metabolite, GS 461203. In rodents, administration of sofosbuvir resulted in the rapid appearance of the metabolite GS-331007 in plasma and liver. Sofosbuvir was not detected in mice or rats immediately following administration (as early as 15 minutes), suggesting rapid conversion to GS-331007 by plasma esterase. The pharmacologically active metabolite, GS.461203 was efficiently formed in rat liver.

Protein binding of SOF was low (&lt; 70%). After oral administration of [14C]SOF to pigmented and nonpigmented rats, drug-related material was rapidly absorbed and widely distributed to tissues. The lowest concentrations of total radioactivity were observed in the CNS, bone, eye lens, and white adipose. Elimination of radioactivity from tissues was nearly complete at the last time point (144 or 168 hours post dose), with most tissue concentrations decreasing to below limit of quantification by 48

<div style=\"page-break-after: always\"></div>

hours post dose. There was no evidence for a specific association of SOF or its metabolites with melanin in rats.

## Velpatasvir

Velpatasvir was highly protein bound in plasma from all species (&gt; 99.5% bound). After oral administration of [14C]VEL to mice and to pigmented and non-pigmented rats, drug-related material was quickly distributed to most tissues, especially the liver. Although VEL likely binds to melanin, it is quickly removed from pigmented skin. Low levels of radioactivity were transiently detected in mouse brain and in mouse and rat testes, suggesting that [14C]VEL-derived radioactivity poorly crossed the blood:brain barrier in mice and the blood:testis barrier in mice and rats.

## Voxilaprevir

Single-dose intravenous and oral PK of VOX was evaluated in Sprague-Dawley rat, beagle dog, and cynomolgus monkey.

Voxilaprevir was highly protein bound in plasma from all species tested (&gt; 99% bound). The tissue distribution of [14C]VOX was determined from 0.5 to 168 hours after a single oral dose administered to intact male Sprague Dawley and Long Evans rats. [14C]VOX derived radioactivity was widely distributed to most tissues by 2 to 4 hours post-dose. Most of the tissues reached Cmax by 4 to 8 hours post-dose and radioactivity was eliminated from all tissues by 48 hours. Generally, the radioactivity was preferentially distributed into organs of elimination. The tissues showing the highest maximum concentrations of radioactivity included liver, kidneys, and adrenal gland. Low levels of radioactivity were detected in brain, eyes and testis(es), suggesting that [14C]VOX derived radioactivity poorly crossed the blood:brain, blood:eye, and blood:testis(es) barriers. Distribution trends in pigmented and non-pigmented rats suggested that VOX did not preferentially associate with melanin.

Characterisation of in vivo metabolites in rats, dogs and humans were performed using [14C]VOX with the radiolabel introduced at the carbonyl of the carbamate group. VOX was the only analyte detected in plasma of all species.

The excretion of radioactivity was determined after administration of a single oral dose of [14C]VOX at 30 mg/kg to male bile duct intact and BDC Sprague-Dawley rats, and at 10 mg/kg to male bile duct intact and BDC beagle dogs. In BDC rats administered [14C]VOX labelled on the carbonyl of the carbamate group, a mean of 72.4%, 22.6%, and 0.163% of the administered radioactivity dose was excreted in faeces, bile, and urine, respectively. In BDC dogs, a mean of 63.3%, 21.9%, and 0.204% of the administered radioactivity was excreted in faeces, bile, and urine, respectively.

## 2.3.4. Toxicology

The toxicology documentation provided for sofosbuvir (SOF) and velpatasvir (VEL) in support of the fixed dose formulation is, with a few exceptions, the same as for the individual components. For voxilaprevir (VOX), a full toxicology program in accordance with ICH M3 has been conducted. The rat and dog were used as toxicology species for the pivotal 6- and 9-month repeat-dose toxicity studies, respectively. The choice of species was based on the results of non-clinical pharmacokinetic studies, showing similar metabolism and elimination profiles in rats, dogs and humans (see Pharmacokinetics). All repeat-dose toxicity studies utilized oral administration (oral gavage in rodents, gelatin capsules in dogs) as this is the clinical route of administration.

<div style=\"page-break-after: always\"></div>

## Single dose toxicity

The lethal dose of SOF following oral dosing in rats was greater than 1800 mg/kg. No formal single dose toxicity studies with VEL have been conducted. Single doses up to 600 mg/kg in rats and 200 mg/kg in dogs were well tolerated in pharmacokinetic studies.

No formal single-dose toxicity studies with VOX have been conducted. Single doses up to 300 mg/kg in rats and 40 mg/kg in dogs were well tolerated in pharmacokinetic studies. In the rat micronucleus study, 2 doses of either 500, 1000, or 2000 mg/kg were administered 24 hours apart. One of 3 rats from each of the 500 and 1000 mg/kg groups was found dead on Day 3, at exposures &gt; 800-fold higher than the clinical AUC.

## Repeat dose toxicity

## Sofosbuvir

SOF has been evaluated in repeat-dose oral toxicity studies in mice (up to 3 months), rats (up to 6 months) and dogs (up to 9 months).Target organs for toxicity were the heart, liver, gastrointestinal (GI) tract, and haematopoietic cells.

## Heart

Myocardial degeneration was observed in the 7-day rat study, at a high dose (2000 mg/kg/day). In longer duration studies, no cardiac toxicity occurred at 5-fold exposure levels to clinical AUC. Vacuolar degeneration of the myocardial muscle fibres was observed in a pre-terminally killed dog in the 9month study. No histopathological myocardial changes were observed in other dogs, in any of the conducted studies.

QT prolongation was present in male dogs dosed at 1500 mg/kg/day in the 7-day study, but did not occur in the longer term dog studies. The systemic exposure (Cmax) to GS-331007 (predominant metabolite) was 69-fold higher than the clinical exposure in patients treated with the combination of SOF (400 mg)/VEL (100 mg)/VOX (100 mg).

## GI tract

Diarrhoea and other clinical signs related to effects on the GI tract occurred both in rats and dogs. In some studies, the GI effects were associated with decreased body weight/body weight gain and decreased food consumption. Margins to clinical exposure were generally small (2-fold based on AUC). Haemorrhage was observed in the lamina propria of occasional dogs across the studies.

## Liver

Increased liver weights were observed in both rats and dogs, correlating with hepatocellular hypertrophy in dogs and an increase in CYP2A1 activity in rats. In dogs administered 1500 mg/kg/day for 7 days, hepatocyte apoptosis, microvesiculation, decreased intracellular glycogen, and Kupffer cell pigmentation were observed. These findings were associated with increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and bilirubin. There was also mononuclear cell infiltration in the gall bladder. Except for the decreased glycogen, the margin to the NOAEL for these effects was 8-fold based on AUC. All histopathological liver findings and associated clinical chemistry changes in the 7-day dog study were reversible after a 14-day recovery period. No histopathological liver findings were present in the longer term dog studies at doses up to 500 mg/kg/day, corresponding to a 15-fold exposure margin (GS-331007) as based on AUC in the 9-month study.

<div style=\"page-break-after: always\"></div>

## Haematopoietic cells

Effects on erythropoiesis were present in the 7-day rat study and in all dog studies, from 7 days up to 9 months. The lowest exposure margin to NOAEL in dogs for these effects was 4- to 5-fold, as based on AUC (dog 1-month study). Haematology analysis showed decreased red blood cell count and lower haemoglobin and/or haematocrit concentrations. The decreased erythron mass was reflected in bone marrow changes such as lower percentage of erythroid precursors and depression of erythropoiesis. Both the peripheral and bone marrow changes were reversible.

## Velpatasvir

In repeat-dose studies up to 4 week in mice, 26 weeks in rats and 39 weeks in dogs, no specific target organs were identified. In the mouse, lower mean white blood cell count, absolute neutrophil, and absolute lymphocyte count were observed in males administered 1500 mg/kg/day. In the 39-week dog study, a slight increase in the incidence of vomitus was observed at 100 mg/kg/day. Females at 100 mg/kg/day showed lower food consumption, decreased fibrinogen and globulin concentrations and increased albumin:globulin ratio. Exposure (AUC) at NOAELs was 3- to 5-fold (rat) and 6- to 7-fold (dog) above clinical exposure following combination treatment with SOF/VEL/VOX.

## Voxilaprevir

In repeat-dose toxicity studies up to 6 months (rat) and 9 months (dog), the haematopoietic cells, hepatobiliary system, GI tract, and kidney, were identified as target organs of toxicity.

## Haematopoietic cells

In all rat studies at doses &gt; 30 mg/kg/day, decreased red blood cells, haematocrit and haemoglobin, accompanied by increased reticulocytes and red cell distribution width, were observed. Mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC) were decreased at higher dose levels, probably reflecting the increased absolute reticulocyte count. The peripheral haematological changes were correlated with higher spleen weights, and increased extramedullary haematopoiesis in the spleen, as well as increased cellularity in the bone marrow. The findings were fully reversible.

According to the Applicant, the most likely mechanism behind the observed effects was blood loss in the non-glandular stomach, leading to a compensatory erythroid regenerative response. However, there was no microscopic evidence of haemorrhage in the pivotal toxicity studies, only in a 5-day nonGLP study. Margins between the lowest NOAEL (10 mg/kg/day in the 3-month study) and clinical exposure (AUC) were 1- to 2-fold.

## Hepatobiliary system

Two types of liver effects were observed in rats: increased liver weight probably associated with CYP450 induction (4.5-fold increase in CYP3A activity in females at 100 mg/kg in the 14-day study), and minimal bile duct hyperplasia in females. The first effect is considered adaptive and non-adverse. The bile duct hyperplasia occurred at 100 mg/kg/day in the 3-month study, but at &gt; 30 mg/kg/day in the 6-month study, indicating that longer term treatment may cause changes at clinically relevant dose levels (exposure margin based on AUC at the lowest NOAEL = 2-fold). However, there was no progression of severity of the change over time. Bile duct hyperplasia was not reversible following a 1month recovery period.  Increased ALT, ALP and bilirubin, and decreased total protein, albumin and globulins were observed in rats at corresponding dose levels where bile duct hyperplasia was seen, but there was no obvious correlation with bile duct hyperplasia.

<div style=\"page-break-after: always\"></div>

Dogs showed minimal to slight epithelial vacuolation in the gall bladder at &gt; 3 mg/kg/day, in all studies (14 days to 9 months). At &gt; 10 mg/kg/day, additional changes in the form of minimal to slight epithelial hyperplasia and minimal to moderate mononuclear cell infiltration were observed. In the 9month study, gall bladder vacuolation showed partial reversibility while hyperplasia was not reversible following the 4-week recovery period. Exposure (AUC) at the NOAEL for these effects was in the same range as the clinical exposure level.

## GI system

In all rat studies, effects on the non-glandular stomach suggestive of local irritation were observed. The changes comprised minimal to moderate epithelial hyperkeratosis/hyperplasia, mixed cell infiltration and edema, and (in a 5-day non-GLP study) hemorrhage and erosions/ulcerations. In the 3and 6-month studies, there was also edema and mixed cell infiltration in the submucosa of the glandular stomach. Effects on the non-glandular/glandular stomach were seen at doses &gt; 70 mg/kg/day and were fully reversible. Increased white blood cell count, lymphocytes, neutrophils and other subsets of white blood cells were observed in all rat studies and may possibly be linked to the inflammatory changes in the non-glandular/glandular stomach. GI effects in rats occurred at exposure levels &gt; 45-fold above (pivotal toxicity studies) or 33-fold above (5-day non-GLP study) above clinical AUC and are thus not considered clinically relevant.

In dogs, increased vomiting was observed in all studies, at &gt; 10 mg/kg/day. In the 3-month study, two females at 15 mg/kg/day showed minimal to slight neutrophil infiltration with minimal hemorrhage or erosion in the caecum/rectum. Exposure at NOAEL for GI effects in dogs was in the same range as the clinical exposure level.

## Kidney

In the 14-day and 3-month rat studies, increased kidney weights, higher urine volume and urobilinogen, and lower urine specific gravity, were observed at 100 mg/kg/day. Inorganic phosphorus was increased, and potassium, sodium and chloride decreased, in serum. In the 6-month rat study, similar effects on serum electrolytes and urine parameters were present at 70 mg/kg/day (increased urobilinogen at &gt; 30 mg/kg/day), but no increased kidney weight was observed. The increase in urobilinogen was most likely associated with an increase in serum bilirubin, supposedly linked to OATP inhibition. The majority of effects were fully reversible.

In dogs, minimal tubular epithelial vacuolation was observed in the kidney at &gt; 10 mg/kg/day in the 3month study, but not in the 9-month study at similar or higher exposures. There were no changes in serum electrolytes or urine parameters. In the 14-day dog study, increased urobilinogen was observed in females at 20 mg/kg, correlating with increased serum bilirubin possibly linked to OATP inhibition.

The mechanism behind the renal effects other than increased urobilinogen is not clear. The effects occurred at high exposure margins (&gt; 45-fold) in rats, were not seen in the 9-month dog study, and are considered non-adverse in nature. Therefore, the observed renal effects are considered to be of no or limited clinical relevance.

## Other changes

Some changes in serum chemistry parameters and organ weights were sporadically observed in the repeat-dose toxicity studies with VOX. Since these changes were not consistently observed, and were not associated with any histopathological alterations, they are not considered toxicologically relevant. Inflammation in the prostate gland was observed in two dogs treated with 10 and 20 mg/kg/day, respectively, in the 3-month study. Since this is a common spontaneous background finding in Beagle

<div style=\"page-break-after: always\"></div>

dogs, and no prostate changes were present in the 9-month study, it is not considered toxicologically relevant.

## Sofosbuvir/velpatasvir/voxilaprevir

The Applicant did not perform any combination repeat-dose toxicity study, based on the contention that there was no overlapping toxicity at clinically relevant exposures and thus the combination product is unlikely to exacerbate toxicities of the individual agents. This is acceptable (see Discussion on Non-clinical aspects).

## Genotoxicity

A complete package of genotoxicity studies in agreement with the ICH S2 (R1) guideline, including tests for gene mutations and chromosomal aberrations in vitro , and chromosomal aberrations in vivo , has been performed with SOF, VEL and VOX as individual substances. All tests were negative. Based on the results of the conducted genotoxicity studies, the overall conclusion is that none of the substances has any genotoxic potential. No combination genotoxicity studies were performed. In accordance with ICH M3, combination genotoxicity studies generally are not recommended to support clinical trials or marketing if the individual agents have been tested according to current standards. No additional studies are considered necessary.

## Carcinogenicity

## Sofosbuvir

There was no evidence of a carcinogenic effect after 2-year daily oral gavage administration of SOF to rats or mice. At the highest doses tested, exposures to the main metabolite GS-331007 were 3.7/16.7 (male/female) and 7.5/9.8 (male/ female) times higher in mice and rats, respectively, as compared to the clinical exposure when SOF 400 mg is given in combination with VEL/VOX.

## Velpatasvir

There was no evidence of a carcinogenic effect of VEL in a 6-month oral carcinogenicity study in transgenic RasH2 mice. At the highest dose tested (1000 mg/kg/day), the exposure (extrapolated from a dose-range finding study) was &gt; 40-fold above clinical exposure levels.  A 2-year carcinogenicity study in Sprague Dawley rats is ongoing; thus it is not possible to conclude fully on the carcinogenic potential of VEL at the moment.

## Voxilaprevir

In accordance with ICH S1A, carcinogenicity studies have not been conducted as treatment with VOX-containing regimens will be less than 6 months. This is acceptable.

Combination carcinogenicity studies are not considered warranted.

<div style=\"page-break-after: always\"></div>

## Reproductive toxicity

## Fertility and early embryonic development

Sofosbuvir and velpatasvir had no adverse effects on fertility and early embryonic development in rats, at exposure margins (AUC) in the range of 3- to 6-fold above the clinical exposure when the substances are administered in combination (SOF 400 mg/VEL 100 mg/VOX 100 mg).

Voxilaprevir had no adverse effects on fertility and early embryonic development in rats treated up to 100 mg/kg/day, corresponding to exposure margins (AUC) 129-fold and 170-fold, in males and females respectively, above the clinical therapeutic exposure of VOX as given in combination with SOF/VEL.

## Embryo-foetal development

Sofosbuvir did not affect intrauterine growth and survival, or external, visceral, and skeletal foetal morphology, at doses up to 500 mg/kg/day in rats (NOAEL). The exposure (AUC) of GS-331007 at this dose level was 6-fold above the clinical exposure of SOF as given in combination with VEL/VOX. Pregnant rabbits tolerated daily oral doses of SOF up to 300 mg/kg during the period of major organogenesis without any adverse effects on either the dams or developing foetuses. The NOAEL for developmental toxicity was 300 mg/kg/day, corresponding to exposure margins of 5- and 15.6-fold above clinical AUC for SOF and its metabolite GS-331007, respectively.

Velpatasvir did not cause maternal or embryo-fetal toxicity in mice and rats up to the highest doses tested (1000 mg/kg/day in mice, 200 mg/kg/day in rats). Exposure margins were 23-fold (mouse) and 4-fold (rat) above the clinical exposure (VEL 100 mg given in combination with SOF/VOX). In rabbits, there was an increase in visceral malformations in rabbits administered 100 and 300 mg/kg/ day VEL compared to vehicle control animals. Although malformations were at a low incidence, mostly seen in a single fetus, showed no clear dose-relationship, or did not exceed historical control ranges, a possible teratogenic effect of VEL could not be excluded. The NOAEL for maternal toxicity was 100 mg/kg/day and the LOAEL for embryo-fetal development was 100 mg/kg/day. At the developmental LOAEL in rabbits, the exposure margin was 0.5-fold compared with the clinical exposure (AUC of VEL when given in combination with SOF/VOX). The text in sections 4.6 and 5.3 of the proposed SmPC contains adequate information concerning the possible teratogenic effect of VEL, and is identical with the text in the SmPC for Epclusa.

Voxilaprevir at doses up to 100 mg/kg/day in rats and 600 mg/kg/day in rabbits did not cause adverse maternal or foetal toxicity. The exposure margins at the NOAELs were 141- and 3.5-fold higher, in rats and rabbits, respectively, than the clinical exposure of VOX when administered in combination with SOF/VEL.

In the rabbit EFD study, some variations (increased incidences of supernumerary branch of the carotid artery, supernumerary spleen, and pre-sacral vertebra-27) were observed at higher incidence in the VOX-treated groups. The Applicant provided historical control data from the testing facility, showing that the incidences were within historical control ranges and thus may be regarded as incidental background findings.

## Pre- and postnatal development

Sofosbuvir at doses up to 500 mg/kg/day had no maternal effects, and caused no effects on behaviour, reproduction, or development of the offspring in rats. Maternal AUC exposure to the

<div style=\"page-break-after: always\"></div>

metabolite GS-331007 was 83.3 μg·h/ml on LD10, corresponding to a 6.5-fold margin to clinical exposure when SOF is administered in combination with VEL/VOX.  F1 pups were found to be exposed to ~50 times lower levels of GS-331007 (AUC0-24 1.5 μg·h/ml in the 500 mg/kg/day group) on PND10.

Velpatasvir at doses up to 200 mg/kg/day in rats had no maternal effects, and no effects on behaviour, reproduction, or development of the offspring. VEL maternal exposure (LD10 AUClast 13.9 μg·h/mL) at the maternal and F1 offspring NOEL in the pre- and postnatal development study was 3-fold higher than the clinical exposure of VEL when administered in combination with SOF/VOX.

Voxilaprevir at doses up to 100 mg/kg/day in rats had no maternal effects, and caused no effects on survival and general development of F1 offspring except for slightly lower pre- and early post-weaning body weight at 100 mg/kg/day (normalized during the latter half of the post-weaning period). Reproductive performance of F1 offspring was not affected by treatment with VOX. The auditory startle response as tested on PND60 (sexual maturity) showed lower PEAK values in mainly females at all dose levels. No similar clear effect was seen at PND20 (with the exception of a minor transient effect in male pups). The differences in response are encompassed within the historical control data and there was no consistent dose-response profile or sex-specific response. In addition, males at &gt; 30 mg/kg/day showed longer mean time to escape and higher mean number or errors in the first 5 trials out of 12 trials in total in the Biel maze swimming test on PND22 but not at PND62. It is unclear if this indicates a minor initial male-specific learning effect on PND22 but there were no overall effects across the whole study (male or female).

## Juvenile toxicity

No juvenile toxicity studies have been conducted with SOF, VEL or VOX. This is acceptable, since the presently sought indication of SOF/VEL/VOX is confined to the adult population.

## Local tolerance

Sofosbuvir caused emesis (dog) and soft stools/diarrhea (dog, rat) in the oral repeat-dose toxicity studies. These effects may partly have been vehicle-related. SOF is predicted to be a non-corrosive/ non-severe eye irritant based on results from an in vitro Bovine Corneal Opacity and Permeability (BCOP) assay and was classified as a non-irritant in a dermal irritation study in rabbits.

Velpatasvir did not have any notable effects on the GI tract, as evaluated in oral repeat-dose toxicity studies in rats and dogs. VEL was classified as a non-irritant to skin, and was not considered a severe irritant to eyes.

## Voxilaprevir

The local tolerance of VOX in the GI tract was evaluated in the repeat-dose toxicity studies in rats and dogs. Inflammation and hyperplasia/hyperkeratosis in the rat non-glandular stomach, and inflammation/edema in the glandular stomach, indicate a potential for GI irritancy. However, since these effects occurred at exposure margins &gt; 45-fold relative to the clinical exposure they are not considered clinically relevant. VOX was classified as a non-irritant to eye (BCOP assay) and skin (in vitro EPISKIN test).

<div style=\"page-break-after: always\"></div>

## Antigenicity

The skin sensitization potential of SOF, VEL and VOX was investigated in the murine local lymph node assay (OECD 429). The results indicate that none of the drugs are skin sensitizers.

## Impurities

## Sofosbuvir

With the present application, a new single-dose study in rats with a 14-day recovery period was submitted (TX-334-2013). The purpose was to determine if there were any unexpected toxic effects from SOF drug substance. Two different batches of SOF at 500 mg/kg/day were administered to Sprague Dawley rats. Exposure was similar following dosing with both lots, and no adverse effects were observed.

## Velpatasvir

With the present application, two single-dose studies in rats with 14-day recovery phases were submitted (TX-281-2044, TX-281-2045). The purpose was to determine if there were unexpected toxic effects from VEL . No adverse treatment-related effects were observed and there were no differences in exposure between animals treated with material and comparator lots.

## Voxilaprevir

Potential VOX-related process impurities were evaluated in a 2-week repeat-dose oral gavage toxicity in rats, using two different lots administered up to 30 mg/kg/day. Exposure was similar with both lots. No adverse effects were observed. In the liver, minimal to slight Kupffer cell hypertrophy was observed in all groups including vehicle-treated controls, and was most likely a vehicle-related effect.

## Phototoxicity

## Sofosbuvir

No phototoxicity study has been performed with SOF. This is acceptable since SOF was shown not to absorb light within the range of 290 to 700 nm and since no accumulation in dermal or ocular tissues has been detected.

## Velpatasvir

VEL was positive in the Balb/c 3T3 neutral red uptake phototoxicity assay. In an in vivo phototoxicity study in Long-Evans rats, VEL at doses up to 200 mg/kg/day (4-fold exposure margin versus clinical Cmax) did not produce any reactions indicative of phototoxicity.

## Voxilaprevir

VOX was positive in the Balb/c 3T3 neutral red uptake phototoxicity assay. In an in vivo phototoxicity study in Long-Evans rats, VOX at doses up to 100 mg/kg/day (190-fold exposure margin versus clinical Cmax) did not produce any reactions indicative of ocular or cutaneous phototoxicity.

<div style=\"page-break-after: always\"></div>

## Other studies

The Applicant has provided acceptable justification for not having conducted stand-alone immunotoxicity studies, or studies on dependency and metabolites.

## 2.3.5. Ecotoxicity/environmental risk assessment

## Sofosbuvir (SOF):

Neither the pro-drug (SOF) nor its active moiety (GS-461203) enter the environment at &gt;10% of the administered dose. The ERA is therefore based on the drug residue GS-331007 (2'-Deoxy-2'-fluoro-2'C-methyluridine) which is detected in total excreta at &gt;10% of the applied radioactive dose (GS331007 accounted for 79.6%). GS-331007 is highly hydrophilic with a n-octanol/water partition coefficient at log KOW = -0.576, i.e. not triggering a PBT assessment. A prevalence-based Fpen of 0.052 (representing Italy as the EU member state with the highest HCV prevalence) was used to calculate the predicted environmental concentration in surface water (PECSW). This gave PECSW = 10.4µg/L for GS-331007 (&gt;&gt;0.01 µg/L action threshold), triggering ERA phase II assessment. GS331007 was found to be degraded in surface waters (i.e. non-persistent) but also partition significantly to sediment with &gt;10% of AR (from day 3 and onwards). It has low adsorption to activated sludges and soils (Koc &lt; 10 000L/kg). Also, GS-331007 transformation products have been detected. One major transformation product (&gt;10%) was measured in a water-sediment system at Day 100 (41.1% and 36.8% applied radioactivity or AR) in the silt loam and sand systems, respectively. The major transformation product is not likely to exhibit toxicity greater than the parent SOF compound; the total residue approach is adopted and considered acceptable. The minimum NOEC in the standard aquatic toxicity package was 10mg/L (fathead minnow, 28d fish early life-stage test). The associated NOEC for sediment-dweller toxicity in C. riparius was 4.6mg/L. The sludge microorganism NOEC was 100 000 µg/L indicating low toxic potential against microorganisms. Based on environmental fate studies, no terrestrial toxicity assessment was necessary.

Ecological risk: The applicant has provided a set of risk quotients/ratios (RQs) that are clearly below 1 which are based on a total EU consumption forecast (PECR1SW = 0.0037ug/L) and a highest EU member state prevalence forecast (Italy prevalence 5.1%; PECR2SW = 0.02713ug/L). Overall, there are no major differences in environmental risk assessment conclusions between the total EU and Italyspecific approach.

## Velpatasvir:

Velpatasvir (VEL) is highly lipophilic with its n-octanol/water partition coefficient at log D = 6.31 (at pH 8); i.e. above the action limit for a PBT assessment. Using a Phase I prevalence Fpen of 5.2%, the PECSW value (PECSW = 2.60μg/L) was above the Phase I action limit of 0.01μg/L, triggering ERA Phase IIA assessment. VEL was not found to be readily biodegradable in sludge, to have a sludge Koc &lt; 10 000L/kg, to shift relatively quickly to the sediment from surface water (&gt;70% within 14d) and also to be only slowly degraded there (DT50 233-269d at 12 ° C). The minimum NOEC in the standard aquatic toxicity package was 6.56µg/L (Daphnia reproduction test). The associated NOEC for sediment-dweller toxicity in C. riparius was 870mg/L. The sludge microorganism NOEC was 105 mg/L indicating low toxic potential against microorganisms. Based on environmental fate studies, no terrestrial toxicity assessment was necessary.

PBT: The persistence of VEL in sediment is above the action thresholds for PBT and vPvB persistence (DT50 233-269d at 12 ° C is &gt; 120d for PBT and &gt;180d for vPvB respectively). The Daphnia toxicity

<div style=\"page-break-after: always\"></div>

NOEC is below 10µg/L, triggering the T-assignation in PBT. Based on its environmental fate profile, any potential bioaccumulation is most likely to occur among sediment-dwellers. A study with adult Lumbriculus variegatus was conducted. The outcome was a normalized BAF of 0.122, indicating that VEL is rapidly eliminated and has very little potential for bioaccumulation in sediment-dwellers. That being said, as no definite equilibrium or kinetic bioaccumulation factor (BAFss; BAFk) could be determined, some uncertainty remains and it is therefore not possible to draw an final conclusion on the PBT status of VEL.

Ecological risk : Based on refined PECSW calculations, the applicant has provided a set of risk quotients/ratios (RQs) that are clearly below 1  which are based on a total EU consumption forecast (PECR1SW = 0.00112ug/L) and a highest EU member state prevalence forecast (Italy prevalence 5.1%; PECR2SW = 0.00290ug/L). Overall, there are no major differences in environmental risk assessment conclusions between the total EU and Italy-specific approach.

Based on the new data, an updated ERA summary table for VEL is shown in Table 1:

Table 1. Summary of main studies for Velpatasvir

| Substance (INN/Invented Name): Velpatasvir                       | Substance (INN/Invented Name): Velpatasvir                                                                                    | Substance (INN/Invented Name): Velpatasvir                                                                                                                                                     | Substance (INN/Invented Name): Velpatasvir                                                                                    | Substance (INN/Invented Name): Velpatasvir                                                                                    |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| CAS-number (if available): 1377049-84-7                          | CAS-number (if available): 1377049-84-7                                                                                       | CAS-number (if available): 1377049-84-7                                                                                                                                                        | CAS-number (if available): 1377049-84-7                                                                                       | CAS-number (if available): 1377049-84-7                                                                                       |
| PBT screening                                                    |                                                                                                                               | Result                                                                                                                                                                                         | Conclusion                                                                                                                    |                                                                                                                               |
| Bioaccumulation potential log K ow                               | OECD123                                                                                                                       | log D = 6.31 (at pH8)                                                                                                                                                                          | Potential PBT (Y)                                                                                                             |                                                                                                                               |
| PBT-assessment                                                   | PBT-assessment                                                                                                                | PBT-assessment                                                                                                                                                                                 | PBT-assessment                                                                                                                | PBT-assessment                                                                                                                |
| Parameter                                                        | Result relevant for conclusion                                                                                                |                                                                                                                                                                                                | Conclusion                                                                                                                    |                                                                                                                               |
| Bioaccumulation                                                  | log K OW                                                                                                                      | log D = 6.31 (at pH8)                                                                                                                                                                          | Possibly B                                                                                                                    |                                                                                                                               |
|                                                                  | BCF                                                                                                                           | Sediment BAF = 0.122 Considering the tendency for velpatasvir to shift into sediment, bioaccumulation in sediment dwellers is likely to be more relevant.                                      | Unlikely but no final conclusion for B as there was some equilibrium issues in the OECD TG315 study.                          |                                                                                                                               |
| Persistence                                                      | DT 50 or ready biodegradability                                                                                               | Sedim. DT 50 = 109-136d (20 ◦ C) Sedim. DT 50 = 233-269d (12 ◦ C)                                                                                                                              | P as P > 120d vP as P > 180d                                                                                                  |                                                                                                                               |
| Toxicity                                                         | NOEC or CMR                                                                                                                   | Daphnia NOEC = 5.56ug/L                                                                                                                                                                        | T as NOEC < 10ug/L                                                                                                            |                                                                                                                               |
| PBT-statement :                                                  | No final conclusion on PBT-status. vP and T are positive but as B is uncertain, velpatasvir remains a possible PBT candidate. | No final conclusion on PBT-status. vP and T are positive but as B is uncertain, velpatasvir remains a possible PBT candidate.                                                                  | No final conclusion on PBT-status. vP and T are positive but as B is uncertain, velpatasvir remains a possible PBT candidate. | No final conclusion on PBT-status. vP and T are positive but as B is uncertain, velpatasvir remains a possible PBT candidate. |
| Phase I                                                          | Phase I                                                                                                                       | Phase I                                                                                                                                                                                        | Phase I                                                                                                                       | Phase I                                                                                                                       |
| Calculation                                                      | Value                                                                                                                         | Unit                                                                                                                                                                                           | Conclusion                                                                                                                    |                                                                                                                               |
| PEC SW , default or refined (i.e. max HCV prevalence from ECDC)  | Prevalence : 2.60                                                                                                             | µ g/L                                                                                                                                                                                          | Prevalence PEC SW > 0.01 ug/L threshold (Y)                                                                                   |                                                                                                                               |
| Other concerns (e.g. chemical class)                             | NA                                                                                                                            | NA                                                                                                                                                                                             | (N)                                                                                                                           |                                                                                                                               |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate                                                                                | Phase II Physical-chemical properties and fate                                                                                                                                                 | Phase II Physical-chemical properties and fate                                                                                | Phase II Physical-chemical properties and fate                                                                                |
| Study type                                                       | Test protocol                                                                                                                 | Results                                                                                                                                                                                        | Remarks                                                                                                                       |                                                                                                                               |
| Adsorption-Desorption                                            | OECD TG106                                                                                                                    | K d soil: 294-3062 L/kg K d soil mean = 1009 L/kg K oc soil > 10 000 L/kg K d sludge : 1355-4387 L/kg K d sludge mean = 2672 L/kg K oc sludge: 3673 - 11 544 L/kg K oc sludge mean = 7137 L/kg | Based on average sludge-values, not considered a terrestrial toxicity risk via agricultural sludge application.               |                                                                                                                               |
| Ready Biodegradability Test                                      | OECD TG301                                                                                                                    | Not readily biodegradable                                                                                                                                                                      |                                                                                                                               |                                                                                                                               |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD TG308                                                                                                                    | DT 50, water (20 ° C) = 1.3-1.7d DT 50, sediment (20 ° C) = 109- 136d DT 50, whole system (20 ° C) = 62.4d % shifting to sediment =                                                            | Arrhenius equation correction to 12 ° C for sediment: DT 50, sediment (12 ° C) = 233-269d                                     |                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                               |                          | >10%                     | AR at D14.               | AR at D14.               |                                                    |
|-----------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------------------------|
| Phase IIA Effect studies                      | Phase IIA Effect studies | Phase IIA Effect studies | Phase IIA Effect studies | Phase IIA Effect studies | Phase IIA Effect studies                           |
| Study type                                    | Test protocol            | Endpoint                 | value                    | Unit                     | Remarks                                            |
| Algae, Growth Inhibition Test/ Species        | OECD TG201               | NOEC                     | 49                       | µg/L                     | P. subcapitata                                     |
| Daphnia sp . Reproduction Test                | OECD TG211               | NOEC                     | 6.56                     | µg/L                     | D. magna                                           |
| Fish, Early Life Stage Toxicity Test/ Species | OECD TG210               | NOEC                     | 200                      | µg/L                     | P. promelas                                        |
| Activated Sludge, Respiration Inhibition Test | OECD TG209               | NOEC                     | 105                      | mg/L                     | Sludge microorganisms                              |
| Phase IIB Studies                             | Phase IIB Studies        | Phase IIB Studies        | Phase IIB Studies        | Phase IIB Studies        | Phase IIB Studies                                  |
| Bioaccumulation in sediment- dwellers         | OECD TG315               | BAF                      | 0.122                    |                          | L. variegatus See comment in PBT assessment above. |
| Sediment dwelling organism                    | OECD TG218               | NOEC NOEC OC10           | 870 4142.9               | mg/kg                    | C. riparius                                        |

## Voxilaprevir:

Voxilaprevir (VOX) is lipophilic but slightly below the PBT/OSPAR action threshold (log KOW 4.5) with an n-octanol/water partition coefficient of log KOW = 4.3 (pH 7). The default Phase I surface water PEC (PECSW) was calculated using a HCV prevalence Fpen (0.052) to PECSW = 2.6µg/L (&gt;0.01 µg/L action threshold), triggering ERA phase II assessment. VOX demonstrates a clear shift from water to sediment (AR &gt;10% after 14d). A temperature correction to 12°C (as described in ECHA, R.11, 2014d) gives a the DT50 total system a value of 162 d (i.e. &gt;120d for freshwater sediments). Furthermore it was not possible to calculate a DT50 for sediment only, because no significant decrease can be observed though there is only a negligible amount of the parent compound in water. In the other system a relevant transformation product occurs (M9) which is also persistent (no significant decrease from d63 onwards). Overall, VOX is therefore likely to be persistent in water-sediment systems. VOX is not readily biodegradable in sludge and is binding to sewage solids to such a degree (KFOC &gt; 10 000L/kg) that it is likely that it will reach the terrestrial soil environment via sludge spreading on agricultural land. It has DT50 values between 164d and 238d for soil, indicating it to be persistent in soil.

The minimum aquatic toxicity NOEC for VOX was 6200µg/L (Daphnia reproduction test). VOX demonstrated sex-specific effects on sediment-dweller midge developmental rate (NOEC for male developmental rate at 500mg/kg dry weight and a NOEC for female developmental rate at 1000mg/kg). The NOEC remains to be corrected for sediment organic carbon content. Soil microorganism NOEC was 3200µg/kg and earthworm acute toxicity NOEC was 1000mg/kg. Seedling phytotoxicity was found in corn ( Zea mays ), Garden cress ( Lepidium sativum ), Oat ( Avena sativa ) and Wheat ( Triticum aestivum ). Corn was the most sensitive species with a growth effect NOEC of 12mg/kg. Garden cress demonstrated phytotoxicity for both seedling emergence and growth at NOEC 111mg/kg. Toxicity data for soil arthropods (OECD TG232) is ongoing and the applicant committed to provide the study with an updated ERA for voxilaprevir in December 2017.

Bioaccumulation : As the log KOW value &gt; 3 (the case-by-case ECHA action threshold) a bioconcentration study in fish will be provided in December 2017 with an updated ERA for voxilaprevir.

Ecological risk : Based on refined PECSW calculations, the applicant has provided a set of risk quotients/ratios (RQs) that are below 1. These are based on a total EU consumption forecast (PECR1SW = 0.00095ug/L) and a highest EU member state prevalence forecast (Italy prevalence 5.1%; PECR2SW = 0.00046ug/L). Overall, there are no major differences in environmental risk assessment conclusions between the total EU and Italy-specific approach.

<div style=\"page-break-after: always\"></div>

Based on the new data, an updated ERA summary table for VOX is shown in Table 2:

Table 2. Summary of main studies for Voxilaprevir

| Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):   | Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):   | Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):                                                                                                     | Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):                                                                                                     | Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):                                                                                                     | Substance (INN/Invented Name): Voxilaprevir CAS-number (if available):                                |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| PBT screening                                                            |                                                                          |                                                                                                                                                                            | Result                                                                                                                                                                     | Result                                                                                                                                                                     | Conclusion                                                                                            |
| Bioaccumulation potential- log K ow                                      | OECD TG123                                                               | OECD TG123                                                                                                                                                                 | 4.3                                                                                                                                                                        | 4.3                                                                                                                                                                        | Potential PBT?                                                                                        |
| PBT-assessment                                                           |                                                                          |                                                                                                                                                                            |                                                                                                                                                                            |                                                                                                                                                                            |                                                                                                       |
|                                                                          | Result relevant for conclusion                                           | Parameter                                                                                                                                                                  | Parameter                                                                                                                                                                  | Parameter                                                                                                                                                                  | Conclusion                                                                                            |
| Bioaccumulation                                                          | log K ow BCF                                                             | 4.3                                                                                                                                                                        | 4.3                                                                                                                                                                        | 4.3                                                                                                                                                                        | potentially B B/not B                                                                                 |
| Persistence                                                              | DT50 or ready biodegradability                                           | Not readily biodegradable in sludge. Likely to be persistent in sediment-systems.                                                                                          | Not readily biodegradable in sludge. Likely to be persistent in sediment-systems.                                                                                          | Not readily biodegradable in sludge. Likely to be persistent in sediment-systems.                                                                                          | submitted. P (based on DT50 estimations)                                                              |
| Toxicity                                                                 | NOEC or CMR                                                              | > 10ug/L.                                                                                                                                                                  | > 10ug/L.                                                                                                                                                                  | > 10ug/L.                                                                                                                                                                  | not T                                                                                                 |
| PBT-statement :                                                          | The compound is not considered as PBT.                                   | The compound is not considered as PBT.                                                                                                                                     | The compound is not considered as PBT.                                                                                                                                     | The compound is not considered as PBT.                                                                                                                                     | The compound is not considered as PBT.                                                                |
| Phase I                                                                  |                                                                          |                                                                                                                                                                            |                                                                                                                                                                            |                                                                                                                                                                            |                                                                                                       |
| Calculation                                                              | Value                                                                    | Unit                                                                                                                                                                       | Unit                                                                                                                                                                       | Unit                                                                                                                                                                       | Conclusion                                                                                            |
| PEC surfacewater , default or refined (e.g. prevalence, literature)      | 2.6                                                                      | µ g/L                                                                                                                                                                      | µ g/L                                                                                                                                                                      | µ g/L                                                                                                                                                                      | > 0.01 threshold Yes                                                                                  |
| Other concerns (e.g. chemical class)                                     |                                                                          |                                                                                                                                                                            |                                                                                                                                                                            |                                                                                                                                                                            | No                                                                                                    |
| Phase II Physical-chemical properties and fate                           | Phase II Physical-chemical properties and fate                           | Phase II Physical-chemical properties and fate                                                                                                                             | Phase II Physical-chemical properties and fate                                                                                                                             | Phase II Physical-chemical properties and fate                                                                                                                             | Phase II Physical-chemical properties and fate                                                        |
| Study type                                                               | Test protocol                                                            | Results                                                                                                                                                                    | Results                                                                                                                                                                    | Results                                                                                                                                                                    | Remarks                                                                                               |
| Adsorption-Desorption                                                    | OECD TG106                                                               | K F ads sludge = 5110-12452 K F ads soil = 12.7-57.8 K F OC ads sludge = 13343-28172 K F OC ads soil = 1275-3593 K F OC des sludge =15078-33993                            | K F ads sludge = 5110-12452 K F ads soil = 12.7-57.8 K F OC ads sludge = 13343-28172 K F OC ads soil = 1275-3593 K F OC des sludge =15078-33993                            | =2815-4467                                                                                                                                                                 | Triggers Phase IIB terrestrial ecotoxicity assessment together with OECD TG301B.                      |
| Ready Biodegradability Test                                              | OECD TG301B                                                              | Not readily biodegradable.                                                                                                                                                 | Not readily biodegradable.                                                                                                                                                 | Not readily biodegradable.                                                                                                                                                 | 2.5% biodegradation after 28d in activated sludge                                                     |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems         | OECD TG308                                                               | Voxilaprevir DT 50, water (20 ° C) = 6-15d DT 50, whole system (20 ° C) = 30-76d Transformation products DT 50, whole system = 28-29d AR% shifting to sediment after 14d > | Voxilaprevir DT 50, water (20 ° C) = 6-15d DT 50, whole system (20 ° C) = 30-76d Transformation products DT 50, whole system = 28-29d AR% shifting to sediment after 14d > | Voxilaprevir DT 50, water (20 ° C) = 6-15d DT 50, whole system (20 ° C) = 30-76d Transformation products DT 50, whole system = 28-29d AR% shifting to sediment after 14d > | M1 is a transformation product with AR > 10%. Arrhenius equation: DT 50, whole system (12 ° C) = 162d |
| Phase IIa Effect studies                                                 | Phase IIa Effect studies                                                 | Phase IIa Effect studies                                                                                                                                                   | Phase IIa Effect studies                                                                                                                                                   | Phase IIa Effect studies                                                                                                                                                   | Phase IIa Effect studies                                                                              |
| Study type                                                               | Test protocol                                                            | Endpoint                                                                                                                                                                   | Endpoint                                                                                                                                                                   | value Unit                                                                                                                                                                 | Remarks                                                                                               |
| Algae, Growth Inhibition Test/ Species                                   | OECD TG201                                                               | NOEC yield                                                                                                                                                                 | NOEC yield                                                                                                                                                                 | 000 000 µg/L                                                                                                                                                               | P. subcapitata                                                                                        |
| Daphnia sp . Reproduction Test                                           | OECD TG211                                                               | NOEC growth NOEC Mortality NOEC Juvenile                                                                                                                                   | NOEC growth NOEC Mortality NOEC Juvenile                                                                                                                                   | 13000 6200 13000 µg/L                                                                                                                                                      | D. magna                                                                                              |
| Fish, Early Life Stage Toxicity Test/ Species                            | OECD TG210                                                               | NOEC                                                                                                                                                                       | NOEC                                                                                                                                                                       | 11000 µg/L                                                                                                                                                                 | P. promelas                                                                                           |
| Activated Sludge, Respiration Inhibition Test                            | OECD TG209                                                               | NOEL EC 50 1000 >1000                                                                                                                                                      | NOEL EC 50 1000 >1000                                                                                                                                                      | mg/L                                                                                                                                                                       | Not inhibitory to sludge microorganisms                                                               |

<div style=\"page-break-after: always\"></div>

| Phase IIb Studies                                 | Phase IIb Studies   | Phase IIb Studies                                                            | Phase IIb Studies      | Phase IIb Studies   | Phase IIb Studies                                                  |
|---------------------------------------------------|---------------------|------------------------------------------------------------------------------|------------------------|---------------------|--------------------------------------------------------------------|
| Bioaccumulation in fish                           | OECD TG305          | BCF                                                                          | NA                     | L/kg                | %lipids: Study ongoing                                             |
| Aerobic and anaerobic transformation in soil      | OECD TG307          | Soil DT 50 %CO 2 (122d)                                                      | 164-238d <3%           |                     | Soils tested: Speyer 2.2, Speyer 2.3, Speyer 2.4 Speyer 6S         |
| Soil Microorganisms: Nitrogen Transformation Test | OECD TG216          | EC 10 nitrate level EC 25 nitrate level EC 50 nitrate level NOEC rate%       | 13 132 >320 3.2        | mg/ kg              | 10.2% to 34.1% increase in nitrate production rate at ≥10 mg/kg.   |
| Terrestrial Plants, Growth Test/ Species          | OECD TG208          | NOEC Corn NOEC Oat NOEC Wheat NOEC Garden cress NOEC Tomato NOEC Ch. cabbage | 12 37 37 111 1000 1000 | mg/ kg              | Species tested: Tomato Chinese cabbage Garden cress Oat Corn Wheat |
| Earthworm, Acute Toxicity Tests                   | OECD TG207          | NOEC                                                                         | 1000                   | mg/ kg              | E. fetida                                                          |
| Collembola, Reproduction Test                     | OECD TG232          | NOEC                                                                         | NA                     | mg/ kg              | Folsomia candida Study is ongoing                                  |
| Sediment dwelling organism                        | OECD TG218          | NOEC emergence NOEC male growth NOEC female growth                           | 1000 500 1000          | mg/ kg              | C. riparius NOEC not OC10% corrected.                              |

## 2.3.6. Discussion on non-clinical aspects

## Pharmacology

Primary pharmacodynamics is presented and discussed in the section on Clinical Pharmacodynamics.

No novel non-clinical pharmacology studies with sofosbuvir or velpatasvir have been submitted with this application. The studies supporting the use of these substances have been assessed for previous applications for now approved products (Sovaldi and Epclusa), and a novel assessment has not been performed. There were no findings in studies on secondary pharmacology or safety pharmacology to be considered specifically in the safety evaluation of the triple combination.

There are no findings in the secondary pharmacology or safety pharmacology studies with voxilaprevir to be considered in the safety evaluation. No toxicokinetics analysis was performed in the in vivo safety pharmacology studies, but extrapolation from other toxicokinetics data is acceptable. The results showed an exposure margin of 105 to clinical Cmax in the rat (CNS and respiratory) and 46 in the dog (cardiovascular).

## Pharmacokinetics

No novel nonclinical pharmacokinetics studies with sofosbuvir or velpatasvir have been submitted with this application. The studies supporting the use of these substances have been assessed for previous applications for now approved products (Sovaldi and Epclusa), and a novel assessment has not been performed. There were no findings in these studies on pharmacokinetics to be considered specifically in the safety evaluation of the triple combination.

<div style=\"page-break-after: always\"></div>

The pharmacokinetics of voxilaprevir has been adequately evaluated. Of importance for the nonclinical safety evaluation, no circulating metabolites have been detected in any species, including humans.

## Toxicology

The Applicant considers the VOX-induced bile duct hyperplasia in rats, and gall bladder vacuolation/ hyperplasia in dogs, to be non-adverse effects. By definition, both bile duct hyperplasia and gall bladder epithelial hyperplasia are proliferative changes and as such classified as potentially preneoplastic findings. Based on this, both findings should be considered adverse. Nevertheless, it is recognized that so called 'typical' bile duct hyperplasia in rats, being confined to the portal area, is a common finding in repeat-dose toxicity studies and generally is regarded as harmless unless accompanied by inflammatory/fibrotic changes. Therefore the minimal biliary hyperplasia in females treated with VOX can be regarded as non-adverse.

The serum chemistry changes observed in rats treated with VOX (increased ALT and ALP; decreased albumin, globulin and total protein) seem to be more related to hepatocellular effects than effects on the biliary epithelium. Since there were no correlating histopathological findings, these changes are not considered adverse.

Regarding the gall bladder changes in dogs, it is agreed that epithelial vacuolation is a non-adverse effect. In contrast, epithelial hyperplasia is considered adverse, since it is a proliferative effect, and since it was accompanied by an inflammatory reaction in the form of mononuclear cell infiltration in the lamina propria, in the 14-day and 3-month studies.  The NOAEL in the pivotal 3- and 9-month dog studies is considered to be 3 mg/kg/day, corresponding to a 1-fold margin to clinical therapeutic exposure. Although the margin to clinical therapeutic exposure is minimal, the gall bladder findings in dogs are not considered to be of major clinical concern, based on their minimal to slight degree, and the lack of progression in severity over time.

The Applicant was asked to discuss potential overlapping toxicity with SOF and VOX in the hepatobiliary system, GI tract and haematopoietic cells. In the discussion provided it was pointed out that although the same organ systems were affected, the target cells and mechanisms involved differed between SOF and VOX. Clinical data was presented, showing no difference in the incidence of adverse effects on the hepatobiliary and hematopoietic systems in patients administered SOF/VEL/VOX as compared with only SOF/VEL. Overall the Applicant's discussion is considered adequate and supports the notion that there is no evidence for clinically relevant overlapping toxicity when VOX and SOF are given in combination.

## Environmental risk assessment

The studies for Collembola reproduction (OECD TG232) and the fish bio-concentration (OECD TG305) are ongoing. The updated ERA report will make appropriate corrections to the NOEC value for organic content and the active ingredient voxilaprevir will be described as very persistent (vP) in soil.

The outstanding final reports and updated ERA report will be available by the end of 2017.

## 2.3.7. Conclusion on the non-clinical aspects

There are no objections to an approval of Vosevi from a non-clinical point of view.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

The efficacy of combination therapy with SOF, VEL, and VOX (as SOF/VEL/VOX or SOF/VEL+VOX) in DAA experienced and DAA naive subjects with chronic HCV infection has been evaluated in 4 Phase 2 and 4 Phase 3 studies (Table 5). Newly reported Phase 1 studies that involved VOX, alone (n=8) or in combination (n=7) is given in Table 4. More than 2000 subjects have been treated with SOF/VEL/VOX or SOF/VEL+VOX in the US, France, Germany, the United Kingdom, Canada, Australia, and New Zealand (Table 3).

Table 3. Number of Subjects Enrolled and Treated with SOF/VEL/VOX or SOF/VEL+VOX in Studies Included in the Submission by Region

|                   |   US |   Europe |   Rest of World |   Total Enrolled |
|-------------------|------|----------|-----------------|------------------|
| Phase 3 Studies a |  569 |      316 |             171 |             1056 |
| Phase 2 Studies b |  368 |        0 |             175 |              543 |
| Phase 1 Studies c |  418 |        0 |               0 |              418 |
| TOTAL             | 1355 |      316 |             346 |             2017 |

a Phase 3 studies included Studies GS-US-367-1171 (POLARIS-1), GS-US-367-1172 (POLARIS-2), GS-US-367-1173 (POLARIS-3), and GS-US-367-1170 (POLARIS-4).

b Phase 2 studies included Studies GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, and GS-US-367-1871 (TRILOGY-3).

c Phase 1 studies included Studies GS-US-367-1176, GS-US-367-1905, GS-US-367-1657, GS-US-367-1726, GS-US-367-1727, GS-US-367-1909, and GS-US-380-1999.

Table 4. Overview of SOF/VEL/VOX Clinical Studies Contributing Information to the Summary of Clinical Pharmacology

| Study           | Objective                                                         | VOX                                         | Dose (mg)   |   n | OTHER                           |               |
|-----------------|-------------------------------------------------------------------|---------------------------------------------|-------------|-----|---------------------------------|---------------|
| GS-US-338- 1120 | Safety and PK of VOX, the effect of food and solution formulation | 10-mg, 50-mg, 100-mg tablet 100-mg solution | 30 100 300  |  72 | VOX placebo                     | Fasted or Fed |
| GS-US-338- 1121 | Safety, PK, and antiviral activity of VOX                         | 10-mg, 50-mg, 100-mg tablet                 | 50 100 300  |  89 | VOX placebo SOF/VEL 400/100-mg  | Fasted or Fed |
| GS-US-338- 1123 | Effect of VOX on QT/QTc                                           | 100-mg tablet                               | 300 900     |  48 | VOX placebo moxifloxacin 400-mg | Fed           |
| GS-US-338- 1124 | VOX ADME                                                          | 0.78 mg [ 14 C] VOX and 49.22 mg VOX        | 100         |   8 | Not applicable                  | Fed           |
| GS-US-338- 1125 | VOX in severe renal impairment                                    | 100-mg tablet                               | 100         |  20 | Not applicable                  | Fed           |
| GS-US-338- 1126 | VOX in hepatic impairment                                         | 100-mg tablet                               | 100         |  33 | Not applicable                  | Fed           |

<div style=\"page-break-after: always\"></div>

| GS-US-338- 1130   | DDI with HCV antivirals                  | 10-mg, 50-mg, 100-mg tablet   | 100 200 300 600 900      |   133 | SOF/VEL 400/100-mg tablet LDV/SOF 90/400-mg tablet                                         | Fasted or Fed   |
|-------------------|------------------------------------------|-------------------------------|--------------------------|-------|--------------------------------------------------------------------------------------------|-----------------|
| GS-US-338- 1417   | DDI with probe drugs                     | 100-mg tablet                 | 100                      |    98 | ciclosporin 100-mg rifampin 300-mg voriconazole 200-mg gemfibrozil 600-mg grapefruit juice | Fed             |
| GS-US-367-1 176   | Bioavailability and effect of food       | SOF/VEL/VOX SOF/VEL VOX       | 400/100/1 00 400/100 100 |    68 | Not applicable                                                                             | Fasted or Fed   |
| GS-US-367-1 657   | DDI with HIV ARVs                        | SOF/VEL/VOX+ VOX              | 400/100/1 00 100         |    90 | FTC/RPV/TAF EVG/COBI/FTC/TAF DRV/r + FTC/TDF                                               | Fed             |
| GS-US-367-1 726   | DDI with H2RA or PPI                     | SOF/VEL/VOX                   | 400/100/1 00             |   104 | famotidine omeprazole                                                                      | Fed             |
| GS-US-367-1 727   | DDI with probe substrates and inhibitors | SOF/VEL/VOX + VOX             | 400/100/1 00 100         |    71 | PRA, ROSU, DAB, DRV/r, ATV/r, EVG, COBI                                                    | Fed             |
| GS-US-367-1 905   | PK Japanese and non-Japanese             | SOF/VEL/VOX + VOX             | 400/100/1 00 100         |    40 | Not applicable                                                                             | Fed             |
| GS-US-367-1 909   | DDI with OC                              | SOF/VEL/VOX + VOX             | 400/100/1 00 100         |    15 | norgestimate/ ethinyl estradiol                                                            | Fed             |
| GS-US-380- 1999   | DDI with BIC/FTC/TAF                     | SOF/VEL/VOX + VOX             | 400/100/1 00             |    30 | BIC/FTC/TAF                                                                                | Fed             |

<div style=\"page-break-after: always\"></div>

Table 5. Design of Phase 2 and Phase 3 Studies

|                                           |       |                                                              | Subject Population   | Subject Population                                                             | Subject Population                          |
|-------------------------------------------|-------|--------------------------------------------------------------|----------------------|--------------------------------------------------------------------------------|---------------------------------------------|
| Study Number                              | Phase | Treatment Regimen a                                          | HCV Genotype         | Prior HCV Treatment                                                            | Cirrhosis Status                            |
| GS-US-337- 1468 (LEPTON, Cohorts 4 and 5) | 2     | SOF/VEL+VOX for 4, 6, or 8 weeks                             | 1 or 3               | Treatment-naive and treatment-experienced (including DAA-experienced) subjects | Approximately 50% of subjects had cirrhosis |
| GS-US-367- 1168                           | 2     | SOF/VEL+VOX for 6, 8 (with or without RBV), or 12 weeks      | 1                    | Treatment-naive and DAA-experienced subjects                                   | Approximately 50% of subjects had cirrhosis |
| GS-US-367- 1169                           | 2     | SOF/VEL+VOX for 6, 8, or 12 weeks                            | 1, 2, 3, 4, or 6     | Treatment-naive and treatment-experienced (including DAA-experienced) subjects | Approximately 50% of subjects had cirrhosis |
| GS-US-367- 1871 (TRILOGY-3)               | 2     | SOF/VEL/VOX with or without RBV for 12 weeks                 | 1                    | DAA-experienced subjects                                                       | Approximately 50% of subjects had cirrhosis |
| GS-US-367- 1171 (POLARIS-1)               | 3     | SOF/VEL/VOX for 12 weeks or SOF/VEL/VOX Placebo for 12 weeks | 1, 2, 3, 4, 5, or 6  | NS5A inhibitor DAA-experienced subjects                                        | Approximately 40% of subjects had cirrhosis |
| GS-US-367- 1170 (POLARIS-4)               | 3     | SOF/VEL/VOX for 12 weeks or SOF/VEL for 12 weeks             | 1, 2, 3, or 4        | Non-NS5A inhibitor DAA-experienced subjects                                    | Approximately 50% of subjects had cirrhosis |
| GS-US-367- 1172 (POLARIS-2)               | 3     | SOF/VEL/VOX for 8 weeks or SOF/VEL for 12 weeks              | 1, 2, 3, 4, 5, or 6  | DAA-naive subjects                                                             | Approximately 20% of subjects had cirrhosis |
| GS-US-367- 1173 (POLARIS-3)               | 3     | SOF/VEL/VOX for 8 weeks or SOF/VEL for 12 weeks              | 3                    | DAA-naive subjects                                                             | All subjects had cirrhosis                  |

DAA = direct-acting antiviral; NS5A = nonstructural protein 5A; RBV = ribavirin

The SOF/VEL/VOX dose was 400/100/100-mg FDC tablet once daily; the SOF/VEL dose was 400/100-mg FDC tablet once daily; the VOX single-agent dose was 100-mg tablet once daily; the RBV dose was 1000 or 1200 mg divided daily dose (for subjects who weighed &lt; 75 kg, the RBV dose was 1000 mg/day divided; for subjects who weighed ≥ 75 kg, the RBV dose was 1200 mg/day divided); and the Peg-IFN dose was 180 µg weekly.

## 2.4.2. Pharmacokinetics

Voxilaprevir (VOX) is a new chemical entity and full pharmacokinetic documentation is required. Since voxilaprevir has a wide safety margin the clinical pharmacology has been investigated in both healthy volunteers and HCV patients.

Sofosbuvir (SOF) and velpatasvir (VEL) have been subject for Regulatory assessment previously (Sovaldi ® sofosbuvir, 2013, Harvoni ® sofosbuvir/ledipasvir, 2014 and Eplcusa ® , sofosbuvir/velpatasvir 2016).

## Analytical methods

The bioanalytical methods for the measurement of VOX, VEL, SOF and SOF metabolites (GS-566500 and GS-331007) concentrations in human plasma were based on deuterium and/or  13 C labelled internal standards and LC/MS/MS. The sample preparation for VEL was liquid-liquid extraction and for VOX, SOF and metabolites sample preparation was protein precipitation extraction. All methods were validated. The SOF intracellular active metabolite GS-461203 has not been possible to measure in vivo.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic data analysis

Standard statistical methods and non-compartmental methods were used to characterize the pharmacokinetics. Population PK analysis was characterised by non-linear mixed effects modelling including data from healthy subjects in phase I studies and patients in phase II/III studies.

## Formulations

All phase III studies and a majority of the DDI studies were performed with the intended commercial fixed dose combination (FDC) formulation, SOF/VEL/VOX (400 mg/100 mg/100 mg) or SOF/VEL FDC (400 mg/100 mg) + VOX (100 mg) as two tablets. The SOF/VEL/VOX FDC tablet at 400mg/100mg/100mg showed similar AUCinf and Cmax for SOF, GS-566500, GS-331007, VEL and VOX as compared to administrating SOF/VEL + VOX (400mg/100mg + 100 mg). The 90% CI for all primary PK parameters were contained within the PK equivalence bounds of 70% to 143% and the point estimates for AUCinf and Cmax (%GLSM ratio) were within 95-113%.

## Absorption

## Voxilaprevir

After an oral dose the median tmax of voxilaprevir was observed at ca. 4 h after administration of the SOF/VEL/VOX FDC tablet in healthy volunteers in fed state. The solubility is low but not pH dependent (in FaSSIF and FeSSIF the solubility was 0.2 mg/mL). In vitro, VOX was shown to be a BRCP and P-gp substrate. Co-administration of a single dose of 600 mg Cyclosporin A (CsA) increased the exposure (AUC and Cmax) to voxilaprevir approximately 9-fold and 19-fold, respectively. The absolute bioavailability of voxilaprevir has not been determined in humans.

## Velpatasvir

Velpatasvir was relatively rapidly absorbed with a tmax of 4 h after administration of the SOF/VEL/VOX FDC tablet with food in healthy volunteers. The solubility is pH dependent (3.6 mg/mL at pH 2 and &lt;0.1 mg/mL at pH 5) and in FaSSIF and FeSSIF the solubility was &lt;0.1 mg/mL and 0.1mg/mL, respectively. In vitro, VEL was shown to be a BRCP and P-gp substrate. Co-administration of a single dose of 600 mg Cyclosporin A (CsA) increased the exposure to velpatasvir approximately 2-fold. The absolute bioavailability of VEL has not been determined in humans.

## Sofosbuvir

For sofosbuvir, following a single dose of the SOF/VEL/VOX FDC tablet in fed state, the tmax was ca. 2 h and 4 h for SOF and GS-331007, respectively.

In vitro studies show that SOF is subject to marked efflux, mediated by P-gp and/or BCRP. Coadministration of a single dose CsA increased the exposure to sofosbuvir 4.5-fold. The bioavailability of drug related material is at least 50%, although the absolute value is unknown.

## Food effect

The effect of food on PK after a single-dose of SOF/VEL/VOX was investigated in healthy volunteers. Different types of food were investigated light-, moderate- and high-fat. The effect on SOF, GS331007

<div style=\"page-break-after: always\"></div>

and VEL was limited (&lt;2-fold, see Table 6). For VOX the food effect was large, when given with a moderate and high-fat meal AUC was increased ~3-fold and ~5-fold, respectively. The pivotal efficacy and safety studies were performed in the fed conditions and thus SOF/VEL/VOX should be administered with food.

Table 6. Effect of food on PK of SOF and its metabolite GS-331007, VEL and VOX

|         | GS-US-367-1176 (SOF/VEL/VOX Fed High-Fat/High-Calorie vs Fasted)   | GS-US-367-1176 (SOF/VEL/VOX Fed High-Fat/High-Calorie vs Fasted)   | GS-US-367-1176 (SOF/VEL/VOX Fed High-Fat/High-Calorie vs Fasted)   | GS-US-367-1176 (SOF/VEL/VOX Fed High-Fat/High-Calorie vs Fasted)   |
|---------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|         | SOF                                                                | GS-331007                                                          | VEL                                                                | VOX                                                                |
| AUC inf | ↑ 64%                                                              | ↔                                                                  | ↑ 40%                                                              | ↑ 435%                                                             |
| C max   | ↔                                                                  | ↓ 35%                                                              | ↑ 37%                                                              | ↑ 680%                                                             |
|         | GS-US-338-1130 (SOF/VEL+VOX Fed Moderate-Fat Meal vs Fasted)       | GS-US-338-1130 (SOF/VEL+VOX Fed Moderate-Fat Meal vs Fasted)       | GS-US-338-1130 (SOF/VEL+VOX Fed Moderate-Fat Meal vs Fasted)       | GS-US-338-1130 (SOF/VEL+VOX Fed Moderate-Fat Meal vs Fasted)       |
|         | SOF                                                                | GS-331007                                                          | VEL                                                                | VOX                                                                |
| AUC inf | ↑ 144%                                                             | ↔                                                                  | ↑ 129%                                                             | ↑ 185%                                                             |
| C max   | ↑ 76%                                                              | ↔                                                                  | ↑ 146%                                                             | ↑ 259%                                                             |
|         | GS-US-338-1130 (SOF/VEL+VOX Fed Light Meal vs Fasted)              | GS-US-338-1130 (SOF/VEL+VOX Fed Light Meal vs Fasted)              | GS-US-338-1130 (SOF/VEL+VOX Fed Light Meal vs Fasted)              | GS-US-338-1130 (SOF/VEL+VOX Fed Light Meal vs Fasted)              |
|         | SOF                                                                | GS-331007                                                          | VEL                                                                | VOX                                                                |
| AUC inf | ↑ 118%                                                             | ↔                                                                  | ↑ 166%                                                             | ↑ 112%                                                             |
| C max   | ↑ 73%                                                              | ↔                                                                  | ↑ 187%                                                             | ↑ 147%                                                             |

90% CIs of the GLSM ratio were within ( ↔ ), extended above ( ↑ ), or extended below ( ↓ ) the predetermined lack of PK alteration boundaries of 70% to 143%

## Distribution

## Voxilaprevir

Voxilaprevir is highly protein bound in plasma (unbound fraction 0.4%). The mean unbound fraction in human liver microsomes was 0.26 at 0.5 µM. In severe renally impaired subjects the unbound fraction was similar to subjects with normal renal function (~0.3-0.4%). The VOX unbound plasma conc. was approximately 2-fold higher in subjects with severe hepatic impairment compared to healthy controls. The mean whole blood-to-plasma concentration ratio ranged from 0.5 to 0.8. In the population PK analysis for a typical HCV-infected male subject without cirrhosis not taking a calcium channel blocker, the estimated apparent oral volume of distribution of the central compartment (Vc/F) was 707 L, and peripheral compartment (Vp/F) was 259 L.

## Velpatasvir

Velpatasvir is highly protein bound in plasma (in vitro, fraction unbound 0.3-0.5%) and independent of concentration (0.1-2 µM). In severe renally impaired subjects the unbound fraction was similar to subjects with normal renal function (~0.3%). Unbound plasma concentration in subjects with hepatic impairment (HI) was determined in vitro and was found to be similar (0.2-0.3%) in plasma from in subjects with mild, moderate or severe HI compared to subjects with normal liver function. The mean whole blood-to-plasma concentration ratio ranged from 0.52 to 0.67. In the population PK analysis for a typical HCV-infected male subject without cirrhosis the estimated Vc/F was 286 L and Vp/F was 135 L.

<div style=\"page-break-after: always\"></div>

## Sofosbuvir

The unbound plasma fraction of SOF was approximately 15% ex vivo and seems to be independent of concentration. No effect of renal impairment was seen on degree of binding. GS-331007 is minimally bound to plasma proteins. The mean whole blood-to-plasma concentration ratio was approximately 0.71. In the population PK analysis for a typical HCV-infected male subject with CLCR of 111mL/min the estimated Vc/F was 302 L. For GS-331007 the popPK analysis for a typical white male, 80 kg and CRCL 111 mL/min, the estimated Vc/F was 207 L and Vp/F was 804 L.

## Elimination

From the population PK analysis the estimated CL/F in a typical HCV patient (for covariates see distribution above) was 66 L/hr, 33 L/hr and 273 L/h, and t½ was 21 h, 18 h and 0.77 h, for voxilaprevir, velpatasvir and sofosbuvir, respectively.

## Excretion

## Voxilaprevir

In the human mass balance study following a single dose of 100 mg voxilaprevir (100 µCi  14 C[VOX]), the mean cumulative urinary and fecal recovery was 94% nearly all recovered within 12 days and with all radioactivity recovered in faeces. VOX was the major compound found in feces accounting for on average 40% of the administered dose. Voxilaprevir is a substrate for hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 and 1B3, and also efflux transporters P-gp and BCRP, but not a substrate for organic cation transporter (OCT) 1.

## Velpatasvir

In the human mass balance study following a single dose of 100 mg of velpatasvir the mean cumulative urinary and fecal recovery of [ 14 C]-radioactivity was 95% with relative recovery of 0.4% in urine and 94% in faeces. Velpatasvir was the major compound found in faeces accounting for on average 77% of the administered dose. Unchanged parent drug was &lt;0.1% of dose in urine. Velpatasvir is a substrate for hepatic uptake OATP1B and efflux transporters P-gp and BCRP, but not an OCT 1 substrate.

## Sofosbuvir

Following a single 400 mg oral dose of [ 14 C]-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. This data indicate that renal clearance is the major elimination pathway for GS-331007 with a large part actively secreted. While subject to active tubular secretion, GS 331007 is not a substrate for renal transporters including organic anion transporter (OAT) 1 or 3, OCT2, MRP2, P gp, BCRP or MATE1. Sofosbuvir is not a substrate for hepatic uptake transporters, OATP1B1 or 1B3, and OCT1.

<div style=\"page-break-after: always\"></div>

## Metabolism

## Voxilaprevir

Voxilaprevir was relatively stable when incubated in human microsomes. In the human ADME study most (~91%) of the total radioactivity in the AUC-pooled plasma samples up to 72 h was attributed to [ 14 C]VOX. No metabolite was identified in plasma, all were &lt;1%. In faeces, parent compound on average accounting for 40% of the administered dose, followed by M19 accounting for 22% of the dose (For structures see Figure 4).

Figure 4. Proposed major biotransformation and excretion Pathways of VOX in humans

<!-- image -->

## Velpatasvir

Velpatasvir was relatively stable when incubated in human microsomes or hepatocytes. In the human ADME study most (~99%) of the total radioactivity in the AUC-pooled plasma samples was attributed to parent compound with 0.4% and 0.5% attributed to metabolites hydroxy-GS-5816-1 (M18) and desmethyl-GS-5816 (M19). In faeces, parent compound on average accounting for 77% of the administered dose, followed by M18 and M19, accounting for 6% and 3% of the dose up to 144 hours

<div style=\"page-break-after: always\"></div>

post-dose, respectively (Figure 5). In addition 2 unknown metabolites M7 and M11 were detected in feces each accounted for 2.8% and 0.5% of the dose, respectively.

Figure 5. Proposed major biotransformation and excretion Pathways of velpatasvir (GS-5816) in humans

<!-- image -->

Valuesreportedare%ofdoseadministered Total[14C]-radioactivityRecovery~95%:94%inFeces,0.4%inUrine

## Sofosbuvir

Sofosbuvir is subject to extensive first-pass metabolism in the intestine and in the liver. The active metabolite GS-461203 is formed through several metabolic steps (Figure 6). In vitro, SOF is rapidly hydrolysed by CatA and CES1 to form GS-566500 which is further metabolised to eventually form the active triphosphate nucleoside analogue GS-461203. Sofosbuvir and GS-331007 are not substrates of UGT1A1 or CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzymes.

In plasma, GS-331007 constituted the majority (90%) of measured radioactivity. The intermediate metabolite GS-566500 has a tmax of 1 h and has a half-life of 2 h. The major metabolite GS-331007 peaks at 2 h and has a half-life of 26 h. GS-331007 and GS-566500 are not active metabolites.

Figure 6. Intracellular metabolism pathway of SOF (GS-7977)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependency

Dose proportionality was studied in healthy subjects in the fed state. Voxilaprevir exposure increased far more than in proportion. A dose increase from 100 mg to 300 mg, a nearly 8-fold increase AUC was observed and over the whole dose range studied (100 mg to 900 mg) the AUC increased &gt;100-fold. No overt time dependency has been observed. Comparing Day 1 AUCinf with Day 10 AUCtau there was an accumulation of ~2-fold.

Velpatasvir exhibited nonlinear PK after single dose across the dose range of 5 to 450 mg. Increase in exposure was larger than dose-proportional from 5 to 50 mg and increased less than in proportion to dose at doses from 50 mg to 450 mg in healthy subjects. In HCV patients, after multiple dosing there was no clear systematic deviations from dose proportionality for velpatasvir in the range 25 to 150 mg. There was no evidence of time-dependent PK for VEL over a 3 day period.

For sofosbuvir no indication of non-linearity was observed in the range 200-1200 mg. There was no evidence of time-dependent PK for SOF over a 7 day period.

## Intra- and inter-individual variability

The inter-individual variability in CL/F estimated in the PopPK analysis was 70%, 55% and 42% (CV%) for VOX, VEL and SOF, respectively. No estimate of intra-occasion variability (IOV) is available.

## Pharmacokinetics in target population

A population PK analysis was performed and included HCV-infected patients enrolled into the four Phase 2 and four Phase 3 studies with SOF/VEL/VOX from which intensive and/or sparse plasma concentration data were obtained. The PopPK model was built using a standard modelling approach and was shown to describe the data well. Resulting PK parameters is given in Table 7.

## Voxilaprevir

The analysis of VOX was based on ~10000 plasma samples from 1591 patients. The structural model to describe VOX PK was a two-compartment model with first-order absorption, first-order elimination from the central compartment, and a lag time. The final PopPK model included effects of cirrhosis, female gender and concomitant use of calcium channel blockers on CL/F and cirrhosis on Vc/F. Based on the PopPK analysis VOX CL/F, Vc/F, Vp/F, Q/F, Ka, and Tlag for the 'typical' male HCV infected subject without cirrhosis and not on a calcium channel blocker estimated to be 66 L/h, 707 L, 259 L, 11 L/h, 0.40 h -1 , and 0.46 h, respectively. The estimated CL/F for patients with cirrhosis (CPT-A), females or patients taking concomitant calcium channel blockers were 42.6%, 10.6% and 13.8% lower than for the typical subject. Estimated Vc/F for those with cirrhosis (CPT-A) was 44.7% lower than for non-cirrhotics. The effects of cirrhosis, sex and calcium channel blockers (individually or combined) on steady state exposures was modest. Combination of cirrhosis, calcium channel blocker usage and female sex resulted in VOX steady-state AUCtau, Cmax and Ctau 126%, 107% and 187% higher, respectively, than the typical patient. These effects were not deemed to be clinically significant. Other tested covariates, including age, body weight, race, renal function, HVC genotype, ribavirin usage did not show any statistically significant impact on the PK of voxilaprevir.

<div style=\"page-break-after: always\"></div>

## Velpatasvir

The population PK of velpatasvir was described by a 2-compartment model with first order absorption, first order elimination from the central compartment and an absorption lag time. Female gender and hepatic function were statistically significant covariates on CL/F and Vc/F. Females had lower CL/F and V/F compared to males. HCV infected subjects with cirrhosis (CPT-A) had higher V/F compared to noncirrhotic subjects. However, no covariate had a clinically meaningful impact on velpatasvir exposure. Other tested covariates, including age, weight, race, renal function, genotypes, IL28B status did not show any statistically significant impact on the PK of velpatasvir.

## Sofosbuvir

For sofosbuvir a one-compartment model with first order absorption, first order elimination from the central compartment and an absorption lag time was used for description of plasma PK. Female gender and creatinine clearance were statistically significant covariates for CL/F. Females had lower CL/F compared to males. However, no covariate had a clinically meaningful impact on sofosbuvir exposure. Other tested covariates, such as age, weight, race, (compensated) cirrhosis, genotypes, IL28B status did not show any statistically significant impact on the PK of sofosbuvir.

Table 7. VOX, VEL, SOF, and GS-331007 PK Parameters Following Once-Daily Administration of SOF/VEL+VOX or SOF/VEL/VOX in HCV-Infected Subjects (Demographic Population PK Analysis Set)

| PK Parameter      | Mean (% CV)   |
|-------------------|---------------|
| VOX               | (N = 1591)    |
| AUC tau (h*ng/mL) | 2577 (73.7)   |
| C max (ng/mL)     | 192 (85.8)    |
| C tau (ng/mL)     | 47 (82.0)     |
| VEL               | (N = 1595)    |
| AUC tau (h*ng/mL) | 4041 (48.6)   |
| C max (ng/mL)     | 311 (56.1)    |
| C tau (ng/mL)     | 51 (64.7)     |
| SOF               | (N = 1038)    |
| AUC tau (h*ng/mL) | 1665 (30.1)   |
| C max (ng/mL)     | 678 (35.4)    |
| GS-331007         | (N = 1593)    |
| AUC tau (h*ng/mL) | 12,834 (29.0) |
| C max (ng/mL)     | 744 (28.3)    |

## Special Populations

## Hepatic impairment

## Voxilaprevir

Single dose PK (100 mg administered after a moderate fat breakfast) of VOX was investigated in subjects with moderate (Child-Pugh-Turcotte-B, CPT-B) and severe (CPT-C) hepatic impairment (HI). For the total plasma concentration, both AUC and Cmax were increased by grade of HI. The VOX AUCinf and Cmax were 299% and 238% higher, respectively, in subjects with moderate hepatic impairment and 500% and 614% higher, respectively, in subjects with severe hepatic impairment vs. those with

<div style=\"page-break-after: always\"></div>

normal hepatic function. The VOX half-life was similar in subjects with HI and subjects with normal liver function. The unbound fraction was similar in subjects with normal hepatic function and moderate HI, and was approximately 2-fold higher in subjects with severe HI.

In addition to the dedicated hepatic impairment study, the effect of compensated cirrhosis (CPT-A) was examined with population PK analysis in the Phase 2 and 3 studies. Population PK modelling identified compensated cirrhosis to be the greatest contributor VOX PK. Voxilaprevir exposure parameters were increased (AUCtau 73%, Cmax 74%, and Ctau 83%) in subjects with compensated cirrhosis compared with subjects without cirrhosis.

## Velpatasvir

Single dose (100 mg) PK of VEL was investigated in subjects with moderate (Child-Pugh-Turcotte-B, CPT-B) and severe (CPT-C) hepatic impairment. The plasma exposure (AUC) was marginally affected while Cmax was lowered in subjects with both moderate and severe hepatic impairment compared to subjects with normal liver function. The VEL half-life was slightly increased in subjects with HI compared to subjects with normal liver function.

## Sofosbuvir

The pharmacokinetics of sofosbuvir were studied following 7 day dosing of 400 mg sofosbuvir in HCV infected patients with moderate and severe hepatic impairment (CPT Class B and C).  Relative to patients with normal hepatic function, sofosbuvir AUC0-24 was 126% and 143% higher in moderate and severe hepatic impairment, while GS-331007 AUC0-24 was 18% and 9% higher, respectively.

## Renal impairment

## Voxilaprevir

The pharmacokinetics of VOX was studied in HCV negative subjects after a single dose of 100 mg after a moderate fat breakfast to subjects with normal renal function (n=10, mean 115 mL/min) matched to subjects with severe renal impairment (n=10, actual mean CrCL 21.2 ml/min (range 13-29.8 ml/min) by Cockcroft-Gault). The exposure (AUC and Cmax) of VOX was approximately 70% and 45% higher, respectively, in the subjects with severe renal impairment as compared to subjects with normal renal function. The increase in VOX exposure in severe renal impairment is not considered clinically relevant.

## Velpatasvir

The pharmacokinetics of velpatasvir was studied with a single dose of 100 mg in HCV negative subjects with severe renal impairment median (CrCL&lt;30 ml/min by Cockcroft-Gault). The exposure (AUC) of VEL was approximately 50% higher, with similar Cmax, in the subjects with severe renal impairment as compared to subjects with normal renal function.

## Sofosbuvir

The pharmacokinetics of sofosbuvir were studied in HCV negative patients with mild (eGFR ≥50 and &lt;80 mL/min/1.73 m 2 ), moderate (eGFR ≥30 and &lt;50 mL/min/1.73 m 2 ), severe renal impairment (eGFR &lt;30 mL/min/1.73 m 2 ) and patients with ESRD requiring haemodialysis following a single 400 mg dose of sofosbuvir.  Relative to patients with normal renal function (eGFR &gt;80 mL/min/1.73 m 2 ),

<div style=\"page-break-after: always\"></div>

the sofosbuvir AUC was 61%, 107% and 171% higher in mild, moderate and severe renal impairment, while the GS 331007 AUC was 55%, 88% and 451% higher, respectively.  In patients with ESRD, sofosbuvir AUC was 28% higher when sofosbuvir was dosed 1 h before haemodialysis compared with 60% higher when dosed 1 hour after haemodialysis, respectively. The AUC0-inf of GS-331007 in patients with ESRD administered with sofosbuvir 1 hour before or 1 h after haemodialysis was at least 10-fold and 20-fold higher, respectively.  GS 331007 is efficiently removed by haemodialysis with an extraction coefficient of approximately 53%. Following a single 400 mg dose of sofosbuvir, a 4 h haemodialysis removed 18% of administered dose.

## Age, sex, race, body weight

## Voxilaprevir

Female subjects had a lower CL/F of VOX compared to male subjects, resulting in an approximately 17% higher AUC, compared to male subjects.

The Population PK analyses did not suggest a significant effect of race (described as White, Black, Asian and Other), body weight or age on the PK of VOX.

## Race - Japanese population

In a dedicated study the VOX PK between Caucasian (no parents/grandparents of Asian origin) and first generation (with Japanese diet) Japanese healthy subjects was explored. The distribution of OATP genotypes is given in Table 8. After administrating (SOF/VEL/VOX 400/100/100 mg tablet + VOX 100 mg tablet) on Day 1, the VOX AUC0-24 and Cmax were ~108% and 194% higher, respectively, in Japanese subjects while at steady-state (Day 10) the corresponding values were ~75% and 123% higher. VOX C24 and Ctau were also higher on Day 1 (C24: 27%) and Day 10 (Ctau: 49%) in Japanese subjects.

Table 8. Genetic OATP1B variants and frequencies in study GS-US-367-1905

| Characteristic       | Japanese (N = 20)   | Caucasian (N = 20)   | Total (N = 40)   |
|----------------------|---------------------|----------------------|------------------|
| OATP Genotype, n (%) |                     |                      |                  |
| *15/*15              | 1 (5.0%)            | 0                    | 1 (2.5%)         |
| *1A/*15              | 4 (20.0%)           | 2 (10.0%)            | 6 (15.0%)        |
| *1A/*1A              | 4 (20.0%)           | 5 (25.0%)            | 9 (22.5%)        |
| *1A/*1B              | 6 (30.0%)           | 8 (40.0%)            | 14 (35.0%)       |
| *1A/*5               | 0                   | 2 (10.0%)            | 2 (5.0%)         |
| *1B/*15              | 2 (10.0%)           | 0                    | 2 (5.0%)         |
| *1B/*1B              | 3 (15.0%)           | 3 (15.0%)            | 6 (15.0%)        |

## Sofosbuvir/Velpatasvir

Female subjects had a lower CL/F of VEL and SOF compared to male subjects, resulting in an approximately 50% and 20% higher exposure, respectively, compared to male subjects.

The Population PK analyses of SOF, GS-331007 and VEL did not suggest a significant effect of race (described as White, Black, Asian and Other) on the kinetics of either compound.

<div style=\"page-break-after: always\"></div>

Body weight (range 40 - 182 kg) did not have a clinically significant effect on VEL or SOF exposure according to the population pharmacokinetic analysis.

No formal PK study in elderly patients has been conducted. However, the impact of age (range 18 - 82 years) on the PK of SOF and VEL has been evaluated as a covariate in the population PK analyses. No clinically significant effect on VEL exposure was observed in subjects ≥75 years administered velpatasvir, however the number of subjects was limited (n=14).

## SOF/VEL/VOX

The safety and efficacy of VOX in children and adolescents aged &lt;18 years have not yet been established. The SOF/VEL/VOX FDC is not indicated in patients less than 18 years.

## Drug-Drug Interactions

## Effects of other medical products on the pharmacokinetics of voxilaprevir and SOF/VEL/VOX

VOX is a substrate of P-gp, BCRP, OATP1B1, OATP1B3 and CYP3A4.

When VOX was administered after repeated dosing (7 days) of rifampicin (strong inducer of metabolising enzymes and drug transporters) the resulting decrease in exposure was large (~70% decrease). The effect of rifampicin was extensive also on the SOF and VEL exposure (70-80% decrease when studied as the mono-components). The large decrease in exposure for all three compounds SOF, VEL and VOX leads to a contraindication with strong CYP3A4 and P-pg inducers (e.g. rifampicin, rifabutin, St. John's wort, carbamazepine, phenobarbital and phenytoin). The contraindication is due to that the decrease in exposure could result in a lack of efficacy. Furthermore, medicinal products that are moderate inducers (e.g. oxcarbazepine, efavirenz, modafinil) are not recommended as concomitant medical products to SOF/VEL/VOX treatment.

To investigate the importance of CYP3A4 metabolism of VOX an in vivo DDI study with voriconazole (CYP3A4 inhibitor) and grapefruit juice (intestinal CYP3A4, P-gp and OATP2B1 inhibitor) was performed. There was an increase of VOX AUC 84% (point estimate) and no effect on Cmax when coadministered with voriconazole. In addition, the t½ was prolonged (from 32 to 39 h) with voriconazole indicating that hepatic CYP3A4 was inhibited. There was no change in VOX exposure following coadministration with grapefruit juice, suggesting that intestinal OATP inhibition is not important.

Single dose studies with rifampicin (OATP1B1/3 inhibitor at single dose) and cyclosporine A (multiple transporter inhibitor, P-gp, BCRP, MRP2, OATP1B1/3) have been performed, resulting in a large increase of VOX exposure when co-administered compared to VOX administered alone. When VOX was co-administrated with cyclosporine A (CsA) or RIF, AUC increased ~9- fold and ~8- fold, respectively, and Cmax ~19-fold and ~11-fold, respectively.

The solubility of VOX is not pH dependent and therefore medical products that increase gastric pH are not expected to have an influence on plasma concentration of VOX. This was confirmed in a DDI study using the SOF/VEL/VOX FDC co-administered with famotidine or omeprazole. When co-administered with omeprazole AUC was unchanged and Cmax of VOX was slightly decreased, however this is not considered to be clinically relevant. Also SOF and its metabolites and VEL were monitored in this DDI study. The solubility of VEL is pH dependent and therefore medical products that increase gastric pH are expected to decrease plasma concentration of VEL. Co-administration of SOF/VEL/VOX FDC with famotidine did not have an effect on VEL and SOF/GS-331007 exposure. When co-administered with omeprazole (20 mg) VEL and SOF AUC and Cmax decreased. Two dosing regimens were investigated;

<div style=\"page-break-after: always\"></div>

omeprazole dose 2 h prior to SOF/VEL/VOX or omeprazole administered 4 h after SOF/VEL/VOX. In the former case SOF exposure decreased ~25% and VEL ~50%. In the latter regimen SOF exposure was unchanged and VEL exposure decreased ~50%. An effect of omeprazole on SOF and VEL exposure has been shown previously with Epclusa.

SOF/VEL/VOX (400/100/100 mg) has been studied in several combinations of antiretroviral treatments. In a DDI study following co-administration of SOF/VEL/VOX with a single dose of ATV+RTV, a significantly higher VOX exposure was shown (&gt;4-fold), while the half-life of VOX was not altered. A summary of the effect of HIV ARV regimens on the SOF/VEL/VOX PK in healthy subjects is given in Table 9. For the combination EVG/COBI/FTC/TAF, there was an increase of the VOX exposure (AUC 2.7-fold increase), the higher VOX exposures was attributed to inhibition of OATP, CYP3A, P-gp and BCRP by COBI. A similar increase of VOX exposure was observed with the DRV/r + FTC/TDF combination. The higher VOX exposures following co-administration with DRV/r + TVD were attributed to the net inhibition of OATP, CYP3A and efflux transporters by DRV and/or RTV. For the combination FTC/RPV/TAF there was no increase of the VOX exposure.

Combinations containing efavirenz regimens are not recommended as it has been previously shown that the exposure of VEL decreased (~50%). An effect on P-gp and possibly enzymes by EFV (inducer) is likely the mechanism for the change in exposure of VEL. No DDI study with VOX has been performed. It is expected that also VOX exposure would decrease if co-administered with the inducer efavirenz.

<div style=\"page-break-after: always\"></div>

Table 9. Effect of co-administered antiretrovirals (ARV) on PK of SOF, GS-566500, GS-331007 (SOF metabolites), VEL, VOX and effect of SOF/VEL/VOX on PK of co-administered ARV regimens

| SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   | SOF/VEL/VOX+VOX + ARVs / SOF/VEL/VOX+VOX   |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Cohort 1: FTC/RPV/TAF                      | VOX                                        | VEL                                        | VEL                                        | SOF                                        | SOF                                        | GS-566500                                  | GS-566500                                  | GS-331007                                  |
| AUC tau                                    | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          |
| C max                                      | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          |
| C tau                                      | ↔                                          | ↔                                          | ↔                                          | NA                                         | NA                                         | NA                                         | NA                                         | NA                                         |
| Cohort 2: EVG/COBI/FTC/TAF                 | VOX                                        | VEL                                        | VEL                                        | SOF                                        | SOF                                        | GS-566500                                  | GS-566500                                  | GS-331007                                  |
| AUC tau                                    | ↑ 171%                                     | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↑ 43%                                      |
| C max                                      | ↑ 92%                                      | ↔                                          | ↔                                          | ↑ 27%                                      | ↑ 27%                                      | ↔                                          | ↔                                          | ↔                                          |
| C tau                                      | ↑ 350%                                     | ↑ 46%                                      | ↑ 46%                                      | NA                                         | NA                                         | NA                                         | NA                                         | NA                                         |
| Cohort 3: DRV+RTV+FTC/TDF                  | VOX                                        | VEL                                        | VEL                                        | SOF                                        | SOF                                        | GS-566500                                  | GS-566500                                  | GS-331007                                  |
| AUC tau                                    | ↑ 143%                                     | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↔                                          |
| C max                                      | ↑ 72%                                      | ↔                                          | ↔                                          | ↓ 30%                                      | ↓ 30%                                      | ↔                                          | ↔                                          | ↔                                          |
| C tau                                      | ↑ 300%                                     | ↔                                          | ↔                                          | NA                                         | NA                                         | NA                                         | NA                                         | NA                                         |
| SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              | SOF/VEL/VOX+VOX + ARVs / ARVs              |
| Cohort 1: FTC/RPV/TAF                      | FTC                                        | FTC                                        | RPV                                        | RPV                                        | TAF                                        | TAF                                        | TFV                                        | TFV                                        |
| AUC tau a                                  | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↑ 52%                                      | ↑ 52%                                      | ↑ 79%                                      | ↑ 79%                                      |
| C max                                      | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↑ 32%                                      | ↑ 32%                                      | ↑ 64%                                      | ↑ 64%                                      |
| C tau                                      | ↔                                          | ↔                                          | ↔                                          | ↔                                          | NA                                         | NA                                         | ↑ 89%                                      | ↑ 89%                                      |
| Cohort 2: EVG/COBI/FTC/TAF                 | EVG                                        | COBI                                       | COBI                                       | FTC                                        | FTC                                        | TAF                                        | TAF                                        | TFV                                        |
| AUC tau a                                  | ↔ ↑                                        | ↔ ↑                                        | 50% ↔                                      | 50% ↔                                      | ↔                                          | ↔                                          | ↔                                          | ↔                                          |
| C max                                      | ↔ ↔                                        | ↔ ↔                                        | ↔                                          | ↔                                          | ↓ 21%                                      | ↓ 21%                                      | ↔                                          | ↔                                          |
| C tau                                      | ↑ 32% ↑                                    | ↑ 32% ↑                                    | 250% ↔                                     | 250% ↔                                     | NA                                         | NA                                         | ↔                                          | ↔                                          |
| Cohort 3: DRV+RTV+FTC/TDF                  | DRV                                        | DRV                                        | RTV                                        | RTV                                        | FTC                                        | FTC                                        | TFV                                        | TFV                                        |
| AUC tau                                    | ↔                                          | ↔                                          | ↑ 45%                                      | ↑ 45%                                      | ↔                                          | ↔                                          | ↑ 39%                                      | ↑ 39%                                      |
| C max                                      | ↔                                          | ↔                                          | ↑ 60%                                      | ↑ 60%                                      | ↔                                          | ↔                                          | ↑ 48%                                      | ↑ 48%                                      |
| C tau                                      | ↓ 34%                                      | ↓ 34%                                      | ↔                                          | ↔                                          | ↔                                          | ↔                                          | ↑ 47%                                      | ↑ 47%                                      |

NA = not applicable

aAUClast is presented for TAF.

## Effects of other medical products on the pharmacokinetics of velpatasvir and SOF/VEL

Velpatasvir is relatively metabolically stable in incubations in human microsomes and hepatocytes and the majority of the administered oral radioactive dose was found as parent compound in faeces. The major elimination pathway(s) for VEL is not fully understood, however most likely biliary excretion is a major pathway. In vitro, VEL was determined to be a substrate for P-gp and BCRP and indicated to be an OATP1B3 substrate, but not an OCT1 or OATP1B1 substrate.

Velpatasvir was administered with both single and repeated dosing of rifampicin. The duration of the repeat dosing was a bit short (7 days) for full effect of induction, but the resulting decrease in exposure was 70-80% decrease.

The effect of ketoconazole (P-gp and CYP3A4 inhibitor) was limited on the exposure of VEL (AUC increased 70%) and administration of single dose rifampicin (OATP1B1/3 inhibitor as single dose) resulted in 47% increase of AUC. In addition, velpatasvir exposure was approx. 2-fold when coadministered with CsA (an inhibitor of multiple transporters).

SOF/VEL (400/100 mg) has been studied in several combinations of antiretroviral treatments. Summary of the effect of HIV ARV regimens on the SOF/VEL PK in healthy subjects is given in Table

<div style=\"page-break-after: always\"></div>

10. For the combinations EVG/COBI/FTC/TDF, RAL+ FTC/TDF, FTC/RPV/TDF, E/C/F/TAF and DTG there was no or slight increase of the VEL exposure. For the combination with ATV+RTV+ FTC/TDF the increase was substantial. When SOF/VEL was administered with EFV/FTC/TDF the exposure of VEL decreased substantially (50-60%). Both VEL and SOF exposure decreased up to 30-40% when coadministered with LPV/r+ FTC/TDF and SOF exposure decreased up to 30-40% when co-administered with DRV+RTV+ FTC/TDF.

Table 10. Summary of PK parameters of VEL, SOF and metabolites and evaluated antiretroviral treatment when SOF/VEL were administered alone compared with administration of SOF/VEL + ARVs

|                   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   | SOF/VEL+ARV / SOF/VEL   |
|-------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                   | SOF PK Parameters       | SOF PK Parameters       | SOF PK Parameters       | GS-566500 PK Parameters | GS-566500 PK Parameters | GS-331007 PK Parameters | GS-331007 PK Parameters | VEL PK Parameters       | VEL PK Parameters       | VEL PK Parameters       |
| ARVs              | AUC                     | C max                   | AUC                     | C max                   | AUC                     | C max                   | C tau                   | AUC                     | C max                   | C tau                   |
| EFV/FTC/TDF       | ↔                       | ↑ 38%                   | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↓ 53%                   | ↓ 47%                   | ↓ 57%                   |
| FTC/RPV/TDF       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       |
| DTG               | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       |
| EVG/COBI/FTC/TAF  | ↑ 37%                   | ↔                       | ↔                       | ↔                       | ↑ 48%                   | ↔                       | ↑ 58%                   | ↑ 50%                   | ↑ 30%                   | ↑ 60%                   |
| EVG/COBI/ FTC/TDF | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↑ 45%                   | ↔                       | ↔                       | ↑ 37%                   |
| DRV+RTV+ FTC/TDF  | ↓ 28%                   | ↓ 38%                   | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↓ 24%                   | ↔                       |
| ATV+RTV+ FTC/TDF  | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↑ 42%                   | ↑ 142%                  | ↑ 55%                   | ↑ 301%                  |
| LPV/r+ FTC/TDF    | ↓ 29%                   | ↓ 41%                   | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↓ 30%                   | ↑ 63%                   |
| RAL+ FTC/TDF      | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       | ↔                       |

90% CIs of the %GLSM ratios were within ( ↔ ), extended above ( ↑ ), or extended below ( ↓ ) the predetermined alteration boundaries of 70% to 143%

## Effects of voxilaprevir and SOF/VEL/VOX on the pharmacokinetics of other medical products

In vitro, voxilaprevir showed no direct inhibition or time dependent inhibition on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or UGT1A1 at systemic concentrations. At intestinal level the risk of clinically relevant inhibition of CYP3A4 and UGT1A1 caused by VOX is considered to be low. Based in vitro data, no relevant induction signal was observed for AhR (CYP1A2), CAR (CYP2B6) or CYP3A4 (PXR).

In vitro studies showed that VOX was not likely to be a clinically relevant inhibitor of drug transporters BSEP, MATE1, MRP2, OAT1, OAT3, OCT1 or OCT2, at systemic concentrations. Furthermore, VOX showed a concentration-dependent inhibition of OATP1B1 and OATP1B3 with IC50 of 0.18 and 0.70 μM, respectively. These results indicate that a clinically relevant interaction between VOX and OATP1B1 and OATP1B3 substrates cannot be excluded. In vitro, inhibition of P-gp and BCRP up to 10 μM was investigated and did not cause inhibition of P-gp and only slight inhibition of BCRP (6.7%) at 10 μM.

In vivo, there was no effect on cyclosporine (CYP3A4 substrate) exposure following co-administration with VOX 100 mg relative to cyclosporine administered alone (point estimate was 94-95%).

A relevant P-gp probe (dabigatran) was investigated in vivo co-administered with SOF/VEL/VOX. Dabigatran AUC and Cmax were 2.6-fold and 2.9-fold higher, respectively, following co-administration

<div style=\"page-break-after: always\"></div>

with SOF/VEL/VOX, relative to dabigatran administration alone. Furthermore, in vivo, the exposure (AUC) was 2.2-fold higher and 7.4-fold for pravastatin (OATP1B1, MRP2 and CYP3A4 substrate) and rosuvastatin (OATP1B1/3 and BCRP substrate), respectively, following co-administration with SOF/VEL/VOX, relative to statin administrated alone (Table 11). The median half-life for both pravastatin and rosuvastatin was similar with and without SOF/VEL/VOX. (see discussion on clinical pharmacology).

The effect of VOX on the PK of a representative hormonal oral contraceptive (OC) medication (norgestimate 0.180 mg/0.215 mg/0.250 mg/ethinyl estradiol 0.025 mg) was studied. Similar systemic exposures of norelgestromin and norgestrel were achieved following OC co-administration with and without VOX. An approximate 20% increase in point estimate in ethinyl estradiol AUCtau (90% CI 106-138) was observed when VOX was co-administered with OC compared to OC alone. No loss in contraceptive efficacy is expected following administration of combined hormonal contraceptives containing norgestimate/ethinyl estradiol with VOX based on PK and PD results.

SOF/VEL/VOX has been studied in several combinations of antiretroviral treatments. A summary of the effect of SOF/VEL/VOX 400/100/100 mg on the PK of HIV ARV regimens in healthy subjects is given in Table 13. It was shown in DDI studies that there was no clinically relevant change in exposure in DRV, RPV, EVG, FTC, COBI, or TAF when co-administered with SOF/VEL/VOX in relevant antiretroviral combinations. The exposure of tenofovir (TFV) increased in combination with SOF/VEL/VOX. The increase in TFV exposure was similar to that observed with SOF/VEL, indicating that VOX did not cause additional effects on the PK of TFV (from TDF). A caution involving renal monitoring for these combinations is reflected in the SmPC.

Table 11. Summary: Effect of SOF/VEL/VOX+VOX, VOX, VEL, and SOF on the PK of Co-administered Drugs in Healthy Subjects

| Change in PK           | GS-US-367-1727(SOF/VEL/VOX+VOX)             | GS-US-367-1727(SOF/VEL/VOX+VOX)             | GS-US-367-1727(SOF/VEL/VOX+VOX)             | GS-US-367-1727(SOF/VEL/VOX+VOX)             | GS-US-367-1727(SOF/VEL/VOX+VOX)             |
|------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                        | Pravastatin                                 | Rosuvastatin                                | Dabigatran                                  | Dabigatran                                  | Dabigatran                                  |
| Parameter              |                                             |                                             | Total                                       | Total                                       | Free                                        |
| AUC inf                | ↑ 116%                                      | ↑ 639%                                      | ↑ 161%                                      | ↑ 161%                                      | ↑ 122%                                      |
| C max                  | ↑ 89%                                       | ↑ 1788%                                     | ↑ 187%                                      | ↑ 187%                                      | ↑ 134%                                      |
| Change in PK Parameter | GS-US-367-1909 (SOF/VEL/VOX+VOX)            | GS-US-367-1909 (SOF/VEL/VOX+VOX)            | GS-US-367-1909 (SOF/VEL/VOX+VOX)            | GS-US-367-1909 (SOF/VEL/VOX+VOX)            | GS-US-367-1909 (SOF/VEL/VOX+VOX)            |
| Change in PK Parameter | Norgestimate/Ethinyl Estradiol              | Norgestimate/Ethinyl Estradiol              | Norgestimate/Ethinyl Estradiol              | Norgestimate/Ethinyl Estradiol              | Norgestimate/Ethinyl Estradiol              |
| Change in PK Parameter | EE NG                                       | EE NG                                       | EE NG                                       | NGMN                                        | NGMN                                        |
| AUC tau                | ↔ ↔                                         | ↔ ↔                                         | ↔ ↔                                         | ↔                                           | ↔                                           |
| C max                  | ↔ ↔                                         | ↔ ↔                                         | ↔ ↔                                         | ↔                                           | ↔                                           |
| C tau                  | ↔ ↔                                         | ↔ ↔                                         | ↔ ↔                                         | ↔                                           | ↔                                           |
| Change in PK           | Study GS-US-338-1417 (VOX individual agent) | Study GS-US-338-1417 (VOX individual agent) | Study GS-US-338-1417 (VOX individual agent) | Study GS-US-338-1417 (VOX individual agent) | Study GS-US-338-1417 (VOX individual agent) |
| Parameter              | CsA                                         | CsA                                         | CsA                                         | CsA                                         | CsA                                         |
| AUC inf                | ↔                                           | ↔                                           | ↔                                           | ↔                                           | ↔                                           |
| C max                  | ↔                                           | ↔                                           | ↔                                           | ↔                                           | ↔                                           |
| Change in PK           | GS-US-281-0115 (VEL individual agent)       | GS-US-281-0115 (VEL individual agent)       | GS-US-281-0115 (VEL individual agent)       | GS-US-281-0115 (VEL individual agent)       | GS-US-281-0115 (VEL individual agent)       |
| Parameter              | Pravastatin                                 | Rosuvastatin                                | Rosuvastatin                                | Digoxin                                     | CsA                                         |
| AUCinf or AUCtau       | ↑ 35%                                       | ↑ 169%                                      | ↑ 169%                                      | ↑ 34%                                       | ↓ 12%                                       |
| Cmax                   | ↑ 28%                                       | ↑ 161%                                      | ↑ 161%                                      | ↑ 88%                                       | ↔                                           |
| Change in PK           | P7977-1819 (SOF individual agent)           | P7977-1819 (SOF individual agent)           | P7977-1819 (SOF individual agent)           | P7977-0814 (SOF individual                  | P7977-0814 (SOF individual                  |
| Parameter              | CsA                                         | Tacrolimus                                  | Tacrolimus                                  | R-Methadone                                 | S-Methadone                                 |
| AUCinf or AUCtau       | ↔                                           | ↑ 9%                                        | ↑ 9%                                        | ↔                                           | ↔                                           |
| Cmax                   | ↔                                           | ↓ 27%                                       | ↓ 27%                                       | ↔                                           | ↔                                           |

<div style=\"page-break-after: always\"></div>

CsA = cyclosporine (cyclosporin A) EE = ethinyl estradiol; NG = norgestrel; NGMN = norelgestromin (the primary and pharmacologically active metabolite of norgestimate)

Ninety percent CIs of the GLSM ratio were within ( ↔ ), extended above ( ↑ ), or extended below ( ↓ ) the predetermined lack of PK alteration boundaries of 70% to 143% for Studies GS-US-367-1909, GS-US-367-1727, GS-US-338-1417, GS-US-281-0115 except for digoxin and CsA (80% to 125%) and P79770814.

Bioequivalence boundaries of 80% to 125% were used for Study P7977-1819.

## Effects of velpatasvir and SOF/VEL on the pharmacokinetics of other medical products

Velpatasvir showed no direct inhibition on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or UGT1A1. Based in vitro data, no relevant induction signal was observed for AhR (CYP1A2) and CAR (CYP2B6). An in vitro induction signal was detected for PXR (CYP3A4), however based on clinical data interactions due to induction of PXR is considered low.

In vitro studies showed that VEL was not an inhibitor of drug transporters BSEP, MATE1, MRP2, OAT1, OAT3, OATP1A2, OATP2B1, OCT1, OCT2, or NTCP (sodium taurocholate cotransporter protein) at clinically relevant concentrations. In vitro, VEL showed a concentration-dependent inhibition of OATP1B1, OATP1B3, P-gp and BCRP with IC50 of 1.5, 0.26, 20.6 and 0.30 μM, respectively. These results indicate that a clinically relevant interaction between VEL and OATP1B1 and 1B3 and intestinal inhibition of P-gp and BCRP by VEL substrates cannot be excluded. The inhibitory potential of VEL on OATP1B1/3, P-gp and BCRP has been investigated in clinical DDI studies.

There was a limited effect on the cyclosporine (CYP3A4 substrate) exposure (slightly decreased) following co-administration after multiple dosing with VEL relative to CsA administered alone.

For pravastatin (OATP1B1 and MRP2 and possibly CYP3A substrate) the in vivo exposure (AUC) was approximately 1.4-fold following co-administration with VEL, relative to pravastatin administration alone. Rosuvastatin (OATP1B1/3 and BCRP substrate) exposure was 2.7-fold following coadministration with VEL, relative to rosuvastatin administration alone. The median half-life for both pravastatin and rosuvastatin was similar with and without velpatasvir.

Digoxin (P-gp probe) exposure increased following co-administration with VEL, relative to digoxin administration alone.

It can be concluded that VEL is an in vivo P-gp, BCRP and OATP1B1/3 inhibitor.

The effect of VEL on the PK of a representative hormonal contraceptive (OC) medication (norgestimate /ethinyl estradiol) was studied. Similar systemic exposures of norelgestromin and norgestrel were achieved following OC co-administration with and without VEL (exposure decreased 3% to 10% point estimates). An approximate 39% increase in ethinyl estradiol Cmax and decrease in Ctau (approximately 17% point estimate 90% CI 65, 106) were observed with no change in AUCtau when VEL was co-administered with OC compared with OC alone.

<div style=\"page-break-after: always\"></div>

Table 12. Effect of VEL on the PK of Co-administered Drugs in Healthy Subjects

|                    | GS-US-281-0101 a    | GS-US-281-0101 a    | GS-US-281-1058 b               | GS-US-281-1058 b               | GS-US-281-1058 b               |
|--------------------|---------------------|---------------------|--------------------------------|--------------------------------|--------------------------------|
| Change in PK       | SOF                 | GS-331007           | Norgestimate/Ethinyl Estradiol | Norgestimate/Ethinyl Estradiol | Norgestimate/Ethinyl Estradiol |
| Parameter          |                     |                     | ethinyl estradiol              | Norgestrel                     | norelgestromin c               |
| AUC inf or AUC tau | ↑ 138%              | ↔                   | ↔                              | ↔                              | ↔                              |
| C max              | ↑ 81%               | ↓ 36%               | ↑ 39%                          | ↔                              | ↔                              |
| C tau              | ND                  | ND                  | ↓ 17%                          | ↔                              | ↔                              |
| GS-US-281-0115 b   | GS-US-281-0115 b    | GS-US-281-0115 b    | GS-US-281-0115 b               | GS-US-281-0115 b               | GS-US-281-0115 b               |
|                    | Digoxin Pravastatin | Digoxin Pravastatin | Rosuvastatin Cyclosporine      | Rosuvastatin Cyclosporine      | A                              |
| AUC inf            | ↑ 34% ↑ 35%         | ↑ 34% ↑ 35%         | ↑ 169% ↓                       | ↑ 169% ↓                       | 12%                            |
| C max              | ↑ 88% ↑ 28%         | ↑ 88% ↑ 28%         | ↑ 161%                         | ↑ 161%                         | ↔                              |
| C tau              | ND ND               | ND ND               | ND                             | ND                             | ND                             |

90% CIs of the GLSM ratio were within ( ↔ ), extended above ( ↑ ), or extended below ( ↓ ) the predetermined lack of PK alteration boundaries of 70% to 143% except for digoxin and CsA (80% to 125%).

SOF/VEL has been studied in several combinations of antiretroviral treatments. Summaries of the effect of SOF/VEL 400/100 mg on the PK of HIV ARV regimens in healthy subjects are given in Table 13. The exposure of tenofovir (TFV) increased in all cohorts with the highest increase with the EFV/FTC/TDF combination.

## Sofosbuvir

## Effects of other medical products on the pharmacokinetics of sofosbuvir

Renal secretion is involved in the elimination of GS-566500 and GS-331007. The transporter(s) involved are unknown, but it has been shown that GS-331007 is not a substrate for renal transporters OAT1 or 3, OCT2, MRP2, P-gp, BCRP or MATE1. Sofosbuvir is a substrate of P-gp and BCRP, but not a substrate for hepatic uptake transporters, OATP1B1, OATP1B3, or OCT1.

A 600 mg single dose of CsA had a large effect on SOF exposure with a 4.5-fold increase. However, the exposure to GS-331007 was not statistically different. Tacrolimus did not affect exposure to SOF or its metabolites.

The in vivo effect on SOF exposure of the strong P-gp inducer rifampicin was significant. Medicinal products that are potent P-gp inducers (e.g. rifampicin, rifabutin, St. John's wort, carbamazepine, phenobarbital and phenytoin) are contraindicated with sofosbuvir (Sovaldi ® , Post Approval Measurement EMEA/H/C/002798/II/0018). In addition, medicinal products that are moderate CYP and P-gp inducers (e.g. oxcarbazepine and modafinil) are not recommended to be co-administered with sofosbuvir.

## Effects of sofosbuvir on the pharmacokinetics of other medical products

Sofosbuvir and its metabolite, GS-331007 did not show detectable in vitro inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP2D6, CYP3A or UGT1A1.

<div style=\"page-break-after: always\"></div>

Induction of CYP3A4 and CYP2B6 was observed in vitro. An in vivo DDI study with oral contraceptives co-administered with sofosbuvir for 7 days did not show any sign of reduced exposure.

Sofosbuvir and GS-331007 are not inhibitors of drug transporters P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3 and OCT1. GS-331007 is not an inhibitor of OAT1, OCT2, and MATE1.

DDI studies have been performed in healthy volunteers and patients to evaluate effect of SOF on the PK of methadone, CsA and tacrolimus. Further, the effect of these medications on the PK of SOF and its metabolites has been evaluated. Methadone exposure was unaffected by SOF as were exposures to sA and tacrolimus, although Cmax for tacrolimus was decreased by almost 30%.

<div style=\"page-break-after: always\"></div>

Table 13. Summary of PK parameters of antiretroviral treatments when ARVs were administered alone compared with administration of SOF/VEL + ARVs

| GS-US-342-1167   |
|------------------|

Ninety percent CIs of the GLSM ratio were within ( ↔ ), extended above ( ↑ ), or extended below ( ↓ ) the predetermined lack of PK alteration boundaries of 70% to 143% (except for RAL: 50% to 200 %) for Studies GS US 342 1167 and GS US 342-1326 .

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Sofosbuvir

Sofosbuvir, a prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is ultimately converted to the pharmacologically active nucleoside analogue triphosphate form (GS-461203) within hepatocytes. GS-461203 can be incorporated by the HCV NS5B polymerase and acts as a chain terminator. Sofosbuvir is a HCV NS5B directed inhibitor with broad genotypic activity in vitro.

## Velpatasvir

Biochemical confirmation of NS5A inhibition by VEL is not currently possible because NS5A has no known enzymatic function. Nevertheless, several lines of experimental evidence support the conclusion that NS5A is the target of VEL: cell-based studies demonstrated that replicons bearing some resistance mutations to first-generation NS5A inhibitors are cross-resistant to VEL; replicon resistance selection studies that identified VEL resistance mutations within the NS5A gene; and biochemical studies demonstrated that VEL lacks activity against NS3/4A protease, NS5B polymerase, and the HCV internal ribosome entry site (IRES). In addition, VEL monotherapy demonstrated selection of NS5A mutations.

## Voxilaprevir

Voxilaprevir (VOX) is a NS3/4A protease inhibitor with potent antiviral activity against HCV genotypes 1 to 6 and an improved resistance profile compared with previous HCV PIs. Voxilaprevir acts as a noncovalent, reversible inhibitor of NS3 protease.

## Inhibition of NS3 proteolytic activity in enzymatic assays and crystal structure

VOX was tested for its ability to inhibit genotype 1b and 3a wild-type NS3 proteases in enzymatic assays using recombinant NS3 protease domains and isogenic NS4A peptide cofactors provided in trans.

Table 14 presents the potency data for VOX. Voxilaprevir was a potent inhibitor of both genotype 1b and genotype 3a NS3 proteases in biochemical assays.

<div style=\"page-break-after: always\"></div>

Table 14. Enzymatic Activity of VOX Against HCV Genotype 1b and 3a NS3 Proteases

|     | Ki (nM)a      |               |
|-----|---------------|---------------|
| VOX | 0.038 ± 0.010 | 0.066 ± 0.018 |

Values represent the mean ± SD of 2 or more independent experiments.

A competition study was performed to determine the mode of inhibition for VOX against a peptide substrate of the genotype 1b NS3 protease. Voxilaprevir was competitive with substrate in this assay.

The crystal structure of VOX bound to the active site of the genotype 1a NS3 protease domain was determined to 1.4 angstrom resolution. The crystal structure of the HCV protease in complex with VOX confirmed that the inhibitor binds non-covalently to the active site of the NS3 protease.

## Activity against HCV replicons or infectious systems

The antiviral activity of VOX was determined in a panel of genotype 1 to 6 HCV replicons.

Table 15 presents VOX antiviral activity against HCV genotypes 1 to 6. Voxilaprevir exhibits potent pangenotypic antiviral activity with EC50 ranging from 0.33 to 6.6 nM across genotypes 1 to 6. The antiviral activity of VOX against genotypes 2a/b and 3 is within 2-fold of the genotype 1 potency. Voxilaprevir exhibited low cellular cytotoxicity (range of CC50: 18,300 to 21,000 nM) resulting in selectivity indices &gt; 3000 across the tested genotypes (PC-338-2001). The VOX EC50 value was 0.8 nM in a tissue culture-adapted genotype 2a J6/JFH infectious virus assay.

Table 15. VOX Antiviral Activity Against HCV Genotypes 1 to 6

| Genotype   | HCV Replicon Strain   | Full Length or NS3 Chimera   | VOX EC 50 (nM) ± SD a   |
|------------|-----------------------|------------------------------|-------------------------|
| 1a b       | H77                   | Full length                  | 3.9 ± 1.5               |
| 1b b       | Con1                  | Full length                  | 3.3 ± 1.4               |
| 2a b       | JFH-1                 | Full length                  | 3.7 ± 1.6               |
| 2a b       | J6                    | Full length                  | 4.5 ± 1.5               |
| 2b c       | J8                    | Full length                  | 1.8 ± 1.2               |
| 2b c       | HM568433              | Chimera                      | 6.6 ± 1.4               |
| 3a c       | S52                   | Full length                  | 6.1 ± 1.5               |
| 4a b       | ED43                  | Full length                  | 2.9 ± 1.5               |
| 4d b       | QC382                 | Full length                  | 3.2 ± 1.3               |
| 5a c       | SA13                  | Chimera                      | 1.9 ± 1.4               |
| 6a b       | HK6a Consensus        | Full length                  | 4.0 ± 1.3               |
| 6a b       | GSI6a-1               | Full length                  | 3.0 ± 1.1               |
| 6e c       | DQ314805              | Chimera                      | 0.33 ± 1.5              |
| 6n c       | DQ835768              | Chimera                      | 2.9 ± 1.2               |

In the presence of 40% serum, the potency of VOX was reduced by 6.8-fold against the genotype 1a HCV replicon. The effect of protein binding was also evaluated using an equilibrium dialysis assay in which VOX in human plasma was dialyzed against cell culture medium (CCM) containing 10% fetal bovine serum. The concentration of VOX in human plasma was 12-fold higher than in CCM. The resultant protein adjusted EC50's ranged from 3.96 to 72 nM for HCV genotypes 1 to 6.

<div style=\"page-break-after: always\"></div>

## Effects of VOX on clinical isolates in vitro

Table 16 presents the mean and median VOX EC50 results against the chimeric replicons encoding NS3 protease genes from clinical isolates of 332 DAA-naive and DAA-experienced subjects with genotypes 1 through 6, including 30 different subtypes. The median EC50 values were similar to the results of laboratory replicons.

Table 16. VOX Activity Against Chimeric Replicons Containing NS3 from Genotype 1 to 6 Clinical Isolates

|                   | Replicons Containing NS3 Protease from Clinical Isolates   | Replicons Containing NS3 Protease from Clinical Isolates   | Replicons Containing NS3 Protease from Clinical Isolates   | Replicons Containing NS3 Protease from Clinical Isolates   |
|-------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Replicon Genotype | Number of clinical isolates                                | Mean VOX EC50 ± SD, nM                                     | Median VOX EC 50 , nM                                      | Range (Min, Max)                                           |
| 1a                | 58                                                         | 1.51 ± 2.92                                                | 0.59                                                       | (0.14-19.16)                                               |
| 1b                | 29                                                         | 0.64 ± 0.52                                                | 0.50                                                       | (0.19-2.87)                                                |
| 2a                | 18                                                         | 3.33 ± 1.37                                                | 2.8                                                        | (1.78-6.72)                                                |
| 2b                | 43                                                         | 2.95 ± 1.98                                                | 2.1                                                        | (0.92-8.3)                                                 |
| 3a                | 32                                                         | 6.4 ± 3.36                                                 | 6.3                                                        | (1.3-21.48)                                                |
| 4a                | 58                                                         | 0.61 ± 0.37                                                | 0.52                                                       | (0.12-1.7)                                                 |
| 4d                | 11                                                         | 0.80 ± 0.23                                                | 0.85                                                       | (0.41-1.1)                                                 |
| 4r                | 1                                                          | 1.15                                                       | 1.15                                                       | NA                                                         |
| 5a                | 16                                                         | 2.12 ± 1.27                                                | 1.8                                                        | (0.87-5.63)                                                |
| 6a                | 15                                                         | 3.05 ± 2.07                                                | 2.7                                                        | (0.23-7.35)                                                |
| 6e                | 12                                                         | 0.23 ± 0.09                                                | 0.2                                                        | (0.12-0.43)                                                |

Additionally, the susceptibility to VOX of low-frequency variants that were observed in clinical isolates was tested. NS3 protease sequences containing different patterns of resistance-associated polymorphisms were synthesized and tested against a VOX. The majority of genotype 1 variants showed no resistance or low resistance to VOX. Two genotype 1a variants, Q80K+D168Y and Q41H+F43L+Q80K+D168Y, showed high levels of resistance to VOX with 116.5- and 232.7-fold increase in EC50, respectively. Genotype 2b (R155M+D168Y), genotype 4 (R155Q+D168V, Q80K+D168Y), and genotype 6a (L80K+D168E) variants showed no resistance to VOX.

The antiviral activity of VOX was further assessed for polymorphism in and near the NS3 protease active site for HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, and 6a. Voxilaprevir retained full activity against the major polymorphism in genotype 1a, Q80K (no shift in EC50). All polymorphisms assessed across HCV genotypes 1b, 2a, 3b, 3a, 4a, and 6a also remained susceptible to VOX (&lt; 1.2-fold shift) with the exception of the D168E polymorphism in genotype 6a, which showed 6-fold reduced susceptibility compared with the parent replicon.

## In vitro resistance selection

To determine the in vitro resistance profile of VOX, drug-resistant colonies were selected with VOX in HCV genotypes 1a, 1b, 2a, 3a, 4a, 5a, and 6a.

HCV replicon cell colonies emerged with significant resistance to VOX at NS3 positions 156 and 168 in genotypes 1 through 6. Genotypes 1a, 1b (Con-1), 2a (JFH-1 and J6), 3a (S52), and 4a (ED43) replicon cells selected A156L, A156V, or A156T substitutions. Replicon clones with A156L, A156V, or A156T demonstrated &gt; 253-fold reduced susceptibility to VOX. Variants at position 168 were selected in genotype 2a replicons (D168E in genotype 2a JFH-1 and J6 cells), genotype 5a (D168A/H/R/Y), and genotype 6a (D168H/Y) replicon cells. These variants confer no-to-low levels of resistance (1.5- to 17.8-fold). In genotypes 5 and 6, double variants Q41R+D168H/Y and Q41R+D168H were predominantly selected, respectively. The double variants conferred higher levels of resistance to VOX (35- to 39-fold) compared with the single variants (2.7- to 13.5-fold).

<div style=\"page-break-after: always\"></div>

Other less common single variants observed in the NS3 protease and helicase regions were also phenotyped, including Q9R, P67S, Q89R, V113L, A200G, A200D, D249A, I359V, K583E, and S332P. None of these substitutions conferred any meaningful resistance to VOX.

Additionally, when tested in HCV replicon colony reduction assays, VOX has a higher resistance barrier compared with GZR, requiring 9-fold lower drug concentrations than GZR in genotype 3a to suppress comparable amounts of colony formation cells.

## In vitro activity of VOX against known NS3/4A protease inhibitor RAVs

To determine the susceptibility of individual and combination variants to VOX, variants were engineered by site-directed mutagenesis across genotypes 1 through 6, and their susceptibility to VOX was tested. Overall, 347 replicons were cloned, including 236 single, 86 double, and 25 triple variants. Of the 347 substitutions, 284 replicated, while 47 single, 13 double, and 3 triple variants showed low replication signals or had no replication signal. The 284 single, double, and triple variants that replicated were grouped based on their levels of resistance to VOX and categorized as having no resistance (≤ 2.5-fold EC50 change), low-level resistance (2.5- to 20-fold EC50 change), moderate-level resistance (20- to 100-fold EC50 change), or high-level resistance (&gt; 100-fold EC50 change).

In genotype 1a, 77% (49 of 64) tested single variants showed ≤ 2.5-fold resistance to VOX and 3% (2 of 64) tested single variants showed &gt; 100-fold resistance to VOX. The single variants conferring high-level of resistance were A156T and A156L with 2532- and 581-fold change, respectively, to VOX. A156 RAVs are problematic for all macrocyclic PIs, due to disruption of the binding site by amino acid substitution at this position. However, the viral fitness of A156T/V variants is significantly lower than that of other resistant variants and thus they are not frequently observed in HCV-infected patients (Tong 2006).

Of the 44 genotype 1a variants tested for VOX, 28 (64%) demonstrated ≤ 2.5-fold reduced susceptibility, and only 1 (2%), showed high-level resistance (&gt; 100-fold). The only double variant that conferred &gt; 100-fold resistance to VOX was Q41R+A156T. The majority of the triple variants tested in genotype 1a did not confer resistance to VOX; these same triple variants conferred moderate- to high-levels of resistance to several other tested NS3/4A PIs, including paritaprevir (PTV), ASV, and SMV.

In genotype 1b, ≤ 2.5-fold resistance to VOX, was observed for 69% (22 of 32) single variants. Variants at position 168 (D168A/V/Y) which demonstrate high-level resistance to earlier generation PIs (including PTV, ASV, and SMV) showed &lt; 3.5-fold resistance to VOX. A156T and A156V demonstrated high levels of resistance to VOX. All genotype 1b double variants tested demonstrated &lt; 3.4-fold reduced susceptibility to VOX.

The majority of the single mutants in genotypes 2a, 2b, 3a, and 4a displayed no to low-level resistance to VOX. In genotype 2a, A156T had moderate-level resistance to VOX (38-fold), and A156V and A156L were the only NS3 RAVs that demonstrated high-level resistance to VOX (&gt; 129-fold). In genotype 3, 1 double mutant Y56H+Q168R demonstrated high-level resistance to VOX (286-fold). In genotype 4a, variants at position 156 (A156L/T/V) conferred &gt; 143, reduced susceptibility to VOX. In genotype 5, VOX demonstrated no to moderate-level resistance to variants at position 168 (D168A/E/H/K/R/V/Y). In genotype 6a, variants at position 168 (D168A/E/H/V/Y) demonstrated 1.5- to 4.2-fold resistance to VOX.

<div style=\"page-break-after: always\"></div>

## Cross-resistance to NS5A and NS5B inhibitors RAVs

Voxilaprevir was tested against a panel of replicons encoding substitutions conferring resistance to NS5A inhibitors (Y93H in genotype 1a; Y93H and L31V in genotype 1b), NS5B nucleoside polymerase inhibitors (S282T in genotype 1b; S282T or M289L in genotype 2a), non-nucleoside polymerase inhibitors (including NS5B NNI RAVs at positions 316, 414, 419, 423, 445, 448, 452, and 486). Voxilaprevir maintained full activity against replicons encoding a variety of NS5A inhibitor-, NS5B NI-, and NS5B NNI resistance mutations.

## 2.4.4. Discussion on clinical pharmacology

## Pharmacokinetics

Basic pharmacokinetic characteristics for voxilaprevir such as absorption, distribution and elimination have in general been sufficiently investigated.

## ADME

## Dose proportionality and time dependency:

Voxilaprevir exposure increased far more than in proportion, when the dose increased from 100 mg to 900 mg the AUC increased &gt;100-fold. VOX is a P-gp, BCRP and OATP1B1/3 substrate, but is also an inhibitor of the same substrates. The nonlinearity may be due to inhibition of any of these transporters and it could be at intestinal and/or hepatic level.

The accumulation of VOX after 10 days repeated dosing was ~2-fold. This is in line with the expected for a substance with a 35 h half-life (calculated accumulation 2.6-fold).

Elimination: In the ADME study the profiling was conducted for pooled plasma over 0-72 h, which is not optimal considering that the half-life of radioactivity was 53 h. Results show that unchanged VOX accounted for 91% of the radioactivity but, based on the radioactivity AUC0-inf (918 ng.h/mL) and the VOX AUC (667 ng.h/mL), VOX only accounts for 73% of the AUC. Metabolite profiling is a stepwise process and it would have been appropriate to also attempt to investigate all available plasma time points i.e. up to 120 h. It is generally recommended that metabolites contributing to &gt;10% of the AUC of drug related material are structurally characterised. However, in this case in plasma no human unique or large metabolite has been indicated up to 72 h and it is acknowledged that the levels of radioactivity are low at later time-points.

The mean faecal recovery of [ 14 C]-radioactivity was 91%, while no radioactivity was detected in urine. VOX was the major compound found in faeces accounting for on average 40% of the administered dose. Eleven metabolites was found in faeces, M19 (hydrolysis) accounted for 22% and M9 (dehydrogenation) for 7.5% of radioactive dose, while all other metabolites accounted for ≤5% each.

The absolute bioavailability has not been determined. As the fraction absorbed (Fabs) is unknown, it is not known whether the parent compound in faeces is unabsorbed VOX or excreted as parent compound. In general parent excreted after 48 h can be considered systematically available, however in this case with a long t½ (35 h) this may be less useful.

The hydrolysed metabolites M19 (sulphonamide hydrolysis) and secondary metabolites M21, M22, M25 and M26 were found in faeces only and was not formed in vitro. This suggests that this pathway is likely catalysed by the intestinal microflora. However, no experiments e.g. incubation in faeces have

<div style=\"page-break-after: always\"></div>

been performed to verify this. In total, this pathway accounts for 34% including secondary metabolites, in addition ca. 40% was found as parent compound, i.e. approximately 74% was likely unabsorbed or biliary excreted. Accordingly, a relevant fraction could also be eliminated via metabolism. The metabolites M7, M8, M9 and M11 were detected in vitro in microsomes. These four metabolites accounted for ca. 11% in faeces.

In the in vivo DDI study with voriconazole (CYP3A4 inhibitor, but not a P-pg inhibitor), it was shown that CYP3A4 is likely responsible for the metabolism of VOX, as the AUC increased by 84% when coadministered with voriconazole. Most of this is likely due to inhibition of systemic metabolism as also the VOX half-life was increased (from 32 to 39 h).

There was a large influence of food on the exposure of VOX. When VOX was given as the SOF/VEL/VOX FDC after a light, moderate and high fat meal the AUC increased by 2-fold, ~3-fold and ~5-fold, respectively and Cmax 2.5-fold, 3.5-fold and ~8-fold, respectively. This indicates that the Fabs is rather limited, i.e. at most 20% in the fasted state. However, all studies (mass balance, DDIs, Phase II and III) were performed in fed state (likely mostly moderately fat food). VOX was shown to be a substrate for P-gp, BCRP and OATP1B1/3, but not for OCT1. Co-administration with a single dose rifampicin (an inhibitor of OATP1B1/3) increased VOX AUC and Cmax 8-fold and 11-fold, respectively. Also, coadministration with cyclosporine A (an inhibitor of P-pg, BCRP, OATP1B1/3) increased VOX AUC and Cmax 9-fold and 19-fold, respectively. Thus, the hepatic uptake transporters OATP1B1/3 has been identified and confirmed in vivo to be involved in the elimination of VOX. Although the bioavailability/fraction absorbed is not fully understood it can be concluded that the major elimination pathways are via bile, transported by hepatic uptake transporter OATP1B1/3 and efflux transporters P-gp and BCRP and also via metabolism with CYP3A4.

## Pharmacokinetics in target population

VOX AUC and Cmax were ~260% higher in HCV-infected patients after a single dose of VOX 100 mg given alone in the monotherapy efficacy study vs. similarly dosed healthy subjects. Therefore healthy subjects were dosed with SOF/VEL/VOX+VOX (100 mg) with food in Phase 1 studies resulted in steady-state VOX levels slightly higher (although with overlapping ranges) than those in HCV-infected patients in Phase 2/3 studies, including those with cirrhosis. This is acceptable since the effects observed in DDI studies data can be considered relevant to what can be expected to occur with typical exposures in patients.

The VOX population PK model focuses on identifying the important covariates in patients rather than an additional understanding of the PK behaviour. All data were from Phase 2 and 3 studies at a limited range of doses and in the fed state so that any understanding of the non-linearity or the effect of food cannot be obtained from the model.

The diagnostics are largely acceptable, as is shrinkage on clearance and Vd. It is noted that there is a slight tendency to under-predict Cmax. The model over-predicts the variability at later time points but the data at later time points are very limited. The criteria used for selection of covariates are quite strict with an acceptance p-value of 0.01 (forward addition) or 0.001 (backward elimination). This allows identification of significant covariates but not an in-depth understanding of the causes of the variability and it is noted that remaining residual variability is still quite high (60%). Intra-occasion variability was not determined and may improve the model. The Applicant suggests that this is not necessary due to a lack of bias in plots versus time. This is accepted however it remains that the residual variability is high and the determination of intra-occasion variability would help to understand factors contributing to this.

<div style=\"page-break-after: always\"></div>

## Special populations

## Renal impairment:

The exposure (AUC and Cmax) of VOX was approximately 70% and 45% higher, respectively, in the subjects with severe renal impairment as compared to subjects with normal renal function. Although VOX is not excreted via kidney the higher exposure in severe RI subjects could be due to that intestinal and/or hepatic transporters may be affected. The VOX half-life was not altered in RI subjects compared to normal function, which could indicate that the increase in exposure might be due to an alteration in the absorption/first-pass process. Independent of the reason for increased exposure of VOX in severe renal impaired subjects, the change is not considered clinically relevant as the safety margin for VOX is large.

## Hepatic impairment:

For the total plasma concentration, both AUC and Cmax were increased by grade of HI (AUC increased 5-fold CPT-B and in CPT-C 7-fold compared to normal subjects). The VOX half-life was similar in subjects with HI and subjects with normal liver function, which could indicate that the elimination of VOX is similar, provided that the distribution is unchanged. The unbound fraction was similar in subjects with normal hepatic function and moderate HI, and was approximately 2-fold in subjects with severe HI. The increase in unbound concentration was associated with lower plasma albumin.

## Elderly subjects:

In the initial application dossier the POPPK analyses showed that exposure parameters were 26% to 30% higher in those aged &gt;65 years of age, of whom 49.5% were cirrhotic compared to 41% of those aged &lt; 65 years, but there was no further breakdown by age subset. The initial analysis was heavily driven by the number in the age subset 65-74 years, which accounted for the vast majority of those aged ≥65 years (175/190). Of the 14 subjects aged 75- 84 years there were 7 (54%) cirrhotic subjects. The difference in proportion with cirrhosis vs. the two younger subsets does not seem to explain the almost doubling (182% vs. &lt;65 years) in VOX AUC. Nevertheless, the predicted AUC is within the overall 95% percentile of exposures derived from the POPPK analysis. Therefore it can be agreed that section 4.2 of the SmPC should state that no dose adjustment is needed in the elderly. However, Section 5.2 should reflect the ~2-fold higher AUC in the age group ≥75-≤85 (n=14) vs. those aged &lt;65 years. Only one subject aged ≥85 years, i.e. no conclusion can be drawn about the effect of extreme age.

## Drug- drug interactions

## Effects of other medical products on the PK of VOX and SOF/VEL/VOX

For the elucidation of elimination pathways in the human mass balance study and DDI studies (voriconazole, cyclosporine A or single dose rifampicin) VOX was administrated as mono component. In the SOF/VEL/VOX FDC tablet VEL has an effect on VOX exposure as VEL is an OATP1B, BCRP, P-gp inhibitor. For a FDC it is strongly recommended to perform the mass balance study with the substance of interest as labelled, but also include the other active compounds as unlabelled. However, in this case VEL appears to have a minor effect on the VOX elimination and mostly limited to pre-systemic effect.

<div style=\"page-break-after: always\"></div>

## OATP1B:

VOX is a substrate of the hepatic uptake transporters OATP1B1/3, as reflected by the Applicant's proposal that concomitant use of OATP inhibitors not be recommended. The efficacy of the triple combination was assessed at the doses of each FDC component proposed for clinical use. Therefore any inhibition of VOX uptake into hepatocytes that may occur due to VOX and VEL is accounted for in and 11-fold, respectively. These results may also be relevant to patients with genetic polymorphisms impacting OATP1B1 (SLCO1B1) function. There is also a theoretical concern that reduced OATP1B function might lower intrahepatic concentrations (i.e. in the effector compartment).

From an efficacy point of view, although a decreased OATP1B mRNA expression has been shown in experience with SOF/VEL/VOX in subjects with or without cirrhosis has shown reassuring efficacy.

the posology. Single dose rifampicin (an inhibitor of OATP1B1/3) increased VOX AUC and Cmax 8-fold From a safety point view OATP1B1 polymorphism appears not to be a concern as the systemic exposure (although very limited data, n=4, on *15/*15 poor function genotype) was found to be similar as other genotypes. This is in line with what is found for statins (sensitive OATP1B1 substrates). For example for pitvastatin a 3-fold increase of the plasma AUC was observed for *15/*15 poor function genotype (Ieiri et al CPT 2007, VOL 82, 541). Therefore, the effect on plasma exposure for reduced function OATP1B1 genotype is likely to be limited for VOX and not cause a safety concern. Regarding effect of liver function which is associated with decreased OATP1B expression, it was shown that subjects with CPT-A had slightly higher exposure of VOX (73%) compared to subjects without cirrhosis. No safety signal has been identified in this population. HCV cirrhotic patients (Ogasawara et al Drug Metab Pharm. 2010 vol 25 (2) pp 190-199) the clinical

The Applicant provided literature data based on PBPK modelling to address the potential decreased exposure in hepatocytes due to reduced OATP1B1 function. However, the PBPK platform is not yet qualified for such transporter simulations. Although, given the exclusive hepatic route of elimination, the hepatic concentration of voxilaprevir is not expected to be affected by OATP1B1 function (or OATP1B inhibitor). Due to the impaired transporter function, a higher plasma concentration will be accumulated up to a steady-state level where other transporters and/or passive diffusion compensate for the lower OATP1B1 activity. This is in line with the extended clearance concept. Evidence for this has been shown for rosuvastatin (sensitive OATP1B substrate) with PET imaging in rats (He et al Mol Pharmaceutics 2014 vol 11 (8) pp 2745-2754). In brief, rats were administrated 11C-rosuvastatin with and without the OATP1B inhibitor rifampicin (RIF). The resulting plasma AUC was ca. 3-fold higher in rats with RIF compared to controls. The AUC in liver was similar with and without RIF, while Cmax was slightly lower (ca. 20%) in rats treated with RIF.

## P-gp/OATP1B:

Single dose studies with rifampicin (OATP1B1/3 inhibitor at single dose) and cyclosporine A (multiple transporter inhibitor, P-gp, BCRP, MRP2, OATP1B1/3) have been performed, resulting in large increase of VOX exposure when co-administered compared to administered alone. When co-administrating VOX with CsA, a ~9-fold increase of AUC and ~19-fold Cmax was observed. The safety for such an increase of exposure has not been established and the combination is not recommended according to the Applicant. This is agreed. When co-administrating VOX with rifampicin the increase in exposure of VOX was less compared to CsA, a ~8- fold increase of AUC and ~11-fold Cmax was observed. As rifampicin is a selective OATP1B1/3 inhibitor it can be concluded that the OATP1B1/3 are important for the elimination of VOX. The SmPC states that co-administration with strong OATP1B1/3 inhibitors is not recommended with SOF/VEL/VOX.

<div style=\"page-break-after: always\"></div>

The difference in increase of VOX exposure when co-administered as single dose with ATV/r (~4-fold) or DRV/r (~50% increase) was rather large. Although ritonavir is an OATP1B inhibitor a plausible explanation is that ATV is also contributing to the increase in exposure of VOX as ATV also is an OATP inhibitor. It is difficult to separate the effect from ritonavir. In the SmPC the combination with ATV/r is not recommended. This is acceptable. The DDI with DRV/r was further investigated at multiple dosing in the DRV/r + FTC/TDF combination. The resulting VOX AUC was 2.4-fold when co-administered with DRV/r + FTC/TDF compared to VOX administered alone. The SmPC states that no dose adjustment is needed.

## Induction:

When VOX was administered with repeated dosing (7 days) of rifampicin the resulting decrease in exposure was large (~70% decrease). The duration of the rifampicin dosing was a bit short as the recommended duration to obtain full induction effect is 10-14 days. The effect of rifampicin was extensive also on the SOF and VEL exposure (decrease of 70-80% when studied as the monocomponents) The large decrease in exposure for all three compounds SOF, VEL and VOX led to a phenobarbital and phenytoin). Moderate inducers - combinations not recommended (e.g. efavirenz, oxycarbazepine). This is agreed and is reflected in the SmPC (Section 4.3, 4.4 and 4.5).

contraindication with strong P-pg inducers (e.g. rifampicin, rifabutin, St. John's wort, carbamazepine, No DDI study with the moderate inducer efavirenz has been performed with VOX. When efavirenz was co-administered with Epclusa a 50% decrease in VEL exposure was observed. In section 4.5 it is presently suggested that co-administration of SOF/VEL/VOX with efavirenz is not recommended. Similar decrease in exposure of VEL was obtained when SOF/VEL/VOX was co-administered with omeprazole 20 mg, although this did not lead to restrictions other than a 20 mg as maximum dose for omeprazole. The Applicant has clarified that the absolute exposure of VEL is higher (approximately 2fold) in the SOF/VEL/VOX combination compared to SOF/VEL FDC. Thus a ~50% decrease of VEL when co-administered with PPIs will still achieve VEL exposure at maximal antiviral activity (&gt;99% of Emax).

## Effects of VOX and SOF/VEL/VOX on PK of other medical products

## In vitro:

Based on IC50 values it cannot be excluded that VOX is a CYP3A4 and UGT1A1 inhibitor at intestinal level. In a DDI study with Cyclosporine A (CsA) there was no relevant effect on CsA exposure caused by SOF/VEL/VOX. Even though, CsA is not a very sensitive CYPA4 substrate this indicates that CYP3A4 inhibition caused by VOX at intestinal level is limited. UGT1A1 is also expressed in the intestine (IC50 ~5 µM and intestinal cut-off concentration ~50 µM). In a DDI study with bictegravir there was no effect on BIC exposure caused by SOF/VEL/VOX. Although BIC is not a well-known and not approved substance, the Applicant has provided data showing that BIC appears to be a relevant in vivo probe for UGT1A1 and this indicates that UGT1A1 inhibition caused by VOX at intestinal level is limited.

## In vivo:

After co-administration of SOF/VEL/VOX with dabigatran, the AUC and Cmax of dabigatran increased 2.6 and 2.9-fold, respectively. From Pradaxa ®  SmPC, co-administration with ketoconazole showed a 2.4 fold increase of dabigatran for both Cmax and AUC. Furthermore this combination is contraindicated. The SmPC states that concomitant use of Vosevi with dabigatran etexilate is contraindicated.

<div style=\"page-break-after: always\"></div>

Regarding the other direct-acting oral anticoagulants apixaban, edoxaban and rivaroxaban, it is not fully agreed that no clinically significant DDIs are expected. Apixaban (Elquis) and Rivaroxaban (Xarelto) are both substrates of both CYP3A4 and P-gp. The SmPCs indicate that drugs that strongly inhibit both CYP3A4 and P-gp are not recommended to be co-administrated. However, they are less affected by drugs that are not strong inhibitors of both CYP3A and P-gp. SOF/VEL/VOX is not indicated to inhibit CYP3A4 and therefore it is proposed that no dose adjustment is required. In addition apixaban and rivaroxaban are not indicated to be OATP1B substrates. Edoxaban (Lixiana) is a P-gp substrate and the major metabolite M4 is an OATP1B1 and P-gp substrate. As an example, coadministration of edoxaban with CsA increased AUC of metabolite M4 7-fold. As VEL and VOX are inhibitors of OATP1B1 and P-gp the combination is not recommended and this is reflected in the SmPC.

Regarding co-administration with statins the DDI potential is complex and therefore difficult to predict, i.e. in general the statin needs to be studied in vivo in order to provide correct dosing recommendations. Pravastatin (substrate of OATP1B1 and OATP1B3) was studied in vivo and following co-administration with SOF/VEL/VOX, an increase of pravastatin exposure was similar to that observed when pravastatin was co-administered with clarithromycin (Cmax to 2.1 fold, AUC to 2.3-fold). Pravastatin doses should not exceed 40 mg QD with clarithromycin (Pravachol pravastatin sodium). Similarly, when pravastatin is administered with SOF/VEL/VOX, it is proposed that the pravastatin dose should not exceed 40 mg. This is agreed.

Rosuvastatin (OATP1B1/3 and BCRP substrate) AUC increased 7.4-fold and Cmax 19-fold when coadministered with SOF/VEL/VOX. This is similar to when ROSU is co-administered with cyclosporine (AUC increased 7.1-fold). From Crestor ®  SmPC it can be extracted that co-administration with cyclosporine is contraindicated. If a patient is established on rosuvastatin and requires 8-12 weeks of therapy for HCV using SOF/VEL/VOX (Vosevi) a switch to an alternative HMG CoA reductase inhibitor can be made as the co-administration of Vosevi with rosuvastatin is contraindicated (reflected in section 4.3 and 4.5 of the SmPC).

Regarding other statins that have not been studied the recommendation in section 4.5 reads 'Coadministration not recommended'.

The applicant should consider conducting additional DDI studies to support adequately supported recommendations for use with other agents in this class.

Methadone may be an important co-medication in this patient population. A DDI study with methadone has only been performed with SOF and no effect on methadone exposure was observed. Methadone is primarily metabolized via CYP3A4, CYP2B6 and CYP2C19 and the risk of a clinically relevant DDI with the addition of VOX in the FDC is considered to be low.

SOF/VEL/VOX has been studied in several combinations of antiretroviral treatments. Summaries of the effect of SOF/VEL/VOX 400/100/100 mg on the PK of HIV ARV regimens in healthy subjects are given in Table 13. It was shown in DDI studies that there was no clinically relevant change in exposure in DRV, RPV, EVG, FTC, COBI, or TAF when co-administered with SOF/VEL/VOX in relevant antiretroviral combinations. The exposure of tenofovir (TFV) increased in combination with SOF/VEL/VOX and a caution involving renal monitoring is reflected in the SmPC (section 4.4 and 4.5) when tenofovir disoproxil fumarate (TDF) is part of the regimen.

## Pharmacodynamics

VOX binds non-covalently to the active site of the NS3 protease and exhibits pangenotypic antiviral activity with EC50 ranging from 0.33 to 6.6 nM across genotypes 1 to 6. The antiviral activity of VOX

<div style=\"page-break-after: always\"></div>

against genotypes 2a/b and 3 is close to the genotype 1 potency. VOX retains full in vitro activity against the majority of known NS3 RAVs including the major polymorphism in genotype 1a, Q80K.

It is notable that while no dose-response relation was seen in monotherapy in GT1a, this was seen in GT3 (see section on clinical efficacy). The observation of a rightward-shift in exposure-response for GT3 compared to other genotypes, given similar in vitro EC50 values, has previously been seen, e.g., for velpatasvir, and may be due to increased steatosis and lower drug penetration to the target site in GT3.

Replicon clones with A156L, A156V, or A156T demonstrated &gt; 253-fold reduced susceptibility to VOX. A156 RAVs are often problematic in macrocyclic PIs, due to disruption of the binding site. However, the viral fitness of A156T/V variants is significantly lower than that of other RAVs (and wild-type virus) and these have not been frequently observed in HCV-infected patients unexposed to NS3/4A inhibitors.

RAVs at position 168 were selected in genotype 2a replicons (D168E in genotype 2a JFH-1 and J6 cells), genotype 5a (D168A/H/R/Y), and genotype 6a (D168H/Y) replicon cells. These variants confer no-to-low levels of resistance (1.5- to 17.8-fold). In genotypes 5 and 6, double variants Q41R+D168H/Y and Q41R+D168H were predominantly selected, respectively. The double variants conferred higher levels of resistance to VOX (35- to 39-fold) compared with the single variants (2.7- to 13.5-fold) and could potentially arise also in vivo .

The majority of the single mutants in genotypes 2a, 2b, 3a, and 4a displayed no to low-level resistance to VOX. In genotype 2a, A156T had moderate-level resistance to VOX (38-fold), and A156V and A156L were the only NS3 RAVs that demonstrated high-level resistance to VOX (&gt; 129-fold). In genotype 3, one double mutant Y56H+Q168R demonstrated high-level resistance to VOX (286-fold). In genotype 4a, variants at position 156 (A156L/T/V) conferred &gt; 143, reduced susceptibility to VOX. In genotype 5, VOX demonstrated no to moderate-level resistance to variants at position 168 (D168A/E/H/K/R/V/Y). In genotype 6a, variants at position 168 (D168A/E/H/V/Y) demonstrated 1.5to 4.2-fold resistance to VOX.

## 2.4.5. Conclusions on clinical pharmacology

VOX is a third-generation PI with pangenotypic activity. RAVs that mediate high-level resistance are uncommon in vivo. The mechanism of actions is well-characterized, and the addition of a PI to the existing SOF/VEL-combination is appealing as a completely new pharmacological target is introduced.

There are no objections to an approval of SOF/VEL/VOX from a clinical pharmacology point of view.

## 2.5. Clinical efficacy

## Dose-response studies and main clinical studies

## Voxilaprevir dose-response

The dose of VOX 100 mg was selected based on safety, antiviral activity, and PK data from the Phase 1 proof-of-concept study (GS-US-338-1121) and Phase 2 studies in HCV-infected subjects (GS-US-3671168, GS-US-367-1169, GS-US-337-1468 [Cohorts 4 and 5]).

Study GS-US-338-1121 evaluated VOX administered once daily as monotherapy for 3 days in subjects with genotype 1 to 4 HCV infection. Subjects with genotype 1a HCV infection received VOX 50, 100, or 300 mg under fasted conditions; subjects with genotype 3 HCV infection received VOX 50, 100, or 300

<div style=\"page-break-after: always\"></div>

mg under fasted conditions or 100 mg under fed conditions; subjects with genotype 2 or 4 HCV infection received VOX 100 mg under fasted conditions.

Similar median antiviral responses (change from baseline HCV RNA on Day 4) of &gt; 3.0 log10 reduction were observed in subjects with genotypes 1a, 1b, 2, and 4 HCV infection following VOX doses of 50, 100 or 300 mg under fasted conditions, yielding a flat VOX exposure-response relationships for antiHCV activity.

In contrast, in subjects with genotype 3 HCV infection, an exposure-response relationship was observed for VOX and is presented in Figure 7.

Table 17 presents the Emax models developed using genotype 3 HCV infected subjects and subjects with non-genotype 3 HCV infection. Based on these relationships near maximal antiviral response (≥ 90% of Emax) will be achieved at a VOX dose of 100 mg within SOF/VEL/VOX (mean AUC: 2577.2 h*ng/mL) administered under fed conditions and doses &gt; 100 mg are unlikely to cause further meaningful reductions in HCV RNA.

Figure 7. GS-US-338-1121: Observed Versus Predicted Exposure (AUCtau on Day 3) - Response (change from baseline HCV RNA on Day 4) for Genotype 3 HCV-Infected Subjects

<!-- image -->

'Phase 3 Mean Exposure' marker encompasses mean ± 90% CI

Table 17. GS-US-338-1121: Model Parameter Estimates for On-Treatment Suppression of HCV RNA Following Monotherapy with VOX (PK/PD Analysis Set)

|                                         | Model Parameter Estimates   | Model Parameter Estimates   |
|-----------------------------------------|-----------------------------|-----------------------------|
| Exposure Parameter                      | E max (log 10 IU/mL)        | EC 50 (h*ng/mL)             |
| VOX AUC tau (Genotype 3)                | 3.82                        | 249                         |
| VOX AUC tau (Genotype 1a, 1b, 2, and 4) | 3.62                        | <0.1                        |

<div style=\"page-break-after: always\"></div>

## Phase 2 studies

In phase 2, four studies investigated the combination of SOF/VEL + VOX and SOF/VEL/VOX.

Table 18. SOF/VEL+VOX or SOF/VEL/VOX Phase 2 Duration Evaluation and Efficacy Studies

|                                          |                                                         | Subject Population                                                                              | Subject Population                                                               | Subject Population                          |
|------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------|
| Study Number                             | Treatment Regimens a                                    | HCV Genotype (N) b                                                                              | Prior HCV Treatment                                                              | Cirrhosis Status                            |
| GS-US-337-1468 (LEPTON; Cohorts 4 and 5) | SOF/VEL+VOX for 4, 6, or 8 weeks                        | 1 or 3 (Genotype 1: 120; Genotype 3: 40; Indeterminate: 1)                                      | Treatment-naive and treatment- experienced (including DAA- experienced) subjects | Approximately 50% of subjects had cirrhosis |
| GS-US-367-1168                           | SOF/VEL+VOX for 6, 8 (with or without RBV), or 12 weeks | 1 (205)                                                                                         | Treatment-naive and DAA- experienced subjects                                    | Approximately 50% of subjects had cirrhosis |
| GS-US-367-1169                           | SOF/VEL+VOX for 6, 8, or 12 weeks                       | 1, 2, 3, 4, or 6 (Genotype 1: 1; Genotype 2: 33; Genotype 3: 74; Genotype 4: 17; Genotype 6: 3) | Treatment-naive and treatment- experienced (including DAA- experienced) subjects | Approximately 50% of subjects had cirrhosis |
| GS-US-367-1871 (TRILOGY-3)               | SOF/VEL/VOX with or without RBV for 12 weeks            | 1 (49)                                                                                          | DAA-experienced subjects                                                         | Approximately 50% of subjects had cirrhosis |

## GS-US-337-1468 (LEPTON)

Cohorts 4 and 5 evaluated SOF/VEL+VOX taken QD with food (unspecified).

- Cohort 4 -15 treatment-naive (TN) patients with GT1 without cirrhosis received VOX 100 mg on Day 1 and then QD dosing with SOF/VEL + VOX 100 mg for 6 weeks.
- Cohort 5 -SOF/VEL + VOX 100 mg QD (2 x 50 mg original or 100 mg modified formulation) in GT1 or GT3 patients, sub-grouped by cirrhosis and TN/TE, for 4, 6 or 8 weeks.

SVR12 rates ranged from 26.7% to 100.0%. Relapse was more common with the shorter treatment durations of 4 or 6 weeks and 8 weeks gave SVR12 rates ≥ 89%.

Seventeen TN patients (16 relapsed) and 13 TE patients did not achieve SVR12, of which 28 had virologic failure. Using the 1% assay cut-off, 79/159 patients had baseline RAVs in at least 1 of the 3 target genes but the presence of specific baseline RAVs did not appear to impact on the SVR12 rates. None of the virologic failures had NS5B NI treatment-emergent RAVs. One had a new NS3 RAV (V55A) in GT1a after 6 weeks treatment but this did not confer reduced susceptibility to VOX. One had a new NS5A RAV (Y93H) in GT1a after 8 weeks treatment that gave a 609-fold reduction in susceptibility to VEL.

## GS-US-367-1168

This study evaluated SOF/VEL + VOX 100 mg QD with food for treatment of GT1. One sub-group of Cohort 1 (TN, cirrhotic) also received RBV. The DAA TE patients had failed prior treatment with a NS5A inhibitor or ≥ 2 classes of DAAs with or without IFN. All DAA-experienced patients treated with SOF/VEL+VOX for 12 weeks achieved SVR12 as did 97.0% of TN patients with or without cirrhosis treated for 8 weeks. Addition of RBV did not improve SVR12 rates.

<div style=\"page-break-after: always\"></div>

The 18 patients who failed to achieve SVR12 relapsed. Using the 1% assay cut-off the SVR12 rate was lower for those with baseline NS5A RAVs who received 6 or 8 weeks. None had NS5A or NS5B treatment-emergent RAVs while 3 had treatment-emergent NS3 RAVs (Q41R, A156T, V170T or V36M).

## GS-US-367-1169

This study evaluated SOF/VEL + VOX 100 mg QD with food for treatment of patients with non-GT1 infections.  All except for one patient treated for 12 weeks achieved SVR12. The 7 patients who did not achieve SVR12 all relapsed before Week 12 follow-up and none had NS5A or NS5B emergent RAVs while one had an NS3 RAV (Q80R) using the 1% assay cut-off. Six of the 7 were female, 3 were GT4, 2 were GT2 and 2 GT3. Six were TN and one had previously received PEG-IFN/RBV.

## GS-US-367-1871 (TRILOGY)

This study evaluated use of 12 weeks treatment with the SOF/VEL/VOX FDC taken with food, with or without RBV (1000 or 1200 mg per day by weight), in patients with GT1 previously treated with a DAA regimen.

All except one patient (who relapsed in the RBV group and had failed 24 weeks LDV/SOF) achieved SVR12 and SVR24, including 54% and 67% per group with NS3 RAVs and 50% and 38% with NS5A RAVs at baseline (based on ≥1% assay cut-off). The patient who relapsed had baseline NS5A RAVs M28V (1.7%), Q30H (3.2%) and L31M (&gt;99%). At relapse there were treatment-emergent NS3 RAVs (M28T &gt;99%; Q30L 2.4%; Q30R 97.3%) and additional NS5A RAVs (V36M &gt;99%; Q41R &gt;99%; D168G 96.4% [this triple mutant gives 11.5-fold reduced susceptibility to VOX]; D168S 2.4%).

## SOF/VEL/VOX main studies - POLARIS-1,-2,-3,-4

The phase 3 program of SOF/VEL/VOX consists of four studies; POLARIS-1 and -4 in DAA experienced subjects (12 weeks of treatment) and POLARIS-2 and -3 in DAA naïve subjects (8 weeks of treatment). Common properties of these studies are described below, whereas particulars are described in relation to each study.

POLARIS-1 to 4 share the following inclusion criteria of the study population:

- -Male or female, age ≥ 18 years
- -Body mass index (BMI) ≥ 18 kg/m2
- -HCV RNA ≥ 10 4  IU/mL at screening
- -Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy
- -Cirrhosis Determination
- o Presence of cirrhosis was defined as any 1 of the following:
-  FibroTest® score &gt; 0.75 and aspartate aminotransferase (AST):platelet ratio index (APRI) &gt; 2 during screening
-  Liver biopsy showing cirrhosis (eg, Metavir score = 4 or Ishak score ≥ 5)
-  Transient elastography (FibroScan®) with a result of &gt; 12.5 kPa
- o Absence of cirrhosis was defined as any 1 of the following, unless the definition of cirrhosis has been met:

<div style=\"page-break-after: always\"></div>

-  FibroTest score ≤ 0.48 and APRI ≤ 1 performed during screening
-  Liver biopsy within 2 years of screening showing absence of cirrhosis
-  Transient elastography (FibroScan) with a result of ≤ 12.5 kPa within 6 months of baseline/Day 1
- -Liver imaging within 6 months prior to baseline/Day 1 was required in cirrhotic subjects to exclude HCC.
- -Females of childbearing potential were required to have a negative serum pregnancy test at screening and a negative urine pregnancy test on baseline/Day 1 prior to enrollment.
- -Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse agree to use protocol-specified method(s) of contraception.
- -Lactating females agreed to discontinue nursing before starting study drug.
- -Subjects were in generally good health, with the exception of chronic HCV infection, as determined by the investigator.

Common exclusion criteria include:

- 1) Current or prior history of any of the following:

a) Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the clinical study protocol; subjects currently under evaluation for a potentially clinically significant illness (other than HCV) were also excluded.

b) Gastrointestinal disorder or postoperative condition that could interfere with the absorption of the study drug

- c) Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
- d) Hepatic decompensation (eg, clinical ascites, encephalopathy, and/or variceal hemorrhage)
- e) Solid organ transplantation
- f) Significant cardiac disease

g) Unstable psychiatric condition including hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within 2 years prior to screening h) Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (eg, basal cell skin cancer). Subjects under evaluation for possible malignancy were not eligible.

- i) Significant drug allergy (e.g., hepatotoxicity)
- 2) Screening electrocardiogram (ECG) with clinically significant abnormalities
- 3) Subject had the following laboratory parameters at screening:
- a) Alanine aminotransferase (ALT) &gt; 10 × the upper limit of normal (ULN)
- b) AST &gt; 10 × ULN
- c) Direct bilirubin &gt; 1.5 × ULN
- d) Platelets &lt; 50,000/µL

<div style=\"page-break-after: always\"></div>

- e) Hemoglobin A1c (HbA1c) &gt; 8.5%
- f) Creatinine clearance &lt; 50 mL/min as calculated by the Cockcroft-Gault equation
- g) Hemoglobin &lt; 10 g/dL
- h) Albumin &lt; 3 g/dL
- i) International Normalized Ratio of prothrombin time (INR) &gt; 1.5 × ULN unless subject had known hemophilia or was stable on an anticoagulant regimen affecting INR
- 4) Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
- 5) Infection with hepatitis B virus (HBsAg+) or HIV (anti-HIV)
- 6) Clinically-relevant alcohol or drug abuse within 12 months of screening.
- 7) Used any prohibited concomitant medications
- 8) Known hypersensitivity to the study drug, the metabolites, or formulation excipient

## GS-US-367-1171 (POLARIS-1)

This phase 3 randomized, placebo-controlled, double-blind study assessed the antiviral efficacy, safety, and tolerability of 12 weeks of SOF/VEL/VOX treatment compared with 12 weeks of placebo treatment in DAA-experienced subjects with chronic HCV infection who have previously been treated with an NS5A inhibitor.

## Study participants

Subjects were enrolled across 108 study sites in the United States (US), France, Canada, the United Kingdom, Germany, Australia, and New Zealand. For general inclusion and exclusion criteria, see above.

## Treatments, randomization and blinding

Subjects with genotype 1 were randomized 1:1 into one of treatment groups below. Randomization was stratified by cirrhosis status (presence or absence). These subjects were blinded to treatment group.

- -SOF/VEL/VOX 12 Week group: SOF/VEL/VOX FDC (400/100/100 mg) once daily with food for 12 weeks
- -Placebo 12 Week group: SOF/VEL/VOX placebo once daily with food for 12 weeks

Subjects with genotype 2, 3, 4, 5, or indeterminate HCV infection, regardless of cirrhosis status, were enrolled into the SOF/VEL/VOX 12 Week group only.

## Participant flow

A total of 520 subjects were screened for the study, and 104 subjects (20.0%) failed screening. Of the 99 subjects who did not meet eligibility criteria, the 3 primary reasons for screen failure were laboratory values outside of the acceptable ranges (47.5%, 47 subjects), subjects not meeting the inclusion criteria of having HCV RNA ≥ 104 IU/mL at screening (14.1%, 14 subjects), and liver imaging

<div style=\"page-break-after: always\"></div>

not performed within 6 months of baseline/Day 1 (14.1%, 14 subjects). Of the 4 screen failure subjects who did meet eligibility criteria, the reason for not enrolling was withdrawal of consent.

Figure 8. POLARIS-1 - disposition of Subjects (All Screened Subjects)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 19. Demographics by Overall Study Total and Treatment Group (Safety Analysis Set)

|                                     | Overall Study Total (N=415)   | Placebo 12 Weeks (N=152)   | SOF/VEL/VOX 12 Weeks (N=263)   |
|-------------------------------------|-------------------------------|----------------------------|--------------------------------|
| Age at Baseline (Years)             |                               |                            |                                |
| N                                   | 415                           | 152                        | 263                            |
| Mean (SD)                           | 58 (8.3)                      | 59 (8.0)                   | 58 (8.5)                       |
| Median                              | 59                            | 60                         | 59                             |
| Q1, Q3                              | 54, 63                        | 55,64                      | 54,63                          |
| Min, Max                            | 27,84                         | 29, 80                     | 27,84                          |
| Age at Baseline Category            |                               |                            |                                |
| < 65 Years                          | 343 (82.7%)                   | 121 (79.6%)                | 222 (84.4%)                    |
| >= 65 Years                         | 72 (17.3%)                    | 31 (20.4%)                 | 41 (15.6%)                     |
| Sex at Birth                        |                               |                            |                                |
| Male                                | 321 (77.3%)                   | 121 (79.6%)                | 200 (76.0%)                    |
| Female                              | 94 (22.7%)                    | 31 (20.4%)                 | 63 (24.0%)                     |
| Race                                |                               |                            |                                |
| White                               | 335 (80.7%)                   | 124 (81.6%)                | 211 (80.2%)                    |
| Black or African American           | 60 (14.5%)                    | 22 (14.5%)                 | 38 (14.4%)                     |
| Asian                               | 14 (3.4%)                     | 6 (3.9%)                   | 8 (3.0%)                       |
| Native Hawaiian or Pacific Islander | 3 (0.7%)                      | 0                          | 3 (1.1%)                       |
| Not Disclosed                       | 1 (0.2%)                      | 0                          | 1 (0.4%)                       |
| American Indian or Alaska Native    | 1 (0.2%)                      | 0                          | 1 (0.4%)                       |
| Other                               | 1 (0.2%)                      | 0                          | 1 (0.4%)                       |
| Ethnicity                           |                               |                            |                                |
| Hispanic or Latino                  | 25 (6.0%)                     | 10 (6.6%)                  | 15 (5.7%)                      |
| Not Hispanic or Latino              | 389 (93.7%)                   | 142 (93.4%)                | 247 (93.9%)                    |
| Not Disclosed                       | 1 (0.2%)                      | 0                          | 1 (0.4%)                       |

<div style=\"page-break-after: always\"></div>

Table 20. Baseline Characteristics by Overall Study Total and Treatment Group

|                                    | Overall Study Total (N=415)   | Placebo 12 Weeks (N=152)   | SOF/VEL/VOX 12 Weeks (N=263)   |
|------------------------------------|-------------------------------|----------------------------|--------------------------------|
| Region                             |                               |                            |                                |
| US                                 | 236 (56.9%)                   | 101 (66.4%)                | 135 (51.3%)                    |
| Non-US                             | 179 (43.1%)                   | 51 (33.6%)                 | 128 (48.7%)                    |
| Baseline Body Mass Index (kg/m2)   |                               |                            |                                |
| N                                  | 415                           | 152                        | 263                            |
| Mean (SD)                          | 28.7 (5.57)                   | 28.5 (5.80)                | 28.8 (5.45)                    |
| Median                             | 27.8                          | 27.9                       | 27.8                           |
| Q1, Q3                             | 25.3, 31.3                    | 25.0, 31.2                 | 25.4, 31.3                     |
| Min, Max                           | 18.0, 66.7                    | 18.0, 61.2                 | 18.4, 66.7                     |
| Baseline Body Mass Index Category  |                               |                            |                                |
| < 30 kg/m2                         | 279 (67.2%)                   | 100 (65.8%)                | 179 (68.1%)                    |
| >= 30 kg/m2                        | 136 (32.8%)                   | 52 (34.2%)                 | 84 (31.9%)                     |
| HCV Genotype/Subtype by Sequencing |                               |                            |                                |
| Genotype 1                         | 300 (72.3%)                   | 150 (98.7%)                | 150 (57.0%)                    |
| 1a                                 | 218 (52.5%)                   | 117 (77.0%)                | 101 (38.4%)                    |
| 1b                                 | 76 (18.3%)                    | 31 (20.4%)                 | 45 (17.1%)                     |
| 1 Other                            | 6 (1.4%)                      | 2 (1.3%)                   | 4 (1.5%)                       |

<div style=\"page-break-after: always\"></div>

| Genotype 2                     | 5 (1.2%)    | 0           | 5 (1.9%)    |
|--------------------------------|-------------|-------------|-------------|
| Genotype 3                     | 78 (18.8%)  | 0           | 78 (29.7%)  |
| Genotype 4                     | 22 (5.3%)   | 0           | 22 (8.4%)   |
| Genotype 5                     | 1 (0.2%)    | 0           | 1 (0.4%)    |
| Genotype 6                     | 8 (1.9%)    | 2 (1.3%)    | 6 (2.3%)    |
| Unknown                        | 1 (0.2%)    | 0           | 1 (0.4%)    |
| Cirrhosis                      |             |             |             |
| Yes                            | 172 (41.4%) | 51 (33.6%)  | 121 (46.0%) |
| No                             | 243 (58.6%) | 101 (66.4%) | 142 (54.0%) |
| IL28B                          |             |             |             |
| CC                             | 74 (17.8%)  | 27 (17.8%)  | 47 (17.9%)  |
| Non-CC                         | 341 (82.2%) | 125 (82.2%) | 216 (82.1%) |
| CT                             | 258 (62.2%) | 93 (61.2%)  | 165 (62.7%) |
| TT                             | 83 (20.0%)  | 32 (21.1%)  | 51 (19.4%)  |
| Baseline HCV RNA (log10 IU/mL) |             |             |             |
| N                              | 415         | 152         | 263         |
| Mean (SD)                      | 6.3 (0.66)  | 6.3 (0.63)  | 6.3 (0.68)  |
| Median                         | 6.3         | 6.4         | 6.3         |
| Q1, Q3                         | 5.9, 6.7    | 5.9, 6.7    | 5.8, 6.7    |
| Min, Max                       | 1.6, 7.7    | 3.7, 7.6    | 1.6, 7.7    |
| Baseline HCV RNA Category      |             |             |             |
| < 800.000 IU/mL                | 109 (26.3%) | 36 (23.7%)  | 73 (27.8%)  |
| >= 800,000 IU/mL               | 306 (73.7%) | 116 (76.3%) | 190 (72.2%) |
| Baseline ALT (U/L)             |             |             |             |
| N                              | 415         | 152         | 263         |
| Mean (SD)                      | 84 (77.0)   | 74 (84.3)   | 89 (72.0)   |
| Median                         | 59          | 54          | 64          |
| Q1, Q3                         | 40,97       | 38,85       | 43,106      |
| Min, Max                       | 10,922      | 10,922      | 13,412      |
| Baseline ALT Category          |             |             |             |
| <= 1.5 x ULN                   | 213 (51.3%) | 93 (61.2%)  | 120 (45.6%) |
| > 1.5 x ULN                    | 202 (48.7%) | 59 (38.8%)  | 143 (54.4%) |

<div style=\"page-break-after: always\"></div>

| Prior HCV Treatment Experience                                                    |               |               |               |
|-----------------------------------------------------------------------------------|---------------|---------------|---------------|
| Treatment-Experienced                                                             | 415 (100.0%)  | 152 (100.0%)  | 263 (100.0%)  |
| DAA-Experienced                                                                   | 415 (100.0%)  | 152 (100.0%)  | 263 (100.0%)  |
| NS5A +/- DAA(s)                                                                   | 413 (99.5%)   | 151 (99.3%)   | 262 (99.6%)   |
| NS5A + NS5B                                                                       | 242 (58.3%)   | 81 (53.3%)    | 161 (61.2%)   |
| NS5A + NS3 +/-NS5B                                                                | 144 (34.7%)   | 61 (40.1%)    | 83 (31.6%)    |
| NS5A +/- Other(s)                                                                 | 27 (6.5%)     | 9 (5.9%)      | 18 (6.8%)     |
| Other(s)                                                                          | 2 (0.5%)      | 1 (0.7%)      | 1 (0.4%)      |
| Estimated Glomerular Filtration Rate Using the Cockcroft- Gault Equation (mL/min) |               |               |               |
| N                                                                                 | 415           | 152           | 263           |
| Mean (SD)                                                                         | 116.9 (35.02) | 113.1 (33.64) | 119.2 (35.66) |
| Median                                                                            | 113.4         | 106.1         | 118.1         |
| Q1, Q3                                                                            | 92.7, 136.4   | 90.3,133.6    | 94.2, 139.2   |
| Min, Max                                                                          | 39.9, 229.2   | 54.5,215.1    | 39.9,229.2    |

Baseline value is the last available value on or prior to first dose date of any study drug.

Body Mass Index (BMI) = [weight (kg) / (height (m)^2)].

The summary is based on eCRF (cirrhosis status) and virology (HCV genotype by sequencing) data reported at time of analysis.

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0 with limit of quantitation 15 IU/mL

As only subjects with GT1 were randomized whereas other genotypes were included in the SOF/VEL/VOX group, the baseline characteristics differ somewhat between study groups. Of note, there is a slightly lower proportion of cirrhotic subjects (33.6% vs 41.4%) in the placebo group.

## Outcomes

Table 21. SVR12 in NS5A-inhibitor experienced patients by HCV genotype in study POLARIS-1*

|                                   | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    | SOF/VEL/VOX 12 weeks(n = 263)    |
|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                   | Total (all GTs) a (n = 263)      | GT-1                             | GT-1                             | GT-1                             | GT-2 (n = 5)                     | GT-3 (n = 78)                    | GT-4 (n = 22)                    | GT-5 (n = 1)                     | GT-6 (n = 6)                     |
|                                   | Total (all GTs) a (n = 263)      | GT-1a (n = 101)                  | GT-1b (n = 45)                   | Total b (n = 150)                | GT-2 (n = 5)                     | GT-3 (n = 78)                    | GT-4 (n = 22)                    | GT-5 (n = 1)                     | GT-6 (n = 6)                     |
| SVR12                             | 96% (253/263)                    | 96% (97/101)                     | 100% (45/45)                     | 97% (146/150)                    | 100% (5/5)                       | 95% (74/78)                      | 91% (20/22)                      | 100% (1/1)                       | 100% (6/6)                       |
| Outcome for patients without SVR  | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR |
| On- treatment virologic failure c | <1% (1/263)                      | 1% (1/101)                       | 0/45                             | 1% (1/150)                       | 0/5                              | 0/78                             | 0/22                             | 0/1                              | 0/6                              |
| Relapse d                         | 2% (6/261)                       | 1% (1/100)                       | 0/45                             | 1% (1/149)                       | 0/5                              | 5% (4/78)                        | 5% (1/21)                        | 0/1                              | 0/6                              |
| Other e                           | 1% (3/263)                       | 2% (2/101)                       | 0/45                             | 1% (2/150)                       | 0/5                              | 0/78                             | 5% (1/22)                        | 0/1                              | 0/6                              |

<div style=\"page-break-after: always\"></div>

c. Pharmacokinetic data for the 1 patient with on-treatment virologic failure was consistent with non-adherence.

d. The denominator for relapse is the number of patients with HCV RNA &lt; LLOQ at their last on-treatment assessment.

e. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.

As anticipated, no patient in the placebo group achieved SVR.

Table 22. Virologic outcomes for subjects in the SOF/VEL/VOX 12 Week Group

|                              | SOF/VEL/VOX 12 Weeks (N=263)   |
|------------------------------|--------------------------------|
| SVR12                        | 253/263 (96.2%)                |
| Overall VirologicFailure     | 7/263 (2.7%)                   |
| Relapse                      | 6/261 (2.3%)                   |
| Completed Study Treatment    | 6/260 (2.3%)                   |
| Discontinued Study Treatment | 0/1                            |
| On-TreatmentVirologicFailure | 1/263 (0.4%)                   |
| Other                        | 3/263 (1.1%)                   |

The overall SVR12 was high (96.2%) in the SOF/VEL/VOX group, with a total of 7 virologic failures (2.7%). Numerically lower SVR12 are seen in blacks vs non-blacks (92.1% vs 96.9%), in cirrhotics vs non-cirrhotics (93.4% vs 98.6%) and in subjects with low adherence to treatment. SVR12 rates were fairly consistent across genotypes 1-3 while the number of subjects with genotypes 4-6 is too low to allow a direct conclusion on clinical efficacy.

All subjects (83/83) previously treated with an NS3/NS5A +/- NS5B combination reached SVR12 compared to 93.8% (151/161) in the group previously treated with a NS5A + NS5B combination.

From the low number of subjects with virologic failure, SVR12 rates are seemingly unaffected by the overall presence of NS3 and NS5A RAVs (using a 15% population cutoff for RAVs).  However, see the section on integrated virology for further details regarding RAVs.

## GS-US-367-1170 (POLARIS-4)

This is a phase 3, randomized, open-label study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed-dose combination for 12 weeks and sofosbuvir/velpatasvir for 12 weeks in DAA-experienced subjects with chronic HCV infection who have not received an NS5A inhibitor

## Study participants

Subjects were enrolled across 101 study sites in the United States, Canada, New Zealand, Australia, France, Germany, and the United Kingdom. For general inclusion and exclusion criteria, see above.

## Treatments, randomization and blinding

Subjects were randomized or enrolled into 1 of the following 2 treatment groups:

- SOF/VEL/VOX 12 Week group: SOF/VEL/VOX (400/100/100 mg) once daily with food for 12 weeks

<div style=\"page-break-after: always\"></div>

- SOF/VEL 12 Week group: SOF/VEL (400/100 mg) once daily without regard to food for 12 weeks

Randomization was stratified by HCV genotype (1, 2, or 3) and cirrhosis status (presence or absence). The target enrolment for subjects with genotype 1, 2, and 3 HCV infection were 200, 50, and 100 subjects, respectively.

The 30 additional subjects with genotype 4, 5, or indeterminate HCV infection (including those with genotype 6 HCV infection due to the inability of the assay to distinguish this HCV genotype at screening), regardless of cirrhosis status, were enrolled in the SOF/VEL/VOX 12 Week group only.

This study was open label.

## Participant flow

A total of 397 subjects were screened for the study, and 64 subjects (16.1%) failed screening. Of the 64 subjects who failed screening, 4 subjects met the eligibility criteria, but did not enrol due to lost to follow-up or withdrawal of consent (2 subjects each). Of the 60 subjects who did not meet eligibility criteria, the 3 primary reasons for screen failure were screening laboratory values not within acceptable ranges (50.0%, 30 subjects), history of clinically significant illness or any other major medical disorder (21.7%, 13 subjects), and ineligible prior HCV treatment history (15.0%, 9 subjects).

A total of 333 subjects were randomized or enrolled into the study. All randomized or enrolled subjects received at least 1 dose of study drug and were included in the Full Analysis Set and Safety Analysis Set (182 in the SOF/VEL/VOX 12 Week group and 151 in the SOF/VEL 12 Week group).

<div style=\"page-break-after: always\"></div>

Figure 9. POLARIS-4 - Subject Disposition (All Screened Subjects)

<!-- image -->

## Baseline data

The demographics and baseline characteristics are roughly similar between study groups. A significant proportion of cirrhotic and high-viremic patients were included, groups that historically have been more difficult to treat.

<div style=\"page-break-after: always\"></div>

Table 23. Demographics by treatment group

|                                     | SOF/VEL/VOX 12 Weeks (N = 182)   | SOF/VEL 12 Weeks (N = 151)   | Overall Study Total (N = 333)   |
|-------------------------------------|----------------------------------|------------------------------|---------------------------------|
| Age at Baseline (Years)             |                                  |                              |                                 |
| N                                   | 182                              | 151                          | 333                             |
| Mean (SD)                           | 57 (9.0)                         | 57 (7.3)                     | 57 (8.3)                        |
| Median                              | 58                               | 58                           | 58                              |
| Q1, Q3                              | 54,62                            | 52,62                        | 53,62                           |
| Min, Max                            | 24,85                            | 24, 80                       | 24, 85                          |
| Age at Baseline Category            |                                  |                              |                                 |
| < 65 Years                          | 149 (81.9%)                      | 135 (89.4%)                  | 284 (85.3%)                     |
| ≥65 Years                           | 33 (18.1%)                       | 16 (10.6%)                   | 49 (14.7%)                      |
| Sex at Birth                        |                                  |                              |                                 |
| Male                                | 143 (78.6%)                      | 114 (75.5%)                  | 257 (77.2%)                     |
| Female                              | 39 (21.4%)                       | 37 (24.5%)                   | 76 (22.8%)                      |
| Race                                |                                  |                              |                                 |
| White                               | 160 (87.9%)                      | 131 (86.8%)                  | 291 (87.4%)                     |
| Black or AfricanAmerican            | 16 (8.8%)                        | 13 (8.6%)                    | 29 (8.7%)                       |
| Asian                               | 2 (1.1%)                         | 4 (2.6%)                     | 6 (1.8%)                        |
| Other                               | 2 (1.1%)                         | 1 (0.7%)                     | 3 (0.9%)                        |
| American Indian or Alaska Native    | 2 (1.1%)                         | 0                            | 2 (0.6%)                        |
| Native Hawaiian or Pacific Islander | 0                                | 2 (1.3%)                     | 2 (0.6%)                        |
| Ethnicity                           |                                  |                              |                                 |
| Hispanic or Latino                  | 19 (10.4%)                       | 8 (5.3%)                     | 27 (8.1%)                       |
| Not Hispanic or Latino              | 163 (89.6%)                      | 143 (94.7%)                  | 306 (91.9%)                     |
| Region                              |                                  |                              |                                 |
| US                                  | 101 (55.5%)                      | 87 (57.6%)                   | 188 (56.5%)                     |
| Non-US                              | 81 (44.5%)                       | 64 (42.4%)                   | 145 (43.5%)                     |
| Baseline Body Mass Index (kg/m2)    |                                  |                              |                                 |
| N                                   | 182                              | 151                          | 333                             |
| Mean (SD)                           | 28.7 (5.56)                      | 28.5 (5.84)                  | 28.6 (5.68)                     |
| Median                              | 27.8                             | 27.5                         | 27.7                            |
| Q1, Q3                              | 24.9, 31.8                       | 24.6, 31.8                   | 24.7, 31.8                      |
| Min, Max                            | 18.0, 45.4                       | 17.8, 53.3                   | 17.8, 53.3                      |
| Baseline Body Mass Index Category   |                                  |                              |                                 |
| < 30 kg/m²                          | 120 (65.9%)                      | 98 (64.9%)                   | 218 (65.5%)                     |
| ≥30 kg/m²                           | 62 (34.1%)                       | 53 (35.1%)                   | 115 (34.5%)                     |

Baseline value is the last available value on or prior to first dose date of any study drug.

BMI = [weight (kg) / (height (m)^2)].

<div style=\"page-break-after: always\"></div>

Table 24. Baseline characteristics by treatment group

|                                    | SOF/VEL/VOX 12 Weeks (N = 182)   | SOF/VEL 12 Weeks (N = 151)   | Overall Study Total (N = 333)   |
|------------------------------------|----------------------------------|------------------------------|---------------------------------|
| HCV Genotype/Subtype by Sequencing |                                  |                              |                                 |
| Genotype 1                         | 78 (42.9%)                       | 66 (43.7%)                   | 144 (43.2%)                     |
| 1a                                 | 54 (29.7%)                       | 44 (29.1%)                   | 98 (29.4%)                      |
| 1b                                 | 24 (13.2%)                       | 22 (14.6%)                   | 46 (13.8%)                      |
| Genotype 2                         | 31 (17.0%)                       | 33 (21.9%)                   | 64 (19.2%)                      |
| Genotype 3                         | 54 (29.7%)                       | 52 (34.4%)                   | 106 (31.8%)                     |
| Genotype 4                         | 19 (10.4%)                       | 0                            | 19 (5.7%)                       |
| Cirrhosis                          |                                  |                              |                                 |
| Yes                                | 84 (46.2%)                       | 69 (45.7%)                   | 153 (45.9%)                     |
| No                                 | 98 (53.8%)                       | 82 (54.3%)                   | 180 (54.1%)                     |
| IL28B Genotype                     |                                  |                              |                                 |
| CC                                 | 33 (18.1%)                       | 29 (19.2%)                   | 62 (18.6%)                      |
| Non-CC                             | 149 (81.9%)                      | 122 (80.8%)                  | 271 (81.4%)                     |
| CT                                 | 107 (58.8%)                      | 95 (62.9%)                   | 202 (60.7%)                     |
| TT                                 | 42 (23.1%)                       | 27 (17.9%)                   | 69 (20.7%)                      |
| Baseline HCV RNA (logio IU/mL)     |                                  |                              |                                 |
| N                                  | 182                              | 151                          | 333                             |
| Mean (SD)                          | 6.3 (0.56)                       | 6.3 (0.66)                   | 6.3 (0.61)                      |
| Median                             | 6.4                              | 6.4                          | 6.4                             |
| Q1, Q3                             | 5.9, 6.7                         | 5.9,6.7                      | 5.9, 6.7                        |

<div style=\"page-break-after: always\"></div>

| Min, Max                                                                         | 5.0, 7.5      | 3.6, 7.3      | 3.6, 7.5      |
|----------------------------------------------------------------------------------|---------------|---------------|---------------|
| Baseline HCV RNA Category                                                        |               |               |               |
| < 800,000 IU/mL                                                                  | 46 (25.3%)    | 38 (25.2%)    | 84 (25.2%)    |
| ≥ 800,000 IU/mL                                                                  | 136 (74.7%)   | 113 (74.8%)   | 249 (74.8%)   |
| Baseline ALT (U/L)                                                               |               |               |               |
| N                                                                                | 182           | 151           | 333           |
| Mean (SD)                                                                        | 84 (65.0)     | 85 (67.7)     | 84 (66.1)     |
| Median                                                                           | 65            | 64            | 65            |
| Q1, Q3                                                                           | 42,101        | 33,108        | 39,105        |
| Min, Max                                                                         | 13, 417       | 9,384         | 9,417         |
| Baseline ALT Category                                                            |               |               |               |
| ≤1.5 x ULN                                                                       | 88 (48.4%)    | 72 (47.7%)    | 160 (48.0%)   |
| > 1.5 x ULN                                                                      | 94 (51.6%)    | 79 (52.3%)    | 173 (52.0%)   |
| Prior HCV Treatment Experience                                                   |               |               |               |
| Treatment Experienced                                                            | 182 (100.0%)  | 151 (100.0%)  | 333 (100.0%)  |
| DAA-Naive                                                                        | 0             | 1 (0.7%)      | 1 (0.3%)      |
| DAA-Experienced                                                                  | 182 (100.0%)  | 150 (99.3%)   | 332 (99.7%)   |
| Non-NS5A ± DAAs                                                                  | 182 (100.0%)  | 150 (99.3%)   | 332 (99.7%)   |
| NS5B Only                                                                        | 134 (73.6%)   | 109 (72.2%)   | 243 (73.0%)   |
| NS5B + NS3                                                                       | 46 (25.3%)    | 38 (25.2%)    | 84 (25.2%)    |
| Other(s)                                                                         | 2 (1.1%)      | 3 (2.0%)      | 5 (1.5%)      |
| Estimated Glomerular Filtration Rate Using the Cockcroft-Gault Equation (mL/min) |               |               |               |
| N                                                                                | 182           | 151           | 333           |
| Mean (SD)                                                                        | 123.3 (37.90) | 123.7 (36.31) | 123.5 (37.13) |
| Median                                                                           | 118.9         | 116.3         | 117.9         |
| Q1, Q3                                                                           | 94.8, 140.1   | 98.5, 141.4   | 97.5, 140.1   |
| Min, Max                                                                         | 53.4, 275.7   | 63.6, 232.5   | 53.4, 275.7   |

Baseline value is the last available value on or prior to first dose date of any study drug.

HCV genotype was determined by sequencing.

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0 with limit of quantitation 15 IU/mL.

## Outcomes

The study was not designed for direct statistical comparison between study groups, but rather to a pre-specified SVR12 performance goal of 85%. When reviewing the data post-hoc, the response rate in the SOF/VEL/VOX group is higher than that of SOF/VEL. There was only one (0.5%) virologic failure in the SOF/VEL/VOX group compared to 15 (9.9%) in the SOF/VEL group.

<div style=\"page-break-after: always\"></div>

Table 25. SVR12 (Full Analysis Set)

|                           | SOF/VEL/VOX 12 Weeks (N = 182)   | SOF/VEL 12 Weeks (N = 151)   |
|---------------------------|----------------------------------|------------------------------|
| SVR12                     | 177/182 (97.3%)                  | 136/151 (90.1%)              |
| 95% CI                    | 93.7% to 99.1%                   | 84.1% to 94.3%               |
| p-value (Compared to 85%) | <0.001                           | 0.092                        |

Table 26. Virologic Outcomes (Full Analysis Set)

|                                | SOF/VEL/VOX 12 Weeks (N = 182)   | SOF/VEL 12 Weeks (N=151)   |
|--------------------------------|----------------------------------|----------------------------|
| SVR12                          | 177/182 (97.3%)                  | 136/151 (90.1%)            |
| Overall Virologic Failure      | 1/182 (0.5%)                     | 15/151 (9.9%)              |
| Relapse                        | 1/182 (0.5%)                     | 14/150 (9.3%)              |
| Completed Study Treatment      | 1/182 (0.5%)                     | 13/149 (8.7%)              |
| Discontinued Study Treatment   | 0/0                              | 1/1 (100.0%)               |
| On-Treatment Virologic Failure | 0/182                            | 1/151 (0.7%)               |
| Other                          | 4/182 (2.2%)                     | 0/151                      |

The precision in subgroup estimates are limited by their respective sizes. Numerically, the difference between SOF/VEL/VOX and SOF/VEL (favouring SOF/VEL/VOX) is larger in GT1a, GT3 and cirrhotics.

The low number of virologic failures in the SOF/VEL/VOX groups implies that pre-existing RAVs do not affect treatment outcome.

Table 27. SVR12 by HCV genotype and virologic outcome in study POLARIS-4

|                                  | SOF/VEL/VOX 12 weeks (n = 182)   | SOF/VEL 12 weeks (n = 151)       |
|----------------------------------|----------------------------------|----------------------------------|
| Overall SVR12                    | 98% (178/182)                    | 90% (136/151)                    |
| Genotype 1                       | 97% (76/78)                      | 91% (60/66)                      |
| Genotype 1a                      | 98% (53/54)                      | 89% (39/44)                      |
| Genotype 1b                      | 96% (23/24)                      | 95% (21/22)                      |
| Genotype 2                       | 100% (31/31)                     | 97% (32/33)                      |
| Genotype 3                       | 96% (52/54)                      | 85% (44/52)                      |
| Genotype 4                       | 100% (19/19)                     | 0/0                              |
| Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR |
| On-treatment virologic failure a | 0/182                            | 1% (1/151)                       |
| Relapse b                        | 1% (1/182)                       | 9% (14/150)                      |
| Other c                          | 2% (3/182)                       | 0/151                            |

<div style=\"page-break-after: always\"></div>

## GS-US-367-1172 (POLARIS-2)

This is a phase 3, randomized, open-label study to investigate the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination for 8 weeks compared to sofosbuvir/velpatasvir for 12 weeks in DAA-naïve subjects with chronic HCV infection.

## Methods

## Study participants

Subjects were enrolled across 117 sites in the United States, Canada, the United Kingdom, France, Germany, Australia, and New Zealand. For general inclusion and exclusion criteria, see above.

## Treatments, randomization and blinding

Approximately 780 DAA-naive subjects (750 subjects with genotype 1, 2, 3, or 4 HCV infection and 30 subjects with genotype 5 or genotype indeterminate HCV infection were to be enrolled or randomized 1:1 to 1 of the following 2 treatment groups:

- -SOF/VEL/VOX 8 Weeks (n = 405): SOF/VEL/VOX FDC (400/100/100 mg) once daily with food for 8 weeks
- -SOF/VEL 12 Weeks (n = 375): SOF/VEL FDC (400/100 mg) once daily with or without food for 12 weeks

A target of at least 30% of subjects with genotype 1, 2, or 4 HCV infection was to have cirrhosis. Subjects with genotype 3 HCV infection with cirrhosis were not eligible for participation. For subjects with HCV genotype 1, 2, 3, or 4, randomization was stratified by HCV genotype (1, 2, 3, or 4), cirrhosis status (presence or absence), and treatment history (treatment naive or treatment experienced with an interferon (IFN)-based regimen).

Subjects with genotype 5 or genotype indeterminate HCV (including genotype 6, due to the inability of the screening assay to distinguish this genotype), with or without cirrhosis, were to be enrolled into the SOF/VEL/VOX 8 Week group.

This was an open-label study. The study was design with a 95% power to establish non-inferiority in the SVR12 rates between the two groups. It is based on the assumptions that the non-inferiority margin is 5%, both groups have an SVR12 rate of 97%, and the significance level is 0.025 one-sided.

The original study protocol (21 August 2015) was amended once (09 October 2015), prior to study initiation. Key changes to the protocol were as follows:

- -Subjects with genotype 3 HCV infection with cirrhosis were excluded from study participation. These subjects became eligible for participation in another study (Study GS-US-367-1173; POLARIS-3).
- -The approximate number of subjects by genotype to be randomized or enrolled into each of the 2 treatment groups was revised (i.e. total number of genotype 3 subjects was decreased from 300 to 150).
- -The number of participating investigational sites was increased from 100 to 120.

<div style=\"page-break-after: always\"></div>

## Participant flow

A total of 1116 subjects were screened for the study, and 173 subjects (15.5%) failed screening. Of the 161 subjects who did not meet eligibility criteria, the 3 primary reasons for screen failure were laboratory values not within acceptable ranges (31.1%, 50 subjects), clinically relevant alcohol or drug abuse within 12 months of screening (24.2%, 39 subjects), and no liver imaging within 6 months of baseline/Day 1 (10.6%, 17 subjects). Of the 12 screen failure subjects who did meet eligibility criteria, the reasons for not enrolling were withdrew consent (58.3%, 7 subjects), lost to follow-up (25.0%, 3 subjects), other (8.3%, 1 subject), and outside of visit window (8.3%, 1 subject).

Figure 10. Participant flow

<!-- image -->

## Baseline data

Demographic parameters and baseline characteristics were similar between study groups. As expected from a DAA-naïve cohort, the proportion of cirrhotic patients is lower (18.5%) than in POLARIS-1 and 4, and below the pre-specified target for this study (30%). This is likely related to the study amendment excluding GT3 cirrhotic patients from this study.

<div style=\"page-break-after: always\"></div>

Table 28. Demographics by treatment group (Safety Analysis Set)

|                                     | Total (All Genotypes)       | Total (All Genotypes)    | Overall             |
|-------------------------------------|-----------------------------|--------------------------|---------------------|
|                                     | SOF/VEL/VOX 8 Weeks (N=501) | SOF/VEL 12 Weeks (N=440) | Study Total (N=941) |
| Age at Baseline (Years)             |                             |                          |                     |
| N                                   | 501                         | 440                      | 941                 |
| Mean (SD)                           | 53 (11.1)                   | 52 (11.9)                | 52 (11.5)           |
| Median                              | 55                          | 55                       | 55                  |
| Q1, Q3                              | 47, 60                      | 46, 61                   | 46, 61              |
| Min, Max                            | 18,78                       | 19, 82                   | 18,82               |
| Age at Baseline Category            |                             |                          |                     |
| < 65 Years                          | 451 (90.0%)                 | 397 (90.2%)              | 848 (90.1%)         |
| >= 65 Years                         | 50 (10.0%)                  | 43 (9.8%)                | 93 (9.9%)           |
| Sex at Birth                        |                             |                          |                     |
| Male                                | 255 (50.9%)                 | 237 (53.9%)              | 492 (52.3%)         |
| Female                              | 246 (49.1%)                 | 203 (46.1%)              | 449 (47.7%)         |
| Race                                |                             |                          |                     |
| White                               | 391 (78.0%)                 | 365 (83.0%)              | 756 (80.3%)         |
| Black or African American           | 48 (9.6%)                   | 47 (10.7%)               | 95 (10.1%)          |
| Asian                               | 51 (10.2%)                  | 22 (5.0%)                | 73 (7.8%)           |
| Other                               | 5 (1.0%)                    | 2 (0.5%)                 | 7 (0.7%)            |
| American Indian or Alaska Native    | 3 (0.6%)                    | 2 (0.5%)                 | 5 (0.5%)            |
| Native Hawaiian or Pacific Islander | 3 (0.6%)                    | 2 (0.5%)                 | 5 (0.5%)            |
| Ethnicity                           |                             |                          |                     |
| Hispanic or Latino                  | 32 (6.4%)                   | 52 (11.8%)               | 84 (8.9%)           |
| Not Hispanic or Latino              | 469 (93.6%)                 | 388 (88.2%)              | 857 (91.1%)         |
| Region                              |                             |                          |                     |
| US                                  | 283 (56.5%)                 | 269 (61.1%)              | 552 (58.7%)         |
| Non-US                              | 218 (43.5%)                 | 171 (38.9%)              | 389 (41.3%)         |

<div style=\"page-break-after: always\"></div>

| Baseline Body Mass Index (kg/m2)   |             |             |             |
|------------------------------------|-------------|-------------|-------------|
| N                                  | 501         | 440         | 941         |
| Mean (SD)                          | 26.9 (5.53) | 27.1 (5.17) | 27.0 (5.36) |
| Median                             | 26.0        | 26.3        | 26.1        |
| Q1, Q3                             | 23.1, 29.2  | 23.3, 29.8  | 23.2, 29.6  |
| Min, Max                           | 16.9, 57.3  | 17.9, 54.0  | 16.9, 57.3  |
| Baseline Body Mass Index Category  |             |             |             |
| < 30 kg/m2                         | 385 (76.8%) | 332 (75.5%) | 717 (76.2%) |
| >= 30 kg/m2                        | 116 (23.2%) | 108 (24.5%) | 224 (23.8%) |

Baseline value is the last available value on or prior to first dose date of any study drug.

HCV genotype was determined by sequencing.

Body Mass Index (BMI) = [weight (kg) / (height (m)^2)].

<div style=\"page-break-after: always\"></div>

Table 29. Baseline Characteristics by treatment group (Safety Analysis Set)

|                      | Total (All Genotypes)       | Total (All Genotypes)    | Overall             |
|----------------------|-----------------------------|--------------------------|---------------------|
|                      | SOF/VEL/VOX 8 Weeks (N=501) | SOF/VEL 12 Weeks (N=440) | Study Total (N=941) |
| HCV Genotype/Subtype |                             |                          |                     |
| Genotype 1           | 233 (46.5%)                 | 232 (52.7%)              | 465 (49.4%)         |
| 1a                   | 169 (33.7%)                 | 172 (39.1%)              | 341 (36.2%)         |
| 1b                   | 63 (12.6%)                  | 59 (13.4%)               | 122 (13.0%)         |
| 1 Other              | 1 (0.2%)                    | 1 (0.2%)                 | 2 (0.2%)            |
| Genotype 2           | 63 (12.6%)                  | 53 (12.0%)               | 116 (12.3%)         |
| Genotype 3           | 92 (18.4%)                  | 89 (20.2%)               | 181 (19.2%)         |
| Genotype 4           | 63 (12.6%)                  | 57 (13.0%)               | 120 (12.8%)         |
| Genotype 5           | 18 (3.6%)                   | 0                        | 18 (1.9%)           |
| Genotype 6           | 30 (6.0%)                   | 9 (2.0%)                 | 39 (4.1%)           |
| Unknown              | 2 (0.4%)                    | 0                        | 2 (0.2%)            |
| Cinrhosis            |                             |                          |                     |
| Yes                  | 90 (18.0%)                  | 84 (19.1%)               | 174 (18.5%)         |
| No                   | 411 (82.0%)                 | 356 (80.9%)              | 767 (81.5%)         |
| IL28B                |                             |                          |                     |
| CC                   | 166 (33.1%)                 | 136 (30.9%)              | 302 (32.1%)         |
| Non-CC               | 335 (66.9%)                 | 304 (69.1%)              | 639 (67.9%)         |
| CT                   | 253 (50.5%)                 | 245 (55.7%)              | 498 (52.9%)         |
| TT                   | 82 (16.4%)                  | 59 (13.4%)               | 141 (15.0%)         |

<div style=\"page-break-after: always\"></div>

| Baseline HCV RNA (log10 IU/mL)                                                   |                 |                 |                 |
|----------------------------------------------------------------------------------|-----------------|-----------------|-----------------|
| N                                                                                | 501             | 440             | 941             |
| Mean (SD)                                                                        | 6.1 (0.75)      | 6.2 (0.66)      | 6.2 (0.71)      |
| Median                                                                           | 6.3             | 6.3             | 6.3             |
| Q1, Q3                                                                           | 5.7, 6.7        | 5.8, 6.7        | 5.8, 6.7        |
| Min, Max                                                                         | 2.7,7.6         | 4.0, 7.6        | 2.7,7.6         |
| Baseline HCV RNA Category                                                        |                 |                 |                 |
| < 800.000 1IU/mL                                                                 | 155 (30.9%)     | 138 (31.4%)     | 293 (31.1%)     |
| >= 800.000 IU/mL                                                                 | 346 (69.1%)     | 302 (68.6%)     | 648 (68.9%)     |
| Baseline ALT (U/L)                                                               |                 |                 |                 |
| N                                                                                | 501             | 440             | 941             |
| Mean (SD)                                                                        | 65 (57.4)       | 69 (54.2)       | 67 (55.9)       |
| Median                                                                           | 50              | 54              | 52              |
| Q1, Q3                                                                           | 32,77           | 33,85           | 32,80           |
| Min, Max                                                                         | 5,648           | 10,373          | 5,648           |
| Baseline ALT Category                                                            |                 |                 |                 |
| <= 1.5 x ULN                                                                     | 295 (58.9%)     | 243 (55.2%)     | 538 (57.2%)     |
| > 1.5 x ULN                                                                      | 206 (41.1%)     | 197 (44.8%)     | 403 (42.8%)     |
| Prior HCV Treatment Experience                                                   |                 |                 |                 |
| Treatment-Naive                                                                  | 383/501 (76.4%) | 340/440 (77.3%) | 723/941 (76.8%) |
| Treatment-Experienced                                                            | 118/501 (23.6%) | 100/440 (22.7%) | 218/941 (23.2%) |
| PEG-IFN+RBV                                                                      | 93/118 (78.8%)  | 81/100 (81.0%)  | 174/218 (79.8%) |
| Other                                                                            | 25/118 (21.2%)  | 19/100 (19.0%)  | 44/218 (20.2%)  |
| Estimated Glomerular Filtration Rate Using the Cockcroft-Gault Equation (mL/min) |                 |                 |                 |
| N                                                                                | 501             | 440             | 941             |
| Mean (SD)                                                                        | 111.2 (34.44)   | 111.5 (33.80)   | 111.3 (34.13)   |
| Median                                                                           | 105.6           | 106.3           | 106.0           |
| Q1, Q3                                                                           | 87.8, 128.1     | 87.6, 129.5     | 87.6, 128.9     |
| Min, Max                                                                         | 42.6, 286.1     | 37.8, 240.0     | 37.8, 286.1     |

Baseline value is the last available value on or prior to first dose date of any study drug.

HCV genotype was determined by sequencing.

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0 with limit of quantitation 15 IU/mL.

## Outcomes

The SVR12 rate for the SOF/VEL/VOX 8 Week group did not demonstrate non-inferiority, according to predefined criteria, to the SVR12 rate for the SOF/VEL 12 Week group. The difference (95% CI) in the stratum-adjusted Mantel-Haenszel proportions was -3.4% (-6.2% to -0.6%), the lower bound of which is greater than the pre-specified non-inferiority margin of -5%.

<div style=\"page-break-after: always\"></div>

Table 30. SVR12 (Full Analysis Set)

|        |                            |                          | SOF/VEL/VOX8Weeks Vs. S0F/VEL 12 Weeks   |
|--------|----------------------------|--------------------------|------------------------------------------|
|        | SOF/VEL/VOX 8Weeks (N=501) | SOF/VEL 12 Weeks (N=440) | Prop Diff (95% CI)                       |
| SVR12  | 476/501 (95.0%)            | 432/440 (98.2%)          | -3.4% (-6.2% t0 -0.6%)                   |
| 95% CI | 92.7% t0 96.7%             | 96.4% to 99.2%           |                                          |

Table 31. Virologic outcomes (Full Analysis Set)

|                                | Total (All Genotypes)       | Total (All Genotypes)    |
|--------------------------------|-----------------------------|--------------------------|
|                                | SOF/VEL/VOX 8 Weeks (N=501) | SOF/VEL 12 Weeks (N=440) |
| SVR12                          | 476/501 (95.0%)             | 432/440 (98.2%)          |
| Overall Virologic Failure      | 21/501 (4.2%)               | 3/440 (0.7%)             |
| Relapse                        | 21/498 (4.2%)               | 3/439 (0.7%)             |
| Completed Study Treatment      | 21/497 (4.2%)               | 3/437 (0.7%)             |
| Discontinued Study Treatment   | 0/1                         | 0/2                      |
| On-Treatment Virologic Failure | 0/501                       | 0/440                    |
| Other                          | 4/501 (0.8%)                | 5/440 (1.1%)             |

The overall SVR12 rate in the SOF/VEL/VOX (8 week) arm was inferior to that of the SOF/VEL (12 week) arm. The difference is driven by lower SOF/VEL/VOX SVR12 rates in GT1a, GT4, blacks, cirrhotics, IL28B non-CC, treatment experienced (non DAA) subjects and those with pre-existing RAVs. For further details on the impact of RAVs, see the integrated virology section below.

Similarly to the full SOF/VEL/VOX group in POLARIS-2, the SVR12 rates in non-cirrhotics is lower in patients with GT1a, Q80K/L/R, BMI &gt;30, IL28 non-CC, baseline HCV RNA &gt;800 000 IE/ml. In the presence of one of these negative predictors SVR12 rate estimates range between 90-95%, while two simultaneous negative predictors lead to SVR12 rate estimates between 85-90%.

Table 32 presents the SVR12 by HCV genotype and virologic outcome for the POLARIS-2 trial.

<div style=\"page-break-after: always\"></div>

Table 32. SVR12 by HCV genotype and virologic outcome in study POLARIS-2*

|                                  | SOF/VEL/VOX 8 weeks (n = 501)    | SOF/VEL 12 weeks (n = 440)       |
|----------------------------------|----------------------------------|----------------------------------|
| Overall SVR12 a                  | 95% (477/501)                    | 98% (432/440)                    |
| Genotype 1 b                     | 93% (217/233)                    | 98% (228/232)                    |
| Genotype 1a                      | 92% (155/169)                    | 99% (170/172)                    |
| Genotype 1b                      | 97% (61/63)                      | 97% (57/59)                      |
| Genotype 2                       | 97% (61/63)                      | 100% (53/53)                     |
| Genotype 3                       | 99% (91/92)                      | 97% (86/89)                      |
| Genotype 4                       | 94% (59/63)                      | 98% (56/57)                      |
| Genotype 5                       | 94% (17/18)                      | 0/0                              |
| Genotype 6                       | 100% (30/30)                     | 100% (9/9)                       |
| Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR |
| On-treatment virologic failure   | 0/501                            | 0/440                            |
| Relapse c                        | 4% (21/498)                      | 1% (3/439)                       |
| Other d                          | 1% (3/501)                       | 1% (5/440)                       |

- c. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.

d. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.

Table 33 presents the SVR12 by HCV genotype by cirrhosis status for the POLARIS-2 trial.

Table 33. SVR12 by HCV genotype and virologic outcome in patients who received Vosevi 8 weeks without cirrhosis or with cirrhosis in study POLARIS-2

|                                  | SOF/VEL/VOX 8 weeks              | SOF/VEL/VOX 8 weeks              |
|----------------------------------|----------------------------------|----------------------------------|
|                                  | Without Cirrhosis (411/501)      | With Cirrhosis (90/501)          |
| Overall SVR12 a                  | 96% (395/411)                    | 91% (82/90)                      |
| Genotype 1 b                     | 94% (162/172)                    | 90% (55/61)                      |
| Genotype 1a                      | 92% (109/118) c                  | 90% (46/51)                      |
| Genotype 1b                      | 98% (52/53)                      | 90% (9/10)                       |
| Genotype 2                       | 96% (47/49)                      | 100% (14/14)                     |
| Genotype 3                       | 99% (90/91)                      | 100% (1/1)                       |
| Genotype 4                       | 96% (51/53)                      | 80% (8/10)                       |
| Genotype 5                       | 94% (16/17)                      | 100% (1/1)                       |
| Genotype 6                       | 100% (27/27)                     | 100% (3/3)                       |
| Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR |
| On-treatment virologic failure   | 0/411                            | 0/90                             |
| Relapse d                        | 3% (14/409)                      | 8% (7/89)                        |
| Other e                          | < 1% (2/411)                     | 1% (1/90)                        |

The relation between Q80K/L/R and cirrhosis status was as follows:

<div style=\"page-break-after: always\"></div>

Table 34. GS-US-367-1172: SVR12 by Baseline Q80K RAVs (15% Cut-off) and Cirrhosis Status for Subjects With Genotype 1a Who Were Treated with SOF/VEL/VOX for 8 Weeks (Full Analysis Set)

|                         | SOF/VEL/VOX 8 Weeks                               | SOF/VEL/VOX 8 Weeks                               | SOF/VEL/VOX 8 Weeks                               |
|-------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                         | Subjects with Genotype 1a HCV Infection (N = 169) | Subjects with Genotype 1a HCV Infection (N = 169) | Subjects with Genotype 1a HCV Infection (N = 169) |
| SVR12, n/N (%) [95% CI] | With Baseline Q80K (N = 58)                       | Without Baseline Q80K (N = 108)                   | Q80K Not Determined (N = 3)                       |
| Overall                 | 51/58 (87.9%) [76.7% to 95.0%]                    | 101/108 (93.5%) [87.1% to 97.4%]                  | 3/3 (100.0%) [29.2% to 100.0%]                    |
| Cirrhosis               | 22/24 (91.7%) [73.0% to 99.0%]                    | 24/27 (88.9%) [70.8% to 97.6%]                    | 0                                                 |
| No Cirrhosis            | 29/34 (85.3%) [68.9% to 95.0%]                    | 77/81 (95.1%) [87.8% to 98.6%]                    | 3/3 (100.0%) [29.2% to 100.0%]                    |

Cirrhosis does not explain the lower SVR12 rates observed in GT1a subjects with baseline Q80K. USenrolled subjects presented with lower overall SVR12 rates than those enrolled outside of US, but this is at least partly explained by the greater prevalence of Q80K/L/R in the US-enrolled subset. The regional trends in SVR12 provide no assurance for non-US patients with verified Q80K/L/R as the relative impact of these polymorphisms are comparable between US and non-US subjects. However, when treating patients without knowledge of the Q80K/L/R status, the risk of virologic failure will indeed be lower in a European setting due to these demographic differences.

The difference in impact of Q80K on SVR12 between SOF/VEL/VOX 8 weeks and SOF/VEL 12 weeks indicates that this polymorphism probably correlate to epidemiologic factors that affect 8 week DAA regimens more than those given for 12 weeks. However, without an SOF/VEL 8 week arm with SVR12 data stratified for NS3 Q80K/L/R in the POLARIS-2 study this remains speculative.

## GS-US-367-1173 (POLARIS-3)

This is a phase 3, randomized, open-label study evaluated the antiviral efficacy, safety, and tolerability of SOF/VEL/VOX for 8 weeks and SOF/VEL for 12 weeks in subjects with chronic genotype 3 HCV infection and cirrhosis who are naive to direct-acting antiviral (DAA) treatment.

## Methods

## Study participants

Subjects were enrolled across 84 sites in the United States (US), Canada, the United Kingdom, France, Germany, Australia, and New Zealand.

## Treatments, randomization and blinding

Subjects were randomized (1:1) to 1 of the following 2 treatment groups:

- -SOF/VEL/VOX 8 Week group: SOF/VEL/VOX (400/100/100 mg) once daily with food for 8 weeks
- -SOF/VEL 12 Week group: SOF/VEL (400/100 mg) once daily without regard to food for 12 weeks

<div style=\"page-break-after: always\"></div>

Randomization was stratified by treatment history (treatment-naive or treatment-experienced with an interferon (IFN)-based regimen).

This was an open label study.

## Participant flow

A total of 315 subjects were screened for this study, and 95 subjects (30.2%) failed screening. Of the 94 subjects who did not meet eligibility criteria, the 4 primary reasons for screen failure were absence of cirrhosis (30.9%, 29 subjects), laboratory values not within acceptable ranges (30.9%, 29 subjects), clinically relevant alcohol or drug abuse within 12 months of screening (16.0%, 15 subjects), and clinically significant illness or other major medical disorder (14.9%, 14 subjects). One subject who met eligibility criteria but was not enrolled into the study withdrew consent.

Figure 11. Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 35. Demographics by treatment group (Safety Analysis Set)

|                          | SOF/VEL/VOX 8 Weeks (N=110)   | SOF/VEL 12 Weeks (N=109)   | Overall Study Total (N=219)   |
|--------------------------|-------------------------------|----------------------------|-------------------------------|
| Age at Baseline (Years)  |                               |                            |                               |
| N                        | 110                           | 109                        | 219                           |
| Mean (SD)                | 54 (8.5)                      | 55 (8.4)                   | 55 (8.4)                      |
| Median                   | 55                            | 57                         | 56                            |
| Q1, Q3                   | 50,59                         | 51, 61                     | 50, 60                        |
| Min, Max                 | 25,75                         | 31, 69                     | 25,75                         |
| Age at Baseline Category |                               |                            |                               |
| < 65 Years               | 103 (93.6%)                   | 100 (91.7%)                | 203 (92.7%)                   |
| >= 65 Years              | 7 (6.4%)                      | 9 (8.3%)                   | 16 (7.3%)                     |
| Sex at Birth             |                               |                            |                               |
| Male                     | 74 (67.3%)                    | 83 (76.1%)                 | 157 (71.7%)                   |
| Female                   | 36 (32.7%)                    | 26 (23.9%)                 | 62 (28.3%)                    |

<div style=\"page-break-after: always\"></div>

| Race                                |             |             |             |
|-------------------------------------|-------------|-------------|-------------|
| White                               | 100 (90.9%) | 97 (89.0%)  | 197 (90.0%) |
| Asian                               | 8 (7.3%)    | 9 (8.3%)    | 17 (7.8%)   |
| American Indian or Alaska Native    | 1 (0.9%)    | 1 (0.9%)    | 2 (0.9%)    |
| Black or African American           | 0           | 1 (0.9%)    | 1 (0.5%)    |
| Native Hawaiian or Pacific Islander | 0           | 1 (0.9%)    | 1 (0.5%)    |
| Other                               | 1 (0.9%)    | 0           | 1 (0.5%)    |
| Ethnicity                           |             |             |             |
| Hispanic or Latino                  | 9 (8.2%)    | 8 (7.3%)    | 17 (7.8%)   |
| Not Hispanic or Latino              | 101 (91.8%) | 101 (92.7%) | 202 (92.2%) |
| Region                              |             |             |             |
| US                                  | 50 (45.5%)  | 46 (42.2%)  | 96 (43.8%)  |
| Non-US                              | 60 (54.5%)  | 63 (57.8%)  | 123 (56.2%) |
| Baseline Body Mass Index (kg/m2)    |             |             |             |
| N                                   | 110         | 109         | 219         |
| Mean (SD)                           | 28.3 (6.23) | 27.3 (4.78) | 27.8 (5.57) |
| Median                              | 26.7        | 26.8        | 26.7        |
| Q1, Q3                              | 24.1, 31.1  | 24.2, 29.5  | 24.1, 30.1  |
| Min, Max                            | 19.6, 50.4  | 17.8, 45.5  | 17.8, 50.4  |
| Baseline Body Mass Index Category   |             |             |             |
| < 30 kg/m2                          | 78 (70.9%)  | 84 (77.1%)  | 162 (74.0%) |
| >= 30 kg/m2                         | 32 (29.1%)  | 25 (22.9%)  | 57 (26.0%)  |

Baseline value is the last available value on or prior to first dose date of any study drug.

HCV genotype was determined by sequencing.

Body Mass Index (BMI) = [weight (kg) / (height (m)^2)].

<div style=\"page-break-after: always\"></div>

Table 36. Baseline characteristics by treatment group (Safety Analysis Set)

|                                | SOF/VEL/VOX 8 Weeks (N=110)   | SOF/VEL 12 Weeks (N=109)   | Overall Study Total (N=219)   |
|--------------------------------|-------------------------------|----------------------------|-------------------------------|
| HCV Genotype by Sequencing     |                               |                            |                               |
| Genotype 3                     | 110 (100.0%)                  | 109 (100.0%)               | 219 (100.0%)                  |
| Cirrhosis                      |                               |                            |                               |
| Yes                            | 110 (100.0%)                  | 109 (100.0%)               | 219 (100.0%)                  |
| IL28B                          |                               |                            |                               |
| CC                             | 41 (37.3%)                    | 52 (47.7%)                 | 93 (42.5%)                    |
| Non-CC                         | 69 (62.7%)                    | 57 (52.3%)                 | 126 (57.5%)                   |
| CT                             | 57 (51.8%)                    | 44 (40.4%)                 | 101 (46.1%)                   |
| TT                             | 12 (10.9%)                    | 13 (11.9%)                 | 25 (11.4%)                    |
| Baseline HCV RNA (log10 IU/mL) |                               |                            |                               |
| N                              | 110                           | 109                        | 219                           |
| Mean (SD)                      | 6.0 (0.80)                    | 6.3 (0.63)                 | 6.2 (0.73)                    |
| Median                         | 6.1                           | 6.3                        | 6.2                           |
| Q1, Q3                         | 5.8, 6.6                      | 5.9, 6.8                   | 5.9, 6.6                      |
| Min, Max                       | 1.6, 7.6                      | 4.1, 7.5                   | 1.6, 7.6                      |
| Baseline HCV RNA Category      |                               |                            |                               |
| 800,000 IU/mL                  | 40 (36.4%)                    | 28 (25.7%)                 | 68 (31.1%)                    |
| >= 800,000 IU/mL               | 70 (63.6%)                    | 81 (74.3%)                 | 151 (68.9%)                   |
| Baseline ALT (U/L)             |                               |                            |                               |
| N                              | 110                           | 109                        | 219                           |
| Mean (SD)                      | 111 (62.2)                    | 132 (74.6)                 | 121 (69.3)                    |
| Median                         | 101                           | 123                        | 107                           |
| Q1, Q3                         | 65, 147                       | 72,181                     | 67, 161                       |
| Min, Max                       | 19, 370                       | 28, 390                    | 19, 390                       |
| Baseline ALT Category          |                               |                            |                               |
| <= 1.5 x ULN                   | 20 (18.2%)                    | 20 (18.3%)                 | 40 (18.3%)                    |
| > 1.5 x ULN                    | 90 (81.8%)                    | 89 (81.7%)                 | 179 (81.7%)                   |

<div style=\"page-break-after: always\"></div>

| Prior HCV Treatment Experience                                                   |                |                |                 |
|----------------------------------------------------------------------------------|----------------|----------------|-----------------|
| Treatment-Naive                                                                  | 75/110 (68.2%) | 77/109 (70.6%) | 152/219 (69.4%) |
| Treatment-Experienced                                                            | 35/110 (31.8%) | 32/109 (29.4%) | 67/219 (30.6%)  |
| Peg-IFN+RBV                                                                      | 31/35 (88.6%)  | 30/32 (93.8%)  | 61/67 (91.0%)   |
| Other                                                                            | 4/35 (11.4%)   | 2/32 (6.3%)    | 6/67 (9.0%)     |
| Estimated Glomerular Filtration Rate Using the Cockcroft-Gault Equation (mL/min) |                |                |                 |
| N                                                                                | 110            | 109            | 219             |
| Mean (SD)                                                                        | 126.4 (43.13)  | 120.5 (37.84)  | 123.5 (40.60)   |
| Median                                                                           | 115.4          | 113.4          | 115.2           |
| Q1, Q3                                                                           | 96.6, 148.2    | 97.2, 141.4    | 96.6, 144.0     |
| Min, Max                                                                         | 47.4, 297.5    | 52.0, 225.7    | 47.4, 297.5     |

Baseline value is the last available value on or prior to first dose date of any study drug.

HCV genotype was determined by sequencing.

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0 with limit of quantitation 15 IU/mL.

## Outcomes and estimation

SVR12 rates were high in both study groups, although the precision of the point estimates is limited by the study size. In a post hoc analysis, the 95% CI of proportional difference in SVR12 rates between SOF/VEL/VOX 8 weeks and SOF/VEL 12 weeks was -5.4% to 5.7%.

The limited number of virologic failures (two in each group) makes relevant subgroup comparisons difficult. There were no obvious effects of pre-existing RAVs in this study. Relapses were seen both in treatment (non-DAA) naïve and experienced subjects.

<div style=\"page-break-after: always\"></div>

Table 37. SVR12 (Full Analysis Set)

|                           | SOF/VEL/VOX 8 Wecks (N=110)   | SOF/VEL 12 Weeks (N=109)   |
|---------------------------|-------------------------------|----------------------------|
| SVR12                     | 106/110 (96.4%)               | 105/109 (96.3%)            |
| 95% CI                    | 91.0% to 99.0%                | 90.9% t099.0%              |
| p-value (Compared to 83%) | <0.001                        | <0.001                     |

Table 38. Virologic outcomes (Full Analysis Set)

|                                | SOF/VEL/VOX 8 Weeks (N=110)   | SOF/VEL 12 Weeks (N=109)   |
|--------------------------------|-------------------------------|----------------------------|
| SVR12                          | 106/110 (96.4%)               | 105/109 (96.3%)            |
| Overall Virologic Failure      | 2/110 (1.8%)                  | 2/109 (1.8%)               |
| Relapse                        | 2/108 (1.9%)                  | 1/107 (0.9%)               |
| Completed Study Treatment      | 2/108 (1.9%)                  | 1/107 (0.9%)               |
| Discontinued Study Treatment   | 0/0                           | 0/0                        |
| On-Treatment Virologic Failure | 0/110                         | 1/109 (0.9%)               |
| Other                          | 2/110 (1.8%)                  | 2/109 (1.8%)               |

Table 39 presents the SVR12 and virologic outcome for the POLARIS-3 study.

Table 39. SVR12 and virologic outcome in study POLARIS-3 (HCV genotype 3 with compensated cirrhosis)*

|                                  | SOF/VEL/VOX 8 weeks (n = 110)    | SOF/VEL 12 weeks (n = 109)       |
|----------------------------------|----------------------------------|----------------------------------|
| SVR12                            | 96% (106/110)                    | 96% (105/109)                    |
| Outcome for patients without SVR | Outcome for patients without SVR | Outcome for patients without SVR |
| On-treatment virologic failure   | 0/110                            | 1% (1/109)                       |
| Relapse a                        | 2% (2/108)                       | 1% (1/107)                       |
| Other b                          | 2% (2/110)                       | 2% (2/109)                       |

## Ancillary analyses - integrated phase 3 virology (POLARIS 1-4)

Deep sequencing of NS3, NS5A, and NS5B was performed at baseline for all subjects enrolled in POLARIS-1 to 4. Resistance testing was performed for subjects meeting the criteria of the Resistance Analysis Population. The impact of baseline resistance on treatment outcome uses the Resistance Analysis Population, which includes any subject who received at least 1 dose of a SOF/VEL/VOX or SOF/VEL and had a virologic outcome based on the following criteria:

- -SVR12 : HCV RNA &lt; lower limit of quantitation (LLOQ) 12 weeks after the completion of treatment
- -On-Treatment Virologic Failure : &gt;1 log10 IU/mL increase in HCV RNA over nadir or HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ during the on treatment period, confirmed

<div style=\"page-break-after: always\"></div>

with 2 consecutive values (second confirmation value could be posttreatment) with absolute viral load values ≥ 1000 IU/mL

- -Virologic Failure due to Virologic Relapse : HCV ≥ LLOQ during the posttreatment period having achieved &lt;LLOQ at the end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement, with HCV RNA ≥ 1000 IU/mL
- -Early Discontinuation : HCV RNA &gt; 1000 IU/mL at the time of study discontinuation for any reason

Resistance testing included deep sequencing of the NS3, NS5A, and NS5B genes (performed posttreatment for subjects with virologic relapse), as well as phenotypic testing of subject isolates for a subset of subjects and of site-directed mutants for observed substitutions at baseline and at virologic failure.

Resistance-associated variants (RAVs) were defined as the specific substitutions that either confer a reduced susceptibility to drugs of the given class with a &gt; 2.5-fold change in half-maximal effective concentration (EC50) compared with a genotype-specific reference in a replicon model or that commonly emerge in patients with virologic failure at the time of relapse. For this report, RAVs are presented using 1% and 15% assay cu-toffs.

Resistance-associated polymorphisms (RAPs) were defined as any change from the reference strain amino acid residue sequence at positions that are commonly associated with resistance. For this report, RAPs are presented using 15% assay cu-toffs.

## Overall prevalence of baseline NS3 and NS5A RAVs

NS5A RAVs were very common (75%) in subjects previously treated with an NS5A inhibitor but less common (approx. 20-25%) in NS5A-naïve and completely DAA-naïve subjects. NS3 RAVs were present in 25-30% of subjects except in POLARIS-3 (dedicated to GT3 subjects).

Prevalence of baseline RAVs in DAA-experienced subjects (15% Assay Cut-off)

Table 40. Prevalence of baseline RAVs in DAA-experienced subjects (15% Assay Cutoff)

|                                          | GS-US-367-1171 (POLARIS-1)   | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   |
|------------------------------------------|------------------------------|------------------------------|------------------------------|
|                                          | SOF/VEL/VOX 12 Weeks         | SOF/VEL/VOX 12 Weeks         | SOF/VEL 12 Weeks             |
|                                          | (N = 260)                    | (N =178)                     | (N =151)                     |
| No RAVs                                  | 43/260 (16.5%)               | 85/178 (47.7%)               | 75/151 (49.7%)               |
| With RAVs                                | 205/260 (78.8%)              | 83/178 (46.6%)               | 70/151 (46.4%)               |
| NS3 RAVs only                            | 9/260 (3.5%)                 | 39/178 (21.9%)               | 32/151 (21.2%)               |
| NS5A RAVs only                           | 124/260 (47.7%)              | 40/178 (22.5%)               | 34/151 (22.5%)               |
| NS3+NS5A RAVs                            | 72/260 (27.7%)               | 4/178 (2.2%)                 | 4/151 (2.6%)                 |
| RAVsnot determined for both NS3 and NS5A | 12/260 (4.6%)                | 10/178 (5.6%)                | 6/151 (4%)                   |

<div style=\"page-break-after: always\"></div>

Table 41. Prevalence of Baseline RAVs in DAA-naive subjects (15% Assay Cutoff)

|                                     | GS-US-367-1172 (POLARIS-2)    | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1173 (POLARIS-3)    | GS-US-367-1173 (POLARIS-3)   |
|-------------------------------------|-------------------------------|------------------------------|-------------------------------|------------------------------|
|                                     | SOF/VEL/VOX 8 Weeks (N = 497) | SOF/VEL 12 Weeks (N = 435)   | SOF/VEL/VOX 8 Weeks (N = 108) | SOF/VEL 12 Weeks (N = 107)   |
| No RAVs                             | 228/497 (45.9%)               | 208/435 (47.8%)              | 82/108 (75.9%)                | 78/107 (72.9%)               |
| With RAVs                           | 250/497 (50.3%)               | 218/435 (50.1%)              | 23/108 (21.3%)                | 23/107 (21.5%)               |
| NS3 RAVs only                       | 110/497 (22.1%)               | 97/435 (22.3%)               | 2/108 (1.9%)                  | 4/107 (3.7%)                 |
| NS5A RAVs only                      | 120/497 (24.1%)               | 91/435 (20.9%)               | 20/108 (18.5%)                | 19/107 (17.8%)               |
| NS3+NS5ARAVs                        | 20/497 (4.0%)                 | 30/435 (6.9%)                | 1/108 (0.9%)                  | 0/107                        |
| RAVsnotdeterminedfor bothNS3andNS5A | 19/497 (3.8%)                 | 9/435 (2.1%)                 | 3/108 (2.8%)                  | 6/107 (5.6%)                 |

## DAA-experienced subjects - SVR12 rates by baseline NS3 and NS5A RAVs

The low number of virologic failures makes the analysis of RAV impact on treatment outcome difficult. Of the 8 treatment-experienced subjects with virologic failure in POLARIS-1 and -4 in total, 4 carried the Q80K NS3 RAV, 3 an NS5A RAV at position 30 and 2 an NS5A mutation at position 93 at baseline.

Table 42. SVR12 in DAA-experienced subjects by RAVs and treatment group (15% Assay Cutoff)

|                                     | GS-US-367-1171 (POLARIS-1)   | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   |
|-------------------------------------|------------------------------|------------------------------|------------------------------|
|                                     | SOF/VEL/VOX 12 Weeks         | SOF/VEL/VOX 12 Weeks         | SOF/VEL 12 Weeks             |
|                                     | (N = 260)                    | (N =178)                     | (N =151)                     |
| No RAVs                             | 42/43 (97.7%)                | 84/85 (98.8%)                | 67/75 (89.3%)                |
| With RAVs                           | 199/205 (97.1%)              | 83/83 (100%)                 | 63/70 (90%)                  |
| NS3 RAVs only                       | 9/9 (100%)                   | 39/39 (100%)                 | 29/32 (90.6%)                |
| NS5A RAVs only                      | 120/124 (96.8%)              | 40/40 (100%)                 | 32/34 (94.1%)                |
| NS3+NS5ARAVs                        | 70/72 (97.2%)                | 4/4 (100%)                   | 2/4 (50%)                    |
| RAVsnotdeterminedfor bothNS3andNS5A | 12/12 (100%)                 | 10/10 (100%)                 | 6/6 (100%)                   |

<div style=\"page-break-after: always\"></div>

Table 43. Treatment outcome in DAA-experienced subjects with NS3 RAVs by treatment group (1% Assay Cutoff)

|            | GS-US-367-1171 (POLARIS-1)    | GS-US-367-1171 (POLARIS-1)    | GS-US-367-1170 (POLARIS-4)    | GS-US-367-1170 (POLARIS-4)    | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   |
|------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|------------------------------|------------------------------|
|            | SOF/VEL/VOX 12 Weeks (N =260) | SOF/VEL/VOX 12 Weeks (N =260) | SOF/VEL/VOX 12 Weeks (N =178) | SOF/VEL/VOX 12 Weeks (N =178) | SOF/VEL 12 Weeks (N =151)    | SOF/VEL 12 Weeks (N =151)    |
| NS3RAVs    | Prevalence                    | SVR12                         | Prevalence                    | SVR12                         | Prevalence                   | SVR12                        |
| None       | 120/260 (46.3%)               | 118/120 (98.3%)               | 74/178 (41.6%)                | 73/74 (98.6%)                 | 69/151 (45.7%)               | 63/69 (91.3%)                |
| L/V36A/L   | 3/260 (1.2%)                  | 3/3 (100%)                    | 3/178 (1.7%)                  | 3/3 (100%)                    | 0/151 (0%)                   |                              |
| Q41H/K     | 1/260 (0.4%)                  | 1/1 (100%)                    | 2/178 (1.1%)                  | 2/2 (100%)                    | 5/151 (3.3%)                 | 5/5 (100%)                   |
| F43L       | 1/260 (0.4%)                  | 1/1 (100%)                    | 2/178 (1.1%)                  | 2/2 (100%)                    | 1/151 (0.7%)                 | 1/1 (100%)                   |
| T54A       | 2/260 (0.8%)                  | 2/2 (100%)                    | 0/178 (0%)                    |                               | 0/151 (0%)                   |                              |
| V55A       | 4/260 (1.5%)                  | 4/4 (100%)                    | 0/178 (0%)                    | -                             | 2/151 (1.3%)                 | 2/2 (100%)                   |
| Y56F       | 3/260 (1.2%)                  | 3/3 (100%)                    | 1/178 (0.6%)                  | 1/1 (100%)                    | 3/151 (2%)                   | 2/3 (66.7%)                  |
| Q80K       | 32/260 (12.4%)                | 30/32 (93.8%)                 | 15/178 (8.4%)                 | 15/15 (100%)                  | 9/151 (6%)                   | 7/9 (77.8%)                  |
| Q80L/R     | 1/260 (0.4%)                  | 1/1 (100%)                    | 4/178 (2.2%)                  | 4/4 (100%)                    | 1/151 (0.7%)                 | (%001) I/I                   |
| S122N/R    | 0/260 (0%)                    |                               | 0/178 (0%)                    |                               | 0/151 (0%)                   |                              |
| R1551/L    | 1/260 (0.4%)                  | 1/1 (100%)                    | 0/178 (0%)                    |                               | 2/151 (1.3%)                 | 2/2 (100%)                   |
| A156T      | 1/260 (0.4%)                  | 1/1 (100%)                    | 0/178 (0%)                    |                               | 0/151 (0%)                   |                              |
| D/Q168E/Y  | 5/260 (1.9%)                  | 4/5 (80%)                     | 7/178 (3.9%)                  | 7/7 (100%)                    | 5/151 (3.3%)                 | 5/5 (100%)                   |
| 1170V      | 2/260 (0.8%)                  | 2/2 (100%)                    | 2/178 (1.1%)                  | 2/2 (100%)                    | 2/151 (1.3%)                 | 2/2 (100%)                   |
| Any≥2      | 72/260 (27.8%)                | 70/72 (97.2%)                 | 58/178 (32.6%)                | 58/58 (100%)                  | 46/151 (30.5%)               | 40/46 (87%)                  |
| D168+Other | 38/260 (14.7%)                | 37/38 (97.4%)                 | 28/178 (15.7%)                | 28/28 (100%)                  | 16/151 (10.6%)               | 16/16 (100%)                 |
| R155+Other | 29/260 (11.2%)                | 28/29 (96.6%)                 | 25/178 (14%)                  | 25/25 (100%)                  | 21/151 (13.9%)               | 17/21 (81%)                  |
| Q80K+Other | 53/260 (20.5%)                | 51/53 (96.2%)                 | 42/178 (23.6%)                | 42/42 (100%)                  | 32/151 (21.2%)               | 27/32 (84.4%)                |

Table 44. Treatment outcome in DAA-experienced with NS5A RAVs by treatment group (1% Assay Cutoff)

|                    | GS-US-367-1171 (POLARIS-1)   | GS-US-367-1171 (POLARIS-1)   | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   | GS-US-367-1170 (POLARIS-4)   |
|--------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                    | SOF/VEL/VOX 12Weeks          | SOF/VEL/VOX 12Weeks          | SOF/VEL/VOX 12Weeks          | SOF/VEL/VOX 12Weeks          | SOF/VEL 12Weeks              | SOF/VEL 12Weeks              |
|                    | (N =260)                     | (N =260)                     | (N =178)                     | (N =178)                     | (N =151)                     | (N =151)                     |
| NS5ARAVs           | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        |
| None               | 44/260 (17%)                 | 43/44 (97.7%)                | 107/178 (60.1%)              | 106/107 (99.1%)              | 88/151 (58.3%)               | 78/88 (88.6%)                |
| K/Q/T24G/R         | 0/260                        |                              | 1/178 (0.6%)                 | 1/1 (100%)                   | 2/151 (1.3%)                 | 2/2 (100%)                   |
| F/L/M28T/V         | 6/260 (2.3%)                 | 6/6 (100%)                   | 4/178 (2.2%)                 | 4/4 (100%)                   | 3/151 (2%)                   | 3/3 (100%)                   |
| A/L/Q/R30E/G/K/L/R | 26/260 (10%)                 | 23/26 (88.5%)                | 13/178 (7.3%)                | 13/13 (100%)                 | 5/151 (3.3%)                 | 4/5 (80%)                    |
| L/M31F/I/M/V       | 16/260 (6.2%)                | 16/16 (100%)                 | 15/178 (8.4%)                | 15/15 (100%)                 | 19/151 (12.6%)               | 19/19 (100%)                 |
| H/P/T58D/L/N       | 1/260 (0.4%)                 | 1/1 (100%)                   | 9/178 (5.1%)                 | (%001) 6/6                   | 11/151 (7.3%)                | 10/11 (90.9%)                |
| T/Y93C/H/N         | 50/260 (19.3%)               | 49/50 (98%)                  | 4/178 (2.2%)                 | 4/4 (100%)                   | 3/151 (2%)                   | 3/3 (100%)                   |
| Any≥2              | 105/260 (40.5%)              | 103/105 (98.1%)              | 15/178 (8.4%)                | 15/15 (100%)                 | 14/151 (9.3%)                | 11/14 (78.6%)                |
| Y93+Other          | 10/260 (3.9%)                | 8/10 (80%)                   | 3/178 (1.7%)                 | 3/3 (100%)                   | 1/151 (0.7%)                 | 1/1 (100%)                   |

## DAA-experienced subjects - treatment emergent RAVs

Of the 7 subjects in the SOF/VEL/VOX 12 Week group (Table 45) with sequencing data available, 1 subject with genotype 1a who experienced virologic breakthrough had treatment-emergent NS5A RAVs L31M and Y93H in addition to preexisting NS3 Q80K RAV and NS5A Q30T RAV at baseline utilizing a 15% cutoff. In addition, NS5A RAV Y93H emerged in 1 subject with genotype 4d infection who relapsed. No NS3 or NS5B NI RAVs emerged in any of the remaining 5 subjects who relapsed.

Utilizing a more sensitive 1% assay cutoff, additional emergent RAVs were observed at low levels. In the NS3 gene, 3 subjects had low levels emergent RAVs, including V36A (2.3%), R155G (1.0%), and a

<div style=\"page-break-after: always\"></div>

subject with a combination of Q41K (1.8%), V55A (2.9%), and R155M (1.4%). In NS5A, 1 subject had emergent K24R (1.2%) in addition to a baseline Y93N full mutant. No subject with available data had an emergent NS5B NI RAV observed even with a 1% assay cutoff.

Table 45. POLARIS-1 - baseline and posttreatment sequence analysis in DAA-experienced subjects with virologic failure (1% Assay Cut-off) a

| Geno type   | Treatment group      | NS3 RAVs Baseline                     | NS3 RAVs Relapse                   | NS5A RAVs Baseline       | NS5A RAVs Relapse                     | NS5B NI RAVs Baseline     | NS5B NI RAVs Relapse   |
|-------------|----------------------|---------------------------------------|------------------------------------|--------------------------|---------------------------------------|---------------------------|------------------------|
| 1a          | SOF/VEL/VOX 12 weeks | Q80K (>99%)                           | Q80K (>99%)                        | Q30T (97%)               | Q30T (>99%) L31M (21.0%) Y93H (43.7%) | None                      | None                   |
| 1a          | SOF/VEL/VOX 12 weeks | Q41K (1.2%) F43L (1.1%) Q80K (>99%)   | V36A (2.3%) Q80K (>99.7%)          | H58N (1.2%) Y93N (98.9%) | K24R (1.2%) Y93N (>99%)               | None                      | None                   |
| 3a          | SOF/VEL/VOX 12 weeks | None                                  | R155 (1.0%)                        | A30V (6.6%) Y93H (72.2%) | Y93H (>99%)                           | E237G (96.7%)             | NA                     |
| 3a          | SOF/VEL/VOX 12 weeks | None                                  | None                               | Y93H (30.9%)             | Y93H (>99%)                           | None                      | None                   |
| 3a          | SOF/VEL/VOX 12 weeks | Q80K (1.4%)                           | Q41K(1.8%) V55A(2.9%) R155M(1.4% ) | A30K (>99%)              | A30K (>99%)                           | F289L (1.4%) L320F (1.1%) | None                   |
| 3a          | SOF/VEL/VOX 12 weeks | Q168R (1.0%                           | None                               | None                     | None                                  | None                      | None                   |
| 4d          | SOF/VEL/VOX 12 weeks | Q80K (1.9%) R155L (1.9%) D168Y (2.0%) | None                               | L30R (98.3%) L30S (1.2%) | L30R (>99%) Y93H (98.9%)              | None                      | None                   |

The treatment emergent RAVs in POLARIS-4 are presented in Table 46. For the 1 subject who relapsed in the SOF/VEL/VOX 12 Week group, no NS3, NS5A, or NS5B NI RAVs were detected at baseline or at the time of relapse using a 15% assay cut-off. Using a 1% assay cut-off, the NS5A RAV M28T was detected at lower level (7.5%) at relapse, and no other NS3 or NS5B NI RAVs were detectable utilizing a more sensitive 1% assay cut-off.

In the SOF/VEL 12 Week group, 15 subjects had a virologic failure: 1 subject had on-treatment virologic failure and 14 subjects relapsed. The subject with on-treatment virologic failure had the NS5A RAVs T24S and L31M at baseline and at relapse and also developed treatment-emergent NS5A RAV Y93H and NS5B NI RAV S282T in combination with low level of M289I at the time of viral breakthrough, week 8 of treatment.

Utilizing a 15% assay cut-off, a total of 11 of 14 subjects who relapsed in the SOF/VEL 12 Week group had treatment-emergent NS5A RAVs. These emergent NS5A RAVs included Y93H or H58D+Y93C in 3 subjects with genotype 1a HCV and Y93H in 8 subjects with genotype 3 infection. No treatment emergent NS5B NI RAVs were observed using 15% assay cut-off in any of 14 subjects who relapsed.

At the more sensitive 1% assay cut-off, additional low level variants in NS3, NS5A, and NS5B were observed to emerge posttreatment. In NS5A, a total of 12 subjects developed treatment emergent NS5A RAVs, most were minor variants, at positions 24, 28, 30, 31, 58, and 93. One relapse subject developed an NS5B NI RAV using the 1% cut-off, a low level S282G (1.6%) with a complex mixture of NS5A RAVs.

<div style=\"page-break-after: always\"></div>

Table 46. POLARIS-4 - baseline and posttreatment sequence analysis in DAA-experienced subjects with virologic failure (1% Assay Cutoff) a

| Geno type   | Treatment group           | NS3 RAVs Baseline                                 | NS3 RAVs Relapse                    | NS5A RAVs Baseline       | NS5A RAVs Relapse                                                         | NS5B NI RAVs Baseline   | NS5B NI RAVs              |
|-------------|---------------------------|---------------------------------------------------|-------------------------------------|--------------------------|---------------------------------------------------------------------------|-------------------------|---------------------------|
| 1a          | SOF/VEL/VOX 12 weeks      | None                                              | None                                | None                     | M82T (7.5%)                                                               | None                    | Relapse None              |
| 1a          | SOF/VEL 12 weeks          | R155K (>99%) I170V (. 99%)                        | R155K (>99%)                        | None                     |                                                                           | None                    | S282G (1.6%)              |
| 1a          | SOF/VEL 12 weeks          | Q80K (>99%)                                       | Q80K (>99%)                         | M82T (1.9%) L31M (>99%)  | Q30K (2.1%) L31M (>99%) H58D (80.8%) Y93C                                 | None                    | None                      |
| 1a          | SOF/VEL 12 weeks          | None                                              | Q41K(1.3%) Q80K (1.2%) D168Y (1.3%) | None                     | (18.8%) H58N (1.3%)                                                       | None                    | None                      |
| 1a          | SOF/VEL 12 weeks          | Q41K (1.0%) Q80K (93.8%) Q80R (6.1%) R155K (5.3%) | Assay failure                       | H58N (1.1%)              | M82T (5.7%) Y93H (>99%)                                                   | None                    | None                      |
| 1a          | SOF/VEL 12 weeks          | Q80K (>99%)                                       | Q41K (1.1%) Q80K (>99%)             | K24R (73.6%) H58N (1.0%) | None                                                                      | None                    | None                      |
| 1b          | SOF/VEL 12 weeks          | Y56F (>99%)                                       | Y56F (99.4%)                        | None                     | None                                                                      | None                    | None                      |
| 2a/2 d/2j   | SOF/VEL 12 weeks          | None                                              | None                                | T24S (>99%) L31M (>99%)  | T24S (98.7%) F28C (3.8%) L31M (5.0%) L31V (5.0%) Y93H (89.0%) Y93N (1.3%) | None                    | S282T (>99%) M289I (1.1%) |
| 3a          | SOF/VEL 12 weeks          | Q41K (1.7%) Q80K (1.1%) R155M (1.1%)              | None                                | None                     | Y93H (>99%)                                                               | None                    | None                      |
| 3a          | SOF/VEL 12 weeks          | None                                              | Q80K (1.3%)                         | None                     | Y93H (>99%)                                                               | None                    | None                      |
| 3a          | SOF/VEL 12 weeks          | None                                              | None                                | None                     | Y93H (>99%)                                                               | None                    | None                      |
| 3a          | SOF/VEL                   | None                                              | None                                | None                     | Y93H (>99%)                                                               | None                    | None                      |
| 3a          | 12 weeks SOF/VEL 12 weeks | Q41K (3.7%) F43L (2.5%) Q80K (5.5%)               | None                                | None                     | Y93H (>99%)                                                               | F289L (3.0%) L32F       | None                      |
| 3a          | SOF/VEL 12 weeks          | Q41K (1.1%) Q80K (1.6%)                           | None                                | None                     | Y93H (>99%)                                                               | None                    | None                      |

<div style=\"page-break-after: always\"></div>

| Geno type   | Treatment group   | NS3 RAVs Baseline                   | NS3 RAVs Relapse   | NS5A RAVs Baseline   | NS5A RAVs Relapse       | NS5B NI RAVs Baseline   | NS5B NI RAVs Relapse   |
|-------------|-------------------|-------------------------------------|--------------------|----------------------|-------------------------|-------------------------|------------------------|
| 3a          | SOF/VEL 12 weeks  | None                                | Assay failure      | None                 | Y93H (>99%)             | None                    | None                   |
| 3a          | SOF/VEL 12 weeks  | Q41K (1.6%) F43L (1.1%) Q80K (5.5%) | None               | A30K (>99%)          | Y93H (>99%) A30K (>99%) | L32I (1.0%)             | None                   |

Overall, there were very few treatment emergent NS3 RAVs in the SOF/VEL/VOX 12 week groups and none of clear clinical importance. Also, it appears that the addition of VOX to SOF/VEL reduces the risk of relevant treatment emergent NS5A RAVs (mainly Y93H) in subjects with virologic failure.

## Treatment outcome in relation to previous DAA treatment

Among the 83 subjects in the SOF/VEL/VOX group previously treated with a NS3/NS5A combination (+/- NS5B), none were among the 7 subjects experiencing virologic failure which is reassuring. As PI RAVs generally tend to revert to wild type virus in time, the interval between previous virologic failure and start of SOF/VEL/VOX therapy is of interest.

Table 47. GS-US-367-1171, GS-US-367-1170: Interval between Last NS3 and Start of SOF/VEL/VOX by Baseline NS3 RAVs in NS3/4A PI-Experienced Subjects (15% Cut-off) (Safety Analysis Set)

|                  | NS3/4A PI-Experienced Subjects   | NS3/4A PI-Experienced Subjects   | NS3/4A PI-Experienced Subjects   | NS3/4A PI-Experienced Subjects   |
|------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Interval (Weeks) | Yes (N = 63)                     | No (N = 62)                      | Not Determined (N= 5)            | Total (N = 130)                  |
| Mean (SD)        | 107.4 (70.06)                    | 121.0 (88.63)                    | 71.5 (30.26)                     | 112.5 (78.83)                    |
| Median           | 82.0                             | 99.4                             | 79.9                             | 87.1                             |
| Q1, Q3           | 40.1, 170.6                      | 39.4, 190.6                      | 40.1, 99.1                       | 40.1, 177.1                      |
| Min, Max         | 11.4, 236.9                      | 16.3, 362.3                      | 39.0, 99.6                       | 11.4, 362.3                      |

Overall, the average interval between the previous (PI-containing) DAA-failure and start of retreatment with SOF/VEL/VOX was more than 2 years. RAVs seem to be slightly more common in subjects with more recent DAA-failure. In future clinical practice, when retreatment options are available at time of a confirmed virologic failure, generally 4-12 weeks after cessation of DAA-therapy, it is likely that retreatment will be initiated earlier than in this study setting.

The clinical impact of the length of this interval is unknown. Although pre-existing RAVs were not correlated with a lower SVR12 in the study, it cannot be excluded that the time to retreatment affects efficacy.

Table 48. POLARIS-1 - prior HCV DAAs

|                                                    | Overall study - Total (N=415)                      | Placebo 12 weeks (N=152)                           | SOF/VEL/VOX 12 weeks (all genotypes) (N=263)   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------|
| Prior DAA class and combination of prior DAA drugs | Prior DAA class and combination of prior DAA drugs | Prior DAA class and combination of prior DAA drugs |                                                |
| NS5A + NS5B                                        | 242 (58.3%)                                        | 81 (53.3%)                                         | 161 (61.2%)                                    |
| LDV + SOF                                          | 189 (45.5%)                                        | 76 (50.0%)                                         | 113 (43.0%)                                    |
| DCV + SOF                                          | 36 (8.7 %)                                         | 1 (0.7%)                                           | 35 (13.3%)                                     |
| VEL + SOF                                          | 12 (2.9%)                                          | 2 (1.3%)                                           | 10 (3.8%)                                      |
| DCV + LDV + SOF                                    | 4 (1.0%)                                           | 1 (0.7%)                                           | 3 (1.1%)                                       |
| OMB + DSV                                          | 1 (0.2%)                                           | 1 (0.7%)                                           | 0                                              |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                     | Overall study - Total (N=415)                                                                                                          | Placebo 12 weeks (N=152)                                                                                            | SOF/VEL/VOX 12 weeks (all genotypes) (N=263)                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| NS5A +NS3 +/- NS5B OMB + PRV + DSV VEL + VOX + SOF DCV + ASV EBR + GZR LDV + TPV + SOF DCV + ASV + BCV OMB + PRV LDV + VDV + TEG LDV + SMV + SOF DCV +SMV SAM + SMV ABT530 + ABT493 LDV + VDV + SOF | 144 (34.7%) 36 (8.7%) 11 (2.7%) 11 (2.7%) 11 (2.7%) 10 (2.4%) 10 (2.4%) 7 (1.7%) 7 (1.7%) 5 (1.2%) 5 (1.2%) 4 (1.0%) 2 (0.5%) 2 (0.5%) | 61 (40.1%) 17 (11.2%) 2 (1.3%) 5 (3.3%) 4 (2.6%) 6 (3.9%) 7 (4.6%) 1 (0.7%) 3 (2.0%) 1 (0.7%) 2 (1.3%) 0 0 1 (0.7%) | 83 (31.6%) 19 (7.2%) 9 (3.4%) 6 (2.3%) 7 (2.7%) 4 (1.5%) 3 (1.1%) 6 (2.6%) 4 (1.5%) 4 (1.5%) 3 (1.1%) 4 (1.5%) 2 (0.8%) 1 (0.4%) |

Table 49. POLARIS 1 - baseline and posttreatment RAVs in subjects with virologic relapse in the SOF/VEL/VOX 12 week group (15% Cutoff) b

|    |           | NS3 RAVs   | NS3 RAVs           | NS5A RAVs   | NS5A RAVs          | NS5B NI RAVs   | NS5B NI RAVs   |
|----|-----------|------------|--------------------|-------------|--------------------|----------------|----------------|
| GT | Prior DAA | Baseline   | Relapse            | Baseline    | Relapse            | Baseline       | Relapse        |
| 1a | LDV+SOF   | Q80K       | Q80K               | Q30T        | Q30T L31L/M Y93Y/H | None           | None           |
| 1a | LDV+SOF   | Q80K       | Q80K               | Y93N        | Y93N               | None           | None           |
| 3a | DCV+SOF   | None       | None               | None        | None               | None           | None           |
| 3a | VEL+SOF   | None       | None               | Y93Y/H      | Y93H               | None           | None           |
| 3a | VEL+SOF   | None       | None               | Y93Y/H      | Y93H               | E237G          | Assay failure  |
| 3a | DCV+SOF   | None       | None               | A30K        | A30K               | None           | None           |
| 4d | LDV+SOF   | None       | Data not Available | L30R        | Data not Available | None           | Nonea          |

## DAA-naïve subjects - SVR12 rates by baseline NS3 and NS5A RAVs

In POLARIS-2, the overall SVR12 is lower in subjects with RAVs (Table 50-51). In particular, the SVR12 rate is reduced in SOF/VEL/VOX (8 weeks) GT1a subjects carrying Q80K/L/R in comparison to GT1a subjects in the same treatment group without this RAV, and also in comparison to subjects carrying Q80K/L/R but randomized to SOF/VEL (Table 51). Although there could be epidemiological associations between other factors related to treatment outcome and Q80K/L/R, this should not be the case when comparing to subjects randomized to treatment within the same study. I n vitro data from HCV replicons, however suggest that Q80K/L/R does not affect fold change.

<div style=\"page-break-after: always\"></div>

Table 50. SVR12 in DAA-naive subjects by RAVs and treatment group (15% Assay Cutoff)

|                                     | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   |
|-------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                     | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             |
|                                     | (N = 497)                    | (N = 435)                    | (N = 108)                    | (N =107)                     |
| No RAVs                             | 223/228 (97.8%)              | 206/208 (99.0%)              | 80/82 (97.6%)                | 76/78 (97.4%)                |
| With RAVs                           | 234/250 (93.6%)              | 217/218 (99.5%)              | 23/23 (100%)                 | 23/23 (100%)                 |
| NS3 RAVs only                       | 100/110 (90.9%)              | 97/97 (100.0%)               | 2/2 (100%)                   | 4/4 (100%)                   |
| NS5A RAVs only                      | 114/120 (95.0%)              | 90/91 (98.9%)                | 20/20 (100%)                 | 19/19 (100%)                 |
| NS3+NS5ARAVs                        | 20/20 (100.0%)               | 30/30 (100.0%)               | 1/1 (100%)                   | 0                            |
| RAVsnotdeterminedfor bothNS3andNS5A | 19/19 (100.0%)               | 9/9 (100.0%)                 | 3/3 (100%)                   | 6/6 (100%)                   |

<div style=\"page-break-after: always\"></div>

Table 51. Treatment outcome in DAA-Naive with NS3 RAVs by treatment group (1% Assay Cut-off)

|            | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   |
|------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| NS3        | SOF/VEL/VOX 8 Weeks          | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             | SOF/VEL 12 Weeks             | SOF/VEL/VOX 8Weeks           | SOF/VEL/VOX 8Weeks           | SOF/VEL 12 Weeks             | SOF/VEL 12 Weeks             |
|            | (N = 497)                    | (N = 497)                    | (N = 435)                    | (N = 435)                    | (N =108)                     | (N =108)                     | (N =107)                     | (N =107)                     |
| RAVs       | Prevalencc                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        |
| None       | 257/497 (51.7%)              | 251/257 (97.7%)              | 210/435 (48.3%)              | 207/210 (98.6%)              | 78/108 (72.2%)               | 76/78 (97.4%)                | 71/107 (66.4%)               | 69/71 (97.2%)                |
| L/V36A/L   | 4/497 (0.8%)                 | 4/4 (100%)                   | 2/435 (0.5%)                 | 2/2 (100%)                   | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| Q41H/K     | 3/497 (0.6%)                 | 3/3 (100%)                   | 6/435 (1.4%)                 | 6/6 (100%)                   | 8/108 (7.4%)                 | 8/8 (100%)                   | 8/107 (7.5%)                 | 8/8 (100%)                   |
| F43L       | 6/497 (1.2%)                 | 6/6 (100%)                   | 4/435 (0.9%)                 | 4/4 (100%)                   | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| T54A       | 3/497 (0.6%)                 | 3/3 (100%)                   | 5/435 (1.1%)                 | 5/5 (100%)                   | 1/108 (0.9%)                 | (%001) I/1                   | 1/107 (0.9%)                 | (%001) 1/1                   |
| V55A       | 5/497 (1%)                   | 4/5 (80%)                    | 7/435 (1.6%)                 | 7/7 (100%)                   | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| Y56F       | 11/497 (2.2%)                | (%00DII/II                   | 10/435 (2.3%)                | 10/10 (100%)                 | 0/108 (0%)                   |                              | 1/107 (0.9%)                 | (%001) 1/1                   |
| L/Q80K     | 47/497 (9.5%)                | 41/47 (87.2%)                | 52/435 (12.0%)               | 52/52 (100%)                 | 3/108 (2.8%)                 | 3/3 (100%)                   | 4/107 (3.7%)                 | 4/4 (100%)                   |
| Q80L/R     | 8/497 (1.6%)                 | 5/8 (62.5%)                  | 5/435 (1.1%)                 | 5/5 (100%)                   | 1/108 (0.9%)                 | 1/1 (100%)                   | 0/107 (0%)                   |                              |
| S122N/R    | 6/497 (1.2%)                 | 6/6 (100%)                   | 1/435 (0.2%)                 | (%001) I/I                   | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| R1551/L    | 3/497 (0.6%)                 | 3/3 (100%)                   | 1/435 (0.2%)                 | 1/1 (100%)                   | 1/108 (0.9%)                 | 1/1 (100%)                   | 0/107 (0%)                   |                              |
| A156T      | 1/497 (0.2%)                 | 1/1 (100%)                   | 0/435 (0%)                   |                              | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| D/Q168E /Y | 22/497 (4.4%)                | 22/22 (100%)                 | 13/435 (3%)                  | 13/13 (100%)                 | 2/108 (1.9%)                 | 2/2 (100%)                   | 2/107 (1.9%)                 | 2/2 (100%)                   |
| I170V      | 10/497 (2%)                  | 10/10 (100%)                 | 10/435 (2.3%)                | 10/10 (100%)                 | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| Any≥2      | 88/497 (17.7%)               | 83/88 (94.3%)                | 100/435 (23%)                | 100/100 (100%)               | 11/108 (10.2%)               | (%00D11/11                   | 14/107 (13.2%)               | 14/14 (%001)                 |

|             | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   | GS-US-367-1173 (POLARIS-3)   |
|-------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|             | SOF/VEL/VOX 8 Weeks          | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             | SOF/VEL 12 Weeks             | SOF/VEL/VOX 8 Weeks          | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             | SOF/VEL 12 Weeks             |
| NS3         | (N = 497)                    | (N = 497)                    | (N = 435)                    | (N = 435)                    | (N =108)                     | (N =108)                     | (N =107)                     | (N =107)                     |
| RAVs        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        |
| D168+Oth er | 58/497 (11.7%)               | 57/58 (98.3%)                | 65/435 (14.9%)               | 65/65 (100%)                 | 0/108 (0%)                   |                              | 0/107 (0%)                   |                              |
| R155+Oth    | 23/497 (4.6%)                | 23/23 (100%)                 | 32/435 (7.4%)                | 32/32 (100%)                 | 10/108 (9.3%)                | 10/10 (100%)                 | 6/107 (5.7%)                 | 6/6 (100%)                   |
| Q80K+Oth er | 55/497 (11.1%)               | 53/55 (96.4%)                | 57/435 (13.1%)               | 57/57 (100%)                 | 8/108 (7.4%)                 | 8/8 (100%)                   | 10/107 (9.4%)                | 10/10 (100%)                 |

<div style=\"page-break-after: always\"></div>

Table 52. GT1a - treatment outcome in DAA-Naive with NS3 RAVs by treatment group (1% Assay Cutoff)

|          |                 | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1172 (POLARIS-2)   | GS-US-367-1173     | GS-US-367-1173     | GS-US-367-1173               | GS-US-367-1173               |
|----------|-----------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------|--------------------|------------------------------|------------------------------|
|          |                 | SOF/VEL/VOX 8 Weeks          | SOF/VEL/VOX 8 Weeks          | SOF/VEL 12 Weeks             | SOF/VEL 12 Weeks             | SOF/VEL/VOX 8Weeks | SOF/VEL/VOX 8Weeks | (POLARIS-3) SOF/VEL 12 Weeks | (POLARIS-3) SOF/VEL 12 Weeks |
| HCV      |                 | (N = 497)                    | (N = 497)                    | (N = 435)                    | (N = 435)                    | (N=108)            | (N=108)            | (N=107)                      | (N=107)                      |
| Genotype | NS3 RAVs        | Prevalence                   | SVR12                        | Prevalence                   | SVR12                        | Prevalence         | SVR12              | Prevalence                   | SVR12                        |
| la       | None            | 48/169 (28.4%)               | 48/48 (100%)                 | 44/171 (25.7%)               | 43/44 (97.7%)                |                    |                    |                              |                              |
| la       | V36L            | 1/169 (0.6%)                 | 1/1 (100%)                   | 0/171                        |                              |                    |                    |                              |                              |
| la       | Q41H/K          | 3/169 (1.8%)                 | (100%) 3/3                   | 4/171 (2.3%)                 | (%001) 4/4                   |                    |                    |                              |                              |
| la       | F43S            | 1/169 (0.6%)                 | 1/1 (100%)                   | 1/171 (0.6%)                 | 1/1 (%001)                   |                    |                    |                              |                              |
| la       | T54S            | 2/169 (1.2%)                 | 2/2 (100%)                   | 1/171 (0.6%)                 | 1/1 (%001)                   |                    |                    |                              |                              |
| la       | V55A            | 2/169 (1.2%)                 | 1/2 (50%)                    | 4/171 (2.3%)                 | 4/4 (%001)                   |                    |                    |                              |                              |
| la       | Q80K/L/R        | 43/169 (25.4%)               | 34/43 (79.1%)                | 45/171 (26.3%)               | 45/45 (%001)                 |                    |                    |                              |                              |
| la       | S122N/R         | 5/169 (3%)                   | 5/5 (100%)                   | 1/171 (0.6%)                 | 1/1 (%001)                   |                    |                    | ，                            |                              |
| la       | R155K           | 0/169                        |                              | 1/171 (0.6%)                 | 1/1 (%001)                   |                    |                    |                              |                              |
| la       | D168E/G         | 0/169                        |                              | 3/171 (1.8%)                 | 3/3 (%001)                   |                    |                    |                              |                              |
| la       | I170V           | 10/169 (5.9%)                | 10/10 (100%)                 | 10/171 (5.8%)                | 10/10 (100%)                 |                    |                    |                              |                              |
| la       | Any≥2           | 51/169 (30.2%)               | 47/51 (92.2%)                | 56/171 (32.7%)               | 56/56 (%001)                 |                    |                    |                              |                              |
| la       | 80+ or-Other    | 86/169 (50.9%)               | 74/86 (86%)                  | 89/171 (52%)                 | 89/89 (100%)                 |                    |                    |                              |                              |
| la       | 168+or-Other    | 29/169 (17.2%)               | 29/29 (100%)                 | 32/171 (18.7%)               | 32/32 (100%)                 |                    |                    |                              |                              |
| la       | 155+ or-Other   | 5/169 (3%)                   | (100%) 5/5                   | (5.8%) 10/171                | (100%) 10/10                 |                    |                    |                              |                              |
| la       | 156+ or -Other  | 1/169 (0.6%)                 | 1/1 (100%)                   | 1/171 (0.6%)                 | 1/1 (100%)                   |                    |                    |                              |                              |
| 1a       | D168+Other      | 29/169 (17.2%)               | 29/29 (100%)                 | 22/171 (12.9%)               | 22/22 (100%)                 |                    |                    |                              |                              |
| la       | R155+Other      | 5/169 (3%)                   | 5/5 (100%)                   | (%℃1) 141/6                  | 6/6 (100%)                   |                    |                    |                              |                              |
| la       | R155+D168+Other | 4/169 (2.4%)                 | 4/4 (100%)                   | 7/171 (4.1%)                 | 7.7 (100%)                   |                    |                    |                              |                              |

## DAA-naïve subjects - treatment emergent RAVs

In POLARIS-2, 24 subjects had virologic failure in this study, all of whom relapsed: 21 of 501 subjects (4.2%) in the SOF/VEL/VOX 8 Week group and 3 of 440 subjects (0.7%) in the SOF/VEL 12 Week group. The NS3 and NS5A genes were successfully sequenced at baseline and at relapse for all of the 24 subjects. NS5B was successfully sequenced at baseline and at the time of relapse for 23 subjects; assay failure at baseline and relapse occurred for 1 subject.

Table 53 presents baseline and posttreatment NS3, NS5A, and NS5B NI RAVs for subjects with virologic failure from Study GS-US-367-1172 using a 1% cut-off.

In the SOF/VEL/VOX 8 Week group only 1 subject with genotype 1a infection had emergent NS5A Q30R and L31M at relapse, no other treatment emergent RAVs were observed in the remaining 20

<div style=\"page-break-after: always\"></div>

subjects who relapsed using a 15% assay cut-off. VEL EC50 for the GT1a replicon with NS5A sitedirected mutants Q30R+L31M was198-fold higher than that of the reference GT1a replicon.

Utilizing a more sensitive 1% cut-off, a number of additional low level RAVs were observed to emerge posttreatment in the SOF/VEL/VOX 8 Week group. In the NS3 gene, 5 subjects (2 with genotype 1a, 2 with genotype 4, and 1 with genotype 5) had low-levels emergent NS3 RAVs. These emergent RAVs included Q41H (1.4%), Q41K (2.1%), R155S (1.1%), and D168Y (1.3%) in 1 genotype 1a subject, A156T (2.3%) in 1 genotype 1a subject, L36M (1.8%), Q80K (1.9%), and D168Y (1.4%) in 1 genotype 4a subject, Q80K (1.1%) and R155L (1.1%) in 1 genotype 4d subject, and F43L (1.1%) and D168Y (1.8%) in 1 genotype 5a subject. No NS5A RAVs emerged in any subject. However, 1 subject had the combination of Q30R (99.1%) and L31M (99.6%) enrich from less than 15% of the viral population at baseline. One genotype 5a subject had low level NS5B NI RAV E237G (1.4%) emerge posttreatment.

In the SOF/VEL 12 Week group using a 15% assay cut-off, 1 subject with genotype 1a HCV infection had emergent NS5A Y93N at relapse. No other emergent NS3, NS5A, or NS5B NI RAVs were observed using a 15% assay cut-off.

Using a more sensitive 1% assay cut-off, of the 3 subjects that relapsed the genotype 1a subject had a low level Y93H (7.7%) emerge in addition to a Y93N (91.8%). No emergent NS5B NI RAVs were observed in these subjects.

Table 53. POLARIS-2 - baseline and posttreatment sequence analysis in DAA-naive subjects with virologic failure (1% Assay Cut-off) a

| GT   | Treatment group     | NS3 RAVs Baseline         | NS3 RAVs Relapse                    | NS5A RAVs Baseline                             | NS5A RAVs Relapse   | NS5B NI RAVs Baseline   | NS5B NI RAVs Relapse   |
|------|---------------------|---------------------------|-------------------------------------|------------------------------------------------|---------------------|-------------------------|------------------------|
| 1a   | SOF/VEL/VOX 8 weeks | Q80R (2.4%)               | Q41H (4.6%)                         | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (>99%)               | Q80K (>99%)                         | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (>99%)               | Q80K (>99%)                         | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (>99%)               | Q80K (>99%)                         | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q41H (13.5%) Q80K (>99%)  | Q80K (>99%)                         | M28V (1.1%) Q30H (1.1%) Y93H (1.4) Y93N (4.1%) | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q41H (1.3%) Q80K (1.3%)   | None                                | H58N (1.2%)                                    | H58N (1.1%)         | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80L (>99%) I170V (4.5%)  | Q80L (>99%)                         | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80L (2.3%)               | None                                | None                                           | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (>99%)               | Q80K (>99%)                         | M28V (2.1%)                                    | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | V55A (>99%) I170V (12.1%) | V55A (>99%)                         | M28V (1.3%)                                    | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (>99%)               | Q80K (>99%)                         | M28V (1.2%) H58N (1.3%)                        | None                | None                    | None                   |
| 1a   | SOF/VEL/VOX 8 weeks | Q80K (86.4%)              | Q41H (1.4%) Q41K (2.15) Q80K (1.4%0 | H58N (1.1%)                                    | None                | None                    | None                   |

<div style=\"page-break-after: always\"></div>

| GT   | Treatment group     | NS3 RAVs Baseline         | NS3 RAVs Relapse                     | NS5A RAVs Baseline                                 | NS5A RAVs Relapse        | NS5B NI RAVs Baseline   | NS5B NI RAVs Relapse   |
|------|---------------------|---------------------------|--------------------------------------|----------------------------------------------------|--------------------------|-------------------------|------------------------|
|      |                     |                           | R155S (1.1%) D168Y (1.3%)            |                                                    |                          |                         |                        |
|      | SOF/VEL/VOX 8 weeks | V55A (1.1%)               | A156T (2.3%)                         | M28V (1.3%) Q30H (52.6%) Q30R (10.1% 0 L31M (6.0%) | Q30R (>99%) L31M (>99%)  | None                    | None                   |
|      | SOF/VEL/VOX 8 weeks | Q80L (1.1%)               | None                                 | None                                               | None                     | None                    | None                   |
|      | SOF/VEL/VOX 8 weeks | None                      | None                                 | L31M (98.4%) Y93H (5.1%)                           | L31M (>99%)              | None                    | None                   |
|      | SOF/VEL/VOX 8 weeks | None                      | None                                 | L31M (>99%)                                        | L31M (>99%)              | None                    | None                   |
|      | SOF/VEL/VOX 8 weeks | None                      | None                                 | L31M (>99%)                                        | L31M (>99%)              | None                    | M289I (1.0%)           |
|      | SOF/VEL/VOX 8 weeks | None                      | None                                 | T24S (>99%)                                        | T24S (>99%)              | Assay failure           | Assay failure          |
|      | SOF/VEL/VOX 8 weeks | None                      | L36M (1.8%) Q80K (1.9%) D168Y (1.4%) | none                                               | none                     | None                    | F289L (1.2%)           |
|      | SOF/VEL/VOX 8 weeks | None                      | Q80K (1.1%0 R155l (1.1%)             | L30R (>99%)                                        | L30R (98.9%)             | None                    | None                   |
|      | SOF/VEL/VOX 8 weeks | F43L (1.2%) D168E (35.2%) | F43L (1.2%) D168Y (1.8%)             | Q30R (8.5%)                                        | None                     | None                    | E237G (1.4%)           |
|      | SOF/VEL 12 weeks    | None                      | T54A (3.6%)                          | None                                               | Y93Y (91.8%) Y93Y (7.7%) | None                    | None                   |
| 1b   | SOF/VEL 12 weeks    | None                      | R155L (1.4%)                         | L31M (>99%) Y93Y (>99%)                            | L31M (>99%) Y93Y (>99%)  | V32I (94.1%)            | V32I (>99%)            |
| 4a   | SOF/VEL 12 weeks    | None                      | Q80K (1.5%0 D168Y (1.4%)             | none                                               | None                     | None                    | None                   |

In the POLARIS-3 SOF/VEL/VOX 8 Week group, 2 of 110 subjects (1.8%) experienced virologic relapse. No NS3, NS5A, or NS5B emerged at the 15% assay cutoff level in either of these subjects. Using a more sensitive 1% assay cutoff, 1 of the 2 subjects had low level NS3 RAVs Q41K (1.0%) and Q80K (1.1%) emerge, and the other subject developed Y93H (3.3%) at relapse. No emergent NS5B NI RAVs were observed.

<div style=\"page-break-after: always\"></div>

In SOF/VEL group, 2 of 109 subjects (1.8%) experienced virologic failure with PK data consistent with nonadherence. Both subjects with virologic failure had the NS5A RAV Y93H emerge using a 15% cutoff. No other emergent NS3, NS5A, or NS5B NI RAVs were observed at 15% assay cutoff.

Using a more sensitive 1% assay cutoff, no NS5A or NS5B NI RAVs were detected between the 1% and 15% thresholds.

Table 54. POLARIS-3 - baseline and posttreatment sequence analysis in DAA-naive subjects with virologic failure (1% Assay Cutoff)

| Geno type   | Treatment group      | NS3 RAVs Baseline   | NS3 RAVs Relapse        | NS5A RAVs Baseline   | NS5A RAVs Relapse   | NS5B NI RAVs Baseline   | NS5B NI RAVs Relapse   |
|-------------|----------------------|---------------------|-------------------------|----------------------|---------------------|-------------------------|------------------------|
| 3a          | SOF/VEL/VOX 12 weeks | None                | None                    | None                 | Y93H (3.3%)         | None                    | None                   |
| 3a          | SOF/VEL/VOX 12 weeks | None                | Q41K (1.0%) Q80K (1.1%) | None                 | None                | N142T (95.1%)           | None                   |
| 3a          | SOF/VEL 12 weeks     | None                | None                    | None                 | Y93H (>99%)         | None                    | None                   |
| 3a          | SOF/VEL 12 weeks     | None                | Q168R (1.1%)            | None                 | Y93H (22.1%)        | None                    | None                   |

In summary, although the number of virologic failures was higher in the studies on DAA-naïve subjects, there were no treatment emergent NS3 RAVs of clear clinical importance, and the proportion of subjects failing treatment with emergent NS5A RAVs treated with SOF/VEL/VOX were low in comparison to SOF/VEL. The ongoing study GS-US-367-4181 will document outcomes after 12 weeks of retreatment of those who relapsed after an initial 12-week course across the POLARIS-3 and 4 studies. Since it is unclear why these patients relapsed, the response to retreatment and the attending virological findings will be of considerable interest. The applicant committed to provide study results from study GS-US-367-4181 which are expected to be available by September 2018.

## Phenotypic analysis of VOX in subject-derived isolates from DAA-experienced subjects with virologic failure

To characterize the susceptibility of individual subject isolates before and after virologic failure, phenotypic analysis of the subject-derived NS3 gene was undertaken for a subset of subjects. Notably, none of the clinical HCV isolates from subjects with virologic failure presented with a significant VOX fold-change at baseline or at the time of failure.

## Summary of main efficacy results

Efficacy results from the main studies supporting the present application are summarised in Table 55. For background information on the studies listed, see above. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 55. Summary of SVR12 in phase 3 trials

| Regimen                            | Study          | Treatment Group   |   N | SVR12 n/N (%)   |
|------------------------------------|----------------|-------------------|-----|-----------------|
| DAA-experienced SOF/VEL/VOX12Weeks | GS-US-367-1171 | SOF/VEL/VOX       | 263 | 253/263 (96.2%) |
| DAA-experienced SOF/VEL/VOX12Weeks | GS-US-367-1170 | SOF/VEL/VOX       | 182 | 177/182 (97.2%) |
| DAA-experienced SOF/VEL/VOX12Weeks | GS-US-367-1170 | SOF/VEL           | 151 | 136/151 (90.0%) |
| DAA-NaiveSOF/VEL/VOX 8 Weeks       | GS-US-367-1172 | SOF/VEL/VOX       | 501 | 476/501 (95.0%) |
| DAA-NaiveSOF/VEL/VOX 8 Weeks       | GS-US-367-1172 | SOF/VEL           | 440 | 432/440 (98.2%) |
| DAA-NaiveSOF/VEL/VOX 8 Weeks       | GS-US-367-1173 | SOF/VEL/VOX       | 110 | 106/110 (96.4%) |
| DAA-NaiveSOF/VEL/VOX 8 Weeks       | GS-US-367-1173 | SOF/VEL           | 109 | 105/109 (96.3%) |

## Clinical studies in special populations

## Elderly

In the SOF/VEL/VOX phase 3 programme, subjects aged ≥18 years have been included with no upper age limit. In total, 131 subjects &gt; 65 years have been included in POLARIS 1-4.

Table 56. Summary of SVR12 data by age category in POLARIS 1-4.

| SVR12, n/N (%) [95% CI]                         | Age Category (Years)             | Age Category (Years)             | Age Category (Years)           | Age Category (Years)          |                                  |
|-------------------------------------------------|----------------------------------|----------------------------------|--------------------------------|-------------------------------|----------------------------------|
| SVR12, n/N (%) [95% CI]                         | < 65                             | 65 to 74                         | 75 to 85                       | ≥ 85                          | Total                            |
| GS-US-367-1171 (POLARIS-1) SOF/VEL/VOX 12 Weeks | 213/222 (95.9%) [92.4% to 98.1%] | 33/34 (97.1%) [84.7% to 99.9%]   | 7/7 (100.0%) [59.0% to 100.0%] | 0                             | 253/263 (96.2%) [93.1% to 98.2%] |
| GS-US-367-1172 (POLARIS-2) SOF/VEL/VOX 8 Weeks  | 428/451 (94.9%) [92.4% to 96.7%] | 46/48 (95.8%) [85.7% to 99.5%]   | 2/2 (100.0%) [15.8% to 100.0%] | 0                             | 476/501 (95.0%) [92.7% to 96.7%] |
| GS-US-367-1173 (POLARIS-3) SOF/VEL/VOX 8 Weeks  | 99/103 (96.1%) [90.4% to 98.9%]  | 6/6 (100.0%) [54.1% to 100.0%]   | 1/1 (100.0%) [2.5% to 100.0%]  | 0                             | 106/110 (96.4%) [91.0% to 99.0%] |
| GS-US-367-1170 (POLARIS-4) SOF/VEL/VOX 12 Weeks | 144/149 (96.6%) [92.3% to 98.9%] | 31/31 (100.0%) [88.8% to 100.0%] | 1/1 (100.0%) [2.5% to 100.0%]  | 1/1 (100.0%) [2.5% to 100.0%] | 177/182 (97.3%) [93.7% to 99.1%] |

The SVR12 rates in these older patients do not appear to be lower than in younger patients.

## Renal impairment

In the SOF/VEL/VOX phase 3 programme, subjects with GFR &lt; 50 ml/min were excluded. Hence, there are no efficacy or safety data from subjects with moderate or severe renal impairment. However, SOF/VEL is currently approved for patients with GFR ≥ 30 ml/min and VOX have been studied in subjects with renal impairment in a single-dose study. For further details, see the pharmacokinetic report.

<div style=\"page-break-after: always\"></div>

## Hepatic impairment

Population PK analysis in subjects with HCV infection in the Phase 2 and Phase 3 programs evaluated the effect of compensated cirrhosis on SOF, GS-331007, VEL, and VOX exposures and the effects of moderate and severe hepatic impairment on the PK of SOF, VEL, and VOX were evaluated in Phase 1 studies with the individual drugs. Phase 1 evaluation of VOX PK demonstrated a 299% and 500% higher exposure (AUCinf) of VOX in subjects with moderate and severe hepatic impairment, respectively, compared with subjects with normal hepatic function. MAH proposes no dose adjustment of SOF/VEL/VOX is required for patients with compensated cirrhosis, but that SOF/VEL/VOX should be not recommended in patients with moderate or severe hepatic impairment (CPT B or C).

## 2.5.1. Discussion on clinical efficacy

VOX is a third-generation PI with pangenotypic activity. RAVs that mediate high-level resistance are uncommon in vivo, and according to in vitro data, full effect is retained against Q80K.

The applicant has developed VOX in an FDC in combination with SOF/VEL, and thus as an add-on to the already approved combination marketed as Epclusa. Epclusa therapy for 12 weeks is highly effective in all genotypes. However, the Achilles heel of this combination is the NS5A polymorphism Y93H, which impacts the efficacy of VEL. This occurs naturally in up to 10% of GT3 samples. Furthermore, Y93H is very often selected on virological failure (relapse) with NS5A-inhibitor containing dual-DAA regimens. For this reason, SOF/VEL alone is not an ideal retreatment regimen. Furthermore, preliminary studies indicated that efficacy would fall if SOF/VEL alone are used for 8 weeks of therapy. The SOF/VEL/VOX phase III program has been designed to address the impact of adding VOX with respect to these circumstances.

POLARIS-1 studied patients with prior failure on a regimen containing an NS5A-inhibitor. Patients of all genotypes were recruited, and 41% had compensated cirrhosis. Patients were randomised to SOF/VEL/VOX or to placebo. The placebo control is for safety assessment, since SVR rates in the absence of therapy are 0, and no placebo comparator is needed to assess efficacy. Most patients failing on an NS5A inhibitor develop resistance relevant to the efficacy of VEL. Therefore the activity of SOF/VEL is anticipated to be lower in such patients. 12 weeks of therapy is not anticipated to suffice; according to the Epclusa SmPC, treatment with Epclusa + RBV for 24 weeks can be considered empirically for patients who have failed therapy on an NS5A-containing regimen and who are deemed at high risk for clinical disease progression and do not have alternative treatment options. This is an empirical recommendation without a solid basis in trials; therefore, the conduct of POLARIS-1 against placebo was considered reasonable.

POLARIS-1 demonstrated very high activity of SOF/VEL/VOX for 12 weeks across genotypes (point estimate for SVR 96%), regardless of cirrhosis status. With its 263 treated patients, it is by far the largest study in this important target population, where SOF/VEL/VOX is likely to emerge as standard of care.

POLARIS-4 investigated patients that have failed on a DAA-containing regimen that did not contain an NS5A inhibitor. SOF and VEL are anticipated to retain their full activity against the virus of such patient population. On the other hand, such a population is highly enriched for baseline prognostic factors making patients 'difficult to cure', as they have also proven to be. This is the rationale for adding VOX. The study enrolled patients with genotypes 1-4 and 46% of patients had compensated cirrhosis.

In this study, totally including approximately 330 patients, the point estimate favoured the addition of VOX to SOF/VEL, with 97% and 90% SVR in the respective arms. Notably, SVR12 rates overall and within most subgroups favoured 12 weeks of SOF/VEL/VOX treatment over 12 weeks of SOF/VEL

<div style=\"page-break-after: always\"></div>

treatment, with greater numerical differences in the SVR12 rates for the most common HCV genotypes, specifically genotype 1 and 3. Of note, 7 of the 13 subjects that did not achieve SVR12 in the SOF/VEL 12 Week group had genotype 3 HCV infection and cirrhosis; the SVR12 rate in this subgroup was 76.7%. In contrast, in the SOF/VEL/VOX 12 Week group, 93.5% of subjects with genotype 3 HCV infection and cirrhosis achieved SVR12. All in all, this study indicates the improved efficacy of adding VOX to SOF/VEL when treating patients in whom it has been demonstrably difficult to eradicate HCV, notwithstanding the fact that the activity of SOF and VEL are not impacted by viral drug resistance selected by previous treatment failure.

For reasons that are not fully understood, GT3 infection has turned out to be more difficult to clear than other genotypes, also given similar in vitro efficacy of the direct acting antivirals. Furthermore, the NS5A Y93H polymorphism is present in up to 10% of untreated patients, impacting the efficacy of VEL. While Epclusa marked a significant advance in the treatment of such patients, the SmPC still indicates that adding ribavirin be considered in patients with cirrhosis. The applicant conducted the POLARIS-3 study in DAA-naïve patients with GT3 infection and cirrhosis. Notably, one third of patients had previously failed interferon-based therapy. Patients were randomised to SOF/VEL/VOX for 8 weeks, which is shorter than standard, or to SOF/VEL for 12 weeks. Outcomes showed high efficacy with 96% SVR achieved in both arms following 8 weeks of therapy. However, there were around 100 patients in each arm; therefore, confidence limits are relatively wide.

POLARIS-2 was conducted in DAA-naïve patients with any genotype. Patients could be cirrhotic or noncirrhotic, except for GT3, for whom only non-cirrhotic patients were included (cirrhotics being treated in the dedicated POLARIS-3). Patients were randomised to 8 weeks of SOF/VEL/VOX or to 12 weeks of SOF/VEL. This was a very large study including over 900 patients. A clinically defined (M2) noninferiority margin was set at -5%. It is notable that the applicant did not attempt to show the added value of VOX in a head to head comparison with SOF/VEL at the same treatment duration. The reason for this is that there would have been no added value at 12 weeks, and further, as mentioned above, available data indicate that 8 weeks is too short to maximise efficacy with SOF/VEL alone.

POLARIS-2 recruited 23% patients experienced with interferon regimens and 18% with compensated cirrhosis. Overall SVR rates were 95% in the SOF/VEL/VOX 8 week arm, and 98% in the SOF/VEL arm. The study failed to meet its non-inferiority target, with a lower SVR bound of -6.2%.

The difference is driven by lower SVR12 rates in GT1a, which was unanticipated and remains unexplained from a virological point of view. Virologic failure was associated with the presence of Q80K/L/R at baseline in GT1a, but these RAVs were not enriched or emerged frequently at relapse. Furthermore, neither site directed mutations at NS3 position 80 nor HCV isolates from subjects with virologic failure showed an increased fold change in replicon assays.

Epidemiological associations between other factors related to treatment outcome and Q80K/L/R have previously been described; therefore, GT1a and Q80K may be a proxy for a difficult to treat population that gain SVR with longer duration of therapy, notwithstanding the addition of another drug and/or requiring 12 weeks of therapy regardless of total DAA potency.

Finally and importantly, it is notable that the SOF/VEL/VOX phase III program, including two comparative trials with SOF/VEL, indicates that the addition of VOX increases the barrier to resistance and, in particular, lower the risk of treatment-emergent NS5A resistance upon virologic failure. The precise mechanism behind the reduced risk of NS5A resistance is not clear, but in accordance with general experience from virology, insofar as an increased number of agents with different mechanisms of action tend to raise the barrier to resistance. This is considered an important property and added value of this triple combination.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on the clinical efficacy

SOF/VEL/VOX for 12 weeks has shown excellent efficacy in patients that have previously failed a regimen containing an NS5A inhibitor. A similar 12 week course appears somewhat better than SOF/VEL in patients with previous failure on a DAA-containing regimen without an NS5A inhibitor. An 8 week course of SOF/VEL/VOX was similarly efficacious as 12 weeks of SOF/VEL in a difficult to cure DAA-naïve cirrhotic GT3 cohort. Further, an 8 week course of SOF/VEL/VOX showed an SVR rate of 95% in a DAA-naïve population; however, this did not meet predefined non-inferiority with SOF/VEL for 12 weeks. The addition of VOX appears to increase the barrier to resistance compared to SOF/VEL alone.

Conclusions concerning recommended use are discussed in the B/R section.

## 2.6. Clinical safety

## Patient exposure

## SOF/VEL

A substantial number of patients have been exposed to sofosbuvir, as part of Sovaldi (sofosbuvir, first approval December 2013), Harvoni (sofosbuvir/ledipasvir, first approval October 2014) and Eplcusa (sofosbuvir/velpatasvir, first approval July 2016). In addition to large scale phase 3 studies for all three products, there are quite extensive post marketing experience. The active substance velpatasvir is approved as part of Epclusa. In the clinical program for the fixed dose combination of sofosbuvir/velpatasvir approximately 1300 patients were exposed to at least 12 weeks of SOF/VEL 400/100 mg as part of the phase 3, including substantial numbers compensated (n=220; ASTRAL 1-3) and decompensated cirrhosis (n=267; ASTRAL 4).

## SOF/VEL/VOX

A total of 2017 subjects have received at least 1 dose of SOF/VEL/VOX or SOF/VEL+VOX, including 1056 subjects in 4 SOF/VEL/VOX Phase 3 studies, 543 subjects in 4 SOF/VEL/VOX or SOF/VEL+VOX Phase 2 studies, and 418 subjects in 7 SOF/VEL/VOX, SOF/VEL+VOX, or SOF/VEL/VOX+VOX Phase 1 studies.

In the Phase 3 and 2 studies, 804 of 809 patients (99.4%) received SOF/VEL/VOX or SOF/VEL+VOX for 8 weeks and 626 of 630 patients (99.4%) for 12 weeks. In the Phase 3 studies, 610 of 611 (99.8%) patients receiving SOF/VEL/VOX for 8 weeks and 443 of 445 (99.6%) receiving SOF/VEL/VOX for 12 weeks completed treatment.

Table 57. Exposure to study regimen, and study treatment status in Phase 1, 2, and 3 Clinical Studies

| Safety data analysis set Study   | Regimen                  | N   | Cirrhotic, N   |
|----------------------------------|--------------------------|-----|----------------|
| Integrated Phase 3 Studies       | SOF/VEL/VOX              |     |                |
| GS-US-367-1171 (POLARIS-1)       | SOF/VEL/VOX for 12 weeks | 263 | 121            |
| GS-US-367-1170 (POLARIS-4)       | SOF/VEL/VOX for 12 weeks | 182 | 84             |
| GS-US-367-1172 (POLARIS-2)       | SOF/VEL/VOX for 8 weeks  | 501 | 90             |
| GS-US-367-1173 (POLARIS-3)       | SOF/VEL/VOX for 8 weeks  | 110 | 110            |

<div style=\"page-break-after: always\"></div>

| Safety data analysis set Study                                                                        | Regimen                                                                                                                         | N    | Cirrhotic, N                            |
|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------|
|                                                                                                       | Total                                                                                                                           | 1056 | 405                                     |
| Phase 2 Studies                                                                                       | SOF/VEL/VOX or SOF/VEL+VOX                                                                                                      |      |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL/VOX for 12 weeks                                                                                                        | 24   |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL/VOX+RBV for 12 weeks                                                                                                    | 25   |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL+VOX for 12 weeks                                                                                                        | 136  |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL+VOX for 8 weeks                                                                                                         | 167  |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL+VOX+RBV for 8 weeks                                                                                                     | 31   |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL+VOX for 6 weeks                                                                                                         | 145  |                                         |
| GS-US-337-1468 (LEPTON, Cohorts 4 and 5), GS-US-367-1168, GS-US-367-1169, GS-US-367-1871 (TRILOGY-3)  | SOF/VEL+VOX for 4 weeks                                                                                                         | 15   |                                         |
|                                                                                                       | Total                                                                                                                           | 543  | 268                                     |
| Phase 1 Studies                                                                                       | SOF/VEL/VOX, SOF/VEL+VOX, or SOF/VEL/VOX+VOX                                                                                    |      |                                         |
| GS-US-367-1176                                                                                        | SOF/VEL/VOX and SOF/VEL+VOX (to evaluate bioavailability and food effect)                                                       | 68   | 0                                       |
| GS-US-367-1657, GS-US-367-1727, GS-US-367-1905, GS-US-367-1909, GS-US-380-1999                        | SOF/VEL/VOX+VOX (to evaluate PK, as a perpetrator of DDIs with hormonal contraceptives, ARVs, and transporter probe substrates) | 231  | 0                                       |
| GS-US-367-1726, GS-US-367-1727                                                                        | SOF/VEL/VOX (dosed to evaluate PK, as a victim of DDIs with ARVs, PPIs, and H2RAs)                                              | 119  | 0                                       |
|                                                                                                       | Total                                                                                                                           | 418  | 0                                       |
| Total Exposure to SOF/VEL/VOX, SOF/VEL+VOX, and SOF/VEL/VOX+VOX in Phase 1, 2, and 3 Clinical Studies | Total Exposure to SOF/VEL/VOX, SOF/VEL+VOX, and SOF/VEL/VOX+VOX in Phase 1, 2, and 3 Clinical Studies                           | 2017 | Compensated N = 673 Decompensated N = 0 |

SOF/VEL/VOX dose was 400/100/100 mg FDC tablet once daily; SOF/VEL dose was 400/100 mg FDC tablet once daily; VOX individual-agent dose was 100 mg tablet once daily; RBV dose was 1000 or 1200 mg divided daily dose (for subjects who weighed &lt; 75 kg, the RBV dose was 1000 mg/day divided; for subjects who weighed ≥ 75 kg, the RBV dose was 1200 mg/day divided).

The safety data base is substantial for sofosbuvir and velpatasvir and sufficient for sofosbuvir/velpatasvir/voxilaprevir as outlined in Table 57. The recommended dose of SOF/VEL/VOX is one 400 mg/100 mg/100 mg tablet, taken orally, once daily with food was used in all phase 3 studies. The SOF/VEL/VOX Phase 3 program included subjects with compensated cirrhosis, but excluded subjects with a history of hepatic decompensation The number of patients with compensated cirrhosis is substantial (N= 673; 37.6%).

<div style=\"page-break-after: always\"></div>

Table 58. Subject Disposition for the SOF/VEL/VOX Integrated Phase 3 Safety Population (Screened Subjects)

| Disposition                                                | SOF/VEL/VOX 8 Weeks                                        | SOF/VEL/VOX 12 Weeks   | SOF/VEL 12 Weeks   | Placebo 12 Weeks   | Total        |
|------------------------------------------------------------|------------------------------------------------------------|------------------------|--------------------|--------------------|--------------|
| Subjects Screened                                          |                                                            |                        |                    |                    | 2348         |
| Subjects Randomized/ Enrolled                              | 612                                                        | 446                    | 702                | 152                | 1912         |
| Subjects Randomized/ Enrolled but Never Treated            | 1                                                          | 1                      | 2                  | 0                  | 4            |
| Subjects in Safety Analysis Set                            | 611                                                        | 445                    | 700                | 152                | 1908         |
| Study Treatment Status, n (%)                              |                                                            |                        |                    |                    |              |
| Completed Study Treatment                                  | 610 (99.8%)                                                | 443 (99.6%)            | 693 (99.0%)        | 149 (98.0%)        | 1895 (99.3%) |
| Discontinued Study Treatment                               | 1 (0.2%)                                                   | 2 (0.4%)               | 7 (1.0%)           | 3 (2.0%)           | 13 (0.7%)    |
| Reason for Premature Discontinuation of Study Treatment, n | Reason for Premature Discontinuation of Study Treatment, n | (%)                    |                    |                    |              |
| Adverse Event                                              | 0                                                          | 1 (0.2%)               | 4 (0.6%)           | 3 (2.0%)           | 8 (0.4%)     |
| Lack Of Efficacy                                           | 0                                                          | 0                      | 2 (0.3%)           | 0                  | 2 (0.1%)     |
| Lost to Follow-Up                                          | 0                                                          | 1 (0.2%)               | 1 (0.1%)           | 0                  | 2 (0.1%)     |
| Pregnancy                                                  | 1 (0.2%)                                                   | 0                      | 0                  | 0                  | 1 (<0.1%)    |

A very high proportion (≥99%) of randomized patients completed study treatment. Only one subject discontinued study treatment (SOF/VEL/VOX) due to reported advents. The subject reported a Grade 3 AE of angioedema on study day 12.  This AE was considered attributed to ramipril which was initiated the day prior to the onset of the AE (one day prior to treatment discontinuation). The AE resolved on posttreatment Day 4.

## Adverse events

AEs reported in patients treated with SOF/VEL/VOX were mostly mild. Numbers stopping therapy due to adverse events were minimal and similar to that seen with placebo. No SAEs were reported as treatment-related.

<div style=\"page-break-after: always\"></div>

## Common AEs

Table 59. Adverse Events Reported for at Least 5% of Subjects for Any Treatment Regimen by Preferred Term in the SOF/VEL/VOX Phase 3 Safety Population (Safety Analysis Set)

| Preferred Term (MedDRA Version 19.0.)   | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   | Total (N=1908)   |
|-----------------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|------------------|
| Number of Subjects Experiencing Any AE  | 444 (72.7%)                   | 346 (77.8%)                    | 495 (70.7%)                | 107 (70.4%)                | 1392 (73.0%)     |
| Headache                                | 161 (26.4%)                   | 116 (26.1%)                    | 174 (24.9%)                | 26 (17.1%)                 | 477 (25.0%)      |
| Fatigue                                 | 134 (21.9%)                   | 99 (22.2%)                     | 164 (23.4%)                | 30 (19.7%)                 | 427 (22.4%)      |
| Diarrhoea                               | 105 (17.2%)                   | 83 (18.7%)                     | 44 (6.3%)                  | 19 (12.5%)                 | 251 (13.2%)      |
| Nausea                                  | 103 (16.9%)                   | 59 (13.3%)                     | 62 (8.9%)                  | 12 (7.9%)                  | 236 (12.4%)      |
| Asthenia                                | 37 (6.1%)                     | 30 (6.7%)                      | 41 (5.9%)                  | 9 (5.9%)                   | 117 (6.1%)       |
| Insomnia                                | 31 (5.1%)                     | 31 (7.0%)                      | 29 (4.1%)                  | 8 (5.3%)                   | 99 (5.2%)        |
| Arthralgia                              | 24 (3.9%)                     | 17 (3.8%)                      | 32 (4.6%)                  | 8 (5.3%)                   | 81 (4.2%)        |
| Dizziness                               | 23 (3.8%)                     | 20 (4.5%)                      | 21 (3.0%)                  | 14 (9.2%)                  | 78 (4.1%)        |
| Abdominal pain                          | 31 (5.1%)                     | 10 (2.2%)                      | 21 (3.0%)                  | 3 (2.0%)                   | 65 (3.4%)        |

Subjects were counted once for each category of AE of interest, and once for each AE preferred term.

Headache and gastrointestinal AE (diarrhoea, nausea, abdominal pain and vomiting) was more frequently reported in the SOF/VEL/VOX treatment groups compared to SOF/VEL or placebo. The absolute majority the cases of diarrhoea and nausea were mild (Grade1) and were not treatment limiting with no subject discontinuing or interrupting treatment.

The Applicant has proposed to include diarrhoea, nausea and headache as very common ADR and abdominal pain and myalgia as common ADR based on identifying treatment-emergent, treatmentrelated AEs reported by ≥ 1% of subjects in either the SOF/VEL/VOX 8 or 12 Week groups AND in a greater numeric proportion of subjects compared with the Placebo 12 Week group in the Phase 3 Integrated Safety Analysis Set including a statistical comparisons. However, based on a further analysis of potential causality, it is considered that also muscle spasms, vomiting, rash and decreased appetite should be added as a common ADR.

Table 60. Gastrointestinal AE and grading of Diarrhoea and Nausea in the SOF/VEL/VOX Integrated Phase 3 Safety Population (Safety Analysis Set)

|                                                                    | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   |
|--------------------------------------------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|
| Number of Subjects Experiencing Any AE in the Gastrointestinal SOC | 258 (42.2%)                   | 177 (39.8%)                    | 188 (26.9%)                | 44 (28.9%)                 |
| diarrhoea                                                          | 105 (17.2%)                   | 83 (18.7%)                     | 44 (6.3%)                  | 19 (12.5%)                 |
| Grade 1 (Mild)                                                     | 100 (16.4%)                   | 74 (16.6%)                     | 38 (5.4%)                  | 15 (9.9%)                  |
| Grade 2 (Moderate)                                                 | 5 (0.8%)                      | 9 (2.0%)                       | 6 (0.9%)                   | 4 (2.6%)                   |
| Nausea                                                             | 103 (16.9%)                   | 59 (13.3%)                     | 62 (8.9%)                  | 12 (7.9%)                  |
| Grade 1 (Mild)                                                     | 98 (16.0%)                    | 56 (12.6%)                     | 58 (8.3%)                  | 12 (7.9%)                  |
| Grade 2 (Moderate)                                                 | 5 (0.8%)                      | 3 (0.7%)                       | 4 (0.6%)                   | 0                          |

<div style=\"page-break-after: always\"></div>

Headache and gastrointestinal AE (diarrhoea, nausea, abdominal pain and vomiting) was more frequently reported in the SOF/VEL/VOX treatment groups compared to SOF/VEL or placebo. The absolute majority the cases of diarrhoea and nausea were mild (Grade1) and were not treatment limiting with no subject discontinuing or interrupting treatment.

## Possibly treatment related AEs

Table 61. AEs considered by the investigator to be related to therapy with frequency ≥5% for any treatment regimen

| Preferred Term (MedDRA Version 19.0.)                               | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   | Total (N=1908)   |
|---------------------------------------------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|------------------|
| Number of Subjects Experiencing Any Treatment-Related Adverse Event | 314 (51.4%)                   | 249 (56.0%)                    | 311 (44.4%)                | 63 (41.4%)                 | 937 (49.1%)      |
| Headache                                                            | 118 (19.3%)                   | 97 (21.8%)                     | 134 (19.1%)                | 21 (13.8%)                 | 370 (19.4%)      |
| Fatigue                                                             | 102 (16.7%)                   | 81 (18.2%)                     | 106 (15.1%)                | 23 (15.1%)                 | 312 (16.4%)      |
| Diarrhoea                                                           | 81 (13.3%)                    | 60 (13.5%)                     | 23 (3.3%)                  | 14 (9.2%)                  | 178 (9.3%)       |
| Nausea                                                              | 81 (13.3%)                    | 52 (11.7%)                     | 44 (6.3%)                  | 10 (6.6%)                  | 187 (9.8%)       |

All treatment related AEs that occurred in ≥ 5% of SOF/VEL/VOX subjects occurred in a similar proportion of subjects in the SOF/VEL and Placebo groups with the exception of diarrhoea and nausea.

## Grade 3 and 4 AEs

The incidence of Grade 3 or above AEs in the SOF/VEL/VOX groups was low (2.0%) and similar to the incidence in the SOF/VEL 12 Week group (1.7%) and Placebo 12 Week group (2.6%).There were no Grade 3 AEs that occurred in more than 1 subject in either SOF/VEL/VOX group. Two subjects (0.2%) in the SOF/VEL/VOX groups had Grade 4 AEs, both of whom received 12 weeks of SOF/VEL/VOX. One subject died of an illicit drug overdose on posttreatment Day 2, and one subject experienced a seizure. Both Grade 4 events were considered unrelated to study drug.

One subject receiving SOF/VEL experienced 2 Grade 4 AEs on posttreatment Day 30 when attempting to commit suicide by motor vehicle accident (AEs of road traffic accident and suicide attempt). The AEs were considered unrelated to study drug.

Table 62. Grade 3 or Grade 4 AE Reported for &gt; 1 Subject in the SOF/VEL/VOX Integrated Phase 3 Safety Population (Safety Analysis Set)

| Preferred Term (MedDRA Version 19.0.)                          | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   | Total (N=1908)   |
|----------------------------------------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|------------------|
| Number of Subjects Experiencing Any Grade 3 or 4 Adverse Event | 14 (2.3%)                     | 7 (1.6%)                       | 12 (1.7%)                  | 4 (2.6%)                   | 37 (1.9%)        |
| Highest Grade                                                  |                               |                                |                            |                            |                  |
| Grade 3 (Severe)                                               | 14 (2.3%)                     | 5 (1.1%)                       | 11 (1.6%)                  | 3 (2.0%)                   | 33 (1.7%)        |
| Grade 4 (Life-Threatening)                                     | 0                             | 2 (0.4%)                       | 1 (0.1%)                   | 1 (0.7%)                   | 4 (0.2%)         |
| Atrial fibrillation                                            | 1 (0.2%)                      | 0                              | 0                          | 1 (0.7%)                   | 2 (0.1%)         |
| Headache                                                       | 0                             | 1 (0.2%)                       | 2 (0.3%)                   | 0                          | 3 (0.2%)         |

<div style=\"page-break-after: always\"></div>

| Preferred Term (MedDRA Version 19.0.)   | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   | Total (N=1908)   |
|-----------------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|------------------|
| Cerebral haemorrhage                    | 1 (0.2%)                      | 1 (0.2%)                       | 0                          | 0                          | 2 (0.1%)         |
| Dizziness                               | 0                             | 1 (0.2%)                       | 0                          | 1 (0.7%)                   | 2 (0.1%)         |
| Depression                              | 1 (0.2%)                      | 0                              | 1 (0.1%)                   | 0                          | 2 (0.1%)         |
| Hypertensive crisis                     | 1 (0.2%)                      | 0                              | 1 (0.1%)                   | 0                          | 2 (0.1%)         |

In the SOF/VEL/VOX groups, Grade 3 elevations in glucose were seen in a small number of subjects (2.2%), all of whom had diabetes and/or elevations in glucose prior to dosing. Grade 4 elevations observed during treatment with SOF/VEL/VOX included lipase (5 subjects with asymptomatic, single isolated or transient, intermittent events) and creatine kinase (4 subjects with elevations related to exercise with no cases of rhabdomyolysis.

## Adverse events in subjects receiving supratherapeutic VOX dosage

GS-US-338-1121: Voxilaprevir 300 mg monotherapy administered for up to 10 days was safe and well tolerated. There was no evidence of a dose-related effect on safety. ADRs were reported for 7/81 who received VOX (4 with diarrhoea) and 1/8 who received placebo.

GS-US-338-1123: single doses of 300 mg and 900 mg VOX in healthy subjects &lt; 45 years of age AEs occurred more frequently with 900 mg vs. 300 mg VOX (53%, 25/47 subjects [23 related] vs. 17%, 8/47 subjects [6 related]). Also, these rates compare with 8.5% (4/47) and 8.3% (4/48) in the placebo and moxifloxacin groups. The differences in AE and ADR rates between groups were mainly driven by diarrhoea, vomiting and nausea in those who received VOX but they were of Grade 1 or 2 severity. Single dose of 900 mg VOX achieved supratherapeutic exposures that were approximately 15.8- and 16.1-fold higher by Cmax and AUC, respectively, compared with the therapeutic VOX exposure in HCV-infected subjects with cirrhosis receiving SOF/VEL+VOX in Phase 2 studies.

Table 63. GS-US-338-1123: Treatment-Emergent Adverse Events Reported in ≥ 2 Subjects by Treatment Group (Safety Analysis Set)

| Adverse Events by Preferred Terma,b   | VOX 300 mg (N = 47) n (%)   | VOX 900 mg (N = 47) n (%)   | Placebo (N = 47) n (%)   | Moxifloxacin 400 mg (N=48) n (%)   |
|---------------------------------------|-----------------------------|-----------------------------|--------------------------|------------------------------------|
| Any AE                                | 8 (17.0%)                   | 25 (53.2%)                  | 4 (8.5%)                 | 4 (8.3%)                           |
| Diarrhoea                             | 3 (6.4%)                    | 16 (34.0%)                  | 1 (2.1%)                 | 0                                  |
| Vomiting                              | 0                           | 9 (19.1%)                   | 0                        | 0                                  |
| Nausea                                | 1 (2.1%)                    | 8 (17.0%)                   | 0                        | 0                                  |
| Headache                              | 1 (2.1%)                    | 4 (8.5%)                    | 0                        | 1 (2.1%)                           |
| Pain in Extremity                     | 0                           | 1 (2.1%)                    | 1 (2.1%)                 | 3 (6.3%)                           |
| Dizziness                             | 0                           | 2 (4.3%)                    | 0                        | 0                                  |

<div style=\"page-break-after: always\"></div>

## Serious adverse events and deaths

## SAEs

The only SAE that occurred in &gt;1 subject receiving SOF/VEL/VOX was cerebral haemorrhage, which occurred in two females 64 and 75 years old on study day 52 and 56, respectively. Both patients had typical risk factors.

One subject in the SOF/VEL/VOX 8 Week group, was a 64-year-old female with a history of diabetes, hyperlipidemia and hypertension (baseline/Day 1 blood pressure of 150/71 mmHg), who experienced a Grade 3 AE of cerebral hemorrhage on study Day 52 which was continuing at the time of data finalization.

One subject in the SOF/VEL/VOX 12 Week group, was a 75-year-old female who had a history of hypertension for which she was taking metoprolol. Baseline/Day 1 blood pressure was 180/90 mmHg and an AE of blood pressure fluctuation was reported on baseline/Day 1. Worsening blood pressure was noted (AE of blood pressure abnormal with a measurement of 190/110 mmHg on Day 29). The subject experienced a Grade 3 SAE of cerebral hemorrhage on study Day 56, as well as Grade 2 AEs of dysphagia and hemiparesis and a Grade 3 AE of neurologic neglect syndrome. On Day 85, the subject had a Grade 4 SAE of seizure. The SAEs of cerebral hemorrhage and seizure resolved on study Day 65 and study Day 85, respectively.

Table 64. Serious Adverse Events Reported for &gt; 1 Subject in the SOF/VEL/VOX phase 3 studies

| Preferred Term (MedDRA Version 19.0.)   | SOF/VEL/VOX 8 Week (N = 611)   | SOF/VEL/VOX 12 Week (N = 445)   | SOF/VEL 12 Week (N = 700)   | Placebo 12 Week (N = 152)   | Total (N = 1908)   |
|-----------------------------------------|--------------------------------|---------------------------------|-----------------------------|-----------------------------|--------------------|
|                                         | 1 (0.2%)                       | 0                               | 0                           | 1 (0.7%)                    | 2 (0.1%)           |
| Pneumonia                               | 0                              | 1 (0.2%)                        | 1 (0.1%)                    | 0                           | 2 (0.1%)           |
| Pyelonephritis                          | 1 (0.2%)                       | 0                               | 1 (0.1%)                    | 0                           | 2 (0.1%)           |
| Road traffic accident                   | 0                              | 0                               | 2 (0.3%)                    | 0                           | 2 (0.1%)           |
| Cerebral haemorrhage                    | 1 (0.2%)                       | 1 (0.2%)                        | 0                           | 0                           | 2 (0.1%)           |

The incidence of SAE in the SOF/VEL/VOX group was low (&lt;2.0%) and similar to the incidence in the SOF/VEL group and the Placebo group. No SAEs in any treatment group was considered related to study drug. The safety profile of SOF/VEL/VOX is favourable.

## Deaths

One treatment-emergent death and 1 non-treatment emergent death were reported for the Integrated Phase 3 Safety Population, none consider related to therapy by the investigator.

Two deaths were reported among 1056 SOF/VEL/VOX subjects. Reviewing the data, it was agreed that none of these deaths were indicative of causality to therapy.

## AEs of special interest

Adverse events of interest were defined as AEs that have previously been associated with administration of nucleoside/nucleotide inhibitors or other DAAs.

<div style=\"page-break-after: always\"></div>

## Cardiac safety

## Cardiac Failure

One subject receiving SOF/VEL/VOX for 12 weeks had a cardiac failure event which was considered unrelated to study drug. The subject was an 85-year-old male with a history of hypertension, chronic atrial fibrillation, and experienced a Grade 3 SAE of congestive heart failure on baseline/Day 1, which led to an interruption of study drug on Days 6 and 7. On study Day 2, the subject reported shortness of breath and swelling. He was admitted to the hospital and responded to treatment with diuretics. Repeat transthoracic echocardiogram demonstrated an ejection fraction of 55% to 60%. The AE resolved on study Day 7 and treatment with SOF/VEL/VOX was restarted on Day 8.

## Cardiac arrhythmias/bradycardia

Seven subjects in the four Phase 3 SOF/VEL/VOX studies had cardiac arrhythmias/bradycardia events: 1/611 subject in the SOF/VEL/VOX 8 Week group, 2/455 subjects in the SOF/VEL/VOX 12 Week group, 2/700 subjects in the SOF/VEL 12 Week group, and 2/152 subjects in the Placebo 12 Week group:

## SOF/VEL/VOX 8 w

- Atrial fibrillation on study Day 21 in a 69-year old man with no significant cardiac history. The event was assessed as unrelated to study drug by the investigator. The event did not result in any change in dosing.

## SOF/VEL/VOX 12 w

- Asymptomatic QT prolongation at week 1 (QTc &gt; 450 ms, increase from screening ECG normal QTc) in a 61-year-old male with hypertension. The event was considered related to study drug by the investigator and resolved on study Day 85. The event did not result in any change in dosing.
- A 65-year-old male with a history of hypertension and chronic obstructive pulmonary disease (COPD) had an AE of sinus tachycardia from posttreatment Day 20 to 23, assessed as not related to study drug by the investigator.

## SOF/VEL 12 w

- A 62-year-old male with history of atrial fibrillation, developed atrial fibrillation on study Day 25, was considered resolved on study Day 26 and assessed unrelated to study drug by the investigator and. The event did not result in any change in dosing.
- A 61-year-old male with mild/moderate aortic stenosis and left atrial enlargement, had asymptomatic atrial flutter posttreatment Day 1, which spontaneously reverted by posttreatment Week 4. The investigator attributed the atrial flutter to pre-existing structural heart disease.

The incidence of cardiac arrhythmias/bradycardia AE in the SOF/VEL/VOX group was low (&lt;0.3 %) and similar to the incidence in the SOF/VEL group and the Placebo group.

## Adverse Events by use of beta- and calcium channel blockers

All AEs were Grade 1 or Grade 2 in severity and only the event of acute myocardial infarction and the congestive cardiac failure were considered serious. All events of palpitations and dizziness were considered related to study drug. None of these AEs resulted in an interruption or modification of dosing apart from the case of cardiac failure (dosing interrupted on Day 5 and resumed on Day 8). All subjects completed study treatment.

<div style=\"page-break-after: always\"></div>

Table 65. Adverse Events of Interest for Subjects Who Were or Were Not Using Beta Blockers during the First 2 Weeks of Study Treatment

| Beta Blocker Use                                 | SOF/VEL/VOX 8 Week                      | SOF/VEL/VOX 12 Week                          | SOF/VEL 12 Week   | Placebo 12 Week                                      |
|--------------------------------------------------|-----------------------------------------|----------------------------------------------|-------------------|------------------------------------------------------|
| Yes                                              | 5/65 (7.7%)                             | 3/56 (5.4%)                                  | 0/64              | 1/26 (3.8%)                                          |
| No                                               | 16/546 (2.9%)                           | 11/389 (2.8%)                                | 13/634 (2.1%)     | 8/126 (6.3%)                                         |
| Description of AE event in beta blocker user (N) | Palpitations (2) Dizziness (2) AMI* (1) | Dizziness (2) Congestive cardiac failure (1) |                   | Ventricular fibrillation and atrial fibrillation (1) |

* acute myocardial infarction, assessed as not related to study drug by the investigator and did not result in any change in dosing.

Subjects using beta blockers experienced a slightly higher incidence of Grade 1 or Grade 2 AE (palpitations or dizziness), but no relevant changes in the ECGs and no interruption or modification of dosing were required. Of note, there were no subjects in any treatment group taking stable calcium channel blockers.

## Amiodarone Use

Only 1 subject in the Placebo 12 Week group received amiodarone during treatment. The subject, with family history of sudden cardiac death, had AEs of ventricular fibrillation and atrial fibrillation and was treated for these events with amiodarone on study Day 14. These AEs were considered unrelated to study drug.

Concomitant use of sofosbuvir and amiodarone is an identified important risk and such use should be avoided as stated in SmPC section 4.4.

## Impact on QTc

Comprehensive QTc studies have been performed for the individual agents of SOF, VEL, and VOX (Studies P7977-0613, GS-US-281-1054, and GS-US 338-1123, respectively); SOF, VEL, or VOX did not have an effect on cardiac repolarization or prolongation of the QTcF interval, and no PR changes were noted.

Study GS US 338-1123 was a Phase 1, Partially-Blinded, Randomized, Placebo- and Positive-Controlled Study to Evaluate the Effect of VOX on ECG parameters in 49 healthy subjects 18-45 years old, the PK of VOX, and the relationships between changes in QTc and VOX plasma concentrations were explored, along with the safety and tolerability of VOX. Subjects were randomized to a single dose of VOX 300 mg, VOX 900 mg, moxifloxacin 400mg (positive control) or placebo

SOF, VEL, or VOX did not have a detectable effect on cardiac repolarization or prolongation of the QTcF interval in health subjects, and no PR changes were noted.

## Other Adverse Events of Interest

No patients in the SOF/VEL/VOX groups experienced any of the 'Other Events of Interest': dermatologic events, pancytopenia (including aplastic anaemia) events, psychiatric events relevant to suicide ideation or attempt, pancreatitis events, rhabdomyolysis/myopathy events, and renal failure events. One subject experienced a dermatologic event of angioedema that led to discontinuation of SOF/VEL/VOX. The angioedema was assessed as unrelated to study drug and attributed to ramipril initiated the day prior to the onset of the AE (one day prior to treatment discontinuation).

Thus, no cardiac events of special interest or other AEs of special interest occurred in the SOF/VEL/VOX program.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology Parameters

There were no meaningful changes from baseline in haemoglobin, white blood cell count (including lymphocytes and neutrophils), or platelets observed during treatment in the SOF/VEL/VOX groups, and similar and stable haematology parameters for subjects who were treated with the SOF/VEL/VOX 8week and 12-week regimens and the SOF/VEL 12-week and Placebo 12-week regimens. Across groups, few subjects had Grade 3 or 4 haematology laboratory abnormalities (&lt; 1% for each parameter). None of the Grade 3 or 4 haematology abnormalities was considered clinically important with regard to study treatment.

Table 66. Grade 3 or 4 Haematology Laboratory Abnormalities in the SOF/VEL/VOX phase 3 studies

|                              |                              | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   |
|------------------------------|------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|
| Number of patients evaluated | Number of patients evaluated | 611                           | 444                            | 698                        | 152                        |
| Haemoglobin                  | Grade 3                      | 3 (0.5%)                      | 1 (0.2%)                       | 1 (0.1%)                   | 1 (0.7%)                   |
| Lymphocytes                  | Grade 3                      | 3 (0.5%)                      | 1 (0.2%)                       | 3 (0.4%)                   | 1 (0.7%)                   |
|                              | Grade 4                      | 1 (0.2%)                      | 0                              | 2 (0.3%)                   | 1 (0.7%)                   |
| Neutrophils                  | Grade 3                      | 2 (0.3%)                      | 0                              | 5 (0.7%)                   | 0                          |
|                              | Grade 4                      | 0                             | 1 (0.2%)                       | 0                          | 0                          |
| Platelets                    | Grade 3                      | 4 (0.7%)                      | 5 (1.1%)                       | 5 (0.7%)                   | 0                          |
| WBC                          | Grade 3                      | 0                             | 0                              | 1 (0.1%)                   | 0                          |

The incidence of Grade ≥ 3 Haematology Laboratory Abnormalities in the SOF/VEL/VOX group was low (&lt;1.1%) and similar to the incidence in the SOF/VEL group and the Placebo group.

## Liver parameters

The incidence of ALT and AST elevations in the SOF/VEL/VOX group was low and similar to the incidence in the SOF/VEL group but lower than in the Placebo group. The rates of Grade 3 or 4 elevations in total bilirubin, ALT, and AST among subjects receiving SOF/VEL/VOX were low and similar to those receiving SOF/VEL. During treatment the median ALT and AST values decreased in the active treatment groups as compared to the Placebo group. Decreases from baseline in median total bilirubin values during treatment were observed in the SOF/VEL 12 Week group, but not in the SOF/VEL/VOX or Placebo groups. This comparative lack of decrease in the SOF/VEL/VOX group, compared to the SOF/VEL group, is likely due to VOX inhibition of OATP1B1 and OATP1B3 which transports bilirubin into hepatocytes.

## Chemistry parameters

Across the treatment groups, the most common Grade 3 or 4 laboratory abnormalities were increased glucose, increased lipase, and increased creatine kinase.

<div style=\"page-break-after: always\"></div>

Table 67. Grade 3 or 4 Chemistry Laboratory Abnormalities in the SOF/VEL/VOX phase 3 studies

|                                      | Grade   | SOF/VEL/VOX 8 Weeks (N=611)   | SOF/VEL/VOX 12 Weeks (N=445)   | SOF/VEL 12 Weeks (N=700)   | Placebo 12 Weeks (N=152)   |
|--------------------------------------|---------|-------------------------------|--------------------------------|----------------------------|----------------------------|
| Coagulation                          |         |                               |                                |                            |                            |
| Number of patients evaluated         |         | 577                           | 423                            | 676                        | 150                        |
| INR                                  | 3       | 1 (0.2%)                      | 0                              | 1 (0.1%)                   | 2 (1.3%)                   |
| Chemistry                            |         |                               |                                |                            |                            |
| Number of patients evaluated         |         | 611                           | 444                            | 698                        | 152                        |
| ALT                                  | 3       | 0                             | 1 (0.2%)                       | 1 (0.1%)                   | 2 (1.3%)                   |
|                                      | 4       | 0                             | 0                              | 0                          | 1 (0.7%)                   |
| AST                                  | 3       | 2 (0.3%)                      | 2 (0.5%)                       | 1 (0.1%)                   | 7 (4.6%)                   |
| Creatine Kinase                      | 3       | 2 (0.3%)                      | 3 (0.7%)                       | 1 (0.1%)                   | 2 (1.3%)                   |
|                                      | 4       | 3 (0.5%)                      | 1 (0.2%)                       | 2 (0.3%)                   | 0                          |
| Creatinine                           | 3       | 0                             | 0                              | 0                          | 0                          |
| Glucose (Hyperglycaemia)             | 3       | 15 (2.5%)                     | 8 (1.8%)                       | 9 (1.3%)                   | 7 (4.6%)                   |
| Lipase                               | 3       | 6 (1.0%)                      | 5 (1.1%)                       | 3 (0.4%)                   | 3 (2.0%)                   |
|                                      | 4       | 1 (0.2%)                      | 4 (0.9%)                       | 2 (0.3%)                   | 1 (0.7%)                   |
| Sodium (Hyponatremia)                | 3       | 0                             | 0                              | 2 (0.3%)                   | 0                          |
| Total Bilirubin (Hyperbilirubinemia) | 3       | 0                             | 1 (0.2%)                       | 1 (0.1%)                   | 0                          |

Elevations in glucose were observed primarily among subjects with a history of diabetes or subjects. Elevations in lipase were asymptomatic, generally isolated or transient and intermittent, and no trends in lipase elevations over time. All elevations in creatine kinase, except for 2, were related to exercise or physical exertion, with concomitant Grade 3 AST elevation according to the investigator.

Generally, in all treatment groups, the most common Grade 3 or 4 chemistry laboratory abnormalities were the same, with higher rates of Grade 3 or 4 chemistry laboratory abnormalities seen in subjects receiving placebo compared to those receiving SOF/VEL/VOX or SOF/VEL. No relevant Grade 3 or 4 AEs on haematology or other lab chemistry parameters were seen with sofosbuvir/velpatasvir/voxilaprevir.

In Study GS-US-367-1909, A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of 42 SOF/VEL/VOX on the Pharmacokinetics and safety of Norgestimate/Ethinyl Estradiol in 15 healthy premenopausal females between 18 and 45 years of age. Gastrointestinal AEs (Grade 1-2) were more frequently reported during treatment with NGM/EE + SOF/VEL/VOX+VOX (66.7%) compared with NGM/EE alone (20.0%), but coadministration of SOF/VEL/VOX with NGM/EE was generally safe and well tolerated. However 1/15 subject, a 19-year-old female, had a Grade 2 elevation in ALT on Study Day 43 after completion of dosing with NGM/EE + SOF/VEL/VOX which increased to Grade 3 on Day 49-52 and went back to normal at Day 63. This case is discussed below, under the heading of ontreatment liver-related abnormalities.

## On-Treatment Liver Related Abnormalities

On-treatment elevations in liver-related laboratory parameters (eg, bilirubin, ALT, AST) can occur in subjects with HCV infection due to their underlying liver disease, drug-induced liver injury, or other causes. Analyses of subjects meeting 1 or more of 3 criteria for liver-related abnormalities (defined

<div style=\"page-break-after: always\"></div>

below) were performed for subjects in the Integrated Phase 3 Safety. The 3 laboratory criteria assessed were:

- AST or ALT &gt; 3 × upper ULN and total bilirubin &gt; 2 × ULN
- ALT &gt; 5 × ULN
- Total bilirubin &gt; 2 × ULN

## Assessment of Potential Drug-Induced Liver Injury by an Independent Adjudication Committee (IAC)

Based on the historic association of NS3/4A PIs with hepatotoxicity and the inclusion of VOX, a NS3/4A PI, in SOF/VEL/VOX, the US Food and Drug Administration requested that an IAC be convened to identify cases of potential drug-induced liver injury (DILI) in subjects in the SOF/VEL/VOX clinical program. Table 68 summarizes the criteria met for the total of 46 cases which the IAC evaluated for possible DILI.

Table 68. On-Treatment Liver-Related Laboratory Abnormalities in the SOF/VEL/VOX phase 3 and phase 2 studies

| Treatment Regimen                    | Number of cases   | Other   | AST or ALT > 3 × ULN and Total Bilirubin > 2 × ULN   | ALT > 5 × ULN   | Total Bilirubin > 2 × ULN   |
|--------------------------------------|-------------------|---------|------------------------------------------------------|-----------------|-----------------------------|
| Integrated Phase 3 Safety Population |                   |         |                                                      |                 |                             |
| SOF/VEL/VOX 8 Week (N = 611)         | 3                 |         | 0                                                    | 2               | 1                           |
| SOF/VEL/VOX 12 Week (N = 445)        | 15                | 1 a     | 1 d                                                  | 7               | 8                           |
| SOF/VEL 12 Week (N = 700)            | 8                 |         | 0                                                    | 7               | 1                           |
| Placebo 12 Week (N = 152)            | 9                 | 1 b     | 1                                                    | 7               | 1                           |
| Phase 2 Safety Population            |                   |         |                                                      |                 |                             |
| SOF/VEL/VOX 12 Weeks (N = 24)        | 0                 |         | 0                                                    | 0               | 0                           |
| SOF/VEL/VOX+RBV 12 weeks (N = 25)    | 2                 |         | 0                                                    | 1               | 1                           |
| SOF/VEL+VOX 12 Weeks (N = 136)       | 2                 |         | 0                                                    | 0               | 2                           |
| SOF/VEL+VOX 8 Weeks (N = 167)        | 3                 |         | 0                                                    | 1               | 2                           |
| SOF/VEL+VOX+RBV 8 Weeks (N = 31)     | 4                 |         | 0                                                    | 1 c             | 3                           |
| SOF/VEL+VOX 6 Weeks (N = 145)        | 0                 |         | 0                                                    | 0               | 0                           |
| SOF/VEL+VOX 4 Weeks (N = 15)         | 0                 |         | 0                                                    | 0               | 0                           |
| Total                                | 46                | 2       | 2                                                    | 26              | 19                          |

Overall, 44 cases were assessed by the IAC as 'Unlikely'. Of the remaining 2 cases, 1 case was identified as 'Probably' DILI and 1 case as 'Possibly' DILI.

- c) Probably DILI: GS US 367-1168-; SOF/VEL+VOX+RBV for 8 weeks

## Case narrative from Study GS-US-367-1168

The subject was a 50-year-old female with chronic genotype 1a HCV infection and cirrhosis enrolled in Study GS-US-367-1168. Medical history included asthma, bursitis, and seasonal allergies. Baseline BMI

<div style=\"page-break-after: always\"></div>

was 41.5 kg/m2. Concurrent medications included salbutamol; budesonide with formoterol; naproxen; and Anovlar (reported Loestrin, EE and norethindrone) for contraception, which was started in August 2015 (exact date unknown). The subject started open-label, daily treatment with SOF/VEL (400/100 mg) + VOX (100 mg) + RBV (1200 mg) on 01 September 2015 .

The subject experienced Grade 1 (mild) adverse events (AEs) of abnormal ALT and AST tests starting on Study Day 15 that were considered related to study drugs by the investigator (Table 69). On Study Day 1, the subject's ALT and AST were within normal limits (ALT 23 U/L and AST 19 U/L). On Study Day 15, the subject's ALT was 205 U/L (normal range: 6-34 U/L) and AST was 130 U/L (normal range: 9-34 U/L). On Study Day 22, repeat testing confirmed the ALT and AST elevations (ALT 193 U/L, AST 105 U/L), and the subject met the protocol specified stopping criterion of ALT and AST &gt; 5 × Day 1 values; other laboratory tests, with the exception of an isolated Grade 1 increased total bilirubin (1.3 mg/dL on Study Day 15), were within normal limits.

Additional tests, including evaluation for cytomegalovirus; Epstein-Barr virus; and hepatitis A, B, and E viruses, were negative. The subject denied alcohol or illicit drug use or new concomitant medications. The subject continued Anovlar and discontinued all study drugs on Study Day 24. Five days after stopping study drugs, ALT and AST remained elevated (ALT 226 U/L and AST 109 U/L). Twenty-six days after stopping study drugs, the Grade 1 AEs of abnormal ALT and AST were considered resolved, with ALT 66 U/L and AST 38 U/L.

Table 69. Laboratory Results for the subject

| Analysis Visit   | Laboratory Date (Study/FU* Day)   | ALT (U/L) (× ULN)   | AST (U/L) (× ULN)   | Alkaline Phosphata se (U/L) (× ULN)   | Total Bilirubin (mg/dL) (× ULN)   | Direct Bilirubin (mg/dL (× ULN)   |
|------------------|-----------------------------------|---------------------|---------------------|---------------------------------------|-----------------------------------|-----------------------------------|
| Normal Range     |                                   | 6-34                | 9-34                | 35-123                                | 0.2-1.2                           | 0.1-0.4                           |
| Screening        | 2015-08-11 (-21)                  | 30                  | NA                  | 78                                    | 0.6                               | NA                                |
| Screening        | 2015-08-24 (-8)                   | 28                  | NA                  | 72                                    | 0.7                               | NA                                |
| Screening        | 2015-08-27 (-5)                   | 27                  | 28                  | 75                                    | 0.5                               | 0.2                               |
| Baseline         | 2015-09-01 (1)                    | 23                  | 19                  | 77                                    | 0.5                               | 0.2                               |
| Week 1           | 2015-09-08 (8)                    | 41                  | 37                  | 68                                    | 1.1                               | 0.3                               |
| Week 2           | 2015-09-15 (15)                   | 205 (6.0×)          | 130 (3.8x)          | 64                                    | 1.3                               | 0.4                               |
| Week 4           | 2015-09-22 (22)                   | 193 (5.7×)          | 105 (3.1×)          | 62                                    | 0.9                               | 0.3                               |
| FU day 5         | 2015-09-29                        | 226 (6.6×)          | 109 (3.2×)          | 63                                    | 0.7                               | 0.2                               |
| FU day 26        | 2015-10-20                        | 66                  | 38                  | 52                                    | 0.5                               | 0.2                               |

## d) Possibly DILI: GS-US-367-1170 - (POLARIS 4); SOF/VEL/VOX for 12 weeks

54-year-old male with chronic genotype 3 HCV infection and liver cirrhosis with a medical history included hypertension, anxiety, seasonal allergy, insomnia, herniated lower back disk, nausea and a history of heavy alcohol use. Concomitant medications reported ongoing at baseline included lisinopril, clonazepam, fluticasone, trazodone, ibuprofen, gabapentin, Vicodin and ondansetron. The ALT, AST and total bilirubin were elevated at baseline, improved overall during the first 4 weeks of treatment, and then increased again at Week 8, and subsequently decreased at posttreatment Day 8.

A review of these 46 cases of potential drug induced liver injury support the assessments by the IAC. In the phase 3 active treatment groups, 20/26 cases assessed had cirrhosis, and 19/20 cirrhotic subjects had GT3 HCV infection. In total 24/26 achieved SVR. The 11 subjects in the phase 2 trials were all cirrhotic (100%) and all but one (the case assessed as 'probably DILI', stopped treatment on day 28) achieved SVR. No cases of decompensation (except in the placebo group) were identified. In

<div style=\"page-break-after: always\"></div>

conclusion, reviewing available SOF/VEL/VOX data, the incidence of on treatment potential drug induced liver injury DILI seems low.

Furthermore, there was a case of acute hepatitis in a DDI study of SOF/VEL/VOX and norgestimate/ethinyl-estradiol (NGM/EE).

## Case narrative from Study GS-US-367-1909

Subject was a 19-year-old female enrolled in Study GS-US-367-1909. Baseline body mass index (BMI) was 21.0 kg/m 2 . Medical history included mild acne and exercise-induced asthma. There were no concurrent medications prior to enrolment. Per protocol, the subject enrolled in a 28-day lead-in period and began dosing with norgestimate (NGM) 0.180 mg/0.215 mg/0.25 mg/EE 0.025 mg (Ortho TriCyclen ®  Lo) She received NGM/EE with SOF/VEL/VOX (400/100/100 mg) + VOX (100 mg) . The subject completed study dosing of NGM/EE on, after which she discontinued NGM/EE.

Screening, baseline, and Study Day 35 laboratory values were within normal limits. On Study Day 43, 1 day after completion of dosing with NGM/EE + SOF/VEL/VOX+VOX (while still on NGM/EE), ALT, AST, and alkaline phosphatase (ALP) increased to 91 U/L (Grade 2), 52 U/L, and 164 U/L, respectively. Repeat testing on Study Day 49 indicated that ALT, AST, and ALP were 183 U/L (Grade 3), 64 U/L (Grade 1), and 158 U/L, respectively. On Study Day 50, ALT and AST remained high, and ALP was within normal limits. On Study Day 56, ALT, AST, and ALP decreased to 76 U/L (Grade 2), 26 U/L (within normal limits), and 131 U/L (within normal limits), respectively, and NGM/EE was discontinued per protocol. By Study Day 63, 7 days after completion of NGM/EE dosing, ALT, AST, and ALP were within normal limits. Total and direct bilirubin values were normal throughout the study.

The subject had intermittent nausea on Study Days 37 to 42, with a single episode of vomiting on Study Day 38 while taking NGM/EE + SOF/VEL/VOX+VOX. She denied taking any concomitant medications (including herbal products), consuming alcohol, or undergoing any strenuous exercise. Additional laboratory tests to evaluate for cytomegalovirus; Epstein-Barr virus; hepatitis A, B, C, and E viruses; and autoimmune hepatitis were negative.

Table 70. Laboratory results for one subject GS-US-367-1909 showing Grade 3 ALT elevations. SOF/VEL/VOX was administered during day 36-42.

| Study Day       | ALT (U/L)     | AST (U/L)    | Total Bilirubin (mg/dL)   | Direct Bilirubin (mg/dL)   |   ALP (U/L) |
|-----------------|---------------|--------------|---------------------------|----------------------------|-------------|
| -36 (Screening) | 9             | 15           | 0.4                       | 0.1                        |          86 |
| -1 (Baseline)   | 28            | 18           | 0.4                       | 0.1                        |          91 |
| 35              | 21            | 22           | 0.3                       | 0.1                        |          96 |
| 43              | 91 (Grade 2)  | 52           | 0.5                       | 0.1                        |         164 |
| 49              | 183 (Grade 3) | 64 (Grade 1) | -                         | -                          |         158 |
| 50              | 207 (Grade 3) | 85 (Grade 1) | 0.4                       | -                          |         145 |
| 52              | 199 (Grade 3) | 77 (Grade 1) | 0.4                       | < 1                        |         152 |
| 56              | 76 (Grade 2)  | 26           | 0.2                       | < 1                        |         131 |
| 63              | 28            | 20           | 0.4                       | 0.1                        |         138 |

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase

NGM/EE was dosed Study Days -28 to 56; SOF/VEL/VOX+VOX was dosed Study Days 36 to 42.

This is a case of potential transaminitis during coadministration of NGM/EE + SOF/VEL/VOX.

<div style=\"page-break-after: always\"></div>

2 cases of hepatitis flare on concomitant ethinylestradiol/norethisterone acetate therapy have been subject for further clarification.

The two cases of hepatitis flare on concomitant EE prompted a request for data on the exposure across the clinical program to date of coadministration of SOF/VEL/VOX or SOF/VEL + VOX with EE or other hormonal contraceptives:

A total of 29 female subjects received SOF/VEL/VOX concomitantly with an ethinyl estradiol (EE)containing contraceptive.

- 15 subjects in the Phase 1 drug-drug interaction study:

- 1 subject in Study GS-US-367-1909, narrative above) had a possibly related treatmentemergent Grad 3 abnormality in ALT

- 14 subjects in the Phase 2 and Phase 3 studies:

- 1 subject in Study GS-US-367-1168, narrative above) had a possibly related treatmentemergent Grad 3 abnormality in ALT

- 3 subjects treatment-emergent Grad 1-2 abnormalities in ALT or AST, assessed as none related

In addition,

- 20 subjects reported concomitant use of a contraceptive that did not contain EE.

- 1 subject had treatment-emergent Grade 3 abnormalities in AST and Grade 1 in ALT with concomitant Grade 4 elevation in Creatinine Kinases possibly related to rigorous physical activity, assessed non-related to study drug

- 38 subjects who reported concomitant use of oestrogens other than as contraceptives (eg, hormone replacement therapy). No treatment-emergent graded elevations in ALT or AST.

Thus, 2/29 subjects with concomitantly exposure of SOF/VEL/VOX and ethinyl estradiol (EE)-containing contraceptive developed likely related treatment-emergent Grade 3 abnormalities in ALT or AST. Even though no pharmacokinetic interactions were detected in pharmacokinetics studies between SOF/VEL/VOX and EE-containing oral contraceptives, these events call for caution, and are also viewed in relation to previous experiences indicating a risk of hepatotoxicity when combining EE with paritaprevir, another macrocyclic PI. The size data set to assess the risk of hepatotoxicity during coadministration with SOF/VEL/VOX and EE is very limited.

It is notable that, given the modest value of adding VOX to SOF/VEL in the major part of the population for which use would be recommended per section 4.2., there is virtually no room for added safety concerns related to VOX exposure. Therefore, the risk indicated by available data on EE coadministration is not considered acceptable. Thus, coadministration of SOF/VEL/VOX and ethinyl estradiol (EE)-containing contraceptive should be added to section 4.3 as a contraindication with a corresponding text in section 4.4. The contraindication should be reflected in section 4.5.

## Vital Signs, Physical Findings, and Other Observations Related to Safety

In the SOF/VEL/VOX Phase 1-3 study population, no notable changes from baseline in mean systolic blood pressure, diastolic blood pressure, pulse, BMI were observed.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Adverse events and laboratory abnormalities were assessed by sex, race, age, BMI, eGFR, history of sulpha allergy, and cirrhosis status in the Integrated Phase 3 Safety Population.

## Gender

The proportion of female patients was 46.2% in SOF/VEL/VOX 8 Week group and 22.9 in the SOF/VEL/VOX 12 Week group. In both these groups the incidence of overall AEs was greater (≥ 10%) for female subjects compared with male subjects (79.4% and 66.9%, respectively, in the 8 Week group; and 87.3% and 74.9%, respectively, in the 12 Week group). This difference was primarily due to a higher incidence of nausea and headache in females. Likewise, in the Placebo 12 Week group, the incidence of overall AEs was slightly higher for female subjects (74.2% and 69.4%, respectively) primarily due to higher incidence of nausea and diarrhoea in females.

The incidence of Grade 3 or 4 AEs and SAEs was similar for both females and males receiving SOF/VEL/VOX

## Race

The majority (&gt;80%) of patients in the SOF/VEL program were white. Overall, the percentage of subjects with Grade 3 or 4 AEs or SAEs did not differ across race categories. However, there was a higher percentage of Grade 3 or above laboratory abnormalities in non-blacks compared with blacks (range: 5.3%-16.2% compared with 1.6%-4.5%, respectively) and a higher percentage of non-black subjects with AEs was greater (&gt; 10%) than the percentage of black subjects with AEs (74.3% and 60.5%, respectively).

## Age

The incidence of subjects with Grade 3 or 4 AEs or SAEs was low and did not differ across age categories. A limited number of patients exposed to SOF/VEL/VOX were ≥65 years old (131/1056; 12%), and only one patient was ≥ 85 years old.

Table 71. Select Adverse Events by Age Category for Subjects who Received SOF/VEL/VOX in the Phase 3 Studies

|                                                  | Age in Years   | Age in Years       | Age in Years      | Age in Years   |
|--------------------------------------------------|----------------|--------------------|-------------------|----------------|
| MedDRA Term                                      | < 65 (N = 925) | 65 to 74 (N = 119) | 75 to 84 (N = 11) | ≥ 85 (N = 1)   |
| Total AEs, n (%)                                 | 693 (74.9%)    | 87 (73.1%)         | 9 (81.8%)         | 1 (100.0%)     |
| Total SAEs                                       | 19 (2.1%)      | 4 (3.4%)           | 2 (18.2%)         | 1 (100.0%)     |
| Fatal                                            | 1 (0.1%)       | 0                  | 0                 | 0              |
| Hospitalization/prolong existing hospitalization | 18 (1.9%)      | 4 (3.4%)           | 1 (9.1%)          | 1 (100.0%)     |
| Life-threatening                                 | 0              | 0                  | 1 (9.1%)          | 0              |
| Disability/incapacity                            | 0              | 0                  | 0                 | 0              |

<div style=\"page-break-after: always\"></div>

| Other (medically significant)                                                         | 0           | 0          | 2 (18.2%)   | 0          |
|---------------------------------------------------------------------------------------|-------------|------------|-------------|------------|
| AEs leading to discontinuation of study drug                                          | 1 (0.1%)    | 0          | 0           | 0          |
| Psychiatric disorders                                                                 | 113 (12.2%) | 11 (9.2%)  | 3 (27.3%)   | 0          |
| Nervous system disorders                                                              | 313 (33.8%) | 34 (28.6%) | 3 (27.3%)   | 0          |
| Accidents and injuries                                                                | 30 (3.2%)   | 3 (2.5%)   | 2 (18.2%)   | 0          |
| Cardiac disorders                                                                     | 12 (1.3%)   | 3 (2.5%)   | 1 (9.1%)    | 1 (100.0%) |
| Vascular disorders                                                                    | 37 (4.0%)   | 6 (5.0%)   | 2 (18.2%)   | 0          |
| Cerebrovascular disorders                                                             | 3 (0.3%)    | 0          | 1 (9.1%)    | 0          |
| Infections and infestations                                                           | 146 (15.8%) | 13 (10.9%) | 4 (36.4%)   | 0          |
| Anticholinergic syndrome                                                              | 0           | 0          | 0           | 0          |
| Quality of life decreased                                                             | 0           | 0          | 0           | 0          |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 44 (4.8%)   | 8 (6.7%)   | 2 (18.2%)   | 0          |
| Other AEs reported more frequently for subjects ≥ 65 years                            |             |            |             |            |
| Asthenia                                                                              | 56 (6.1%)   | 10 (8.4%)  | 1 (9.1%)    | 0          |
| Insomnia                                                                              | 54 (5.8%)   | 7 (5.9%)   | 1 (9.1%)    | 0          |
| Dizziness                                                                             | 36 (3.9%)   | 6 (5.0%)   | 1 (9.1%)    | 0          |
| Dyspepsia                                                                             | 22 (2.4%)   | 6 (5.0%)   | 0           | 0          |

No potential risks were identified in age category 65-74. Data regarding age groups &gt;74 were limited (12 subjects) but no safety issues were identified.

## Body Mass Index

Body mass index (&lt; or &gt; 30 kg/m 2 ) did not appear to have a clinically relevant effect on the incidence of any AEs for patients receiving SOF/VEL/VOX. The rates of Grade 3 or above AEs and SAEs were low for both BMI groups: 1.4% and 1.9%, respectively.

## Renal impairment

Subjects with eGFR &lt; 50 mL/min were excluded in the phase 3 studies. However, 24.2% (461) of subjects in phase 3 studies had mild renal impairment, i.e. eGFR &lt; 90 mL/min at baseline. This group had similar percentages of AEs, Grade 3 or 4 AEs, SAEs, and graded laboratory abnormalities compared to the 1447 subjects with baseline eGFR ≥ 90 mL/min

<div style=\"page-break-after: always\"></div>

## History of Sulfonamide Allergy

Because the structure of VOX contains a sulfonamide, safety was evaluated in subjects with or without a history of sulfonamide allergy. Overall, the percentage of AEs was similar for subjects with a history of sulfonamide allergy and for subjects without a history of sulfonamide allergy (77.8% and 72.8%, respectively). Across treatment groups, there were a total of 54 subjects with a history of sulfonamide drug allergy, 25 of which received SOF/VEL/VOX for either 8 of 12 weeks. Among subjects with and without a history of sulpha allergy, AEs in skin and subcutaneous tissue disorders, including rash, were reported similarly by subjects taking SOF/VEL/VOX, SOF/VEL or placebo. There were no treatmentemergent Grade 3 or Grade 4 AE skin and subcutaneous tissue disorders in reported in subjects with history of sulfonamide allergy.

The Applicant has summarised hypersensitivity events among subjects in Phase 3 studies and conclude that the rate of hypersensitivity events was similar for subjects in the SOF/VEL/VOX (6.4%) and SOF/VEL (7.6%) groups, which was slightly higher than that of the placebo group (3.3%). The most frequent AEs in the hypersensitivity SMQ were pruritus, mouth ulceration, rash, and asthma. All hypersensitivity events were Grade 1 or Grade 2 with the exception of 2 subjects, 1 with Grade 3 asthma and 1 with Grade 3 angioedema, both of which were also considered serious and unrelated to SOF/VEL/VOX. Across the groups and totalling the rashes there seems to be a clear higher rate of skin related AEs with active treatment vs. placebo.

## Hepatic Impairment

The SOF/VEL/VOX phase 3 program included subjects with compensated cirrhosis (37.6%), but excluded subjects with a history of hepatic decompensation.

Overall, the percentage of AEs as well as and the rates of Grade 3 or above AEs and SAEs was approximately the same for subjects with and without cirrhosis.

Across treatment groups with SOF/VEL/VOX and SOF/VEL, Grade 3 or above ALT and AST elevations were less frequent compared to Placebo. Overall Grade 3 and above laboratory abnormalities were more frequent in cirrhotic patients (range: 7.7%-12.0%) than in patients without cirrhosis (range: 3.4%-5.4%), primarily due to increased glucose (4.2% compared to 0.8%) and decreased platelets (2.0%; 0.0%). A slight increase in Grade 1 total bilirubin was observed in subjects receiving SOF/VEL/VOX.

## Use in Pregnancy and Lactation

## Pregnancy

There are no adequate and well-controlled clinical studies in pregnant women. In all clinical studies conducted to date with SOF, VEL, SOF/VEL, and SOF/VEL/VOX, pregnant and breastfeeding women were excluded. Women of childbearing potential included in studies were required to use 2 highly effective methods of birth control. Pregnancy, once determined, required withdrawal of the subject from the study.

Overall, 2 pregnancies were reported for subjects who received SOF/VEL/VOX or SOF/VEL+VOX in the clinical development program.

- In Study GS-US-367-1172, a female subject in the SOF/VEL/VOX 8 Week group prematurely discontinued study drug on Day 28 following confirmation of pregnancy. The pregnancy ended in an elective abortion.

<div style=\"page-break-after: always\"></div>

- In Study GS-US-367-1172, a female subject without cirrhosis in the SOF/VEL/VOX 8 Week group had pregnancy confirmed on posttreatment Day 55, after completing 8 weeks of treatment. The pregnancy ended in a miscarriage, which was reported as a non-treatment emergent SAE.

## Lactation

It is unknown whether sofosbuvir, metabolites of sofosbuvir, velpatasvir or voxilaprevir are excreted in human milk.

Overall, data from Phase 3 Safety Population provides support regarding the safety of SOF/VEL/VOX irrespectively of sex, race and presence or absence of cirrhosis. Safety data in subjects ≥ 65 years of age is rather limited (131/1056) but unremarkable. Safety data is almost absent in those &gt;85 years old. The RMP outline of these issues is without remarks.

## Safety related to drug-drug interactions and other interactions

The drug-drug interaction potential between SOF/VEL/VOX or the components of SOF/VEL/VOX and drugs than may be concomitantly used by patients with HCV infection has been evaluated in several clinical studies following administration of SOF, VEL or VOX as individual agents or in combination.

Medications are prohibited during the screening period and for a minimum of 28 days prior to the baseline/Day 1 visit through the treatment

Hematologic stimulating agents, chronic use of systemic immunosuppressants including, but not limited to, corticosteroids (prednisone equivalent of &gt; 10 mg/day for &gt; 2 weeks), azathioprine, or monoclonal antibodies (eg, infliximab) were disallowed in the study. Also, medications for disease conditions were excluded from the clinical study protocol (eg, transplantation). In addition, the drug classes in Table 72 were disallowed or optionally used with caution. Several of these medications have potentially useful indications in the HCV infected population. Hence, these study limitations may have important ramifications when extrapolation study results to patient populations with specific comorbidities or co-medications.

Table 72. Disallowed medications and concomitant medication to be used with caution

| Drug class                 | Agent disallowed                                                                                                         | Use with caution                   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Antibiotics                | Clarithromycin, Erythromycin                                                                                             |                                    |
| Acid Reducing Agents       | Proton pump inhibitors                                                                                                   | H2-recpetor antagonists, antiacids |
| Anticonvulsants            | Carbamazepine, oxcarbazepine, phenobarbital, phenytoin                                                                   |                                    |
| Antifungals                |                                                                                                                          | Itraconazole,ketoconazole          |
| Antimycobacterials         | Rifabutin, rifapentine, rifampicin                                                                                       |                                    |
| Cardias medications        | Amiodarone,bosentan,digoxin,diltiazem, dronedarone, olmesartan, quinidine, ranolazine, telmisartan, valsartan, verapamil |                                    |
| Herbal/natural Supplements | St. John's wort, Echinacea, milk thistle,(i.e. silymarin) Chinese herb sho-saiko-to (or Xiao-shai-hu-tang)               |                                    |

<div style=\"page-break-after: always\"></div>

| HMG-CoA reductase inhibitors   | Atorvastatin, fluvastatin, lovastatin, pitavastin, pravastatin, rosuvastatin, simvastatin   |
|--------------------------------|---------------------------------------------------------------------------------------------|
| Other                          | Modafinil, sulfadiazine,methotrexate                                                        |

## Discontinuation due to AES

The SOF/VEL/VOX regimen was well tolerated. A very high proportion ( ≥ 99%) of randomized patients completed study treatment. Only one subject (1/1056; 0.1%) in the Phase 3 trails discontinued study treatment (SOF/VEL/VOX) due to reported advents (angioedema), which was assessed unrelated to study drug.

Three subjects (0.3%) receiving SOF/VEL/VOX had AEs leading to interruption of study drug. This was due to intercurrent streptococcal pharyngitis on study Day 7; worsening of fatigue on baseline/Day 1 a Grade 3 SAE of congestive heart failure on baseline/Day 1.

## 2.6.1. Discussion on clinical safety

In the phase 2 and 3 program for the fixed dose combination of SOF/VEL/VOX 804 of 809 patients exposed to SOF/VEL/VOX for 8 weeks and 626 of 630 patients exposed SOF/VEL/VOX for 12 weeks completed treatment (99.4%). The phase 2 and 3 program includes 450 patients with compensated cirrhosis (as part of Polaris 1-4 studies) and 268 patients with compensated cirrhosis in the phase 2 studies. Subjects with a history of hepatic decompensation were excluded from the clinical program.

A favourable safety profile of SOF 400 mg is already well established. A substantial number of patients have been exposed to sofosbuvir, as part of Sovaldi (sofosbuvir, first approval December 2013), Harvoni (sofosbuvir/ledipasvir, first approval October 2014) and Eplcusa (sofosbuvir/velpatasvir, first approval July 2016). In addition to large scale phase 3 studies for all three products, there are quite extensive post marketing experience.

The active substance VOX is not previously approved. Although VOX has not been studied as a single agent for the treatment of hepatitis C outside short term monotherapy studies, it is noted that VOX showed no particular signs of toxicity in pre-clinical studies (no target organ of toxicity found).

The safety profile for SOF/VEL/VOX showed broadly similar frequencies of adverse events as compared to that seen with placebo (control in POLARIS-1). The numbers stopping therapy due to adverse events were very low and similar to that seen with placebo. Only one subject (1/1056; 0.1%) in the Phase 3 trails discontinued SOF/VEL/VOX due to reported advents (angioedema), which was assessed unrelated to study drug. No treatment-related SAE was reported. Among possibly treatment-related AEs, diarrhoea and nausea were more frequently reported in the SOF/VEL/VOX (both 13%) treatment groups compared to SOF/VEL (3% and 6%, respectively) or placebo (9% and 7%, respectively). The absolute majority of the cases of diarrhoea and nausea were mild (Grade1) and were not treatment limiting with no subject discontinuing or interrupting treatment. Other side effect were causality seems reasonably plausible include muscle spasms, vomiting, rash and decreased appetite.

AEs of grade 3 and 4 were infrequent in SOF/VEL/VOX subjects and occurred in a similar proportion of subjects in the SOF/VEL and Placebo groups. The incidence of SAE in the SOF/VEL/VOX group was low (&lt;2.0%) and similar to the incidence in the SOF/VEL group and the Placebo group. No SAEs in any treatment group was considered related to study drug. Two deaths were reported among 1056 SOF/VEL/VOX subjects, none of these deaths were indicative of causality to therapy.

<div style=\"page-break-after: always\"></div>

A number of AEs of special interest were followed, in particular cardiac safety having in mind a recently reported signal for arrhythmic events during therapy with sofosbuvir-based regimens in combination with amiodarone (mechanism unknown). No patient in the POLARIS studies used amiodarone, and of those patients on stable beta-blocker (11% in POLARIS 1-4) no notable changes in vital signs or electrocardiogram findings suggestive of cardiotoxicity were observed. Of note, there were no subjects in any treatment group taking stable calcium channel blocker. There were no events of treatmentrelated cardiac failure. Importantly, VOX did not have a detectable effect on cardiac repolarization or prolongation of the QTcF interval in healthy subjects, and no PR changes were noted. Analysing other AEs of special interest no relevant Grade 3 or 4 AEs on haematology or other lab chemistry parameters were seen with SOF/VEL/VOX.

Regarding potential hepatotoxicity, the incidence of ALT and AST elevations in the SOF/VEL/VOX group was low and similar to the incidence in the SOF/VEL group and lower than in the Placebo group. The rates of Grade 3 or 4 elevations in total bilirubin, ALT, and AST among subjects receiving SOF/VEL/VOX were low and similar to those receiving SOF/VEL. During treatment the median ALT and AST values decreased in the active treatment groups as compared to the Placebo group. Decreases from baseline in median total bilirubin values during treatment were observed in the SOF/VEL 12 Week group, but not in the SOF/VEL/VOX or Placebo groups. This comparative lack of decrease in the SOF/VEL/VOX group, compared to the SOF/VEL group, is likely due to VOX inhibition of OATP1B1 and OATP1B3 which transports bilirubin into hepatocytes. Thus total bilirubin is considered an AE of VOX.

A review of 46 cases of potential drug induced liver injury, of which 31/37 (84%) had had cirrhosis, and all but one achieved SVR. No cases of decompensation (except in the placebo group) were identified. The one case that did not achieve SVR stopped treatment on Day 28 due to hepatitis flare on concomitant ethinylestradiol/norethisterone acetate therapy. Also, in the phase 1 program a 19year-odl woman had a potential transaminitis during coadministration of NGM/EE + SOF/VEL/VOX.

In total, within the development program2/29 subjects with concomitantly exposure of SOF/VEL/VOX and EE-containing contraceptive developed possibly related treatment-emergent Grad 3 abnormalities in ALT. Even though no PK interactions were detected between SOF/VEL/VOX and EE-containing oral contraceptives, these events call for caution, and are also viewed in relation to previous experiences indicating a risk of hepatotoxicity when combining EE and a macrocyclic PI. It is notable that, given the modest value of adding VOX to SOF/VEL in the major part of the population for which use is recommended per section 4.2., there is virtually no room for added safety concerns related to VOX exposure. Therefore, the risk indicated by available data on EE coadministration is not considered acceptable. Therefore, a contraindication of concomitant use seems relevant.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

SOF/VEL/VOX has been studied in a sufficient number of patients, including substantial numbers of patients with compensated cirrhosis. Compared to SOF/VEL and placebo, there were similar rates of AEs overall, with the only notable difference being increased rates of mild (Grade 1) nausea and diarrhoea. Other potentially related AE's including decreased appetite, vomiting, muscle spasms and rash. No treatment-related SAE was reported and only one subject (0.1%) in the Phase 3 trials discontinued SOF/VEL/VOX due to reported advents, assessed unrelated to study drug. There was no general indication of VOX-associated transaminitis, as has been seen with other NS3/4A inhibitors; however, two cases associated with concomitant ethinyl estradiol among a total of 29 objects exposed, which makes co-administration quite questionable. The safety profile of SOF/VEL/VOX for 8 or 12 weeks in patients with compensated liver disease due to HCV infection appears favourable.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## Safety concerns

The applicant identified the following summary of safety concerns in the RMP version 0.2:

## Summary of the Safety Concerns

| Important Identified Risks   | Severe bradycardia and heart block when used with concomitant amiodarone                                                                       |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks   | HBV reactivation in HCV/HBV coinfected patients                                                                                                |
| Important Potential Risks    | Drug-drug interaction with moderate and strong inducers of P-glycoprotein (P-glycoprotein), cytochrome P450 (CYP) CYP3A4, CYP2C8 and/or CYP2B6 |
| Important Potential Risks    | Drug-drug interaction with proton pump inhibitors (PPIs)                                                                                       |
| Important Potential Risks    | Drug-drug interaction with rosuvastatin                                                                                                        |
| Important Potential Risks    | Drug-drug interaction with P-gp substrates with a narrow therapeutic window (eg, digoxin, dabigatran)                                          |
| Important Potential Risks    | Drug-drug interaction with strong inhibitors of organic anion-transporting polypeptide (OATP1B)                                                |
| Important Potential Risks    | Drug-drug interaction with tenofovir disoproxil fumarate (TDF)                                                                                 |
| Important Potential Risks    | Recurrence of HCC                                                                                                                              |
| Important Potential Risks    | Emergence of HCC                                                                                                                               |

Missing

Information

Safety in pregnant or breastfeeding women

Safety in patients with hepatitis C virus (HCV)/ human immunodeficiency virus

(HIV) coinfection

Safety in HCV patients with severe renal impairment or end-stage renal disease

Safety in patients with moderate or severe hepatic impairment

Safety in post-liver transplant patients

Development of resistance

Safety in patients with previous HCC

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

| Study/Title                                                                                                                                                                                | Objectives                                                                                                                                                                                                                                                      | Safety Concerns Addressed                                                                       | Status (Planned, Started)                    | Date for Submission of Interim or Final Reports (Planned or Actual)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------|
| Non-interventional studies (Category 1)                                                                                                                                                    | Non-interventional studies (Category 1)                                                                                                                                                                                                                         | Non-interventional studies (Category 1)                                                         | Non-interventional studies (Category 1)      | Non-interventional studies (Category 1)                               |
| Planned study to assess the impact of DAA treatment on the incidence of HCC recurrence                                                                                                     | To evaluate the impact of DAA treatment on the incidence of HCC recurrence                                                                                                                                                                                      | Important potential risk: Recurrence of HCC                                                     | Planned                                      | Interim study report Q4 2019 Final study report Q2 2021               |
| Interventional clinical studies (Category 3)                                                                                                                                               | Interventional clinical studies (Category 3)                                                                                                                                                                                                                    | Interventional clinical studies (Category 3)                                                    | Interventional clinical studies (Category 3) | Interventional clinical studies (Category 3)                          |
| GS-US-334-0154 A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency                              | To evaluate the safety, efficacy and pharmacokinetics of treatment with SOF+RBV for 24 weeks in subjects with chronic genotype 1 or 3 HCV infection and severe renal impairment                                                                                 | Missing information: Safety in patients with severe renal impairment or end-stage renal disease | Started                                      | Final study report August 2018                                        |
| Non-interventional studies (Category 3)                                                                                                                                                    | Non-interventional studies (Category 3)                                                                                                                                                                                                                         | Non-interventional studies (Category 3)                                                         | Non-interventional studies (Category 3)      | Non-interventional studies (Category 3)                               |
| GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection | To evaluate HCV viral sequences and the persistence or evolution of treatment- emergent viral mutations in subjects who fail to achieve an SVR after treatment with a Gilead oral antiviral containing regimen in a previous Gilead-sponsored hepatitis C study | Missing information: Development of resistance                                                  | Started                                      | Final study report October 2021                                       |
| GS-US-334-1113 A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis                                                          | To evaluate long-term efficacy in adolescents and children who received SOF/VEL/VOX in study GS-US-367-1175                                                                                                                                                     | Missing information: Evaluation of viral relapse.                                               | Started                                      | Final study report October 2023                                       |
| Feasibility                                                                                                                                                                                | To evaluate the                                                                                                                                                                                                                                                 | Important                                                                                       | Planned                                      | June 2017                                                             |

<div style=\"page-break-after: always\"></div>

| Study/Title                                                                                                                    | Objectives                                                                                                           | Safety Concerns Addressed        | Status (Planned, Started)   | Date for Submission of Interim or Final Reports (Planned or Actual)   |
|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------|-----------------------------------------------------------------------|
| analyses on the use of existing cohort studies to assess the impact of DAA treatment on the incidence and type of de novo HCC. | feasibility of using existing cohorts to assess the impact of DAA treatment on the incidence and type of de novo HCC | potential risk: Emergence of HCC |                             |                                                                       |

## Risk minimisation measures

| Safety Concern                                                           | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional Risk Minimization Measures   |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important identified risk(s)                                             | Important identified risk(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Important identified risk(s)            |
| Severe bradycardia and heart block when used with concomitant amiodarone | The SmPC (Sections 4.4, 4.5, and 4.8) includes information that cases of severe bradycardia and heart block have been observed when sofosbuvir in combination with another direct acting antiviral (DAA) is used with concomitant amiodarone with or without other drugs that lower heart rate, that amiodarone should only be used in patients on SOF/VEL/VOX when other alternative anti-arrhythmic treatments are not tolerated or are contraindicated, and that patients who must take amiodarone with SOF/VEL/VOX should be closely monitored.                                                                                                                          | None                                    |
| HBV reactivation in HCV/HBV coinfected patients                          | The EU SmPC (Section 4.4) has been updated to include information that cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with DAAs. HBV screening should be performed in all patients before initiation of treatment. HCV/HBV coinfected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current clinical guidelines. The PIL includes warnings to tell the doctor or pharmacist before taking the medicine if the patient has a current or previous infection with the hepatitis B virus, since the doctor may want to monitor the patient more closely. | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                          | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Additional Risk Minimization Measures   |
|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important potential risk(s)                                                                             | Important potential risk(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Important potential risk(s)             |
| Drug-drug interaction with moderate and strong inducers of P-glycoprotein, CYP3A4, CYP2C8 and/or CYP2B6 | The SmPC (Sections 4.3, 4.5 and 5.2) includes information that strong P-gp and CYP inducers (eg, rifampicin, rifabutin, St. John's wort, carbamazepine, phenobarbital and phenytoin) are contraindicated with SOF/VEL/VOX. The SmPC (Section 4.4) includes information that moderate P-gp and CYP inducers (e.g. oxcarbazepine, efavirenz, modafinil) are not recommended with SOF/VEL/VOX as they can reduce the plasma concentrations of SOF, VEL or VOX leading to reduced therapeutic effect of SOF/VEL/VOX. | None                                    |
| Drug-drug interaction with PPIs                                                                         | The SmPC (Section 4.5) includes information that the administration of SOF/VEL/VOX with PPIs at doses higher than the equivalent dose of 20 mg omeprazole has the potential to decrease VEL plasma concentrations, leading to loss of therapeutic effect of SOF/VEL/VOX.                                                                                                                                                                                                                                         | None                                    |
| Drug-drug interaction with rosuvastatin                                                                 | The SmPC (Section 4.5) includes information that coadministration of SOF/VEL/VOX with rosuvastatin may increase the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis, and that such coadministration is not recommended.                                                                                                                                                                                                                             | None                                    |
| Drug-drug interaction with P-gp substrates with a narrow therapeutic window (eg, digoxin, dabigatran)   | The SmPC (Section 4.5) includes information that coadministration of SOF/VEL/VOX with digoxin or dabigatran may increase the concentration of digoxin/dabigatran, and that caution is warranted, and therapeutic monitoring of digoxin or clinical monitoring of dabigatran is recommended when coadministered with SOF/VEL/VOX.                                                                                                                                                                                 | None                                    |
| Drug-drug interaction with strong inhibitors of OATP1B                                                  | The SmPC (Section 4.4 and 4.5) include information that coadministration of SOF/VEL/VOX with strong OATP inhibitors may substantially increase VOX plasma concentrations, the safety of which has not been established. As such, coadministration of such medicinal products with SOF/VEL/VOX is not                                                                                                                                                                                                             | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                 | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Additional Risk Minimization Measures   |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                                | recommended                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                         |
| Drug-drug interaction with tenofovir disoproxil fumarate (TDF) | The SmPC (Section 4.4 and 4.5) includes information that when coadministered with TDF, SOF/VEL/VOX increases the concentration of tenofovir and that patients receiving TDF and SOF/VEL/VOX concomitantly should be monitored for adverse reactions associated with TDF.                                                                                                                                                                                                                                                                                                                                                                                                                             | None                                    |
| Recurrence of HCC                                              | None The need for risk minimization measures will be reassessed following the availability of the results from a planned study for HCC recurrence.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None                                    |
| Emergence of HCC                                               | None Feasibility analyses on the use of existing cohort studies to assess the impact of DAA treatment on the incidence and type of de novo HCC are being conducted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | None                                    |
| Missing information                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                         |
| Safety in pregnant or breastfeeding women                      | The SmPC (Section 4.6) states that there are no or limited amount of data from the use of SOF/VEL/VOX in pregnant women, that animal studies do not indicate direct or indirect harmful effects for reproductive toxicity for SOF or VOX, that animal studies have shown a possible link to reproductive toxicity with VEL, the human relevance of which is unknown, and that, as a preventive measure, use of SOF/VEL/VOX should be avoided during pregnancy. The SmPC also states that it is unknown whether SOF, its metabolites, VEL or VOX are excreted in human milk, and that a risk to newborns/infants cannot be excluded. Therefore, SOF/VEL/VOX should not be used during breast-feeding. | None                                    |
| Safety in patients with HCV/HIV coinfection                    | The SmPC (Section 4.5) provides warnings and information on coadministration of SOF/VEL/VOX with many common HIV medicines.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                 | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                          | Additional Risk Minimization Measures   |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Safety in HCV patients with severe renal impairment or end-stage renal disease | The SmPC (Sections 4.2 and 4.4) states that no dose adjustment of SOF/VEL/VOX is required for patients with mild or moderate renal impairment (Section 4.2) and that the safety and efficacy of SOF/VEL/VOX have not been assessed in patients with severe renal impairment or ESRD requiring hemodialysis. | None                                    |
| Safety in patients with moderate or severe hepatic impairment                  | The SmPC (Sections 4.2 and 4.4) states that no dose adjustment of SOF/VEL/VOX is required for patients with mild hepatic impairment. However, SOF/VEL/VOX is not recommended in patients with moderate or severe hepatic impairment.                                                                        | None                                    |
| Safety in post-transplant patients                                             | The SmPC (Section 4.4) states that there are no data in this population.                                                                                                                                                                                                                                    | None                                    |
| Development of resistance                                                      | No risk minimization measures are considered necessary.                                                                                                                                                                                                                                                     | None                                    |
| Safety in patients with previous HCC                                           | None The need for risk minimization measures will be reassessed following the availability of the results from the planned study to assess the risk of HCC recurrence.                                                                                                                                      | None                                    |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.2 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion.

## 2.9. New Active Substance

The applicant compared the structure of voxilaprevir with active substances contained in authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer,

<div style=\"page-break-after: always\"></div>

mixture of isomers, complex or derivative of any of them.

The CHMP, based on the available data, considers voxilaprevir to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.10. Product information

## 2.10.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable.

## 2.10.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Sofosbuvir Velpatasvir Voxilaprevir Gilead (sofosbuvir / velpatasvir / voxilaprevir) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination is proposed to be indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults. The prevalence of HCV ranges from 0.4-3.5% in different EU member states. Depending on various risk factors, up to 30% of these patients will develop cirrhosis over time, with a risk of liver decompensation and development of hepatocellular carcinoma (HCC). HCV is the most common single cause of liver transplantation in the Union. Achieving SVR has been shown to significantly reduce the risk of disease progression and related mortality, as well as the development of HCC.

## 3.1.2. Available therapies and unmet medical need

During recent years a large number of new highly effective, well tolerated, direct antiviral regimens have been approved for the treatment of hepatitis C, with SVR rates well above 90% following a treatment that usually runs for 12 weeks. However, there are some subpopulations where there is still an unmet need, or where available therapies are poorly documented. One important such group are those that have failed a previous direct acting antiviral HCV treatment and developed NS5A inhibitor resistance.

From a public health perspective there is also a need for regimens that can be administered with the same simple posology regardless HCV genotype, in order to enable hepatitis C treatment to be handled quick and easy by larger groups of physicians in order to have a meaningful impact on the HCV epidemiology. Indeed, the 2014 World Health Assembly requested the World Health Organization (WHO) to examine the feasibility of eliminating hepatitis B and C, and the 2015 Agenda for Sustainable Development commits to combating viral hepatitis with a goal of eradicating hepatitis B and C by 2030. Effective, and simple, treatment is an important part of achieving that goal.

## 3.1.3. Main clinical studies

The phase 3 program of SOF/VEL/VOX (400/100/100 mg) consists of four studies conducted in patients with compensated liver disease. Two studies were conducted in DAA experienced subjects; POLARIS-1 in subjects previously exposed to an NS5A-containting regimen and POLARIS-4 in subjects exposed to non-NS5A DAAs. Two studies were conducted in DAA naïve subjects; POLARIS-2 in all genotypes excluding GT3 cirrhotics; and the POLARIS-3 study dedicated to this group.

## 3.2. Favourable effects

## NS5A experienced subjects (SOF/VEL/VOX for 12 weeks)

POLARIS-1 was randomized, open-label placebo-controlled, as there are no approved control regimens with convincing efficacy results in this patient group. The reason for the placebo control is safety; the placebo response in terms of SVR is anticipated to be, and was, 0. All HCV genotypes were allowed in the study. However, only subjects with GT1 were randomized while all other genotypes were included

<div style=\"page-break-after: always\"></div>

in the SOF/VEL/VOX arm. The proportion of compensated cirrhotic subjects was relatively high (46% in the SOF/VEL/VOX group) and demographic parameters and baseline characteristics were representative of what is currently expected from a DAA experienced population. In this difficult to treat population, the overall cure rate (SVR12) was 96.2% (CI 93.1-98.2%) which is expected from state-of-the-art DAA treatment in DAA naïve subjects.

## DAA-experienced, NS5A naïve subjects (SOF/VEL/VOX for 12 weeks)

POLARIS-4 was randomized, open-label using SOF/VEL for 12 weeks as comparator. Randomization was stratified by HCV genotype (1, 2, or 3) and cirrhosis status (presence or absence). Subjects with genotype 4, 5, or indeterminate HCV infection, regardless of cirrhosis status, were enrolled in the SOF/VEL/VOX group only. The proportion of cirrhotic subjects was relatively high (46% in the SOF/VEL/VOX group) and demographic parameters and baseline characteristics were representative of what is currently expected from a DAA experienced population. SVR rate in the SOF/VEL/VOX group was 97.3% (CI 93.7-99.1%) in comparison to 90.1% (CI 84.1-94.3%) in the SOF/VEL group. The study was not powered for statistical inference between arms.

## DAA naïve subjects (SOF/VEL/VOX for 8 weeks)

POLARIS-2 was randomized, open label using SOF/VEL for 12 weeks as comparator. Subjects with genotype 1, 2, 3, or 4 HCV infection and 30 subjects with genotype 5 or genotype indeterminate HCV infection were to be enrolled or randomized 1:1. Subjects with genotype 3 HCV infection with cirrhosis were not eligible for participation. For subjects with HCV genotype 1, 2, 3, or 4, randomization was stratified by HCV genotype (1, 2, 3, or 4), cirrhosis status (presence or absence), and treatment history (treatment naive or treatment experienced with an interferon (IFN)-based regimen). The proportion of cirrhotic subjects was relatively low (18.5%). This study was defined as a non-inferiority trial with a pre-set margin of -5%. The SOF/VEL/VOX 8 Week group did not demonstrate noninferiority to the SOF/VEL 12 Week group (proportional difference CI -6.2% to -0.6%).

POLARIS-3 was randomized, open label using SOF/VEL for 12 weeks as comparator. Only subjects with chronic genotype 3 HCV infection and cirrhosis were included and randomized (1:1).31% were treatment experienced with interferon-based regimens.. SVR rates were similar in the SOF/VEL/VOX and SOF/VEL groups, with SVR12 of 96.4% (CI 91.0-99.0%) and 96.3% (CI 90.9-99.0%) respectively. The study was not powered for non-inferiority testing, but in a post hoc analysis, the 95% CI of proportional difference in SVR12 rates between SOF/VEL/VOX 8 weeks and SOF/VEL 12 weeks was -5.4% to 5.7%.

SOF/VEL/VOX was associated with lower rates of treatment emergent drug resistance in case of virological relapse.

## 3.3. Uncertainties and limitations about favourable effects

Given that similar exposures of SOF and VEL is seen with the SOF/VEL/VOX and SOF/VEL FDCs, the efficacy of SOF/VEL/VOX stands on the well-established efficacy profile of SOF/VEL that was assessed prior to the EU approval of Epclusa. The uncertainties therefore mainly concern the add-on effect of VOX in the different patient groups, and the impact of shortening treatment duration to 8 weeks.

The advantage of the triple combination is well established in DAA-experienced patients through POLARIS-1 and -4, the advantage of adding VOX is less well defined in patients that are DAA-naïve.

Although SOF/VEL/VOX for 8 weeks in POLARIS-2 achieved a 95% SVR rate (95CI for proportion 92.7% to 96.7%) this did not meet the pre-specified non-inferiority target in comparison with SOF/VEL for 12 weeks. On the other hand, the same combination and duration achieved a 96% SVR rate in

<div style=\"page-break-after: always\"></div>

POLARIS-3, studying a presumably more difficult to treat cirrhotics with GT3, which was similar to what was seen with SOF/VEL for 12 weeks.

The somewhat lower SVR rate for SOF/VOX/VEL in the POLARIS-2 was notable in patients with GT1a (SVR rate 92%) and more clearly so in subjects with NS3 polymorphisms at position 80 (Q80K/L/R). There is no clear virologic or clinical rationale for this, considering the retained in-vitro activity of voxilaprevir with this mutation, which may be a chance finding or a confounded correlation.

The number of virologic failures on which the assumption of a higher barrier to resistance is based, is relatively small (N=31).

## 3.4. Unfavourable effects

In the clinical phase 3 and 2 program for the fixed dose combination of SOF/VEL/VOX 804 of 809 patients exposed to SOF/VEL/VOX for 8 weeks and 626 of 630 patients exposed SOF/VEL/VOX for 12 weeks completed treatment (99.4%). The phase 2 and 3 program includes 450 patients with compensated cirrhosis (as part of Polaris 1-4 studies) and 268 patients with compensated cirrhosis in the phase 2 studies. Subjects with a history of hepatic decompensation were excluded from the clinical program.

The safety profile of SOF/VEL has been previously characterised and is generally very favourable, with AEs mostly occurring at the same rate as on placebo. The safety profile for SOF/VEL/VOX showed similar frequencies of adverse events as compared to that seen with placebo (control in POLARIS-1). Only one subject (1/1056; 0.1%) in the Phase 3 trials discontinued SOF/VEL/VOX due to reported advents (angioedema), which was assessed unrelated to study drug. Among possibly treatment-related AEs, diarrhoea and nausea were more frequently reported in the SOF/VEL/VOX (both 13%) treatment groups compared to SOF/VEL (3% and 6%, respectively) or placebo (9% and 7%, respectively). The absolute majority the cases of diarrhoea and nausea were mild (Grade1) and were not treatment limiting with no subject discontinuing or interrupting treatment. Other potentially causally related AEs include decreased appetite, vomiting, muscle spasms and rash, which were all mild.

AEs of grade 3 and 4 were infrequent in SOF/VEL/VOX subjects and occurred in a similar proportion of subjects in the SOF/VEL and Placebo groups. The incidence of SAE in the SOF/VEL/VOX group was low (&lt;2.0%) and similar to the incidence in the SOF/VEL group and the Placebo group. No SAEs in any treatment group was considered related to study drug. Two deaths were reported among 1056 SOF/VEL/VOX subjects, none of these deaths were indicative of causality to therapy.

Regarding potential hepatotoxicity, an issue with other NS3/4A inhibitors, the incidence of ALT and AST elevations in the SOF/VEL/VOX group was low and similar to the incidence in the SOF/VEL group and lower than in the Placebo group. The rates of Grade 3 or 4 elevations in total bilirubin, ALT, and AST among subjects receiving SOF/VEL/VOX were low and similar to those receiving SOF/VEL. During treatment the median ALT and AST values decreased in the active treatment groups as compared to the Placebo group. Decreases from baseline in median total bilirubin values during treatment were observed in the SOF/VEL 12 Week group, but not in the SOF/VEL/VOX or Placebo groups. This comparative lack of decrease in the SOF/VEL/VOX group, compared to the SOF/VEL group, is likely due to VOX inhibition of OATP1B1 and OATP1B3 which transports bilirubin into hepatocytes.

No cases of hepatic decompensation (except in the placebo group) were identified. However one patient stopped treatment on Day 28 due to hepatitis flare on concomitant norethisterone /ethinylestradiol (NGM/EE) acetate therapy. Also, in the phase 1 program a 19-year-old woman experienced transaminitis/hepatitis during coadministration of NGM/EE + SOF/VEL/VOX. All in all, 2/29 patients in the program with concomitant EE developed transaminitis/hepatitis.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Like other NS3/4A inhibitors, VOX displays variable and non-linear pharmacokinetics. It is unclear what multiples of exposure might be unsafe; therefore, the major uncertainty pertains to safety in situations with increased drug exposure, such as in case of DDIs. Further, voxilaprevir exposure increases with increasing degrees of liver injury. While there is a large and reassuring safety database in patients with compensated cirrhosis, SOF/VOX/VEL has not been studied in patients with decompensated liver disease.

As stated above, 2/29 patients with co-administered EE developed transaminitis/hepatitis. Of note, another NS3/4A inhibitor (paritaprevir) showed high rates of transaminitis when combined with EE. Given the modest value of adding VOX to SOF/VEL in the major part of the population for which use is recommended per section 4.2., there is virtually no room for added safety concerns related to VOX exposure. Therefore, the risk indicated by available data on EE coadministration is not considered acceptable and concomitant use should be avoided.

## 3.6. Effects Table

Table 73. Effects Table for SOF/VEL/VOX for the treatment of chronic HCV infection

|              | Effect                                                                          | Short Description                                                                              | Outcome                                                                                                                                                                               | Control                                                                                     | Uncertainties/ Strength of evidence                                         |
|--------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Favourable   | SVR12 (clinical cure based on virological endpoint) in DAA experienced patients | Proportion of patients with SVR12 when treated with applicant's recommended regimen (12 weeks) | Overall >90% across all genotypes, demographic parameters and baseline characteristics                                                                                                | Placebo (no spontaneous cure) or SOF/VEL                                                    | Limited numbers of DAA experienced subjects with GT4-6 included in studies. |
| Favourable   | Reduction of treatment emergent NS5A RAVs                                       | Proportion of subjects with virologic failure, presenting with treatment- emergent NS5A RAVs   | SOF/VEL/VOX - 2/8 subjects developed relevant NS5A RAVs vs 12/15 for SOF/VEL                                                                                                          | SOF/VEL 12 weeks (in non-NS5A experienced subjects)                                         | Study not designed for statistical comparison of this outcome measure.      |
| Unfavourable | Treatment- emergent adverse events                                              |                                                                                                | Diarrhoea and nausea were more frequently observed (both 13%). Decreased appetite, vomiting, muscle spasms and rash are potentially related. All of these events were generally mild. | Diarrhoea and nausea SOF/VEL (3% and 6%, respectively) or placebo (9% and 7%, respectively) |                                                                             |
| Unfavourable |                                                                                 | Transaminitis on concomitant ethinylestradiol/ norethisteron treatment                         | 2/29 patients co- treated developed treatment- emergent Grade 3 abnormalities in ALT                                                                                                  |                                                                                             |                                                                             |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The demonstration of very high SVR rates when VOX is added to SOF/VEL in NS5A-experienced patients marks an important advance, demonstrating that there is a likely effective retreatment option for patients that relapse after therapy (since clinical resistance to NS5B is not seen, and treatment emergent resistance to NS3/4A tends to revert over time). This is not only a value to those patients, but also lowers the concern about the availability of retreatment options in case of relapse. Allowing for shorter therapy may be of value for the treatment of hepatitis C in some settings. However, this allowance would pertain to non-cirrhotics, as there is still considered that in cirrhotics there is an urgency not to unduly delay reaching SVR, in order to avoid progression towards decompensated liver disease.

## 3.7.2. Balance of benefits and risks

Very high SVR rates are anticipated in all populations where this combination would be used (including all relevant categories except those with decompensated liver disease or severe renal failure). The safety profile is a relatively large safety database was overall reassuring, with no major safety concerns emerging.

An augmented B/R compared to available therapies can clearly be seen in case of the DAAexperienced, for whom SOF/VEL would either be anticipated to be less effective (NS5A-experienced), or has been shown to be likely less effective (those DAA-experienced patients who are simply selected as the most difficult to cure patients notwithstanding a virus without preselected drug resistance). Also, it is recognised that there are a subpopulation of genotype 3 cirrhotics (e.g., those with baseline NS5A Y93H variants) where SOF/VEL may not be optimally effective.

In the light of the abovementioned observations concerning retreatment options, as well as the fact that treatment emergent drug resistance is relatively uncommon with SOF/VEL/VOX, it seems that uncertainties in retreatment options would not be an argument preventing the potential use of SOF/VEL/VOX for 8 weeks in non-cirrhotic patients. It is acknowledged that an incremental effect of VOX has not been directly demonstrated in the 8 week setting; however, SOF/VEL was not developed for 8 weeks as emerging data did not support sufficient efficacy.

While it is by no means clear that SOF/VEL/VOX would be a standard regimen for non-cirrhotic patients without complicating factors, institutions or public health bodies may argue that a robust 8 week regimen, rather than available 12 week regimens, would be valuable. The emerging safety profile of SOF/VEL/VOX does not preclude such an assessment. For patients with cirrhosis, however, a standard 12 week regimen would still be recommended, as the benefits of one month shorter duration of therapy can hardly be considered to be outweighed by uncertainties about the likelihood of relapse and a delay in achieving SVR.

## 3.8. Conclusions

The overall B/R of Vosevi is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Vosevi is favourable in the following indication:

## Treatment of chronic hepatitis C virus (HCV) infection in adults.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<div style=\"page-break-after: always\"></div>

| Description                                                                                                                                                                                                                                                                                                                                                                     | Due date   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Non-interventional post-authorisation safety study (PASS): In order to evaluate the recurrence of hepatocellular carcinoma associated with Vosevi, the MAH shall conduct and submit the results of a prospective safety study using data deriving from a cohort of a well-defined group of patients, based on an agreed protocol. The final study report shall be submitted by: | Q2 2021    |

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that voxilaprevir contained in the fixed combination medicinal product - Vosevi - is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.